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Patients with inflammatory disorders of the gut often experience central comorbidities, 
which include depression, anxiety and cognitive deficits. This is not surprising considering 
the gastrointestinal tract (GIT; gut) and the central nervous system (CNS, brain and spinal 
cord) are connected by a myriad of bidirectional pathways. The dialogue between the 
peripheral immune system and the brain (neuroimmune interactions) has been implicated 
in the development of sickness behaviours, which interestingly mimic the central 
comorbidities reported by patients with gut inflammatory disorders, particularly those with 
inflammatory bowel diseases and cancer. The neuroimmune system lies at the heart of this 
thesis and its overarching hypotheses. This stems from evidence implicating microglial 
and astrocyte cell reactivity/priming in contributing to central changes via peripheral 
inflammatory events. Once primed, glial cells undergo morphological and functional 
changes which often result in neurotoxicity and neuroinflammation due to their intimate 
relationship with the synapse. In their quiescent state, however, microglial and astrocytes 
are critical in central homeostasis, health and development. Reactive glia induce a 
destructive microenvironment via tissue damage and neuronal loss, contributing to 
pathological pain pathways and neurodegeneration. Whilst glial reactivity is initiated as an 
innate response aimed at assisting the host in healing, often microglia and astrocytes can 
remain primed after the peripheral inflammatory event subsides. Consequently, this thesis 
examined microglial and astrocyte dysregulation in the brain and spinal cord of rodents 
across a range of inflammatory conditions of the gut. This work compared acute and 
chronic models involving a commonly used chemotherapy drug and non-steroidal anti-
inflammatory drug. The chronic models assessed ulcerative colitis and colitis-associated 
colorectal cancer. Finally, this thesis explored the relationship between gut disturbances 
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and cognitive impairment in an Australian breast cancer cohort. The findings from this 
thesis suggest that neuroimmunological manifestations occur in the spinal cord and brain 
of rodents across a range of acute and chronic inflammatory disorders of the gut. 
Importantly, this indicates that current investigations into the central side-effects associated 
with gut inflammatory conditions may be critically missing the direct and indirect 
influence of simultaneously occurring side-effects. Rather than focussing on an individual 
mechanism relating to a specific side-effect of chemotherapy treatment, perhaps we should 
be more accurately reflecting a clinical setting and develop our understanding of how 
multiple side-effects work in unison. The findings from the clinical trial assist us in further 
understanding the relationships between the perceived severity of side-effects associated 
with chemotherapy treatment and identify relationships between allergies, pain, gut 
disturbances and cognition. The mechanistic implications of these findings should be 
further explored to elucidate whether the gut-inflammatory-induced glial dysregulation 
described in this thesis has the potential to modulate brain function and behaviour. 
Ultimately, such studies may critically lead to the development of novel treatment 
approaches that target multiple side-effects and positively influence the central 




The format of my thesis is as follows: a general introduction which highlights important 
background literature to the themes presented. This is followed by two published literature 
reviews, whereby the hypotheses and aims are presented. Therein follows three in vivo 
research chapters, a clinical research chapter, a general discussion, references and three 
appendices. I made significant efforts to publish these chapters throughout my candidature, 
chapters one and two have been published, whilst chapters three-six have been submitted 
to journals. Whilst all the chapters are presented in manuscript format, repetition of 
abbreviation definitions, theoretical concepts and methodological approaches/techniques 
occur throughout these works, particularly in the Background and Methods sections of the 
primary research chapters. The first two appendices contains PDF versions of my 
publications arising from Chapters One and Two, whereas Appendix Three includes a copy 
of the questionnaire designed for Chapter Six (some minor formatting issues remain). Each 
research chapter is presented in its original format, apart from some Background and 
Discussion sections due to word limit restrictions for journal specifications. In my thesis I 
have included further discussion points in the Background and Discussion sections of my 
research chapters.  
Framing the Thesis 
At its core, this thesis stems from my interest in the interactions between body systems 
under inflammatory conditions of the gut, with a particular focus on the neuroimmune 
system, peripheral-to-central immune signalling and gut-brain axis dysregulation. Three 
overarching themes explore the neuroimmunological mechanisms contributing to central 
pathological manifestations associated with chemotherapy-induced gut toxicity (CIGT), 
chronic ulcerative colitis (UC) and colitis-associated colorectal cancer (CA-CRC). First, I 
sought to determine whether acute administration of the commonly utilised chemotherapy 
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drug, 5-Fluorouracil (5-FU), was unique in causing spinal cord glial dysregulation, and to 
clarify whether such changes occur in the hippocampus of rats with experimentally-
induced gut toxicity. Second, I examined whether glial dysregulation would occur in 
chronic inflammatory conditions of the gut lacking chemotherapy exposure, comparing 
chronic UC (non-malignant inflammation) with CA-CRC (inflammation-associated 
malignancy). Using the three gut inflammatory models described above, I covered acute 
versus chronic models, inflammation versus malignancy, and chemotherapy alone whilst 
examining different regions of the alimentary tract, from the small intestine to the colon. 
Finally, I sought to identify whether breast cancer survivors subjectively reported 
chemotherapy-induced gastrointestinal (GI) symptoms that could be correlated with the 
severity of their cognitive changes during their treatment. I also wanted to identify whether 
a relationship between allergies, perceived GI and cognitive disturbances were present. 
In order to address these themes, I characterised the time-point and specific CNS regions 
expressing glial dysregulation in an acute 5-FU-induced gut toxicity (5IGT) rat model and 
intervened with three mechanistically different analgesic interventions. The clinically 
relevant interventions chosen in this study further influenced glial dysregulation as well as 
having effects on small intestinal inflammatory parameters (Research Chapter One). 
Following on from this, the second research chapter compared the glial dysregulation 
observed in the high-dose inflammatory response of the 5IGT rat model with a low-dose of 
indomethacin (non-steroidal anti-inflammatory drug; NSAID), characterising gut toxicity 
and analysing microbiota changes in both models (Research Chapter Three). I then wanted 
to assess glial dysregulation in chronic inflammatory models further along the alimentary 
tract, in the colon of mice. Utilising experimentally-induced chronic UC and CA-CRC 
models, I examined additional higher order brain regions in these studies (Research 
Chapter Four). Findings from the clinical trial in my thesis sought to understand the impact 
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of perceived gut- and cognitive-related side-effects associated with chemotherapy 
treatment in an Australian breast cancer cohort. This study aimed to identify whether the 
perceived severity of chemotherapy-induced GI disturbances positively correlated with the 
perceived severity of cognitive issues reported by these patients. This study also used 
exploratory questions to identify whether allergy susceptibility could be related with the 




Please note that variations in terminology relating to GI toxicity associated with 
chemotherapy occur throughout this thesis. These inconsistencies paradoxically reflect 
advancements as well as failures in the field to adequately define this pathology. During 
the first few years of my research, mucositis, including oral and/or intestinal mucositis was 
the most commonly used term. However, advancements in the field suggested that the 
previously defined characterisation of mucositis by Sonis [1] perhaps more accurately 
reflected the terminology CIGT. As a result of this, and requests made by reviewers during 
the publication stages, I have not changed the terminology from what was used in the 
original publications to avoid altering content. 
Please review the following nomenclature. 
Alimentary tract: any region from the mouth to anus. 
Mucositis: chemotherapy-induced inflammation/ulceration of the mucosal layers of the 
GIT which include the mouth or intestines. 
Oral mucositis: chemotherapy-induced mucosal inflammation/ulceration of the mouth. 
Intestinal mucositis/gut toxicity: chemotherapy-induced mucosal inflammation/ulceration 
of the intestines. 
Please note: unless otherwise stated, the terms glia/glial cells throughout this thesis are 
inclusive of microglial and astrocyte cell types only.  
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From the Bottom Up: Pathways and Signalling in the Gut and the Brain 
Multiple bidirectional, parallel pathways control signalling between the CNS and GIT, 
form the gut-brain axis [for extensive reviews 2, 3-5]. The complexity of this network is 
best appreciated in its ability to integrate information from a variety of systems 
encompassing the central, autonomic and enteric nervous systems, whilst simultaneously 
considering neuroendocrine, enteroendocrine and neuroimmune input (Please review 
Figure 2.1 in Chapter Two) [5]. Nonetheless, a brief analysis of the top down, Bottom Up 
and enteric nervous system (ENS) literature is necessary to appreciate the integration of 
these pathways. In doing so, this will highlight mechanisms by which these pathways 
influence behaviour and impact central comorbidities in disorders of the gut. Firstly, the 
top down (brain-to-gut) signalling will be examined. 
Top Down Signalling 
The branches of the autonomic nervous system (ANS) responsible for brain 
communication to the viscera are the sympathetic and parasympathetic limbs [5]. 
Descending monoaminergic pathways modulate the intensity of spinal reflexes and modify 
dorsal horn excitability. The subcortical regions that generate these outputs are the 
hypothalamus and amygdala which receive inputs from a number of cortical areas, such as 
the anterior cingulate cortex and medial prefrontal cortex (mPFC) [6]. The mPFC receives 
input from the lateral PFC and orbitofrontal cortex containing integrated multisensory 
information about homeostatic gut states, such as food intake, pain and immune insults. 
Output from these networks are projected to the periaqueductal grey [7] where the 
information is relayed to the dorsal vagal complex, locus coeruleus and raphe nuclei in the 
pons and medulla [4].  
This cortico-limbic-pontine network is referred to as the emotional motor system as it 
integrates motor autonomic, neuroendocrine and pain modulatory mechanisms [7]. The 
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medial component regulates spinal reflexes (e.g. serotonergic, noradrenergic and 
opioidergic descending spinal pathways) directly related to GIT function, whilst the lateral 
component integrates and modulates motor autonomic, neuroendocrine and pain 
behaviours [8]. Modulation of descending opioid-dependent pain pathways may occur via 
behavioural and motivational states involving, for example, food intake and fear [9, 10]. 
Top down influences may override local reflexes in response to certain cognitive or 
emotional states that include stress [8], anger [11] and memories, as well as environmental 
stimuli (threat or safety) [4]. Signals are projected from the medullary pontine nuclei to 
sympathetic preganglionic fibres in the spinal cord which modulate function-specific vagal 
and sacral parasympathetic outflows [12]. The hypothalamic pituitary adrenal (HPA) axis 
coordinates adaptive responses to any stressor and forms a part of the limbic system which 
is heavily involved in memory and emotional responses [13]. Cortisol is the key stress 
hormone which has functional effects on many cells in various organs of the body, 
including the gut and the brain. Several lines of neural and hormonal communication 
combine and enable the brain to influence a variety of intestinal cells, such as immune, 
epithelial and enteric neurons. Recently, emerging evidence has revealed that these same 
cells are constantly under the influence of the intestinal microbiota [14]. From this, the 
concept of gut-brain-microbiome axis has been developed and strong evidence has accrued 
supporting its involvement in various pathologies in, not only the GIT but centrally as well 
[5, 14-23]. This fascinating and complex phenomenon extends beyond the scope of these 
works. However, several important findings that specifically support the influence of the 
microbiome in oncology are presented in Chapter Two of this thesis (Table 2.1). Some of 
the key results emphasised in this chapter include the ability of specific microbial strains 
showing anti-tumour potential, mechanisms by which chemotherapy-induced dysbiosis 
influences CIGT, drug efficacy and the complex interplay it has in cancer immunotherapy. 
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The top down effects of sympathetic and parasympathetic interactions have been well 
established [3, 24, 25] but overall their actions suppress secretion, motility and GI transit 
via inhibitory cholinergic transmission including immune- and emotion-related alterations 
[4]. Mucosa and microflora interactions may also be modified by sympathetic innervation 
[26]. Importantly, emotional states such as depression and anxiety have been associated 
with tonic ANS dysfunction involving altered top down signalling. Sympathetic and 
parasympathetic innervation facilitates emotion-related changes in motor, secretory and 
immune activity in the GIT. In turn, distinct facial expressions and postures (facilitated by 
the somatic motor system) reflecting different moods have direct effects on the GIT and 
indirectly influence feedback to the brain [4]. Reduced expression of Toll-like receptors 
(TLRs; discussed later) on epithelial cells is an example of peripheral target cells 
negatively affected by prolonged alterations in ANS output [27]. In a chronic setting, such 
as functional gut disorders, increased efferent signalling has been associated with regional 
brain remodelling [28]. The above literature briefly describes the integration of top down 
signalling pathways which have effects on various gut functions. Simultaneously, the gut 
and ENS are constantly relaying signals up to the brain in a continual feedback loop.  
From the Bottom Up 
The GIT elicits a myriad of functions ultimately resulting in absorption of nutrients and 
expulsion of noxious and pathogenic chemicals, including undigested content. This is 
primarily achieved by muscular contractions mixing contents and propelling them from the 
mouth toward the colon for defecation. The GIT contains an extensive intrinsic nervous 
system (ENS), unique in its ability to control certain functions of the small and large 
intestines even when it is not connected to the CNS [2]. However, the ENS should not be 
considered fully autonomous. The ENS is the largest and most complex division of the 
peripheral nervous system comprising 400-600 million neurons and an extensive network 
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of enteric glial cells (EGC) [24]. EGCs share similarities with astrocytes (discussed later), 
their CNS counterparts, in the mechanisms they adopt to support enteric neurons, including 
their morphology, function and molecular capabilities [29]. Importantly, EGCs play key 
roles in mounting an immune response, particularly during intestinal inflammation.  
Local environmental factors of the gut are signalled to the brain via endocrine, immune 
and neuronal afferent pathways which have been extensively reviewed [3, 4, 24, 25]. 
Signalling molecules communicate gut sensory information to the CNS via functional 
effector cells, such as epithelial cells, smooth muscle cells, interstitial cells of Cajal, 
enterochromaffin cells, intrinsic and extrinsic primary afferent neurons, immune and 
enteroendocrine cells [5]. To further complicate gut-brain crosstalk, various 
neurotransmitters commonly produced centrally, are also expressed by these cells in the 
GIT [25]. One of the most abundantly produced neurotransmitters in the gut is serotonin 
(5-hydroxytryptamine; 5-HT) which is released by epithelial enterochromaffin cells. 5-HT 
activates intrinsic and extrinsic primary afferent neurons and induces peristaltic and 
secretory effects [30]. In the brain, 5-HT regulates many brain functions which result in 
behavioural effects, having implications in cognition, reward pathways and learning and 
memory, to mention a few [31]. Some neuropsychological and gut disorders have a 
serotonergic component, such as Alzheimer’s and Parkinson’s disease, experimental colitis 
and chronic constipation [32-34]. 5-HT has multiple action sites which enable selective 
serotonin re-uptake inhibitors (SSRIs) therapeutic promise in treating various disorders of 
the brain. However, its non-selective nature can also result in less desirable effects in the 
GIT. Consequently, further research on these neurotransmitters expressed in both the gut 
and the brain, such as 5-HT is warranted. 
Recent advances in our understanding of the impact microflora has on the gut-brain axis 
has led to common use of the term microbiota-gut-brain axis [35, 36]. Communication 
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along the microbiota-gut-brain axis has been shown to alter certain aspects of brain 
development, function, mood and cognitive processes [17]. In the gut, disruption of the 
intestinal microbiota can heavily influence pathological intestinal conditions, such as 
inflammatory bowel diseases (IBD) or gut disorders induced by chemotherapy [37, 38]. 
Evidence linking microbial changes to a range of disorders, both in the gut and centrally 
highlights the need for continued research in this area.  
Numerous afferent and efferent pathways connect the gut and brain, presenting the host 
with a multitude of possible platforms for malfunction, dysregulation and disease, both in 
the periphery and centrally. Accumulating evidence has identified the pivotal role gut-brain 
axis dysfunction plays in our mechanistic understanding of various gut disorders and their 
effects on cognition. Disorders of the gut and chronic inflammation often occur 
simultaneously with psychological abnormalities, including anxiety and depression [39]. 
Additionally, physiological responses can be induced by stress, for instance triggering 
relapse in experimental colitis [40]. Recently, great interest has been paid to the 
importance of gut health on mental health and vice versa. This has become particularly 
apparent in anecdotal evidence on the central comorbidities associated with various gut 
disorders, particularly in irritable bowel syndrome (IBS) and IBD [41, 42]. The following 
sections will briefly introduce the central comorbidities associated with these gut disorders 
and identify similarities in oncology. This will lead into an exploration of the complexities 
surrounding cancer and chemotherapy treatment, from the Bottom Up, with an emphasis 
on the gut and central changes associated with chemotherapy treatment.  
Functional Gut Disorders and Central Comorbidities 
A range of gut disorders have been associated with central comorbidities. Specifically, this 
thesis will discuss the central morbidities associated with IBD, IBS, cancer and 
chemotherapy treatment. It is unclear as to whether a cause and effect relationship occurs 
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between the brain and gut in these disorders, nonetheless it is widely accepted that stress 
and psychological challenges contribute to the pathogenesis of functional gut disorders and 
that gut disturbances can contribute to central comorbidities.  
IBS and IBD 
Gut disorders are commonly associated with poorer mental health. For instance, 54-94% of 
IBS patients actively seeking treatment also present with emotional, psychological and 
cognitive comorbidities [42]. Changes in cognitive performance have been identified in 
IBS patients, particularly stress-related impairment in visuospatial memory [43]. Similarly, 
mild forms of memory impairment have been observed in IBD patients, including verbal 
IQ [44, 45]. IBS attacks present episodically and are often triggered by stressors of the 
psychological, physical or environmental kind [46, 47]. Consequently, psychiatric 
conditions, in particular depression and anxiety, play a pivotal role in the development as 
well as the outcome and prognosis of both disorders [48, 49].  
It is for this reason that gut disorders, such as IBS and IBD, involve clinical input from a 
range of health care providers, including general practitioners, gastroenterologists, 
radiologists and psychologists or psychiatrists. The emergence of multidisciplinary 
research and theories in these gut disorders, have resulted in a biopsychosocial model 
which considers a lifetime perspective from the patient’s childhood through to their adult 
life [50]. The model integrates different aspects of the body and the mind to include the 
ENS and intestinal microenvironment, diet, the immune system and the microbiota. In 
addition, this model acknowledges and involves different aspects of the individual’s life, to 
include their genetic makeup, environment, cognitive status, stress, emotions, spirituality 
and traumatic events. Perhaps this kind of multidisciplinary biopsychosocial model should 
be further explored in other gut disorders which also have a central component, such as in 
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oncology where patients often similarly experience physical, mental, immune and gut 
disturbances whilst undergoing anti-cancer treatment. 
IBS and IBD aetiology are complex and multifactorial. Several factors associated with gut-
brain axis dysregulation play a role in the pathological development of IBS and IBD. Some 
of these factors include stress, chronic pain and immune activation, as well as CNS 
modulation, microbiota alterations, genetic susceptibility, HPA dysregulation and visceral 
hypersensitivity [51-53]. Brain imaging studies have reported structural alterations in 
patients with both disorders when compared to healthy controls. Changes in grey matter 
density and volumes have been reported in various cortical regions of IBS and IBD 
patients [28, 54]. Importantly, these cortical regions play a role in cognitive pain 
modulation and hence, alterations may be indicative of impaired inhibitory descending 
nociception.  
Although extensive evidence supports the hypothesis for the involvement of central 
changes in the aetiology of IBS and IBD, a certain level of caution should be employed, as 
it remains unclear whether these changes are specific to both disorders, or if they overlap 
with other disease activity, for example with depression or anxiety. The literature above 
provides clear evidence that IBS and IBD occur simultaneously with central comorbidities. 
Functional gut disorders have been strongly associated with a range of psychological 
comorbidities; yet our understanding of the central consequences of other gut disorders, 
such as in the oncology arena remains unclear. Patients with various cancer types often 
report a myriad of peripheral and central changes which negatively affect quality of life. 
These symptom clusters can include GI disturbances, lack of appetite, malaise, depression, 
anxiety, cognitive deficits, lethargy and sleep disturbances and fatigue, to name a few. The 
following sections will briefly introduce cancer, focussing on breast cancer and CRC and 
CIGT, CICI and immune dysregulation in the context of this thesis. 
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Cancer and chemotherapy 
Cancer 
Since the year 2000, estimates on cancer incidence have increased by approximately 80% 
and yet estimates on deaths resulting from cancer have increased by only 60% [55, 56]. 
Importantly, this highlights that anti-cancer treatment advancements have significantly 
improved the survival rates of cancer survivors. In doing so, increased attention has been 
given to not only the acute but also the delayed side-effects associated with treatment. The 
increasing incidence of cancer diagnoses and use of anti-cancer treatments will result in a 
future with a significant proportion of cancer survivors who will be cancer free, yet may 
still endure some of the side-effects from their anti-cancer treatment.  
Breast cancer and colorectal cancer (CRC) incidence are amongst the top three most 
reported cancers in the world [55]. In women, breast cancer accounts for approximately 
one in every four cancer cases. Overall, CRC ranks third in the context of incidence, but 
second in terms of mortality due to its often-late diagnosis and aggressive nature. These 
stark statistics associated with both cancer types as well as the high incidence of cognitive 
impairment reported in breast cancer patients justified exploration of the central themes 
presented in this thesis.  
Patients with both cancer types often present with simultaneous side-effects in the gut and 
centrally, yet it is unclear as to whether these side-effects are induced by the malignancy or 
by anti-cancer treatments [57-59]. Separate investigations into anti-cancer treatment 
associated gut and cognitive changes have implied various immunological mechanisms 
contributing to the pathogenesis of each disorder [1, 60-65]. Unsurprisingly, at the crux of 
cancer lies immune dysregulation as host immune processes attempt to eliminate 
malignancies, yet paradoxically encourage its progression. The complexities of these 
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treatment-induced disorders will be further discussed after briefly describing immune 
dysregulation within the context of cancer. 
Cancer and Immune Dysregulation 
Cancer and anti-cancer treatments have been associated with complex immune 
maladaptation’s involving inflammatory processes, both surrounding the site of the 
malignancy, within the malignancy itself and as a result of anti-cancer treatments. This is 
further explored in Chapter One of this thesis under the subtitle, “The contradiction: host 
immunity, dysregulation and cancer”. Briefly, in oncology, immune processes become 
compromised in a myriad of contexts and can be considered somewhat paradoxical. For 
example, whilst endogenous immune processes aim to eliminate malignant cells, within the 
malignancy, similar immune processes are initiated which encourage cancer establishment 
and progression [66, 67]. Accordingly, inflammation is now considered one the hallmarks 
of cancer establishment and progression [68]. A strong association exists between chronic 
inflammatory responses and cancer, for example IBD is strongly associated with the 
development of colon cancer [69]. Additionally, allergy (immune dysregulation) has been 
linked to an increased risk for developing certain cancer types [70, 71]. Infectious 
organisms (e.g. lipopolysaccharide (LPS); a cell wall component of gram negative 
bacteria) and exogenous pro-inflammatory cytokine administration triggers inflammatory 
responses, activating innate immune pattern recognition receptors (PRRs), such as TLRs 
which recognise pathogen associated molecular patterns (PAMPs) [72]. The interaction 
between PAMPs and PRRs initiates inflammatory responses which can become 
dysregulated and lead to chronic inflammation, having beneficial effects on tumour 
development [73]. In particular, TLR-4 signalling enhances tumour development yet, is 
capable of initiating the production of cytokines, such as tumour necrosis factor-alpha 
(TNF-α), which can have an anti-tumour effect [74, 75]. Tumour cells also express TLRs 
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and specific ligands, such as TLR-1, -7 and -9, which stimulate tumour growth and protect 
tumour cells from apoptosis [76]. 
Immune dysregulation is further complicated upon commencement of anti-cancer 
treatment. Most chemotherapy drugs, regardless of the mechanism of action, elevate 
circulating pro-inflammatory cytokines and have been linked to chemotherapy-induced 
side-effects, such as pain, fatigue and cognitive impairment [77, 78]. In addition, localised 
inflammatory responses induced by chemotherapy drugs, result in gut toxicity and further 
increased expression of pro-inflammatory cytokines in the circulatory system. From this, 
and evidence confirming the role of pro-inflammatory cytokines in cytokine-induced 
sickness responses (briefly discussed in the following section and in more detail 
throughout this thesis), the complexities surrounding the aetiology of chemotherapy-
induced gut and cognitive impairment may be related to the symptom clusters experienced 
by cancer patients. Although a cytokine-based neuroimmunological mechanism has been 
proposed to contribute to cancer and anti-cancer treatment-related symptom clusters, little 
research has been undertaken in this area [62]. Accordingly, these concepts formed the 
basis of the hypotheses outlined in this thesis.  
Chemotherapy-Induced Symptom Clusters 
Chemotherapy treatment comes with a cost as recipients often experience a cluster of 
symptom side-effects. Chemotherapy recipients may report acute and delayed side-effects 
which include gastrointestinal disturbances, learning and memory difficulties, fatigue, and 
depression [79]. The cytotoxic and non-selective nature of chemotherapy drugs results in 
them targeting non-malignant and healthy rapidly dividing cells. The GIT constantly 
replenishes its cells, having a high regenerative capacity. In the CNS, cellular (neuronal 
and glial) death is a natural part of the aging process and accordingly, like the GIT, the 
CNS must replenish these cells. This primarily occurs in the hippocampal region, 
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specifically the dentate gyrus. It is for this reason that the two organs most susceptible to 
chemotherapy-induced toxicity are the GIT and the CNS.  
Interestingly, chemotherapy-induced symptom clusters mimic cytokine-induced sickness 
responses; a coordinated set of behavioural adaptations which develop in unwell 
individuals during the course of an infection [80]. During infection, the behavioural 
repertoire of individuals changes dramatically as they express little motivation to 
achieve/perform normal daily functions which include eating and drinking, socialising, and 
they are often fatigued and have trouble sleeping [81]. The individual may also experience 
increased sensitivity to pain, trouble concentrating, and are unable to experience pleasure. 
This state has been replicated experimentally in laboratory animals following both central 
and peripheral administration of LPS or recombinant pro-inflammatory cytokines, such as 
interleukin-1 beta (IL-1β) [80-82]. Whilst the sickness response produces negative 
symptoms for the individual, this innate central motivational state actually promotes 
recovery and is mediated by pro-inflammatory cytokines, such as IL-1β, acting directly or 
indirectly in the brain [81, 82]. Whilst the altered immune profile of cancer patients has 
been attributed to cancer progression and some treatment-induced symptom toxicities, the 
role of the neuroimmune system and glial dysregulation in cancer and treatment-induced 
toxicities in the gut and the brain remain elusive.  
Chemotherapy-Induced Toxicities: From the Bottom Up 
Briefly, From the Bottom Up, Sonis (the ‘godfather’ of mucositis) [1] characterised 
chemotherapy-induced mucositis by inflammation, ulceration, mucosal damage and 
malabsorption. Mucositis was defined into four phases including the Initiation Phase, the 
Signalling Phase, the Ulceration Phase and the Recovery Phase [1]. Mucositis may occur 
anywhere along the alimentary tract and usually resolves post treatment cessation. During 
the Ulceration Phase, mucosal integrity is compromised and the clinical symptoms may 
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include diarrhoea, constipation, significant pain, abdominal bloating, nausea and vomiting. 
Although Sonis provided a solid basis for the characterisation of mucositis, research 
groups have more recently reported additional mechanisms directly contributing to gut 
toxicity caused by chemotherapy treatment and accordingly renamed the disorder, CIGT. 
Some mechanisms are discussed further in this thesis within Chapter Two, ‘From the 
Bottom Up: chemotherapy and gut-brain axis dysregulation’ but involve alterations in 
intestinal permeability and microbiome implications. 
Although doctors initially ignored cognitive complaints from chemotherapy recipients, it 
soon became evident that many chemotherapy drugs readily crossed the blood brain barrier 
(BBB). Breast cancer patients called their difficulties with learning and memory, 
‘chemobrain’, yet later this was clinically referred to as CICI [83]. The cognitive deficits 
reported by chemotherapy recipients are typically subtle but in severe cases lead to 
employment issues and relationship breakdowns [57, 58]. The main cognitive domains 
affected in CICI include working memory, executive function and processing speed [57, 
84, 85]. Studying cognitive decline in chemotherapy recipients presents researchers with 
an array of methodological challenges. For example, subjective versus objective findings, 
cognitive reserve, education and other external factors have the potential to influence an 
individual’s susceptibility to CICI. Consequently, investigations utilising rodent models 
have been critical in developing our understanding of mechanisms specifically resulting 
from chemotherapy exposure, in the absence of malignant cells and removing other 
potential individual confounds.  
Systematic rodent studies confirmed that single doses of various chemotherapy drugs with 
different mechanisms of action were having negative behavioural effects, directly related 
to learning and memory deficits [86-88]. Furthermore, the findings from these 
experimental models suggested that the behavioural and memory deficits were 
General introduction 
35 
hippocampal and PFC dependent. Hippocampal neurogenesis is one of the most commonly 
reported changes following systemic chemotherapy treatment [86, 87, 89]. Whilst it is 
widely accepted that neurogenesis in the hippocampus is involved in learning and memory 
processes [90], the precise role of neurogenesis is unclear and debated amongst the 
literature [91, 92]. From this it seems that other neurobiological processes, such as cellular 
apoptosis and neuronal death may contribute to the pathogenesis of CICI. Commonly used 
chemotherapy drugs, such as 5-Fluorouracil (5-FU; discussed below), methotrexate and 
cyclophosphamide have induced hippocampal changes and subsequent cognitive deficits in 
malignancy-absent rodent models [86, 87, 93].  
Mechanisms relating to the pathogenesis of CICI are complex, and the sheer existence of 
the phenomenon has been challenged by some groups in both pre-clinical and clinical 
studies [94, 95]. Nonetheless, a significant proportion of CICI patients report a reduced 
quality of life and continued cognitive changes for many years post chemotherapy 
cessation [96-98]. It is for this reason that I wanted to examine potential mechanisms 
contributing to CICI pathogenesis throughout this thesis. Moreover, studies examining 
either CIGT or CICI focus on single mechanisms relating specifically to each disorder. 
Although these disorders appear separate, it is plausible that inflammatory events in the gut 
may be contributing to central changes and this may be occurring by direct or indirect 
mechanisms. One of the most commonly utilised chemotherapy drugs for breast cancer and 
CRC is 5-FU, which may be used alone or in conjunction with other chemotherapy drugs. 
In addition to this, 5-FU is frequently observed throughout both the CIGT and CICI 
literature as it induces negative physiological changes from the Bottom Up. As a result of 
this, 5-FU was the chemotherapy drug examined in this thesis.  
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The Chemotherapy Drug, 5-FU 
5-FU has been used as a frontline chemotherapy drug improving the prognosis and survival
rate of cancer patients worldwide [99, 100]. This invaluable chemotherapy drug has 
successfully treated various cancer types, including breast [101] and CRC [102]. It formed 
part of a frontline breast cancer regime used with cyclophosphamide and methotrexate in 
the CMF (cyclophosphamide, methotrexate and 5-FU) regime [103]. 5-FU is an anti-
metabolite that misincorporates into RNA and results in DNA mutations, ultimately 
initiating apoptotic pathways and causing cellular death (Figure 2). 
5-FU utilises the same facilitated transport mechanisms as the nucleic acid, uracil, to enter
each cell and is converted into several active metabolites: fluorodeoxyuridine 
monophosphate (FdUMP), fluorodeoxyuridine triphosphate (FUTP) and fluorouridine 
triphosphate (FUTP) [104]. The metabolites of 5-FU disrupt RNA and DNA synthesis, by 
inhibiting the production of thymidylate synthase. The rate limiting enzyme in 5-FU 
metabolism is dihydropyrimidine dehydrogenase (DPD) which converts the metabolites of 
5-FU into dihydrofluorouracil [105]. 5-FU is mostly catabolised in the liver (80%) and the
activities of DPD in laboratory rats are within the same range as humans [106]. 
This widely utilised chemotherapy drug was chosen for studies in this thesis as it induces 
toxicities from the Bottom Up, in both the gut and the brain. GI dysfunction following 5-
FU administration often results in significant challenges surrounding the clinical 
application of this chemotherapeutic drug due to symptom severities and, at times, the need 
to prematurely cease treatment. GI symptoms associated with 5-FU treatment are derived 
from Sonis’ characterisation of mucositis and may include visceral pain, diarrhoea, 
constipation, nausea and vomiting [1].  
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Although mucositis symptoms were originally believed to resolve upon treatment 
cessation, recently long-term GI dysmotility has been reported to outlast the acute 
intestinal inflammatory response in mice treated with 5-FU [65]. Further studies revealed 
this delayed dysmotility to be in part mediated by 5-FU-induced ENS dysfunction, such as 
myenteric neuronal loss [107]. 5-FU induces intestinal dysfunction in various experimental 
models across a wide range of doses and combined treatment regimens [107, 108]. A 
single high-dose of 5-FU induces a significant reduction in bodyweight, shortened 
intestinal villi and crypt depths and an acute intestinal inflammatory response, as routinely 
Figure 2. The mechanism of action of 5-FU. 5-FU enters the cell mimicking uracil where it is metabolised into FUTP, 
FUMP and FdUMP. The 5-FU metabolites inhibit the synthesis of thymidylate synthase and misincorporate into RNA 
and DNA. Misincorporation of 5-FU metabolises into RNA and DNA cause mutations, strand breaks and ultimately 
induces apoptotic pathways, leading to cell death (Figure from Longley, et al., 2003). Fluorodeoxyuridine 
monophosphate;  FdUMP, fluorodeoxyuridine triphosphate; FUTP, fluorouridine triphosphate; FUTP,
dihydropyrimidine dehydrogenase; DPD, dihydrofluorouracil; DHFU.   
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shown by increased myeloperoxidase (MPO) expression [108-110]. MPO is an enzyme 
expressed by neutrophils and elevated expression indicates neutrophil infiltration and thus, 
acute inflammation [111]. MPO has been routinely used as an indicator of acute intestinal 
inflammation and was thus used in the acute studies in this thesis.  
In the CNS, 5-FU rapidly penetrates the brain and cerebrospinal fluid, crossing the BBB 
via simple diffusion [112]. Many breast cancer patients report significant problems with 
concentration and memory, which have negative effects in many facets of their lives [83, 
113]. Neuropsychological testing has confirmed that a certain subset of breast cancer 
patients on the CMF regime showed cognitive impairment in attention, mental flexibility, 
speed of information processing, visual memory and motor function [114]. Experimental 
models have supported these findings, reporting that 5-FU alone and when used in 
combination with other chemotherapy drugs negatively affects spatial working memory 
and executive function [115, 116]. These cognitive changes were linked to 5-FU-induced 
alterations in neurotrophin levels and neurogenesis in the hippocampus of rats, as 
identified by reduced cellular proliferation in the dentate gyrus of 5-FU treated animals. In
vitro and in vivo evidence has linked systemic 5-FU treatment to a syndrome of delayed 
myelin destruction which importantly highlights that 5-FU also targets non-dividing cells 
within the CNS [115]. This study reported increased apoptosis and prolonged cell 
proliferation in the sub-ventricular zone, dentate gyrus and corpus callosum of the 
hippocampus for up to six months post short-term systemic administration of 5-FU in 
mice. Neuronal and oligodendrocyte precursors (another glial cell type) were particularly 
susceptible to 5-FU toxicity and these findings confirm imaging studies of the prevalence 
of white matter tract pathologies developing from systemic chemotherapy administration 
[61, 117]. Taken together, the above evidence indicates mechanisms by which 5-FU 
induces toxicity to the gut and the brain and consequently justifies further examination of 
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the neuroimmunological manifestations of this drug. As proposed, current investigations 
into the mechanisms contributing to CICI may be critically missing the direct and indirect 
influence of other simultaneously occurring treatment-induced side-effects, such as gut 
toxicity. Further, it is highly likely that in many of the CICI studies presented above, a 
significant proportion of those laboratory animals would have been experiencing CIGT, 
though this region was not examined. The neuroimmune interface will now be presented as 
a potential mechanism contributing to the central comorbidities associated with gut 
inflammatory conditions, such as in the case of chronic UC, CRC and CIGT. 
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Tying it All Together: the Neuroimmune Interface 
Multiple lines of evidence have demonstrated that bidirectional communication occurs 
between neurons and glial cells [118-122]. This is now widely accepted as the 
neuroimmune interface [123]. Whilst oligodendrocytes are responsible for myelination, 
microglia and astrocytes are the focus of this thesis and are largely considered the immune-
like cells of the CNS. They play a pivotal role in brain development, function and plasticity 
in both health and various neurodegenerative disease states [121, 122]. Microglia and 
astrocytes are discussed further in Chapter Two of this thesis, in ‘“Little brain” to “big 
brain” inflammation and signalling pathways’. Briefly, when primed from either direct 
(central; e.g. traumatic brain injury) or indirect (peripheral; e.g. bone cancer) insults, 
microglia and astrocytes change their morphology and functional output from a quiescent 
resting state into a ramified state [124]. Reactive glial cells trigger a neuroinflammatory 
response, augmenting the production of pro-inflammatory cytokines, chemokines, 
mediators and prostaglandins all aimed at assisting the host in healing [125]. 
Unfortunately, these functional adaptations often become dysregulated and may persist 
after the initial trigger has resolved. Central to this matter is the synergistic nature of 
microglia and astrocytes activating one another; microglia release substances that activate 
astrocytes and vice versa [126]. 
My fascination with the neuroimmune system stems from the widely accepted mechanism 
by which peripheral inflammatory events induce glial cell reactivity and 
neuroinflammation, having the potential to influence brain functions and behavioural 
outcomes. In the spinal cord microglia and astrocytes become reactive in various models of 
peripheral inflammation, including bone cancer and in chemotherapy-induced peripheral 
neuropathies [127, 128]. In higher order brain regions, they contribute to the pathogenesis 
of central disorders, such as Alzheimer’s and Parkinson’s disease [124, 129-131]. Glial 
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reactivity and neuroinflammation dysregulates synaptic transmission via increased release 
of neuroexcitatory mediators, which are known to contribute to pathological pain states, 
such as allodynia (painful response from non-harmful stimuli), hyperalgesia (heightened 
sensitivity to pain) and in pain associated with CIGT and peripheral neuropathy [123, 132-
135]. The effects of glial dysregulation in the spinal cord and higher order brain regions 
continue to be heavily researched. 
Glial dysregulation has been shown to contribute to pathological pain states at various sites 
involved in pain pathways, including the spinal cord, dorsal root ganglia and peripheral 
nerves. Peripheral nerve injury results in spinal glial activation, which can then amplify 
pain signalling and induce central sensitisation [126, 136]. Considering the influence glial 
cells have on pain pathways, it is not surprising that they are also reactive to analgesics, 
specifically opioids. Chronic morphine administration activates glia and increases pro-
inflammatory cytokine expression in rodents [137, 138]. Further studies have revealed that 
opioid-induced glial activation compromises opioid efficacy as it contributes to opioid 
reward, dependence and withdrawal [139]. The anti-analgesic effects induced by opioids 
can be ameliorated by coadministration of glial attenuators, such as minocycline [140]. 
Opioids also exhibit actions in the GIT affecting motility and fluid secretion [141, 142]. 
The aforementioned studies confirm the complex nature of the background literature 
surrounding this thesis. In particular, these factors can complicate analgesic intervention in 
the oncology arena where pain and anti-cancer treatment toxicities already coexist. It is for 
this reason that the first research chapter of this thesis included the influence of three 
analgesics, including a NSAID, a partial opioid and an atypical opioid in exacerbating 
5IGT-induced glial dysregulation in the brain and spinal cord of rats.  
Few studies have examined the neuroimmunological manifestations of the gut 
inflammatory disorders described in this thesis, which is surprising considering the 
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bidirectional nature of the gut-brain axis and the sensitivity of glial cell to peripheral 
inflammatory events. Taken into consideration, we will now briefly review the proposed 
peripheral-to-central immune signalling pathways proposed to be responsible for the glial 
dysregulation observed in these models. 
Peripheral-to-Central Immune Signalling and Gut Inflammation 
Immune signals and mediators expressed by an inflamed gut are able to signal the brain via 
three main immune signalling pathways: neural, humoral and cellular routes (for an 
extensive review of all pathways, see [143]). For the purpose of this thesis, the neural and 
humoral pathways will only be outlined as they formed a significant element of the 
hypotheses. The neural route is considered the fastest passageway, largely characterised 
via the vagus nerve [144, 145]. Immune signals released from localised peripheral 
inflammation, such as macrophages and epithelial cells in CIGT, are detected by primary 
afferent neurons. This information is transduced into a neural message, which can be 
relayed to higher order brain regions. In the brain parenchyma, the neural message is re-
transduced into an immune message, which produces cytokines that act on nearby neurons 
and glia to evoke behavioural changes. Some of these behaviours can be related to 
cytokine-induced sickness responses, which also include cognitive deficits.  
The humoral route is considered a slower route of transmission which involves molecular 
intermediates at circumventricular organs (devoid of the BBB), such as the choroid plexus 
[144]. At these organ sites, pro-inflammatory cytokines from the periphery directly access 
the brain via a range of mechanisms involving active transport via cytokine-specific 
transport molecules on brain endothelium, endothelial cell activation and subsequent 
release of secondary messengers, such as prostaglandins. In turn, these secondary 
messengers may act on specific brain targets and induce behavioural changes. The concept 
of a direct vs indirect pathway is introduced here. This thesis proposes that pro-
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inflammatory cytokines released from macrophages and monocytes in CIGT will result in 
glial dysregulation in the spinal cord, which is indicative of the neural route being 
activated. In this sense, the indirect actions of the drug (e.g. the gut toxicity) will result in 
spinal cord changes. Whereas, glial dysregulation observed in higher order brain regions 
may be mediated by the humoral immune signalling pathway. It is proposed that systemic 
pro-inflammatory cytokines/mediators or the drug itself will directly cross the BBB via the 
humoral route and induced higher order brain adaptations.  
Concluding Remarks 
The general introduction highlighted the intimate and bidirectional communication 
pathways shared between the gut and the brain. Additionally, it identified that the central 
comorbidities associated across a range of gut inflammatory conditions, including those 
outside of the oncology area (chronic UC) and those within (malignancy-related; CRC and 
chemotherapy-related; CIGT) remains under-investigated. The increasing incidence of gut 
inflammatory disorders and subsequent central comorbidities is ample evidence to 
encourage continued research in this area. In saying so, current research focuses on 
specific mechanisms relating to either the GI or central disorders. Critically, this angle of 
research may be missing the potential influence that other side-effects may be having on 
each disorder. One research area that has not received much attention is the neuroimmune 
interface and, accordingly, this is proposed throughout this thesis. 
During inflammatory disorders of the gut, such as in the case of chronic UC, CRC and 
CIGT, the immune dialogue between the gut and the brain becomes significantly 
compromised, resulting in immune dysregulation. Peripheral cytokines from the gut 
inflammatory disorders described above, have the potential to access the brain via direct 
and indirect peripheral-to-central immune signalling pathways. It is proposed that in the 
chronic models both humoral and neural routes mediate glial dysregulation and 
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neuroinflammation, yet the acute models implicate only the neural pathway. In specific 
higher order brain regions, such as the hippocampus, it is anticipated that glial reactivity 
and neuroinflammation may contribute to the central comorbidities associated with such 
chronic gut inflammatory disorders. Both the higher order brain region and spinal cord 
ramifications warrant further investigation.  
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Chapter One provides an overview of chemotherapy-induced side-effects, focusing on 
CICI and CIGT. Briefly describing the complex immune dysregulation which occurs in 
chemotherapy recipients, this review introduces inflammation in the gut (“the little brain”) 
and the brain (“the big brain”) and presents pathways in which “little brain” inflammation 
results in “big brain” inflammation, neuroinflammation. It proposes that the neuroimmune 
system and glial cell dysregulation may be contributing to or exacerbating CICI via CIGT 
and presents peripheral-to-central immune signalling pathways as potential mechanisms. 
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Abstract 
Chemotherapy drugs reduce quality of life often causing acute and delayed central side-
effects, termed chemotherapy-induced cognitive impairment (CICI). Another dose-limiting 
chemotherapy-induced side-effect is oral and intestinal mucositis which results in 
significant gastrointestinal (GIT) damage and intestinal inflammation. Recent interest has 
been paid to neurological complications arising in patients with gut disorders, yet little 
attention has been paid to the role GIT damage plays in CICI. Our current understanding of 
neuronal adaptations and behavioural consequences resulting from immune system 
dysregulation has paved the way for investigation into the neuroimmunological 
manifestations associated with chemotherapy. In a clinical setting cancer patients 
experience a cluster of symptoms, similar to that manifested in cytokine-induced sickness 
responses. Accordingly, it is suggested that peripheral inflammatory events, such as 
chemotherapy-induced mucositis, may cause glial dysregulation and potentiate cognitive 
changes in CICI. Perhaps it is time to examine the cancer experience in a multidisciplinary 
manner, in order to encapsulate the direct and indirect mechanisms underlying treatment-
related side-effects. Specifically, understanding the neuroimmunological implications of 
chemotherapy-induced mucositis will provide further insight into the direct and indirect 
mechanisms underlying CICI pathogenesis. 
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Background 
Chemotherapy drugs have proven invaluable in treating many cancers and improved the 
outcome for millions of cancer patients worldwide. Whilst the ultimate goal of 
chemotherapy is to prevent malignant cells from metastasizing, chemotherapy drugs are 
generally non-specific as they also target healthy, non-malignant cells. Chemotherapy 
induces a range of acute and delayed side-effects. In the central nervous system (CNS) the 
phenomenon is clinically recognised as chemotherapy-induced cognitive impairment 
(CICI) [1]. Peripherally, chemotherapy drugs negatively affect the gastrointestinal tract 
(GIT) lining causing oral and/or intestinal mucositis. Although mucositis is an acute 
disorder which usually resolves upon treatment cessation, it is often a dose limiting side-
effect due to the painful nature of the disorder [2, 3]. Traditionally, these chemotherapy-
induced side-effects have been considered to be separate disorders. However, recent 
evidence suggests that bidirectional communication pathways connecting the GIT and 
CNS may be implicated in the pathogenesis of both disorders. These pathways regulate a 
myriad of physiological and immune functions in health and various disease states 
manifesting from the periphery or centrally [4]. 
Peripheral inflammatory events or immune insults trigger a characteristic cluster of 
behavioural, cognitive, and affective changes, which are commonly referred to as cytokine-
induced sickness responses [5, 6]. Interestingly, many symptoms associated with cytokine-
mediated sickness responses mimic the cognitive and behavioural changes commonly 
reported by chemotherapy recipients, including learning and memory dysfunction, fatigue 
and depression [7]. Cancer and chemotherapy exposure are associated with substantial 
immune dysregulation, involving inflammation [8], changes in cytokine levels [9] and 
mucositis which may be contributing to cognitive changes. Nonetheless, previous studies 
have failed to determine whether a link exists between these already established, yet 
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disparate side-effects of chemotherapy. This review proposes that neuroimmune 
mechanisms and glial dysregulation may contribute to CICI symptoms both directly and 
indirectly via a peripherally driven inflammatory event: chemotherapy-induced mucositis. 
As we unravel the complex aetiology of CICI, it soon becomes clear that the challenge in 
examining CICI lies within the cluster of symptoms cancer patients’ experience. In a 
clinical setting, cancer patients reporting cognitive dysfunction often concurrently 
experience depression, anxiety, sleep deprivation, fatigue and pain [10-13]. Accordingly, 
Lee et al. [14] proposed a biological basis for cancer (and cancer treatment) related 
symptom clusters; a cytokine-based neuroimmunological mechanism. This concept stems 
from well-established studies which indicate that cytokine-induced sickness behaviours 
can be evoked by exposing animals to either infectious, inflammatory or certain pro-
inflammatory cytokines [5, 6]. Additionally, various gut disorders have been associated 
with psychological and cognitive comorbidities (reviewed below). From this it can be 
concluded that direct and indirect mechanisms may be contributing to cognitive changes 
observed in the chemotherapy setting. Neuroimmunological approaches in managing 
cancer and treatment-related side-effects may pave the way for novel and effective 
therapeutic and preventative approaches, ultimately improving the quality of life of cancer 
patients and survivors worldwide. 
Gut Disorders and Cognition 
CNS dysfunction has been recognised as a prominent feature in functional gut disorders, 
including inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) [15, 16]. 
The idiopathic diseases comprising IBD include ulcerative colitis (UC) and Crohn’s 
disease (CD). UC usually involves the colon and ileum whereas CD mainly involves the 
rectum and colon. IBS, however, is currently viewed as being caused by dysregulation of 
the gut-brain axis. Whilst the symptomatology of both disorders includes pain, altered 
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bowel movements and a host of physical, emotional, psychological and cognitive 
responses, IBD is strongly associated with intestinal inflammation unlike IBS.  
The aetiology of functional gut disorders is complex and multifactorial, however it has 
been suggested and somewhat accepted that IBD and IBS may be triggered by 
psychological, environmental or physical stressors [17, 18]. Consequently, several 
pathophysiological factors negatively affecting the gut-brain axis are pivotal to the 
disorders and include stress, chronic pain and immune activation [19, 20]. Although a 
substantial body of literature exists linking stress, chronic pain and immune activation to 
cognitive deficits, this area in the context of functional gut disorders has received little 
attention. Nonetheless, primary studies assessing these pathological factors in this patient 
population have shown deficits in specific aspects of cognition, such as verbal IQ [21]. In 
CD, regional morphological differences in cortical and subcortical structures have been 
critically linked to abdominal pain [22].  
Psychopathological factors, such as depression and anxiety, are frequently observed to 
have effects in patients with functional gut disorders, and have been shown to play a role in 
cognitive deficits [23]. Approximately 70% of patients with functional gut disorders 
experience some psychological comorbidity [24]. It is unclear as to which disease develops 
first, however it is well accepted that stress and anxiety is associated with IBS/IBD. 
Regardless of this, the impact of functional gut disorders on psychological processes is 
undeniable as the stress associated with symptom progression severely affects patients’ 
quality of life. Taken into account, a biopsychosocial model has been proposed to 
clinically approach and conceptualise IBS pathophysiology [25]. This model encompasses 
a lifetime perspective from the patient’s childhood through to their adult life integrating 
genetic, environmental, learning, stress and traumatic events. Fundamentally, it takes into 
account the interaction of the mind and emotions, the brain, the enteric nervous system 
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(discussed later) and the intestinal microenvironment, including food, the immune system 
and microbiota. Literature demonstrates that functional gut disorders are strongly 
associated with a range of psychological comorbidities, specifically cognitive impairment; 
yet our understanding of the central consequences of other gut disorders, such as 
chemotherapy-related mucositis remains undetermined. Many chemotherapy drugs, such as 
oxaliplatin and 5-Fluororuacil (5-FU) are responsible for inducing both gut disorders and 
cognitive impairment, yet whether these comorbidities interact remains to be elucidated.  
Gut Disorders Caused by Chemotherapy: Mucositis 
The pathogenesis of mucositis was defined in five phases by Sonis [2]. Mucosal barrier 
injury may occur throughout the entire GIT and result in oral and/or intestinal mucositis. 
The rapidly dividing epithelial layer lining the GIT is particularly prone to tissue injury 
from different chemotherapy drugs including 5-FU, methotrexate and cyclophosphamide. 
Consequently, apoptotic pathways are initiated in healthy mucosal tissue causing reduced 
cellular proliferation in the small intestine. Some hallmark characteristics of intestinal 
mucositis include villus atrophy, shallow crypts, inflammation and ulceration. Mucositis 
results in a heightened inflammatory response via the up-regulation and activation of 
various transcription factors, ultimately resulting in elevated circulating pro-inflammatory 
cytokines, in particular interleukin-1 beta (IL-1β) and tumour necrosis factor-alpha (TNF-
α).  
The most significant phase of mucositis for patients is during the ulceration phase as this 
involves loss of mucosal integrity. Painful ulcerating lesions in the GIT become 
susceptible to microbial infiltration and in severe cases can lead to bacteraemia and sepsis 
[2]. The clinical symptoms of mucositis generally begin five to ten days after 
chemotherapy treatment and include significant pain, abdominal bloating, nausea and 
vomiting, diarrhoea and constipation [26]. Although mucositis is an acute phenomenon 
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which usually resolves once chemotherapy treatment has ceased, treatment may be 
prematurely ceased as a result of progressively worsening symptoms. Current guidelines 
for the prevention and management of mucositis fail to reveal effective treatment options 
[27]. Whilst mucositis pathogenesis is well understood, the indirect central effects of 
mucositis remain unknown. The complex neuroimmune axis has been suggested to be 
implicated in depression, a comorbidity of cancer diagnosis, and chemotherapy exposure 
[14]. Neurological manifestations from elevations in cytokine levels imply that 
neuroimmunological mechanisms underlying the pathogenesis of these chemotherapy-
induced side-effects may be at play.  
Cognitive Changes Following Chemotherapy Exposure 
Although reports of cognitive decline in chemotherapy patients pre-date the 1980’s, 
systematic research only commenced in the 1990’s. Patients collectively termed the 
cognitive disturbances ‘chemobrain’ or ‘chemofog’ which heavily impacted daily 
functioning and quality of life, yet initial complaints were dismissed by doctors and the 
scientific community [7]. Previously, it was assumed that the brain was protected from 
systemically administered chemotherapy drugs by the blood-brain barrier (BBB) and 
additionally, cognitive symptoms could be explained by the stress, anxiety and depression 
associated with cancer diagnosis. Extensive research in the recent years clearly indicate 
that many systemically administered chemotherapy drugs readily cross the BBB inducing 
structural, molecular and cellular changes that impact upon cognitive function [1]. 
Mechanisms underlying the pathogenesis of CICI remain to be elucidated although 
suggestions include hippocampal damage and immune dysregulation (discussed below). In 
order to better understand the suggested mechanisms, it is important to review the clinical 
evidence and understand the negative impact imposed upon patients.  
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Clinical Evidence of CICI 
The main cognitive domains affected by CICI are executive functioning, attention and 
concentration, processing speed, reaction time, motor speed and dexterity [1]. Whilst 
current estimates of CICI prevalence differ greatly (14-85%), the worldwide prediction of 
cancer incidence reaching 70 million in 2020 highlights the need for continued research 
[28]. Consequently, the estimate of high survivability rates for many cancers results in 
increased survivor numbers and in turn, we will see an increase in the incidence of post-
treatment issues [29]. Those affected by CICI experience stressors in many facets of their 
lives, including relationships (familial, friends and colleagues), employment, self-
esteem/worth and finances; leading to a reduced quality of life. CICI patients commonly 
expressed frustration in having difficulty with simple tasks, such as remembering names, 
misplacing everyday items and trouble finding common words [30, 31]. Emotions 
regularly described by CICI patients included distress, anxiety, frustration, irritability, 
depression and embarrassment [30, 32, 33]. Many summed up their feelings by describing 
as if they “felt stupid” or were “going crazy” and sometimes related their memory 
disturbances to the fear of being at risk for early dementia or Alzheimer’s disease [30, 34]. 
This evidence collectively supports the negative impact of CICI on patients and 
emphasises the increased amount of effort and time required to complete everyday tasks.  
Breast Cancer Cohorts and Duration of Cognitive Effects 
Whilst the majority of CICI studies focus on breast cancer populations, cognitive deficits 
in a range of cancer types have been investigated, including myeloma, testicular and 
ovarian cancer [35-37]. Nonetheless, breast cancer populations offer researchers 
completion of extensive retrospective studies due to their typically good prognosis, 
allowing for more thorough evaluations of parallel short- and long-term sequelae [38-40]. 
The duration of cognitive changes is of particular interest to patients and for this reason, 
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continues to be an area of much research. There is considerable variability surrounding the 
duration of chemotherapy-induced cognitive deficits or even existence of the phenomenon. 
Majority of the studies report improvement in cognitive symptoms after a period of time, 
yet some studies have indicated the presence of symptoms for ten-twenty years after 
treatment cessation [41-43]. Functional magnetic resonance imaging and 
neuropsychological testing was observed in a group of breast cancer survivors who had 
received adjuvant chemotherapy treatment and was compared with a breast cancer control 
group who were not treated with chemotherapy [42]. The chemotherapy group 
demonstrated hypo-responsiveness in executive functioning tasks performed 10 years post 
treatment, indicating significant long-term cognitive impairments when compared to the 
non-chemotherapy control group. 
Neuroimaging studies have identified structural and molecular changes associated with 
chemotherapy treatment. Reductions in specific brain regions, such as frontal cortex, 
temporal lobes and cerebellar grey matter regions have been reported in breast cancer 
patients [44]. These reductions were evident for twelve months post-chemotherapy 
cessation yet improvements were reported in most regions four years later. Global brain 
networks become re-organised under chemotherapy treatment and thus, indicate a reduced 
ability for information processing [45]. Additionally, chemotherapy-induced white matter 
tract alterations may be interpreted as demyelination or axonal damage [46].  
Animal Models of CICI 
Animal studies have confirmed that central structural and molecular changes may be 
accountable for the cognitive domains affected by common chemotherapy drugs. Several 
studies in rodents report declines in abilities to perform behavioural tasks following single 
drug administration of many chemotherapy drugs, including 5-FU, methotrexate and 
oxaliplatin [47-49]. Rodent behavioural tests have been adopted to understand the central 
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pathological changes following systemic chemotherapy exposure, such as fear 
conditioning, novel object recognition and the Morris Water maze. These behavioural 
adaptations may be interpreted as hippocampal and frontal cortex region alterations which 
importantly, overlap with the brain structures implicated in CICI [1].  
Specific CNS cell populations are sensitive to a range of chemotherapy drugs. One of the 
most widely reported central changes following chemotherapy exposure is reduced 
hippocampal cellular proliferation. This has been documented to occur with 
cyclophosphamide, methotrexate, thioTEPA and 5-FU [50-52]. These CICI animal models 
suggested that the hippocampal changes were associated with the hippocampal-dependent 
behavioural changes and memory deficits. Although cyclophosphamide most frequently 
reports cognitive changes and cellular alterations, negative findings on long-term 
hippocampal changes have also been reported [53]. Nonetheless, stem cells of the dentate 
gyrus are particularly susceptible to chemotherapy toxicity [54-56]. This is important to 
note as neurogenesis within the dentate gyrus is responsible for the proliferation and 
division of neural stem cells that form into new neurons or astrocytes, playing a pivotal 
role in hippocampal circuit plasticity and memory consolidation [57, 58]. Consistent with 
patient observations of leukoencephalopathies and white matter tract lesions, animal and in
vitro studies have shown that both mature oligodendrocytes and their precursors may be 
susceptible to the actions of chemotherapy drugs [1]. Whilst there is clear evidence that 
specific central cell populations are susceptible to reductions in cellular proliferation 
following chemotherapy exposure, some studies have reported no changes [59, 60]. This 
evidence reflects the complex aetiology of CICI, indicating various structural, molecular 
and cellular changes contributing to cognitive impairment following chemotherapy 
exposure. The aforementioned studies fail to take into account neuroimmune mechanisms 
that may be at play, whether directly or indirectly. Perhaps it is time to consider the impact 
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other chemotherapy-induced peripheral inflammatory events may be having on CICI, such 
as immune challenges in the context of malignant tissues, more specifically gut toxicities, 
such as mucositis.   
The Contradiction: Host Immunity, Dysregulation and Cancer 
The ultimate goal of the immune system is to protect and defend the host from infection 
and insults by recognising, repelling and eliminating pathogens and foreign molecules. 
Further, inflammation is an essential defensive response resulting in physiological 
processes critical in host healing. The toll that both malignancies and chemotherapy 
treatments have on the host is particularly enigmatic in the context of the immune system, 
whereby complex inflammatory processes contradict and manipulate responses; a dynamic 
network that primarily ensures protection against foreign pathogens whilst remaining 
tolerant of self-antigens. This somewhat contradictory phenomenon results in immune 
dysregulation which in turn, may result in central effects via the neuroimmune interface 
and signalling pathways.  
Inflammatory processes become dysregulated in cancer and anti-cancer treatments. On one 
hand, endogenous immune processes and inflammatory cascades attempt to eliminate 
malignant cells from the host. Yet, simultaneously within malignant cells, similar pathways 
are initiated and inflammatory signalling molecules contribute to cancer establishment and 
progression. Several lines of evidence have suggested inflammatory processes are the 
seventh hallmark for cancer establishment and progression [8, 61, 62]. To further 
complicate matters, chemotherapy treatments are associated with increased circulating 
inflammatory markers, yet suppression of immune activity is commonly reported 
(discussed below). It is well established that immune dysregulation occurs in several 
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disorders negatively affecting the CNS and in some cases, the gut. To illustrate this point, a 
few disorders, such as neuropathic pain will now be further discussed.  
Immune Dysregulation in Animal Models 
Several convergent lines of experimental and clinical evidence have supported the 
hypothesis, that pro-inflammatory cytokines are pivotal in the pathophysiology of not only, 
cancer-related and anti-cancer treatment-induced symptoms, but other disorders, including 
chronic fatigue syndrome, neuropathic pain and major depression. Elevated circulating 
pro-inflammatory cytokines, such as IL-1 and TNF-α have been reported in clinical studies 
examining chronic fatigue syndrome, major depression and various pain states [63, 64]. IL-
1 action is regulated by a complex network of molecules and is a potent stimulus of 
corticotrophin-releasing hormone, activating the hypothalamic-pituitary-adrenal axis, an 
important stress hormone which has been well documented in major depression [63]. 
Additionally, TNF-α is widely recognised as an important factor in the mediation of major 
depression, chronic fatigue syndrome and neuropathic pain [63-65]. Rodent models have 
reported that intraperitoneal administration of TNF-α resulted in a dose dependent pain 
responsivity, indicative of hyperalgesia (heightened sensitivity to pain) [66]. The 
hippocampus is associated with pain perception and cognition [67] and accordingly, a rat 
model of chronic constriction injury of the sciatic nerve reported increased hippocampal 
TNF-α levels [65]. These studies indeed demonstrate a pivotal role for the aforementioned 
pro-inflammatory cytokines in the pathogenesis of a range of disorders and disease states. 
It should be noted that the disorders mentioned in this section also often occur 
simultaneously in cancer patients undergoing chemotherapy treatment.  
Immune Dysregulation in Cancer and Chemotherapy 
There is growing consensus on two recognised interactions between cancer and the 
immune system. Firstly, host immunity has the ability to recognise and reject malignant 
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cells and immuno-surveillance can prevent tumour development and control recurrence. 
Consequently, activation of the innate immune system leads to the production of highly 
immuno-stimulatory cytokines, systemic inflammation and T- and B-cell activation, with 
the goal of eliminating malignant cells. Secondly, many inflammatory mediators and cells 
involved in detecting and eliminating malignancies also play a key role in the migration, 
invasion and metastasis of malignant cells, thus promoting tumour expansion [68, 69]. This 
double-edged sword results in a plethora of intertwined and complex interactions, in which 
the immune system recognises and tries to reject tumour formations, whilst inflammatory 
processes simultaneously enable tumour progression and development.  
Additionally, chemotherapy drugs also induce inflammatory responses which may be 
either local, around the site of administration or systemic in nature resulting in mucositis. 
Several chemotherapy drugs including 5-FU (anti-metabolite), etoposide (topoisomerase II 
inhibitor) and doxorubicin (anthracycline) elevate pro-inflammatory cytokine production in
vitro [70]. Importantly, this demonstrates that most cytotoxic anti-cancer drugs, regardless 
of their mechanism of action, increase circulating cytokines. Such findings have been 
translated into clinical studies linking circulating pro-inflammatory cytokine elevations 
with common chemotherapy-induced side-effects, such as fatigue, depression, pain and 
cognitive impairment [71, 72]. Extensive studies revealed the importance of elevated 
circulating pro-inflammatory cytokines in sickness responses which often result in 
cognitive changes and interestingly, mimic CICI reports. Finding therapeutic approaches 
that target the immune system has the potential to improve multiple chemotherapy-related 
side-effects which all have an immune component to their aetiology.   
The intimate bidirectional relationship shared between the CNS and the GIT presents as a 
potential mechanism that may contribute to CICI symptom severities. As such, it is 
plausible that chemotherapy-induced peripheral inflammatory events, such as mucositis, 
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may trigger central cell population changes. Peripheral-to-central changes occurring via 
neuroimmunological pathways may result in behavioural (cognitive) changes, similar to 
those apparent in cytokine-induced sickness responses [5, 73, 74]. Although a cytokine-
based neuroimmunological mechanism of cancer-related symptoms has been suggested 
[14], CICI researchers are yet to examine the indirect central effects of chemotherapy-
induced peripheral inflammatory events, such as mucositis. 
“Little Brain” to “Big Brain” Inflammation and Signalling Pathways 
The ability of the enteric nervous system (ENS) to self-regulate (hence “little brain”) and 
act similarly to the CNS (“big brain”) makes it the largest and most complex division of 
the peripheral nervous system [75]. Previous literature has suggested that the GIT is a 
vulnerable passageway through which pathogens may influence the CNS and lead to 
abnormalities, for example, neuroinflammation contributing to autism [76] and multiple 
sclerosis [77]. A well-established link exists between various neurodegenerative diseases 
and the role neuroinflammation plays in their pathogenesis [78, 79]. However, few studies 
have examined the influence of peripheral-to-central immune signalling and 
neuroinflammation in the context of chemotherapy-induced mucositis and CICI. 
Inflammation in the “Little Brain”: ENS Inflammation 
The ENS contains more than 400-600 million neurons [80] and an extensive network of 
enteric glial cells (EGC). Although EGCs support enteric neurons, the precise mechanisms 
by which EGCs support enteric neurons remains to be fully elucidated. EGCs share 
similarities with their CNS counterparts, astrocytes in morphological, functional and even 
molecular capabilities [81]. As well as exerting protective functions, EGCs are key players 
of the ENS during intestinal inflammation and immune responses. Their intimate 
relationship with enteric neurons and their responsiveness to local inflammation makes 
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them a prime target for therapeutic intervention as has been investigated in the CNS with 
targeting glial cells.  
From our understanding of the intimate bidirectional relationship shared between the GIT 
and the CNS, it is not surprising that a diverse range of neurodegenerative diseases arise 
from systemic infections and inflammation, such as multiple sclerosis and Alzheimer’s 
disease [76, 82]. We have all experienced the change in mood, emotion and cognition 
when one is faced with systemic infection, a cold or influenza. Numerous reports indicate 
that this immune response is driven by a dialogue between the peripheral systemic 
infection and our brain [73]. The gastrointestinal immune system is considered the primary 
immune organ of the body as it induces and maintains peripheral immune tolerance. This is 
achieved via complex cellular networks with specialised immuno-regulatory functions, 
including interactions between the microbiota and host. Impaired host immune defences 
and mutations in pattern recognition receptors leads to GIT dysfunction and enables 
invasion of pathogens [83]. The downstream effect of such events results in chronic GIT 
inflammation and/or a loss of control of local immune responses resulting in an unbalanced 
enteric microbiota having substantial implications in the pathogenesis of rheumatoid 
arthritis, IBD and asthma [84-86]. From this evidence it is clear that GIT inflammatory 
events may modify central processes controlling behaviour and aligns with our central 
hypothesis that chemotherapy-induced mucositis may result in central changes via 
neuroimmune mechanisms involving glia, discussed in more detail below.  
Glia; the “Other Brain” 
Glial cells are critical in brain development, function and plasticity in both health and 
disease and fall into three cell types; astrocytes, microglia and oligodendrocytes. Neurons, 
astrocytes and oligodendrocytes arise from neural progenitor cells whilst microglial cells 
originate from peripheral macrophage cell lines [87]. Glia perform a host of regulatory 
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functions within the CNS, from supporting neurons and regulating synaptic 
neurotransmission, to maintaining calcium homeostasis and clearing intracellular ions and 
neurotransmitters [88]. A bidirectional communication occurs between neurons and glia 
(astrocytes and microglia) which is now widely accepted as the neuroimmune interface; the 
tripartite (pre- and post-synapse and astrocyte relationship) and tetrapartite (pre- and post-
synapse, astrocyte and microglia relationship) synapses describes these complex 
intertwined relationships in health and disease [89, 90].  
Glia play a vital role in various aspects of brain function. The ambiguities of glial cells in 
health go far beyond our current understanding and deserve much more attention. An area 
of particular interest is the mechanism by which these central immune cells are involved in 
the pathogenesis of CNS disease states. Several researchers have gained valuable insight to 
this question and begun to unravel the mechanisms by which glia contribute to the 
pathogenesis of neurological and neurodegenerative diseases, such as Alzheimer’s disease, 
neuropathic pain, ischaemia and migraine. The common thread linking these diseases is 
glial priming and subsequent neuroinflammation.  
“Big Brain” Inflammation 
Microglia and astrocytes may become reactive or primed either from direct-central insults 
or indirect-peripheral inflammatory events triggering neuroinflammatory responses. 
Microglia are highly sensitive to insults so are the first to react, unlike astrocytes which 
respond more slowly and in a more controlled manner [88]. In their reactive states, both 
glial cell types undergo morphological changes, augmenting a cascade of detrimental 
functional outcomes leading to tissue damage and neuronal death [91]. In particular, 
reactive glia overproduce prostaglandins, pro-inflammatory cytokines, chemokines, 
mediators and reactive oxygen and nitrogen species, having detrimental effects on neuronal 
function and survival via oxidative stress [92]. Primed glial cells reduce output of anti-
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inflammatory molecules, decrease neurotrophic support, dysregulate calcium, glutamate 
and brain derived neurotrophic factor, resulting in excitotoxicity and neuroinflammation 
[93]. Interestingly, both cell types may remain in a primed state whereby they continue to 
be sensitised after the initial stimulus has resolved. Although primed glial cells appear 
active due to their morphological form, they do not overproduce inflammatory mediators 
until challenged, whereby they react quickly and elicit an exaggerated immune response 
[94]. In particular brain regions this may influence behaviours involving cognition [89, 
95].  
Glia modulate neurotransmission and cause neuronal injury via various mechanisms 
including a reduced ability to produce neurotrophic support, excitotoxic glutamate-receptor 
mediated damage and oxidative stress [96]. Glutamate is the primary excitatory 
neurotransmitter instrumental in neuronal plasticity and thus, key in learning and memory 
consolidation [97]. The glutamate transporters GLAST and GLT-1 are localised on 
astrocyte membranes [98]. Reactive astrocytes undergo reduced expression of glutamate 
transporters and lose their ability to re-uptake glutamate, yet continue to release glutamate 
into the synapse [99, 100]. Additionally, reactive astrocytes inhibit production of glutamine 
synthetase, an enzyme that converts extracellular glutamate to glutamine, vital in 
neuroprotection [101]. From this, it is not difficult to see that a significant feature of many 
neurodegenerative disorders is reactive or primed glia, and subsequent neuroinflammation. 
In the context of chemotherapy exposure, inflammation (central or peripheral) occurring 
via either direct or indirect mechanisms may trigger glial dysregulation and neuronal 
consequences, impacting negatively on cognition.  
The host immune system utilises innate immune signalling to recognise microorganisms, 
detected by molecular structures shared by a large number of pathogens; exogenous 
microbe-associated molecular patterns (MAMPs) and endogenous molecules (danger-
Chapter One. Chemotherapy, mucositis, glia and cognition 
66 
associated molecular patterns; DAMPs). Toll-like receptors (TLRs) represent a class of 
innate immune receptors belonging to the IL-1/TLR superfamily and act as pattern 
recognition receptors capable of responding to MAMPs, DAMPs and more recently, 
xenobiotics (XAMPs) [102]. XAMPs represent foreign chemicals that include alcohol, 
methamphetamine and cocaine [103]. The mechanism by which XAMPs modify glial 
expression levels and morphology via TLRs may then present as a plausible mechanism 
contributing to CICI.  
Although reactive glia might start as a beneficial process responding to an insult (disease, 
trauma, infection or drug exposure), it may, depending on the nature, duration and intensity 
of the insult, turn to a detrimental neuroinflammatory state. Defining neuroinflammation is 
by no means a simple task; however, it is generally accepted to include microglial and 
astrocyte reactivity and increased expression of pro-inflammatory cytokines and 
chemokines [104]. Chronic neuroinflammatory states are known to contribute to neuronal 
loss and central homeostatic disturbances. It is widely accepted that systemic inflammation 
influences brain function and behaviours. The last two decades have revealed the pivotal 
roles microglia, astrocytes and neuroinflammation play in various neurodegenerative 
diseases. In addition to neurodegenerative diseases and central injuries, neuroinflammation 
has also been implicated in neuropathic pain, schizophrenia, epilepsy and perhaps most 
recently, cancer and cognitive decline following chemotherapy exposure [105-109]. Of 
particular interest to this review, is the potential for chemotherapy drugs to influence glial 
cell populations in both the brain and the spinal cord, having implications in cognition and 
pain pathways. Various chemotherapy drugs appear to be causing a generalised glial 
response which is not limited to specific drug classes [108-110]. These studies primarily 
focussed on the direct-central effects of chemotherapy exposure, not accounting for the 
potential of GIT damage to indirectly exacerbate central changes via neuroimmune 
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pathways. Peripheral-to-central immune signalling pathways offer a potential way in which 
peripheral inflammatory events, such as mucositis may be implicated in CICI.  
“Little Brain” to “Big Brain” Signalling 
Histories of abuse, life stressors and other psychological factors have been shown to play 
an important role in the onset of various functional bowel disorders [111, 112]. As 
information is relayed in a bidirectional manner between the gut and the brain, it makes 
sense that the CNS may be modified by gut dysregulation. Information from the “little
brain” to the “big brain” may be relayed via afferent neurons connecting the gut to the 
CNS. Pathways responsible for the transmission of various endocrine, neuronal, paracrine 
and humoral signals are vagal, humoral or neural. The vagus nerve provides a cytokine 
responsive neural pathway indirectly triggering the brain via afferent vagal input or leaky 
circumventricular organs [113].  
Peripheral immune messages, such as focally produced pro-inflammatory cytokines may 
travel indirectly to the CNS via neural signalling pathways, including but not exclusive to 
the vagus nerve [74]. Information detected by primary afferent neurons is transduced into a 
neural message which is then relayed to higher order brain regions. In the brain 
parenchyma this message is then re-transduced back into an immune message where 
locally produced cytokines alter brain function by acting either directly or indirectly on 
neurons or glia. In specific brain regions, this may result in behavioural adaptations, 
involving cognition and mood. Alternatively, the slower and more direct humoral pathway 
occurring at leaky circumventricular organs involves molecular intermediates, such as 
prostaglandins. Local inflammation activates peripheral tissue macrophages to increase 
release of pro-inflammatory cytokines, such as IL-1β and TNF-α. Consequently, 
macrophages and endothelial cells release chemokines and adhesion molecules that attract 
leukocytes [74]. As well as their essential roles in peripheral inflammation, circulating IL-
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1β and TNF-α are also key initiators of neuroinflammation. From this knowledge, we 
present these immune-to-brain signalling pathways as potential mechanisms by which 
chemotherapy-induced intestinal inflammation may directly and indirectly lead to 
neuroinflammation and glial dysregulation. Pro-inflammatory cytokines and mediators 
expressed during the pathogenesis of chemotherapy-induced mucositis may access the 
CNS via leaky circumventricular organs, resulting in a neuroinflammatory response.  
What the Future Holds 
In the year 2020 it is estimated that 70 million cancer survivors will be disease free [7, 28]. 
Nonetheless, a substantial proportion of survivors will have experienced either acute or 
delayed cognitive deficits during or post treatment cessation. Therefore, it is of paramount 
importance to consider the direct and indirect mechanisms underlying CICI to develop new 
strategies and treatments that will improve the quality of life of cancer survivors. To date, 
CICI animal models have failed to consider the impact of peripheral inflammatory 
responses on cognitive deficits. In fact, in most CICI animal studies, it is almost 
unquestionable that mucositis tissue damage would have certainly been present, yet these 
organs were not analysed. This limited angle of analysis may be missing incidental, yet 
crucial mechanisms in the aetiology of CICI. Irrespective of this, we acknowledge the 
many challenges faced by researchers undertaking CICI studies and teasing apart both the 
direct and indirect mechanisms presents with its own myriad of complications. Perhaps 
now is the time to examine chemotherapy-induced side-effects which more accurately 
reflect a clinical setting; elucidating how multiple chemotherapy side-effects work in 
unison.  
One might argue that in general, the two major areas of the human body which become 
dysregulated following chemotherapy exposure are the gut and CNS; the “little” and “big” 
brains. The above sections clearly illustrate the recent substantial increase in literature 
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implying that brain function is somewhat dependent upon gut function and vice versa. 
Many questions still remain and research should continue to clarify how the neuroimmune 
interface and signalling pathways may be implicated in CICI. The literature reviewed 
presents our theory that chemotherapy-induced intestinal inflammation may drive glial 
dysregulation via direct and indirect neuroimmune signalling pathways which may 
ultimately, potentiate cognitive impairment. Harnessing our understanding of these 
mechanisms and outlining ways in which the gut can modulate brain function and 
behaviours via neuroimmune signalling pathways may guide us to novel treatment 
approaches that encapsulate more targeted therapies aimed at treating multiple side-effects 
of chemotherapy treatment.   
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From the Bottom Up: Chemotherapy and Gut-Brain 
Axis Dysregulation 
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Chapter two provides an overview of chemotherapy-induced side-effects from the Bottom 
Up (the GIT to the CNS), briefly describing CIGT and CICI and presents several stages of 
the gut-brain axis which become dysregulated under these conditions. It highlights the 
influence of functional gut disorders (such as IBD and IBS) in the development of central 
comorbidities and links this to CIGT and CICI. It provides a brief overview of 
communication pathways making up the gut-brain axis with a focus on humoral and neural 
mechanisms. Critically, this chapter emphasises the complex nature of gut-brain axis 
dysregulation in the chemotherapy setting. It also examines the pivotal and interchangeable 
role the microbiota plays in intestinal permeability and vice versa, as well as identifying 
mechanisms relating to peripheral nerve and ENS dysfunction.  
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Abstract 
The central nervous system (CNS) and gastrointestinal tract (GIT) form the primary targets 
of chemotherapy-induced toxicities. Symptoms associated with damage to these regions 
have been clinically termed chemotherapy-induced cognitive impairment (CICI) and 
mucositis. Whilst extensive literature outlines the complex aetiology of each pathology, to 
date neither chemotherapy-induced side-effect has considered the potential impact of one 
on the pathogenesis of the other disorder. This is surprising considering the close 
bidirectional relationship shared between each organ; the gut-brain axis. There are complex 
multiple pathways linking the gut to the brain and vice versa in both normal physiological 
function and disease. For instance, psychological and social factors influence motility and 
digestive function, symptom perception, and behaviours associated with illness and 
pathological outcomes. On the other hand, visceral pain affects central nociception 
pathways, mood and behaviour. Recent interest highlights the influence of functional gut 
disorders, such as inflammatory bowel diseases and irritable bowel syndrome in the 
development of central comorbidities. Gut-brain axis dysfunction and microbiota changes 
have served as key portals in understanding the potential mechanisms associated with these 
functional gut disorders and their effects on cognition. In this review we will present the 
role gut-brain axis dysregulation plays in the chemotherapy setting, highlighting 
peripheral-to-central immune signalling mechanisms and their contribution to 
neuroimmunological changes associated with chemotherapy exposure. Here, we 
hypothesise that dysregulation of the gut-brain axis plays a major role in the intestinal, 
psychological and neurological complications following chemotherapy. We pay particular 
attention to evidence surrounding microbiota dysbiosis, the role of intestinal permeability, 
damage to nerves of the enteric and peripheral nervous systems and vagal and humoral 
mediated changes.
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Background 
The chemotherapy experience is associated with powerful psychological, neurological and 
somatic side-effects. Cancer diagnosis and the complications arising from treatment induce 
anxiety and depression, fatigue, pain, and cognitive impairments while patients struggle to 
maintain hope for recovery and continue normal daily functions, routines and roles [57, 
146, 147]. Due to the non-selective and systemic nature of most chemotherapy drugs, they 
also target healthy, rapidly-dividing non-malignant cells. The regions of the body most 
susceptible to the unwanted toxicities of chemotherapy exposure are the gastrointestinal 
tract (GIT) and the central nervous system (CNS) – the gut and brain. Many chemotherapy 
drugs are small enough to readily cross the blood-brain barrier (BBB) and result in 
molecular, structural and functional changes within the CNS, manifesting as cognitive 
changes in a subset of patients [148]. Outside of the CNS, the cells of the GIT are 
particularly vulnerable to damage following chemotherapy exposure. In particular, 
epithelial cells within the mucosal layer lining the alimentary tract form prime targets due 
to chemotherapy drugs targeting proliferating enterocytes [1]. Although the gut and the 
brain appear disparate, they are intimately connected. The complex network of pathways 
linking the gut to the brain will be discussed in more detail below as we present 
mechanisms by which chemotherapy results in gut-brain axis dysregulation.  
This network has a bidirectional relationship. For instance, psychological and social factors 
have the ability to influence motility and digestive function, symptom perception, 
behaviours associated with illness and the pathological outcome [149]. On the other hand, 
visceral pain affects central pain perception and pathways, mood and behaviour [150]. 
Importantly, systemic and gut immunity is tightly regulated by the inflammatory reflex and 
cholinergic anti-inflammatory pathway [151, 152]. Integral components of the 
inflammatory reflex include innate immune cell activation, release of inflammatory 
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mediators, such as cytokines, vagal innervation and responses from higher order brain 
regions, such as the nucleus tractus solitarius. Vagal innervation is of particular importance 
in the chemotherapy setting as it is pivotal in the transmission of chemo and 
mechanosensory information from the gut to the brain (Figure 2.1) [145, 151]. In this 
sense, pro-inflammatory mediators and cytokines, such as interleukin-1 beta (IL-1β) and 
tumour necrosis factor-alpha (TNF-α) activate primary afferent nerve fibres within the 
vagal sensory ganglia. Vagal ganglia signal several nuclei of the dorsal vagal complex 
responsible for the integration of visceral sensory input. This information is relayed to 
higher order brain regions like the hypothalamus, hippocampus and forebrain. Coordinated 
autonomic and behavioural responses are initiated to assist in restoration of homeostasis. 
Importantly, efferent vagal motor activity inhibits cytokine synthesis, creating the 
inflammatory reflex effect. Humoral anti-inflammatory pathways can be activated, 
stimulating the release of adrenocorticotropin hormone. Sympathetic outflow can also 
increase localised adrenaline and noradrenaline expression and further suppress 
inflammation. The activation of these innate components of the inflammatory reflex, 
including the vagally-mediated cholinergic efferent output, ultimately results in the 
regulation of systemic and localised inflammation, having important implications in gut 
immunity (Figure 2.1). A more comprehensive outline of the inflammatory reflex has been 
reviewed elsewhere [151, 152].  
Additionally, activation of the neuroimmune system via glial priming and neurogenic 
inflammation further complicates immune to brain signalling. Although glial cells are non-
neuronal cell types which can be found in the CNS and periphery, such as 
oligodendrocytes and Schwann cells, for the remainder of this manuscript we specifically 
refer to microglia and astrocytes. For an in-depth analysis of glial priming and 
neuroinflammation several excellent reviews exist [121, 122, 124, 143, 153-155]. 
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Nonetheless, to illustrate this point in the context of cancer and chemotherapy, 
inflammation (either centrally or locally derived from either the malignancy or 
chemotherapy) and the release of pro-inflammatory cytokines signals the brain and 
activates neuroimmunological cells, glia (Figure 2.2). Pro-inflammatory cytokines access 
the brain either directly via leaky circumventricular organs or indirectly via a neural route 
(e.g. vagal transmission). Microglia and astrocytes form an integral part of the tri- and 
tetra-partite synapses and maintain a close bidirectional relationship with neurons; the 
neuroimmune interface, which has wide implications in central health and disease [118, 
121, 123, 155]. Reactive glial cells undergo morphological changes and overproduce pro-
inflammatory mediators whilst reducing anti-inflammatory output [125, 156]. Ultimately, 
glial reactivity results in a neuroinflammatory environment whereby neurotoxicity causes 
damage to surrounding tissues and neurons [129, 157, 158]. Centrally derived neurogenic 
inflammation and signalling also contributes to the exacerbation of peripheral 
inflammatory conditions. Although glial reactivity may begin with beneficial intentions by 
responding to insults (disease, trauma, infection or drug exposure), glia may remain in a 
primed state and be sensitised even after the initial insult has resolved, eliciting an 
exaggerated immune response (Figure 2.2). Critically, in particular brain regions primed 
glia and neuroinflammation influence behaviours involving cognition and are involved in 
the pathogenesis of various neurodegenerative diseases and pathological pain states [129, 
159]. Due to the altered immune profile of cancer and chemotherapy patients, it has been 
suggested that neuroinflammatory processes may be contributing to the cognitive deficits 
often experienced by this patient group [61, 160]. This form of innate immune (peripheral-
to-central) signalling represents a plausible mechanism meditating mucositis and 
neurological changes (Figure 2.2).  
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Figure 2.1. The inflammatory reflex. 1) The inflamed zone represents tissue damage, infection and ischemia; 2) Increased 
expression of inflammatory mediators and cytokines, such as Il-1β and TNF-α are released by cells in the inflamed zone; 
3) Cytokines activate primary afferent neurons within the vagal sensory ganglia; 4) Afferent visceral signals are relayed to
nuclei in the DVC, such as the NTS; 5) Visceral information is further relayed from the DVC to higher order brain 
regions, such as the hypothalamus, hippocampus and forebrain; 6) Activation of efferent vagal motor activity inhibits 
cytokine synthesis; 7) Hypothalamus activation stimulates the release of adrenocorticotrophic hormone from the pituitary 
gland, initiating a humoral anti-inflammatory pathway; 8) Sympathetic outflow can increase localised adrenaline and 
noradrenaline expression further suppressing inflammation. IL-1β; interleukin-1 beta, TNF-α; tumour necrosis factor – 
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Following on from this, it is not surprising that interactions between the immune system 
and the brain become dysregulated under cancer and chemotherapy conditions. Further, 
recent evidence has highlighted the impact gut commensal bacteria has in both central and 
peripheral development and health [161]. Importantly, dysbiosis (microbial 
imbalance/maladaptation) and gut-brain axis dysfunction have been associated with 
functional gut disorders having negative effects on cognition [37, 46]. Previously, research 
has focussed on a single pathological manifestation of chemotherapy exposure, for 
example gut toxicity or regional structural brain changes [93, 162]. Such studies have 
failed to consider the indirect effects of simultaneously occurring treatment-induced 
toxicities, which may be contributing to the primary pathology under investigation. 
Consequently, we hypothesise that chemotherapy treatment causes severe and prolonged 
psychosocial impacts on the survivor. Furthermore, we suggest that the gut-brain axis is an 
important mediator of a diverse range of cognitive and emotional disorders similar to those 
experienced by cancer survivors. Here, we will determine whether chemotherapy affects 
the gut-brain axis and present several key stages. Following on from this, we suggest that 
the psychosocial side-effects of chemotherapy treatment could be caused by the effects of 
chemotherapy on the gut-brain axis.  
Following a brief analysis of gut-brain communication, we will review some key studies 
linking gut-brain axis dysregulation to specific psychiatric disorders, highlighting 
similarities between these conditions and the chemotherapy setting. From the Bottom Up 
(GIT to the brain) we will examine chemotherapy-induced gut and central changes and 
present several mechanisms meditating gut-brain axis dysregulation in the chemotherapy 
setting; focussing on the microbiome, intestinal integrity, peripheral neuropathies and 
enteric nervous system (ENS) dysfunction. Finally, we will address the role vagal-, neural- 
and humoral-mediated responses may play in these complex chemotherapy-induced 
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pathological conditions. Overall, we aim to illustrate the complex role gut-brain axis 
dysregulation plays in shaping neurological changes associated with chemotherapy 
exposure.  
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Gut-Brain Cross Talk 
Since Pavlov’s Nobel Prize-winning discovery on the role neural innervation plays in 
gastric secretion – the first functional evidence connecting the gut and brain – our 
understanding of the pathways connecting the CNS and the GIT have significantly 
advanced [163]. The multiple bidirectional pathways responsible for controlling signalling 
from the brain to the gut and vice versa have been extensively reviewed and is outside the 
scope of this manuscript [2-5]. The complexity of this network is best appreciated in its 
ability to integrate information from a variety of systems encompassing the central, 
autonomic and enteric nervous systems (including the influence of the intestinal 
microbiota), whilst simultaneously considering neuroendocrine, enteroendocrine and 
neuroimmune input (summarised in Figure 2.3) [5]. A brief analysis of Bottom Up and 
ENS mechanisms is necessary to appreciate the systems by which the integration of these 
pathways influence behaviour and impact central comorbidities in disorders of the gut. We 
begin this section from the Bottom Up; presenting key pathways, cell types and signalling 
mechanisms involved in communication from the gut to the brain. We also illustrate 
mechanistic evidence relating to disorders of the gut which often have a central 
comorbidity component, such as in the case of inflammatory bowel diseases (IBD) and 
irritable bowel syndrome (IBS). Whilst research covering the central comorbidities 
associated with IBD and IBS continues to expand, the potential mechanisms linking 
neurological and gut changes following chemotherapy exposure remains under 
investigated.  
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Figure 2.3. Schematic of a healthy gut-brain axis. In a healthy system, the gut-brain axis integrates information from 
many systems; the CNS, ANS, ENS, neuroendocrine, enteroendochrine, neuroimmune and HPA. The complex 
bidirectional communication pathways and systems shared between the gut and the brain maintain health and 
homeostasis in the CNS, GIT and microbiota. Efferent signals from the brain involving neuro-endocrine, autonomic 
and HPA outputs influence motility, secretion, nutrient delivery and microbial balance in the GIT. Whilst afferent 
inputs from the GIT, such as intestinal hormones, cytokines and sensory perceptions influence neurotransmitter 
expression, stress, anxiety, mood and behaviour. CNS; central nervous system, chemo; chemotherapy, ANS; 
autonomic nervous system, ENS; enteric nervous system, HPA; hypothalamic-pituitary axis, GIT; gastrointestinal 
tract. 
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From the Bottom Up 
The GIT elicits a myriad of functions ultimately resulting in absorption of nutrients and 
expulsion of noxious chemicals and pathogens via muscular contractions, cellular, 
endocrine and immune mechanisms. Critically, the gut harbours a diverse microbial 
community (e.g. bacteria, fungi, archaea, viruses, and protozoa) and has prolific central 
effects mediating a healthy host [161]. Consequently, changes in gut-microbial 
composition disrupts physiological homeostasis, often contributing to central 
maladaptations [164, 165]. Recent advances in our understanding of the impact the 
microbiota has on the gut-brain axis has led to common use of the term microbiota-gut-
brain axis [35, 36]. Microbiota-gut-brain axis communication alters certain aspects of 
brain development, function, mood and cognitive processes from both the Bottom Up and 
vice versa [5, 14, 15, 17, 36, 166]. Evidence specifically related to chemotherapy-induced 
microbiota changes will be discussed further below (see reviews on microbiota-gut-brain 
axis [14, 17, 35, 36]).  
The GIT maintains an extensive intrinsic nervous system, the ENS which is unique in its 
ability to control certain functions of the small and large intestines even when it is 
disconnected from the CNS [2]. However, the ENS should not be considered fully 
autonomous due to the constant top down input it receives. The ENS is the largest and 
most complex division of the peripheral nervous system comprising 400-600 million 
neurons and an extensive network of enteric glial cells (EGC) [24]. EGCs share similarities 
with astrocytes, their CNS counterparts in the mechanisms they adopt to support enteric 
neurons, including their morphology, function and molecular capabilities [29]. 
Importantly, EGCs play key roles in mounting an immune response, particularly during 
intestinal inflammation.  
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Luminal environmental factors, such as mechanical and chemical changes are signalled 
from the gut to the brain via endocrine, immune and neuronal afferent pathways [3, 4, 24, 
25]. Information regarding the level of distension, concentrations of specific nutrients, 
electrolytes, pH, and the presence of danger and immune signals is transmitted from the 
gut to the brain via a wide variety of neural and systemic communication pathways. 
Visceral changes are detected by a variety of sensory cell types including enterocytes, 
intrinsic and extrinsic primary afferent neurons, immune and enteroendocrine cells [5]. 
Hence, a wide variety of hormones and metabolites from the gut communicate homeostatic 
information to the brain via functional effector cells (enterocytes, smooth muscle cells, 
interstitial cells of Cajal, enterochromaffin cells, intrinsic and extrinsic primary afferent 
neurons, immune and enteroendocrine cells) [5]. Examples of homeostatic information 
relayed from the functional effector cells include but are not exclusive to sensory, pH, 
water metabolism, chemical, danger and immune signals. Each cell type responds to 
luminal environmental changes and secretes specific signalling molecules which may 
include but are not exclusive to ghrelin, cholecystokinin, glucagon-like peptide-1, 
corticotrophin releasing hormone, proteases and cytokines, etc. [25]. To further complicate 
gut-brain crosstalk, various neurotransmitters commonly produced centrally are also 
expressed in the GIT [25]. Gut derived neurotransmitters, such as dopamine, serotonin and 
neuropeptide Y influence many aspects of central homeostasis, yet in the gut are 
responsible for appetite, satiety, hunger, pain and are implicated in the activation of reward 
pathways relating to food and beverage intake [2].  
Numerous afferent and efferent pathways connect the gut and brain, presenting the host 
with a multitude of platforms for malfunction, dysregulation and disease, both in the 
periphery and centrally. Whilst the basic principles outlining top down signalling have 
been extensively reviewed [2, 3, 25] and is outside the scope of this review, it is crucial to 
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acknowledge that these effects occur simultaneously with those described From the 
Bottom Up. Importantly, top down sympathetic and parasympathetic interactions suppress 
secretion, motility and GI transit, having direct effects on immune-, emotion-, mucosa- and 
microflora-related alterations [4, 26]. Gut-brain axis dysfunction has played a pivotal role 
in our mechanistic understanding of various gut disorders and their effects on cognition. 
Indeed, experimentally induced gut disorders have critically developed our understanding 
of the mechanisms underlying central changes induced by disruptions in gut homeostasis. 
Disorders of the gut and chronic inflammation often result in psychological abnormalities, 
such as anxiety and depression [39]. Additionally, physiological responses can be induced 
by stress, for instance triggering relapse in experimental colitis [40].  
Great interest has recently been paid to the importance of gut health on mental health and 
vice versa. This has become particularly evident in the continual expansion of anecdotal 
evidence on the central comorbidities associated with various gut disorders, particularly in 
IBS and IBD [41, 42]. Disorders of the gut are commonly associated with poorer mental 
health. For instance, 54-94% of IBS patients actively seeking treatment also present with 
emotional, psychological and cognitive comorbidities [42] as do chemotherapy recipients. 
The literature presented above provides clear evidence that gut disorders often occur 
simultaneously with central comorbidities, aligning with our hypothesis that gut-brain axis 
dysregulation may be mediating both chemotherapy-induced mucositis and neurological 
changes. Therefore, it is pivotal that we determine the direct and indirect central 
consequences of drug-induced gut disorders, such as chemotherapy-induced mucositis. 
Chemotherapy induces a range of peripheral and central side-effects, significantly reducing 
quality of life. In the gut this has been termed chemotherapy-induced mucositis and in the 
CNS, chemotherapy-induced cognitive impairment (CICI). The current review will now 
explore whether mucositis and CICI are linked and whether they exacerbate other 
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symptoms, such as pain associated with mucositis, or cognitive impairment which are often 
experienced simultaneously in the chemotherapy setting.  
Chemotherapy From the Bottom Up: the Gut and Cognition 
Chemotherapy drugs can be considered paradoxical at the most basic level. Primarily, they 
offer recipients’ survivorship as they target malignant cells in an attempt to rid the host of 
cancer. On the other hand, due to their non-selective nature, they also target healthy cells 
and induce a range of side-effects reducing patient quality of life. The organ where their 
actions are perhaps often first noticed is the GIT due to its high regenerative capacity. 
Mucositis occurs in up to 70% of chemotherapy recipients and may manifest anywhere 
along the alimentary tract, termed oral or intestinal mucositis (Figure 2.4) [167]. It is one 
of the most significant dose-limiting side-effects of intensive anti-cancer therapy due to the 
painful nature of the disorder.  
Sonis classified the pathogenesis of mucositis into five stages [1]. Hallmark characteristics 
of mucositis include villus atrophy, shallow crypts, inflammation and ulceration. Mucositis 
results in a high inflammatory response via the up-regulation and activation of various 
transcription factors, ultimately causing elevations in circulating pro-inflammatory 
cytokines (Figure 2.4), in particular IL-1β and TNF-α [1]. Whilst mucositis is an acute 
phenomenon which usually resolves upon cessation of chemotherapy treatment, clinical 
symptoms generally begin five to ten days post chemotherapy exposure and include 
significant pain, abdominal bloating, nausea and vomiting, diarrhoea and/or constipation 
[168]. Although guidelines for the prevention and treatment of mucositis exist, they fail to 
include effective treatment options [169]. Novel complementary treatment approaches are 
showing positive results utilising naturally sourced products, such as Emu Oil and Rhubarb 
extract [108, 110]. Although these treatment strategies show promise, to date they are still 
in the pre-clinical stages. Our understanding of the central consequences of drug-induced 
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gut disorders, such as mucositis remains elusive, yet evidence on CICI is expanding as 
various mechanisms underlying its pathogenesis are becoming clearer.  
CICI occurs in 15-45% of patients undergoing anti-cancer therapy [170]. Subjective (self-
reported) report rates are considerably higher than objective measures with some studies 
reporting 95% of patients experiencing changes in cognitive performance [57]. Subjective 
measures are nonetheless important as they identify the impact of cognitive impairment 
and the strain it places on patients’ lives and daily functioning [94]. The breast cancer 
population forms the majority of the CICI literature as they offer researchers completion of 
extensive retrospective studies due to their typically good prognosis [113]. Regardless, 
CICI has been investigated in a range of other cancer types including myeloma and 
testicular cancer [171, 172].  
The cognitive domains most commonly reported in CICI are executive functioning, 
attention and concentration, processing speed, reaction time and motor speed and dexterity 
[79]. Perceived cognitive impairment affects various facets of the patient’s life, including 
relationships, employment, self-esteem/worth, finances and independence. The CICI 
experience leaves patients feeling distressed, anxious, frustrated, irritable, depressed and 
embarrassed, often reducing confidence [173, 174]. Current estimates on the duration of 
CICI are varied with some studies identifying deficits up to twenty years post 
chemotherapy cessation, yet most indicate improvements up to twelve months later [96, 
98]. Neuroimaging studies have confirmed molecular and structural changes in the grey 
matter of the frontal and temporal lobes and the cerebellum of breast cancer patients 
following chemotherapy exposure [175, 176]. Additionally, chemotherapy induces white 
matter tract changes and the reorganisation of global brain networks, which have 
undoubtable associative if not causal impacts on cognitive performance [117, 177].  
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Animal studies have begun to unravel various mechanisms underlying the pathogenesis of 
CICI and involve structural and behavioural changes. Hippocampal and frontal cortical 
alterations have correlated with behavioural memory changes in various rodent models [89, 
148, 178]. Neurogenesis occurs in the dentate gyrus and cellular proliferation is critical in 
hippocampal circuit plasticity and memory consolidation [179, 180]. CICI models have 
reported on the vulnerability of stem cells to proliferate in the dentate gyrus irrespective of 
chemotherapy drug class [87, 181]. Considering the pivotal role neural stem cells in this 
region have to divide into new neurons or astrocytes, disruptions in this process present as 
a direct mechanism which may be contributing to CICI. More recently, 
neuroimmunological manifestations, such as glial dysregulation and neuroinflammation, 
have been reported to contribute to CICI [182, 183].  
Currently, effective prevention strategies or treatment approaches for CICI remain 
undetermined although two evidence-based guidelines are available to assist oncologists in 
addressing cognitive deficits [184]. Other interventions for CICI are broadly categorised 
into cognitive training, compensatory strategies, pharmacological, and complementary and 
integrative medicines [185]. Recently, Toll-like receptors (TLRs) have been suggested as a 
common component in the pathology of neuropathy/pain and gut toxicity resulting from 
chemotherapy, presenting a novel and much needed therapeutic approach in the treatment 
of chemotherapy-induced toxicities [186]. TLRs have profound homeostatic effects, tightly 
regulating innate immune and gut functions, modulating pain behaviours [187-192]. 
Wardill et al. [186], hypothesised that TLR-4 mediated glial activation and neuropathy 
driven by the molecular signals released from gut toxicity caused by chemotherapy. 
Primary studies have indicated that an altered TLR expression profile may contribute to 
chemotherapy-induced pain and diarrhoea [189]. This study importantly highlights the 
need for further research examining both peripheral and central toxicities associated with 
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chemotherapy treatment. Interestingly, the selective serotonin reuptake inhibitor, 
fluoxetine, has shown promising results in a rat model of CICI. Fluoxetine co-
administration with the chemotherapy drug improved cognitive performance in rats 
assessed by object location recognition [193]. Whilst cellular proliferation in the dentate 
gyrus significantly reduced in the chemotherapy group, co-administration with fluoxetine 
reversed this reduction. Regardless of the evidence presented here indicating CNS changes 
following chemotherapy exposure, it is important to note that some studies have reported 
no structural or cognitive changes [95, 194]. Various cytotoxic insults have revealed no 
morphological changes to neurons located in the CNS [195, 196]. These negative findings 
could result from a range of factors, including differences in species, drug, dose, type of 
administration and cognitive parameters examined; but importantly, suggests that more 
complex mechanisms are likely to play a role in CICI.   
Whilst the direct mechanisms presented here reflect the complex aetiology of CICI, they 
fail to acknowledge the influence other simultaneously occurring side-effects may be 
having on CICI symptoms. Many of the CICI models described above utilised 
chemotherapy drugs that are also often used to examine mucositis, for example 5-
Fluorouracil (5-FU), methotrexate and oxaliplatin. Although mucositis would have most 
likely been present in these models, the gut tissue would not have been examined and thus, 
the potential for indirect mechanisms relating to gut-brain axis dysregulation would have 
been ignored. In doing so, we may be missing critical mechanisms contributing to or 
exacerbating CICI pathogenesis. In order to explore this theory, we will now consider the 
influence chemotherapy exposure has on the gut-brain axis, opening novel hypotheses 
surrounding how mucositis may contribute to the aetiology of CICI. 
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Chemotherapy Interrupts Several Stages of the Gut-Brain Axis 
As presented above, the two organs most vulnerable to the toxicities of chemotherapy 
treatment are the gut and the brain. Therefore, it is plausible that several stages of the gut-
brain axis may become dysregulated in the chemotherapy setting (Figure 2.4). Here, we 
propose that chemotherapy exposure influences the gut-brain axis via several mechanisms 
which include: altering intestinal microbiota composition and function; upsetting the 
balance of “beneficial” and “detrimental” bacteria in the lumen, deleteriously affecting the 
gut lining, impairing the ENS and activating neuroimmune and pain signalling pathways 
(Figure 2.4). The interaction of the gut-brain axis and the neuropsychological 
comorbidities associated with specific gut disorders have been extensively reviewed, for 
example depression/cognitive deficits and IBS/IBD [42, 45, 47-49]. However, this angle of 
research is yet to be reviewed in the context of chemotherapy exposure and cognitive 
impairment. Research in this area will continue to develop as we begin to appreciate that 
chemotherapy-induced side-effects involving the gut-brain axis may continue to linger for 
some time after treatment cessation, placing significant strain on health care systems and 
importantly, patient quality of life.
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Figure 2.4. Chemotherapy disrupts several stages of the gut-brain axis. We suggest that chemotherapy-induced gut-
brain axis dysregulation plays a major role in the intestinal, psychological and neurological complications experienced 
by many cancer patients. Chemotherapy often results in molecular and structural changes in the brain, e.g. hippocampal 
changes as identified in rodent models. Chemotherapy exposure causes cognitive and behavioural changes to a subset of 
patients and these findings have been supported by some experimental models. The altered immune profile of 
chemotherapy recipients results in increased circulating pro-inflammatory cytokines which have been reported to cause 
cytokine-induced sickness-like responses (which mimic chemotherapy-induced side-effects). Damage to peripheral 
nerves resulting in peripheral neuropathies are experienced by some chemotherapy recipients. Chemotherapy targets the 
intestines by impairing the nerves of the myenteric plexus, damaging intestinal wall parameters and resulting in 
mucositis and causing microbiota dysbiosis. Serotonin dysregulation under chemotherapy conditions may play a role in 
chemotherapy-induced intestinal and neurological changes. Finally, peripheral-to-central immune signalling pathways 
(humoral or neural/vagal) may mediate chemotherapy-induced gut-brain axis dysregulation. 
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The Microbiome 
It has been estimated that our gut contains 100-fold more genes than the human genome 
and approximately 1000 bacterial species [197, 198]. Our gut microbiome coevolves with 
us [199] and changes may be either beneficial or detrimental to human health. In healthy 
individuals, the gut microbiota is responsible for a number of health benefits, such as 
pathogen protection, nutrition, host metabolism and immune modulation [200]. Although a 
core microbial population has been established in individuals, changes can be caused by 
many factors including age, diet, antibiotic and analgesic use and environmental factors 
[201]. The microbiome facilitates intestinal homeostasis and more specifically, has the 
capacity to influence inflammation and immunity, both at the local (mucosal) and systemic 
levels [202]. Commensal bacteria play important roles in anti-viral immunity, regulating 
systemic immune activation [203]. Signals released by commensal bacteria assist in 
immune development and thereby, have important implications for infectious and 
inflammatory disease susceptibility [203, 204], such as in the case of chemotherapy-
induced mucositis. Consequently, dysbiosis can heavily influence pathological intestinal 
conditions with an inflammatory component, for example in experimentally-induced IBD 
[205-208]. Critically, IBD patients reported microbial composition changes with major 
shifts in genomic landscape and functional outcomes [209].  Undoubtedly, the implications 
of such IBD studies have heavily impacted oncology, raising many questions specifically 
relating to the intestinal microbiota, immune, malignancy and anti-cancer treatment 
interactions.  
Whilst Sonis’ five-phase model of mucositis [1] lacked any potential influence on the 
microbiota, unequivocal research has indeed confirmed that intestinal inflammation 
modulates microbiome composition and function [208, 209]. As intestinal inflammation is 
a common characteristic of mucositis, it makes sense that chemotherapy induces functional 
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and compositional changes to the microbiome. It has been suggested that mucositis 
development is influenced by commensal microbiota in multiple pathways involving 
inflammation and oxidative stress, intestinal permeability (discussed below), mucus layer 
composition , epithelial repair mechanisms and via the release of immune effector 
molecules [38]. Indeed, research has begun to unravel the complexities surrounding the 
interactions between the host and the intestinal microbiota following chemotherapy 
exposure and consequently, several excellent reviews exist [38, 208, 210-212]. Commonly 
used chemotherapy drugs, such as 5-FU and irinotecan report drastic shifts in intestinal 
microflora, from commensal bacteria which maintain a symbiotic relationship with the 
host, to elevated levels of Escherichia spp., Clostridium spp., and Enterococcus spp. which 
can be associated with several pathologies involving inflammation and infection [213-216] 
(Table 2.1). Several clinical studies have supported pre-clinical findings describing 
alterations in faecal microbial composition following chemotherapy treatment. Literature 
reveals a general decrease in the overall diversity of bacteria in the microbiota of cancer 
patients undergoing anti-cancer treatment when compared to healthy individuals, 
irrespective of cancer type or chemotherapy regime [217-219] (Table 2.1).  
In addition to the direct effects microorganisms and their enzymes have on cancer 
initiation and progression [16, 220], the microbiota also modifies drug absorption and 
metabolism via gene expression changes [221, 222]. This has become a pivotal research 
angle in oncology as chemotherapy-microbiota-immune interactions have identified 
microbial-mediated innate and adaptive immune responses and their effect on the efficacy 
of cancer immunotherapy and chemotherapy drugs [223-226]. Two crucial studies 
presented in Science (2013) [223, 224] reported that microbiota disruption by antibiotic 
treatment impaired chemotherapy drug efficacy on tumours, utilising cyclophosphamide 
and oxaliplatin. More recent studies have illustrated the important role certain microbial 
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strains (Bifidobacterium) play in anti-tumour immunity [225, 226]. Although these studies 
were performed in mice, their findings indicate the potential risks associated with the use 
of antibiotics during chemotherapy treatment.  
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Table 2.1. Summary of key papers highlighting chemotherapy-microbiota-immune interactions. 
Study Subjects Treatment Commentary 
Lin, et al. Tumour bearing rats Irinotecan alone 
Irinotecan/5-FU 
Increased abundance clostridial





Rats 5-FU Increased facultative and 
anaerobic bacteria 
from the oral cavity. 
Increased facultative anaerobes 
in large intestine. 
Proportion of facultative gram-
negative rods increased in both 
oral cavity and intestine. 
Stringer, et al. Rats Irinotecan Increased jejunal samples of 
Escherichia spp., 
Clostridium spp., 
Staphylococcus spp.,  





Staphylococcus spp. No 
changes in faecal flora except 
E. coli.
Stringer, et al. Rats Irinotecan Extensive changes were
evident in stomach, jejunum,
colon and faeces.
Most significant changes were










Steep reduction in alpha
diversity during chemotherapy.
Decreases in Firmicutes




Manichanh, et al. Patients with 
abdominal tumours 
Pelvic radiotherapy Faecal samples reported
significant microbiota profile
changes in patients with
postradiotherapy diarrhoea.
Not all patients reported
diarrhoea. Importantly, this
study suggests initial microbial









Clostridium cluster IV and
XIVa. C. difficile was present
in three out of seventeen
patients and was accompanied
by a decrease in the genera








Iida, et al. Tumour bearing mice Oxaliplatin and 
cisplatin 
Chemotherapy-induced 
dysbiosis impairs response to 
immunotherapy and 
chemotherapy. 
Viaud, et al. Tumour bearing mice Cyclophosphamide Jejunal and faecal samples 
reported dysbiosis and induces 
translocation of specific Gram-
positive bacteria to secondary 
lymphoid organs whereby they 
stimulate subsets of T cells. 
These results suggest that the 
gut microbiota may affect 
anticancer immune response.   
Sivan, et al. Tumour bearing mice Co-housing, faecal 
transfer, programmed 






Changes to anti-tumour 
immunity were eliminated by 
co-housing and faecal transfer. 
Oral Bifidobacterium
administration improved 
tumour control to same degree 
as PDL-1 therapy; combination 
treatment nearly abolished 
tumor outgrowth. 




blocker) regulates T 
cell activation and 
improves survivability 
of metastatic melanoma 
patients. 
CTLA-4 blockade is influenced 
by the microbiota. Changes in 




control in mice and humans.
The growing field of microbiome research has raised a lot of questions and comments on 
the complex interplay and interwoven relationships between microbes and cancer, 
including anti-cancer treatments [227-231]. Further, some of the above studies [225, 226] 
have implications for microbial therapy in cancer immunotherapy. As our understanding of 
these interactions continues to progress, new knowledge in this area will open up 
possibilities of novel paradigm shifts in treatment approaches which may improve anti-
cancer efficacy and even prevent toxicity. The studies presented in this section suggest a 
role for chemotherapy-induced microbiota changes in intestinal disease pathogenesis and 
chemotherapy-induced gut-brain axis dysregulation (Figure 2.4). As mentioned, 
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commensal bacteria are critical in regulating intestinal homeostasis and more specifically, 
intestinal integrity. In fact, the effects commensal bacteria have on intestinal integrity and 
vice versa, go hand-in-hand. Accordingly, the reciprocal relationship shared between 
commensal bacteria and the intestinal wall will be presented together in the following 
section. Chemotherapy compromises intestinal integrity and leads to profound effects on 
the gut lining, eventually leading to a dysbiotic microbial community and consequently 
risking microbial invasion into the systemic circulation. 
Chemotherapy Impairs Intestinal Barrier-Microbiota Interactions 
The even comprehensively described pathogenesis of mucositis [1] is unable to fully 
encapsulate the mechanisms underlying the pathogenesis of chemotherapy-induced gut 
damage. It does however, cover many essential aspects of the pathological processes 
underlying mucositis, such as epithelial barrier damage. More recently, some research 
groups have re-defined gut damage caused by chemotherapy as chemotherapy-induced gut 
toxicity (CIGT). The proposed term includes additional pathological manifestations caused 
by chemotherapy treatment, such as abnormalities in tight junctions, immune dysfunction 
and microbiota influences [208, 217, 232].  
Nonetheless, the epithelial barrier lining of the GIT is fundamental in ensuring the 
maintenance of intestinal integrity. As well as forming a mechanical barrier to separate the 
inside of the body from the outside world, it is heavily involved in the communication 
shared between the body and the intestinal contents [233]. Tight junctions are intertwined 
throughout the epithelial barrier and regulate diffusion of solutes according to strict size 
and charge limitations [234]. Chemotherapy exposure increases intestinal permeability and 
the most widely studied mechanisms to date have included apoptosis of intestinal crypts 
and villous atrophy [64, 235]. Early clinical studies assessing the severity of intestinal 
damage in high-dose regimes reported abnormalities in intestinal permeability and defects 
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in tight-junction integrity (Figure 2.4) [162]. Convincing rodent evidence has implicated 
mucosal barrier injury and tight junction deficits with gut toxicity induced by various 
chemotherapy drugs, including irinotecan and methotrexate [232, 236]. However, it should 
be noted that rodent model application in gut immunity and microbiome research has 
serious limitations and pitfalls due to compositional microbiota differences between 
species. Whilst the rodent microbiome shares some common features with human 
commensal bacteria, unique commensals in rodents have differential effects in immune 
responses and disease pathogenesis [237]. Consequently, animal models of inflammation 
are different to human models of inflammation in terms of microbial colonisation, 
morphology of lesions and clinical manifestations. Nonetheless, research in experimental 
models continues to provide critical insight into complex interactions between the host, 
microbiota and immune responses. More recently, it has been becoming more evident the 
impact intestinal integrity has on the microbiota, especially under chemotherapy 
conditions. The health and stability of the intestinal wall influences the microbiota and vice 
versa. 
Commensal bacteria in the microbiota have a protective effect on intestinal integrity, 
interacting with TLR and Nuclear Factor kappa B pathways, ensuring the development of 
an innate immune response [188]. These components of innate immunity in the gut and the 
activation of these pathways are pivotal in maintaining barrier function, promoting 
mucosal repair and protecting the gut against injury [192, 238]. Chemotherapy exposure 
alters commensal microbial composition in the microbiota, thus negatively affecting 
barrier function, repair pathways and compromising intestinal integrity [215]. Accordingly, 
further investigations are required to fully appreciate the role chemotherapy-induced 
intestinal permeability changes play in gut-brain axis dysregulation. As intestinal integrity 
becomes compromised under chemotherapy conditions, it is not surprising that nerves of 
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the myenteric plexus and peripheral nerve endings become damaged as these neural 
components also reside outside of the BBB as will be discussed below.   
Chemotherapy Results in Peripheral and Enteric Neuropathy 
The PNS is particularly vulnerable to the cytotoxic nature of different chemotherapy drug 
classes, including platinum analogues, antitubulins, proteasome inhibitors, 
immunomodulatory agents and some newer biologics, such as brentuximab [239]. 
Chemotherapy-induced peripheral neuropathy (CIPN) is experienced by 30-40% of 
chemotherapy recipients and is often responsible for early cessation of treatment, 
decreasing chemotherapeutic efficacy and causing higher relapse [128, 240]. Typically, 
sensorimotor symptoms are more common than motor involvement, presenting in a 
bilateral “glove-and-stocking” distribution in the hands and feet to include paraesthesia, 
numbness, burning pain, allodynia (pain following non-painful stimuli; central pain 
sensitisation) and hyperalgesia (heightened sensitivity to pain) [241]. However, the 
development of motor and autonomic neuropathic symptoms may also occur, such as 
sensory ataxia, pain, weakness of distal muscles, reduced deep tendon reflexes and severe 
numbness that can severely affect the patient’s ability to function and their quality of life 
[242]. Often symptoms fail to improve after cessation of treatment, referred to as a 
“coasting” phenomenon [241].  
The pathogenesis of CIPN is primarily related to axonopathy and neuronopathy in which 
dorsal root ganglia (DRG) are involved. Peripheral nerves and their ganglia are particularly 
susceptible to chemotherapy-induced damage due to their location as they lack the 
protective defences associated with the BBB [25]. For example, chemotherapy interrupts 
the cell cycle, inducing structural and functional changes in DRG which partly explain the 
development of sensory symptoms in CIPN [243, 244]. Many pathophysiological 
mechanisms mediating chemotherapy-induced peripheral nerve damage have been 
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identified. Some examples include, but are not exclusive to dysregulated axonal transport 
and trophic factor support via microtubule structural changes [245], mitochondrial stress 
[246, 247] and reduced blood supply to nerves [245, 248]. Further changes contributing to 
CIPN pathogenesis include dysregulated ion channels, neurotransmitter release and 
receptor sensitivity [249-251]. The evidence presented here clearly describes mechanisms 
by which the PNS is damaged following chemotherapy exposure, forming an important 
element of the proposed central hypothesis (Figure 2.4).  
In addition to peripheral neuropathies, neurons residing within the ENS are also 
susceptible to the deleterious effects of various chemotherapy drugs, including cisplatin, 
oxaliplatin and more recently, 5-FU [107, 252, 253]. Systemic administration of these 
chemotherapy drugs induces structural and functional changes to myenteric neurons 
(Figure 2.4), consequently resulting in downstream negative effects on GI motility. 
Interestingly, acute exposure of 5-FU increases intestinal transit whilst prolonged 
treatment decreases transit time [107]. These findings outline the complex nature of the 
impact chemotherapy drugs have on enteric neurons and altered motility patterns. Here, we 
highlight that chemotherapy results in damage to neurons and ganglia residing outside of 
the BBB, exerting functional maladaptations in both the PNS and ENS. So far, we have 
described several mechanisms relating to chemotherapy-induced gut-brain axis 
dysregulation, yet we have not identified how immune signals from the intestinal cavity 
may communicate to the brain and potentially contribute to the pathogenesis of CICI. In 
the following section we present peripheral-to-central immune pathways as being critical 
in the transmission of signals from the gut to the brain following chemotherapy exposure. 
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Peripheral-to-Central Immune Signalling Pathways Mediating Chemotherapy-
Induced Gut-Brain Axis Dysregulation  
Historically there has been controversy surrounding the theory that a communication 
system existed between the immune system and the CNS [82]. Traditionally it was 
assumed that pro-inflammatory cytokines were unable to pass through the BBB due to 
their size. However, the humoral route explained that cytokines expressed in the periphery 
could in fact, cross the BBB at leaky circumventricular organs through fenestrated 
capillaries. At these sites blood-borne cytokines act on parenchymal astrocytes that express 
secondary mediators, such as nitric oxide and prostaglandins which freely diffuse to nearby 
brain regions, such as the hypothalamus to mediate the effects of pyrogenic and 
corticotropic cytokines [254]. Whilst this hypothesis points towards the existence of a 
communication system between the immune system and the CNS, it was unable to fully 
account for other contributing pathways that may be mediating physiological responses. 
Consequently, it is now widely accepted that peripheral cytokines signal the brain and in 
turn, this triggers sickness behaviour responses [255].  
Central or peripheral immune challenges trigger a range of physiological, behavioural and 
motivational changes to assist the host in healing (Figures 2.2 and 2.4). Non-specific 
symptoms which accompany sickness behaviours include, but are not exclusive to fever, 
depressed activity, a loss of interest in regular activities (e.g. appetite, sexual, cleaning, 
hygiene), weakness, malaise, listlessness and cognitive changes [110]. As demonstrated by 
Dantzer and Kelley [82], the last two decades of research on this phenomenon have 
confirmed that local or systemic pro-inflammatory cytokines expressed at physiological 
levels, during both acute and chronic inflammatory responses, serve as true communication 
molecules between the immune system and brain. For example, direct administration of IL-
1β or TNF-α to the lateral ventricle decreased social exploration and feeding behaviour in 
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rats [110]. In the chemotherapy setting, this phenomenon may be related to either the 
systemic nature of the drugs themselves or localised inflammatory responses occurring as a 
result of the toxicities associated with their use, such as in the case of mucositis (Figure 
2.2). 
Interestingly, whilst IL-1β and TNF-α are key pro-inflammatory cytokines instigating 
sickness behaviours, they also play a pivotal role in the pathogenesis of mucositis. Since 
both pro-inflammatory cytokines play an important role in the pathogenesis of mucositis 
and sickness behaviours which involve cognitive deficits, it is plausible that these 
cytokines and the pathways mediating their activation may present as key mechanisms 
underlying the central hypothesis in this review (Figure 2.4). Various animal models have 
identified that sickness behaviour responses may be induced by a range of clinical 
conditions, such as systemic or central administration of lipopolysaccharide (active 
fragment of gram negative bacteria) or recombinant pro-inflammatory cytokines [82, 134, 
256, 257]. Furthermore, many symptoms associated with cytokine-induced sickness 
responses mimic the cluster of chemotherapy-induced side-effects, including fatigue, 
depression, reduced appetite, heightened sensitivity to pain and cognitive impairment 
(Figure 2.4). As previously mentioned, up to 70% of chemotherapy recipients experience 
mucositis [167] and an altered immune profile due to the systemic nature of anti-cancer 
treatments, yet whether these side-effects may be contributing to CICI remains elusive. 
Accordingly, we present pathways which may be enabling the communication of 
peripheral immune signals to the brain, more specifically defining how mucositis-driven 
inflammation may signal the brain via vagal- and neural-mediated mechanisms and 
contribute to the pathogenesis of CICI. 
Information from pro-inflammatory cytokines and mediators expressed under 
chemotherapy-induced mucositis conditions may signal the brain via a vagal 
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communication pathway (Figure 2.4). Dendritic cells (DCs) are a specialised subset of 
immune cells located within the vagus nerve and surrounding paraganglia [256]. The 
signals (pro-inflammatory cytokines, chemokines and mediators) expressed by DCs are 
capable of communicating to the brain [258, 259]. Vagal immunosensation requires 
primary afferent neuron activation as the initial interface triggering the brain. Following 
chemotherapy exposure, pro-inflammatory cytokines and mediators, such as those from the 
IL-1 family arise from mucositis-induced inflammation. IL-1 binds to receptors on the 
paraganglia surrounding vagal afferents and release neurotransmitters onto the vagus, 
consequently activating vagal fibres. A vagal-mediated neural signal is then carried to the 
nucleus tractus solitarius which projects the message to higher order brain regions, such as 
the hypothalamus and hippocampus, whereby, IL-1 production is increased and other 
neural cascading events are initiated to produce sickness behaviour responses [82, 186]. 
Whilst this evidence clearly demonstrates the role vagal afferent nerves play in peripheral-
to-central transmission of immune messages from the abdominal cavity, to date these 
pathways have not been examined under chemotherapy conditions and are therefore 
presented as potential mechanisms contributing to gut-brain axis dysregulation.    
DCs play a role in immunomodulation and neuroimmune regulation, crucially bridging 
innate and immune adaptive processes. Importantly, DCs express pattern recognition 
receptors for a range of chemicals (e.g. TLRs), chemokines, microorganisms and 
neurotransmitters, such as serotonin [258, 259]. Damage to surrounding GIT tissues and 
increased levels of pro-inflammatory mediators, such as cytokines and chemokines induce 
maturation of DCs [260]. Matured DCs migrate to secondary lymphoid organs to initiate a 
localised immune response via interacting with naïve T cells [258]. Recent data implies an 
emerging role for DC-expressed serotonin and receptor activation in regulating innate and 
immune responses associated with gut inflammatory conditions [261, 262]. Mechanisms 
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underlying DC-mediated serotonin and receptor-sub types affect various levels of localised 
inflammation, even having anti-inflammatory effects preventing excess inflammation and 
tissue damage [261]. These findings coupled with the aforementioned positive cognitive 
effects of fluoxetine in a rat model of CICI [193], serotonin presents as a new therapeutic 
approach for inflammatory disorders, having effects in both the gut and the brain. 
Accordingly, serotonin is presented as an underestimated contributing factor potentially 
implicated in chemotherapy mediated gut-brain axis dysregulation (Figure 2.4).  
From the Bottom Up, the gut and the brain are the two primary organs most susceptible to 
toxicity associated with the non-selective nature of chemotherapy drugs. As chemotherapy 
exposure induces cognitive decline and mucositis in a subset of recipients, it makes sense 
that several stages of the gut-brain axis are prone to negative effects in this setting. The 
gut-brain axis is largely responsible for the maintenance of homeostasis and achieves this 
delicate balance by integrating a vast array of signals and information from many systems, 
as described above and shown in the figures. In this regard, upsetting the balance of any 
stage in the gut-brain axis following chemotherapy treatment has the potential to 
exacerbate side-effects, such as in the case of mucositis and CICI. The findings from our 
review support our main hypotheses that chemotherapy treatment causes severe and 
prolonged psychosocial impacts on the survivor. Secondly, the gut-brain axis is an 
important mediator of a diverse range of cognitive and emotional disorders similar to those 
experienced by cancer survivors. Evidently, chemotherapy affects the gut-brain axis at 
several key stages which are outlined above. Collectively, this review concludes that the 
psychosocial side-effects of chemotherapy treatment may be caused by the effects of 
chemotherapy on the gut-brain axis.  
Apart from chemotherapy treatments crossing the BBB and directly causing damage to 
specific regions, peripheral inflammatory responses from either the malignancy or 
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systemic treatment also indirectly cause cellular changes in the spinal cord. Preliminary 
findings from our group recently demonstrated glial reactivity in the thoracic spinal region 
of rats with 5-FU-induced intestinal mucositis, indicating an indirect regional-specific 
neuroimmune response to CIGT [263]. These data provide evidence that experimentally-
induced jejunal toxicity indirectly dysregulates thoracic astrocytic protein expression. In 
addition to this recent finding, the evidence presented here suggests a role for 
chemotherapy-induced microbiota changes in intestinal inflammation. This further 
complicates intestinal inflammation and ulceration induced by chemotherapy exposure 
which may potentially influence CICI. Neurons in both the ENS and the PNS are also 
vulnerable to the cytotoxic nature of chemotherapy treatments. The implications of co-
administration of pharmacological interventions (e.g. fluoxetine) with chemotherapy drugs 
remains undetermined, although preliminary studies showing improvements in cognitive 
performance warrants further investigation. In view of the aforementioned data, we 
conclude that several stages of the gut-brain axis become dysregulated following 
chemotherapy exposure and may be implicated in the pathogenesis of CICI. Harnessing 
our understanding of the role gut-brain axis dysregulation plays in modulating brain 
function may offer clues for more targeted therapeutic strategies to prevent CICI and 
warrants further investigation. 
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Hypotheses and Aims 
Overarching thesis hypotheses derived from General Introduction and Chapters
One and Two: 
• 5-FU is unique in causing peripheral inflammatory events, such as gut toxicity and glial
dysregulation, in the brain and spinal cord of rats;
• Opioid exposure further exacerbates 5IGT glial dysregulation in the brain and spinal
cord of rats;
• Chronic inflammatory conditions of the gut (malignant and non-malignant) result in
glial cell activation in the brain and spinal cord of mice;
• Acute low inflammation induced in the small intestine of rats with NSAID-enteropathy
is sufficient to induce spinal cord glial reactivity;
• 5-FU-induced glial dysregulation directly (direct effects of drug on brain) or indirectly
(from gut toxicity) may be associated with or potentiate learning and memory deficits,
in the context of CICI; and
• Breast cancer patients undergoing chemotherapy treatment experience perceived GI
symptom severities that may be associated with perceived cognitive disturbances.
Specific hypotheses and aims relating to each research chapter: 
Research Chapter Three 
Hypothesis 1. 5IGT induces microglial and astrocyte dysregulation in the brain and spinal 
cord of rats via humoral and/or neural pathways. 
Aims  
• Quantify glial and pro-inflammatory cytokine protein expression via glial fibrillary
acidic protein (GFAP) for astrocytes, cluster of differentiation molecule 11b (CD11b)
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for microglia, and IL-1β expression changes in the hippocampus and spinal cord of rats 
with 5IGT.  
• Determine whether glial changes are occurring via peripheral-to-central immune
signalling pathways:
▪ Humoral pathway: examine the hippocampal region (indicative that glial changes
are occurring as a result of 5-FU directly crossing the BBB),
▪ Neuronal pathway: examine the thoracic (T6-T9) region (indicative that glial
changes are occurring as a result of the indirect drug actions of 5-FU in the
jejunum).
• Determine whether spinal cord changes are general or region specific:
▪ Examine cervical (C2-C5) region for glial expression changes.
Hypothesis 2. 5-FU-induced microglia and astrocyte reactivity marker expression changes 
persist beyond the Recovery Phase of intestinal mucositis in rats. 
Aims  
• Assess 5-FU-induced glial reactivity (GFAP and CD11b) at day 3 (72 h; Peak Injury
Phase of mucositis) and day 5 (120 h; Recovery Phase of mucositis) via western blot
(WB) analysis.
Hypothesis 3. Analgesia in the form of opioid/NSAID exposure will further impact 
regional glial changes in rats with 5IGT. 
Aim 
• Quantify glial reactivity (GFAP and CD11b) and IL-1β expression via WB in
hippocampus and spinal cord of rats with 5IGT and compare to analgesic intervention.
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Research Chapter Four 
Hypothesis 1. The commonly used NSAID, indomethacin (INDO), induces mild 
enteropathy in rats and increases hippocampal and thoracic microglial and astrocytic 
expression. 
Aims  
• Determine whether spinal glial expression changes occurred as a result of a generalised
(lower) inflammatory response in the small intestine utilising INDO, or whether the glial
changes were specifically related to chemotherapy drug exposure (5IGT).
o Compare GFAP and ionized calcium binding adaptor molecule-1 (Iba-1) changes
in the hippocampus, hypothalamus, pre-frontal cortex and cervical, thoracic and
lumbar spinal regions of rats with 5IGT (high inflammatory response) to INDO-
induced enteropathy (low inflammatory response).
Hypothesis 2. The microbial diversity of rats with 5IGT decreases when compared to 
INDO-induced enteropathy. 
Aim 
• Examine caecally-derived microbial changes using 16S-PCR sequence profiling.
Research Chapter Five 
Hypothesis 1. Chronic inflammation resulting from dextran sulphate sodium (DSS)-induced 
chronic UC would increase glial expression in higher order brain regions and the lumbar 
region of mice. 
Aims 
• Assess glial (GFAP and Iba-1) expression changes in the brain and spinal cord (6 regions
in total) of mice with DSS-induced UC via WB analysis.
o In the brain, the hippocampus, PFC and hypothalamus regions.
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▪ The hippocampus and PFC are implicated in cognitive processes and glial
dysregulation in these regions may directly be mediated by activation of the
humoral pathway, for example, systemic pro-inflammatory cytokines or 5-
FU crossing the BBB and directly exerting effects.
▪ The hypothalamus receives input from the GIT, thus gut inflammation may
indirectly induce glial dysregulation in this region via neurally-mediated
immune signalling mechanisms.
o Examination of the cervical, thoracic and lumbar regions of the spinal cord to
determine whether glial changes are region specific. If regional changes occur in
the spinal cord region that is innervated by the inflamed GIT region, for example
colonic changes infer lumbar regional changes, then this will indicate neural
pathway activation.
Hypothesis 2. Chronic inflammation and malignancy resulting from colitis-associated CRC 
(CA-CRC) would increase glial expression in higher order brain regions and the lumbar 
region of mice. 
Aims 
• As described in first hypothesis aims, assess glial (GFAP and Iba-1) expression changes
in the brain and spinal cord of mice with DSS/azoxymethane (AOM)-induced CRC via
WB.
Research Chapter Six 
Hypothesis 1. Breast cancer patients undergoing chemotherapy treatment experience 
perceived GI symptom severities that may be associated with perceived cognitive 
disturbances. 
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Hypothesis 2. Allergy susceptibility in breast cancer survivors correlates with 
susceptibility of developing perceived GI and cognitive disturbances during treatment. 
Aims 
• Identify relationships between allergies, pain, cognition and gut disturbances using
exploratory questions on participants perceptions following chemotherapy treatment.
• Quantify chemotherapy recipient’s perceived severity of mucositis symptoms and
cognitive deficits using Functional Assessment for Cancer Therapy (FACT) or
Chronic Illnesses Therapy (FACIT) cognitive and gastrointestinal survey measures,
controlling for related variables (depression, anxiety, fatigue, age).
• Approach utilized the following measurement systems:
o Self-report (subjective) online questionnaire (exploratory investigator led
questions in addition to validated scale systems),
o Measured scores using the FACT and FACIT scale systems:
▪ Perceived cognitive measurements (FACT-Cog)
▪ Perceived intestinal disturbances (FACIT-D/AD)
▪ Perceived fatigue symptoms (FACT-Fat)
o Control for variables such as depression and anxiety using the depression,
anxiety and stress scale (DASS)
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CHAPTER THREE, in vivo 
Neuroimmunological Complications arising from 5-
Fluorouracil-Induced Gut Toxicity and Opioid Exposure 
in Rats 
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Statement of context 
This work has currently been submitted for review with the British Journal of Cancer. 
Bajic, JE, Howarth GS, Mashtoub S, Whittaker AL, Bobrovskaya L and Hutchinson MR. 
Chapter Three examines glial and IL-1β dysregulation in the spinal cord and 
hippocampus of rats with 5IGT. It was proposed that peripheral-to-central immune 
signalling pathways mediate these changes and that spinal cord changes would indicate a 
neural route, whereas hippocampal changes would occur via the humoral pathway. It also 
determined whether regional glial dysregulation would continue following resolution of 
the acute gut inflammation, comparing the Peak Injury to Recovery Phases of 5IGT. In 
addition, the neuroimmune complications arising from 5IGT were further explored with 
three analgesic options used to treat pain associated with CIGT, of particular interest was 
the opioid-based interventions, as they are also known for their neuroimmune-modulating 
effects.  
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Abstract 
Background: Cancer patients experience chemotherapy-induced (CI) gut toxicity (CIGT) 
and cognitive impairment (CICI). Analgesic selection for CIGT is difficult as opioids 
induce glial cell activation (neuroinflammation) and unwanted side-effects. Therefore, we 
examined whether peripheral-to-central immune pathways would directly-humorally or 
indirectly-neurally induce neuroinflammation in rats with CIGT being treated with three 
mechanistically different analgesics.  
Methods: Utilising a 5-Fluorouracil-induced GT (5IGT) rat model and analgesic 
intervention (carprofen; CAR, buprenorphine; BUP and tramadol; TRAM), neuroimmune 
consequences were examined via microglial, astrocyte and pro-inflammatory protein 
expression changes (cluster of differentiation molecule 11b; CD11b; glial fibrillary acidic 
protein; GFAP, and interleukin-1 beta; IL-1β). Hippocampal and thoracic spinal cord 
investigation determined the direct and indirect actions of 5IGT and analgesia. 
Results: BUP and TRAM with 5IGT synergistically increased hippocampal GFAP 
expression. 5IGT significantly increased thoracic GFAP (p<0.05) and IL-1β (p<0.0001) 
expression, CAR and BUP ameliorated these effects. CAR administered with 5IGT 
significantly increased hippocampal and thoracic CD11b expression levels (p<0.05).  
Discussion: Peripheral-to-central immune pathways are implicated in the neuroimmune 
adaptations observed here. Opioid-induced hippocampal changes inferred a humorally-
mediated mechanism, whereas thoracic neuroinflammation indicated activation of an 
indirect neural route. Although TRAM ameliorated 5IGT-intestinal inflammation, this 
opioid presents complications relating to bodyweight and regional glial dysregulation 
(neuroinflammation) and may not be optimal to alleviate pain associated with 5IGT 
treatment.  
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Background 
Mucositis is a painful side-effect of cancer treatment, often resulting in reduced or 
premature cessation of treatment and thus, compromising the efficacy of cancer therapy. 
Mucositis incidence occurs in approximately 40% of patients undergoing a standard-dose 
chemotherapy regime and up to 100% of patients undergoing a high-dose regime and stem 
cell or bone marrow transplantation [264, 265]. The condition may occur anywhere along 
the alimentary tract and results in significant pain, ulcerating lesions, abdominal bloating, 
nausea, vomiting, diarrhea and/or constipation [168]. Intestinal mucositis commonly 
occurs in the small intestine and is characterised by inflammation, ulceration, mucosal 
damage and malnutrition, and in severe cases, may lead to bacteraemia and sepsis [1]. In 
addition to the significant impact on patient quality of life, further downstream effects of 
mucositis become evident in longer hospital stays, increased economic burden and 
increased use of analgesic treatment for pain management. Although the pathogenesis of 
intestinal mucositis is gradually becoming more clearly defined, management interventions 
that either prevent or treat the symptoms associated with the disorder remain sub-optimal 
and largely ineffective. Research has identified additional mechanisms contributing to gut 
disturbances induced by chemotherapy drugs, and in doing so have re-named mucositis to 
chemotherapy-induced gut toxicity (CIGT) which is more inclusive of other factors 
contributing to the disorder. For example, defects in tight junctions have been implicated in 
irinotecan-induced mucosal barrier dysfunction [232] and Toll-like receptor (TLR)-4-
mediated mechanisms contributing to CIGT associated pain [134].  
Despite this, pain management remains an important factor in the treatment of CIGT. The 
World Health Organisation (WHO) analgesic ladder is a therapeutic guideline for pain 
associated with cancer [266]. The first line of treatment proposed in the guidelines is a 
non-opioid analgesic, such as a non-steroidal anti-inflammatory drug (NSAID). If the pain 
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persists, a weak opioid should replace the first medication option. Finally, if this treatment 
is insufficient in providing analgesia, a more powerful opioid should be used. The 
challenge with administering opioids to this patient population falls onto the 
neuroimmunological consequences associated with their use as they contribute to the 
development of drug tolerance, addiction and enhanced pain states [126].  
Glia represent the non-neuronal immune-like cells of the central nervous system (CNS) 
and are key players in the modulation of pain pathways, including the pharmacodynamics 
of opioids [136]. They play a pivotal role in various central homeostatic mechanisms due 
to their close relationship with the synapse (reviews [121, 122, 153]); forming the 
tetrapartite synapse [122] and contribute to neuronal consequences involving 
neurodegeneration (reviews [118, 121, 124, 131, 157, 267]). More specifically, opioids 
activate brain and spinal glia as demonstrated by up-regulation of glial fibrillary acidic 
protein (GFAP) expressed on astrocytes and cluster of differentiation 11b (CD11b) for 
microglia, morphologically changing from a ramified (resting) to amoeboid (activated) 
state [136, 139]. This central immune response driven by opioid exposure closely mimics 
the typical immunogen response to lipopolysaccharide (LPS), an endotoxin expressed by 
Gram negative bacteria [240]. LPS relies upon peripheral immune signals to activate glia 
and initiate a central pro-inflammatory immune response; neuroinflammation [268]. 
Alternatively, opioids readily permeate the brain, having direct effects on glia in 
neuroanatomical areas implicated in addiction and acting in a similar manner to 
neurotransmission, now commonly referred to as central immune signalling [269].  
TLRs are innate immune pattern-recognition receptors expressed primarily on glia and 
become up-regulated following immune insults, resulting in downstream activation of 
inflammatory transcription factors (e.g. NF-κB) and up-regulation of chemokines and pro-
inflammatory cytokines (e.g. interleukin-1 beta; IL-1β) [187]. Specifically, opioid-induced 
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glial activation and neuroinflammation are mediated by TLR-4 signalling [190, 191]. 
Certain behavioural adaptations may be induced by immune signals and result in cytokine-
induced sickness responses [80]. Hart (1988) [270] characterised sickness responses as 
anhedonia, malaise, anxiety, social withdrawal, fever, pain, and depression and proposed 
that these adaptive and functional changes were critical for survival.  
In oncology, chemotherapy patients are also prone to experiencing a cluster of physical and 
central symptoms, like cytokine-induced sickness responses [82]. In addition to the initial 
stress, depression and anxiety caused by cancer diagnosis, patients undergoing anti-cancer 
treatment often experience changes in their cognitive performance, clinically termed 
chemotherapy-induced cognitive-impairment (CICI) [271]. Rodent models of CICI have 
widely reported hippocampal-dependent behavioural adaptations following chemotherapy 
exposure, which importantly overlap with brain regions implicated in CICI [86, 116, 272-
274]. Molecular studies have confirmed that the hippocampus is particularly susceptible to 
damage across a range of chemotherapy drug exposures [87, 116, 181, 275]. Various 
chemotherapy drugs reduce hippocampal cellular proliferation, specifically targeting stem 
cells of the dentate gyrus [87, 89, 178, 275]. Critically, these rodent studies support many 
of the subjective and objective reports on CICI indicating that higher order brain 
processing from this region is implicated in CICI [79, 276]. Whilst CIGT would almost 
certainly be present in these CICI models, no intestinal data were reported. Peripheral-to-
central immune pathways offer a mechanism by which gut inflammation can result in 
behavioural changes [143, 144, 277]. Information from peripheral pro-inflammatory 
cytokines and mediators signal the brain via humoral-, neural- and cellular-mediated 
pathways, triggering physiological, behavioural and motivational changes [144]. The 
slower humoral route enables passage of cytokines or drugs (via diffusion) directly to the 
brain at circumventricular organs containing fenestrated capillaries and molecular 
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intermediates, such as prostaglandins and TLRs [268, 278]. Another system transporting 
blood-borne cytokines to the brain utilises specific, saturable carrier systems, for example 
binding to brain endothelial cells [279, 280]. Neural signalling is a more rapid route 
whereby primary afferent neurons detect peripheral immune messages, including pathogen 
associated molecular patterns, transducing them into translatable messages which are 
relayed to higher order brain regions, (e.g. vagal innervation to the nucleus tractus 
solitarius) [281]. The message is then re-transduced into an immune message in the brain 
parenchyma, where the production of cytokines impacts brain function acting either 
directly or indirectly on neurons and/or glia. Although the time course engaging these 
immune-to-brain communication pathways may differ, they all result in glial activation and 
neuroinflammation.  
The mechanisms associated with CIGT continue to be heavily researched, yet the potential 
indirect neuroimmune consequences of CIGT remain elusive. The biology of the system 
and the wider implications associated with opioid exposure and neuroimmunological 
complications during the Peak Injury Phase of CIGT also remain unknown. Thus, we 
hypothesised that glial dysregulation would occur in the brain and spinal cord of rats via 
humoral and neural immune-to-central communication pathways during the Peak Injury 
Phase of CIGT in an acute setting. We also determined whether chemotherapy-induced 
glial changes would persist into the Recovery Phase of CIGT. Finally, we assessed whether 
analgesic intervention, following the WHO analgesia ladder guidelines, would further 
impact regional glial changes in rats with CIGT. The first experiment aimed to characterise 
the time-course of glial dysregulation following chemotherapy exposure using the 
antimetabolite chemotherapy drug, 5-Fluorouracil (5-FU), comparing the Peak Injury to 
Recovery Phase of GT. Secondly, we examined the effects of three analgesics during the 
Peak Injury Phase of 5-FU-induced GT (5IGT), replicating the time-points at which 
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analgesia would be administered in a clinical setting. The analgesics selected were the 
selective COX-2 inhibitor NSAID, carprofen [282]; a partial mu (µ) opioid agonist, 
buprenorphine [283]; and an ‘atypical’ opioid analgesic, tramadol [284]. Ultimately, this 
study determined the wider implications of analgesics on certain aspects of the gut-brain 
axis, specifically their effects on GT and then assessed neuroimmunological adaptations in 
the hippocampus and spinal cord of rats with 5IGT. 
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Materials and Methods 
Female Dark Agouti rats (110-140g, n=80) were sourced from Laboratory Animal 
Services, The University of Adelaide, Adelaide, SA, Australia (barrier maintained 
Specific-Pathogen Free production facility). Female rats were selected for this study as the 
majority of clinical investigations come from the breast cancer population [58, 285]. 
Animal experimentation was approved by the Animal Ethics Committee of the University 
of Adelaide. The animal protocol described in this study minimised pain and discomfort to 
the animals by complying with the National Health and Medical Research Council Code of 
Practice for Animal Care in Research and Teaching (8th Edition, 2013). Rats were 
acclimatised and group housed in a room maintained at 21-23°C with a 12 h reversed light-
dark cycle. All rats were given ad libitum access to water and standard rat chow (Specialty 
Feeds, Glen Forrest, WA, Australia). Depending on group allocation, following 
acclimatisation period rats were either individually housed in metabolic cages (Tecniplast, 
Exton, PA, United States) for a further 2 days [110, 257] or remained in group housing. 
Bodyweight, disease activity index (DAI), feed and water intake, and faecal and urine 
output were recorded daily. 
Experiment One: Determining the Time-Point of 5IGT Glial Changes
The first experimental design determined the time-point with most significant glial changes 
according to intestinal disease progression (Figure 3.1; timeline). In order to achieve this, 
two end-points were examined based on findings from our lab [108]: end-point one (72 h 
post 5-FU administration, Peak Injury Phase); and end-point two (120 h post 5-FU 
exposure, Recovery Phase). Following acclimatisation period (-48 h to 0 h), rats were 
randomly assigned to one of four groups (Figure 3.1): 1. water + saline (SAL; 0.9% NaCl 
w/v); 2. water + 5-FU; 3. water + SAL; and 4. water + 5-FU. Groups 1 and 2 assessed end-
point 1 and groups 3 and 4 assessed end-point 2. SAL or 5-FU (Mayne Pharma Pty, Ltd, 
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Mulgrave, VIC, Australia) were administered via single intraperitoneal injection after the 
acclimatisation period (150mg/kg at 0 h).  
Experiment Two: Direct and Indirect Analgesic-Induced Glial Adaptations in 5IGT 
Glial changes were identified during the Peak Injury Phase of 5IGT in Experiment One and 
thus, the remainder of the study design was focused at 72 h post 5-FU injection (Figure 
3.1). Rats were randomly allocated to one of six groups (group housed): 5. Carprofen 
(CAR; 15mg/kg, Zoetis, US) + SAL; 6. Buprenorphine (BUP; 0.05mg/kg, Reckitt 
Benckiser, NSW) + SAL; 7. Tramadol (TRAM; 12.5mg/kg, CSL Ltd. SA) + SAL; 8. CAR 
(15mg/kg) + 5-FU; 9. BUP (0.05mg/kg) + 5-FU; and 10. TRAM (12.5mg/kg) + 5-FU 
(Figure 3.1). SAL or 5-FU (150mg/kg) was intraperitoneally injected at 0 h and analgesic 
treatments were also commenced depending on group allocation. Subcutaneous injections 
of each analgesic were performed into the scapular region, dosed as per clinical practice, at 
12 hourly intervals for the remainder of the study (6 doses in total).   
Figure 3.1. Timeline of experimental procedures. During Experiment One and Two, 5-FU or SAL was administered 
intraperitoneally at 0 h. During the first experiment euthanasia occurred at 72 h for groups 1 and 2 (Peak Injury Phase of 
5IGT) and 120 h (Recovery Phase) for groups 3 and 4. During Experiment Two, all rats underwent the same 
experimental procedure as groups 1 and 2 in the first experiment. The rats in Experiment Two also commenced one of 
the analgesic interventions subcutaneously administered at 0 h and every 12 h for the remainder of the study (6 doses in 
total). 5-Fluororuacil; 5-FU, saline; SAL, carpro fen; CAR, buprenorphine; BUP, tramadol; TRAM.  
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Tissue Collection 
Metabolic data, including indicators of disease activity, behavioural (pain scores via facial 
grimace) and intestinal measures from 192 animals in 24 groups have been previously 
published and have been reported here, as these data were collected at the same time and 
served as the key controls across multiple studies [108, 110, 286, 287]. The rats in 
Experiment One formed part of larger studies examining the metabolic and intestinal 
efficacy of naturally sourced plant and animal extracts (e.g. Emu Oil, Lyprinol and 
Rhubarb Extract) in 5IGT [108, 110, 286]. The remaining animals in the current study 
formed part of a larger study investigating the analgesic efficacy and welfare of rats with 
5IGT [287]. Importantly, these studies focused on intestinal parameters and behavioural 
outcomes without a multiple injection control group, not considering the direct and 
indirect neuroimmunological implications of 5IGT or analgesic intervention. 
Following CO2 asphyxiation and cervical dislocation, the gastrointestinal contents of each 
animal were emptied and intestines weighed. Biochemical analysis of intestinal samples 
was achieved via myeloperoxidase (MPO) assay [108, 110, 286, 287]. MPO assay was 
used an indicator of intestinal acute inflammation and the method has been extensively 
covered [109, 288]. All remaining visceral organs (thymus, spleen, lungs, heart, liver and 
kidneys) were weighed and discarded. Brain and spinal cord were dissected and snap 
frozen for further processing in western blot analysis.  
Western Blot Protocol for CNS Tissue 
Hippocampal, cervical (C2-C5) and thoracic (T6-T9) regions were dissected and 
homogenised in cell lysis buffer (Tris-base saline; pH 8.0; 50mM, 1% Triton-x100, 1% 
protease inhibitor cocktail; #P8340, Sigma-Aldrich, Castle Hill, NSW, Australia); 300μl 
(spinal cord) and 500μl (hippocampus) aliquots. Samples were sonicated (10 sec followed 
by at least 1 min on ice) until they were homogenised then centrifuged (15,000 x g) for 40 
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min. Total protein concentration in the supernatant was determined via BCA-Protein Assay 
(Pierce® BCA Protein Assay Kit; #23225, Thermo Fisher Scientific Inc., Victoria, 
Australia). Homogenised proteins of known concentrations were suspended in 2 x sample 
buffer (SDS reducing sample buffer: dH2O, 0.5M Tris-HCl pH 6.8, glycerol, 10% SDS 
solution and 0.5% bromophenol blue) and heated at 70˚C for 10 min. Equal amounts of 
protein from each sample (25μg) were loaded and separated by gel electrophoresis in 
acrylamide gradient gels. Gels were homemade (SDS page 8-10%; 40% Acrylamide/Bis, 
gel Buffer (Resolving gel: 1.5M Tris-HCl, pH 8.8 & Stacking gel: 0.5M Tris-HCl pH 6.8); 
10% w/v SDS; 10% ammonium persulfate; TEMED). Protein transfer onto nitrocellulose 
filter paper (Sigma-Aldrich, Castle Hill, NSW, Australia) used boric acid (pH 8.9; boric 
acid, EDTA for 2 h @ 600mA) transfer buffer and ponceau stains were performed. 
Membranes were blocked with either 5% skim milk (lower kDa proteins) or 5% BSA (for 
higher kDa proteins) at room temperature for 1.5 h. Protein expression utilised antibodies 
for glial fibrillary acidic protein (GFAP; 1:2000, #ab7260, Abcam, Cambridge, UK), 
cluster of differentiation molecule 11b (CD11b; Integrin aM (M19); 1:2000, #sc6614, Santa 
Cruz biotechnology, Dallas, Texas, US) and interleukin-1 beta (IL-1β; 1:1000, #ab9722, 
Abcam, Cambridge, UK); indicators of astrocyte, microglia and pro-inflammatory changes, 
respectively. Overnight incubation at 4˚C achieved primary antibody staining. β-actin 
(1:2000, #a2066, Sigma Aldrich) standardised sample loading (control) and accounted for 
protein loading variability during gel electrophoresis. An additional internal sample control 
(2μl from each sample) determined changes between gel integrity and normalised band 
detection. Electrochemiluminescence (ECL) enabled detection of all experimental analyses 
using the following secondary antibodies: Anti-rabbit/sheep/mouse antibody (peroxidase-
conjugated Affinipure Donkey Anti-rabbit/sheep/mouse IgG; 1:20,000; #711-035-152, 
#713-035-003, #715-035-150, Jackson Immuno Research, West Grove, PA, USA). 
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Immunoblots were developed using an in-house ECL reagent (10mL of 100mM Tris HCl 
(pH 8.5), 22μL of 90mM coumaric acid, 50μL of 250mM luminol and 3μL of H202) and 
bands were visualised using the ImageQuant 4100 imaging system (GE Health Care, 
Buckinghamshire, UK) [289]. Ratio-metric analysis quantified band densities and were 
measured as a fold change relative to control group, accounting for normalisation as 
described earlier.  
Statistical Analysis 
Statistical analyses were conducted using GraphPad Prism 6.02 for Windows (GraphPad 
Software Inc., San Diego, CA, USA). Data were assessed for normality using the Shapiro-
Wilks analysis. All parametric data (bodyweight, MPO and western blots) were analysed 
using a two-way analysis of variance (ANOVA) with Tukey’s post hoc comparison tests. 
Whilst some main effects were not observed using an ANOVA, significant interactions at 
different levels were reported utilising post hoc analyses. Consequently, it may be 
anticipated that the main effect would not translate to a post hoc and thus, it is 
acknowledged that this approach of statistical reporting represents a potential limitation of 
this study. Data expressed as mean ± SEM with values of p<0.05 deemed significant. 




Rats administered 5-FU significantly reduced bodyweight during the Peak Injury Phase (72 
h) of 5IGT when compared to saline controls (p<0.0001; Figure 3.2A). During the
Recovery Phase of 5IGT, rats returned to similar baseline bodyweight for the control group 
(p<0.05; Figure 3.2A). During Experiment Two, at the Peak Injury Phase of 5IGT, rats co-
administered CAR and BUP significantly reduced bodyweight compared to the SAL 
control group (p<0.0001; Figure 3.2B). TRAM potentiated the bodyweight reduction in 
rats with 5IGT (p<0.0001; Figure 3.2B).  
130 
Figure 3.2A and B. Effects of 5-FU during the Peak Injury and Recovery Phase of 5IGT on bodyweight change as represented from baseline (A). 5-FU 
significantly reduced bodyweight compared to SAL control group during the Peak Injury Phase but this reduction returned to baseline levels in the Recovery 
Phase of 5IGT. Effects of 5-FU and analgesics on bodyweight change as represented from baseline (B). 5-FU significantly reduced bodyweight compared to 
SAL control group. CAR and BUP also substantially reduced bodyweight in the presence of 5-FU compared to SAL controls. Co-administration of TRAM 
potentiated weight loss when compared to the 5-FU control group. Data represented as mean bodyweight (% change from baseline) ± SEM. ^ indicates 
significance compared to SAL control group. * indicates significance compared to 5-FU control group. ^^/** indicates p<0.01, ^^^^/**** indicates p<0.0001. 5-
Fluorouracil; 5-FU, saline; SAL, carprofen; CAR, buprenorphine; BUP, tramadol; TRAM.  
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Meloperoxidase  
During Experiment One, jejunal and ileal MPO expression significantly increased in rats 
during the Peak Injury Phase of 5IGT compared to SAL controls (p<0.0001; Figure 3.3A). 
In the Recovery Phase of 5IGT, MPO expression returned to baseline SAL expression 
levels (p>0.05; data not shown) [108]. In Experiment Two, jejunal MPO activity was 
attenuated by co-administration of both BUP and TRAM during the Peak Injury Phase of 
5IGT (p<0.01; Figure 3.3B). Whilst there was a downward trend of MPO expression in 
the ileum with all analgesics, this failed to reach significance when compared to the 5-FU 
control group.  
132 
Figure 3.3A and B. Effects of 5-FU and analgesics on myeloperoxidase (MPO) in the jejunum (A) and ileum (B) of rats during the Peak Injury Phase (72 h) of 5IGT. 
5-FU significantly elevated jejunal and ileal MPO expression compared to SAL group during the Peak Injury Phase of 5IGT. BUP and TRAM attenuated this response as
shown by a reduction in jejunal MPO expression compared to rats with 5IGT with no analgesic intervention. In the ileum, all analgesics reduced MPO expression 
compared to 5IGT control group. Data represented as mean (MPO units/g tissue) ± SEM. ^ indicates significance compared to SAL control group. * indicates significance 
compared to 5-FU control group. ^ indicates 0.05, ^^/** indicates p<0.01, *** indicates p<0.001, **** indicates p<0.0001. 5-Fluorouracil; 5-FU, 5-FU-induced gut 
toxicity; 5IGT, saline; SAL, carprofen; CAR, buprenorphine; BUP, tramadol; TRAM. 
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CD11b expression changes 
In Experiment One, no significant CD11b changes were observed during the peak or 
Recovery Phases of 5IGT in the hippocampus, thoracic or cervical regions (p>0.05; 
Recovery Phase data not shown; peak injury hippocampal and thoracic data shown on 
Figures 3.4A and 3.4B). Hippocampal CD11b expression was significantly reduced by co-
administration of CAR during the Peak Injury Phase of 5IGT compared to 5-FU controls 
(p<0.05; Figure 3.4A). Gut toxicity induced by 5-FU had a subtle downward effect on 
thoracic CD11b expression compared to controls although no statistical significance was 
determined (p>0.05; Figure 3.4B). Thoracic CD11b expression was significantly elevated 
by co-administration of CAR during the Peak Injury Phase of 5IGT (p<0.01; Figure 3.4B). 
BUP and TRAM alone significantly elevated thoracic CD11b expression only when 
compared to 5-FU treated animals (p<0.05; Figure 3.4B), although no statistical 
significance was observed when compared to the SAL control group. 
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Figure 3.4A and B. Effects of analgesics on hippocampal (A) and thoracic (B) CD11b expression during the Peak Injury Phase (72 h) of 5IGT. 5-FU alone had no effect on hippocampal 
CD11b expression, yet CAR in the presence of 5-FU significantly reduced CD11b expression compared to 5-FU control group. Although 5-FU alone had no statistically significant effect 
on CD11b expression, a trend in down-regulation is evident. CAR in the presence of 5-FU significantly elevated CD11b expression compared to the 5-FU control group. Data represented 
as mean (CD11b expression relative to β-actin) ± SEM. * indicates p<0.05 and ** indicates p<0.01 significance compared to 5-FU control group. 5-Fluorouracil; 5-FU, saline; SAL, 
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GFAP expression changes 
5IGT had no effect on hippocampal GFAP expression when compared with SAL controls 
(p>0.05; Figure 3.5A). Thoracic GFAP expression was significantly increased in rats with 
5IGT compared to SAL controls (p<0.01; Figure 3.5B). GFAP expression returned to 
baseline levels during the Recovery Phase of 5IGT (p>0.05; data not shown). CAR and 
BUP ameliorated this main effect, significantly reducing GFAP expression (p<0.01 and 
p<0.001, respectively; Figure 3.5B).  However, co-administration with BUP and TRAM 
during the Peak Injury Phase of 5IGT significantly elevated hippocampal GFAP 
expression when compared to 5-FU controls (p<0.0001 and p<0.01, respectively; Figure 
3.5A). Cervical GFAP expression was unchanged by 5-FU administration compared to 
SAL controls, yet CAR alone significantly decreased whilst TRAM alone significantly 
increased GFAP expression when compared to SAL controls (p<0.01 and p<0.0001, 
respectively; Figure 3.5C).   
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Figure 3.5A, B and C. Effects of 5-FU and analgesics on hippocampal (A), thoracic (B) and cervical (C) GFAP expression during the Peak Injury Phase (72 h) of 5IGT. Thoracic GFAP 
expression significantly increased following 5-FU administration compared to SAL controls, CAR and BUP attenuated this response (A). BUP and TRAM in the presence of 5-FU 
significantly increased hippocampal GFAP expression compared to the 5-FU control group (B). CAR in the presence of 5-FU significantly reduced cervical GFAP expression compared 
to the 5-FU control group (C). Cervical GFAP expression was also significantly reduced in CAR alone groups, whereas TRAM alone was increased when compared to the SAL control 
group (C). Data represented as mean (GFAP expression relative to β-actin) ± SEM. ^ indicates significance compared to SAL control group. * indicates significance compared to 5-FU 
control group. **/^^ indicates p<0.01, *** indicates p<0.001, ^^^^/**** indicates p<0.0001. Glial fibrillary-acidic protein; GFAP, 5-Fluorouracil; 5-FU, 5-FU-induced gut toxicity; 
5IGT, saline; SAL, carprofen; CAR, buprenorphine; BUP, tramadol; TRAM.  
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IL-1β expression changes 
Although a subtle up-regulation of hippocampal IL-1β was observed, this failed to reach 
statistical significance during 5IGT compared to vehicle controls (p>0.05; Figure 3.6A). 
BUP in the presence of 5-FU significantly decreased hippocampal IL-1β expression when 
compared to 5-FU controls (p<0.05; Figure 3.6A). BUP alone also significantly reduced 
hippocampal IL-1β expression compared to SAL controls (p<0.05; Figure 3.6A). 
Conversely, hippocampal IL-1β expression significantly increased in rats co-administered 
TRAM with 5-FU and in the TRAM control group when compared to SAL controls 
(p<0.001; Figure 3.6A).  In the thoracic region, IL-1β expression was significantly up-
regulated during the Peak Injury Phase of 5IGT compared to SAL controls (p<0.0001; 
Figure 3.6B). Co-administration of all analgesics attenuated thoracic IL-1β expression 
changes when compared to 5-FU controls (p<0.001; Figure 3.6B). 
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Figure 3.6A and B. Effects of 5-FU and analgesics on hippocampal (A) and thoracic (B) IL-1β expression during the Peak Injury Phase (72 h) of 5IGT. BUP in the presence of 5-FU 
significantly reduced hippocampal IL-1β expression compared to the 5-FU control group yet, TRAM in the presence of 5-FU increased IL-1β expression (A). GFAP expression was 
significantly increased in the thoracic region following 5-FU administration compared to the SAL control group (B). Co-administration of all analgesics attenuated this response when 
compared to the 5-FU control group (B). Data represented as mean (IL-1β expression relative to β-actin) ± SEM. ^ indicates significance compared to SAL control group. * indicates 
significance compared to 5-FU control group. * indicates p<0.05 and *** indicates p<0.001. 5-Fluorouracil; 5-FU, 5-FU-induced gut toxicity; 5IGT, interleukin-1 beta; IL-1β, saline; 
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Discussion 
Whilst research assessing the mechanisms relating specifically to CIGT continues to 
expand, the indirect neuroimmune consequences and wider implications of opioid 
treatment during the Peak Injury Phase of CIGT remain elusive. This is the first study 
characterising glial complications arising in the brain and spinal cord of rats treated with 
analgesics under 5IGT conditions. Most investigations on chemotherapy side-effects have 
focused on direct mechanisms relating to a specific side-effect, such as gut toxicity or 
cognitive impairment. Whilst these studies have importantly shaped our understanding of 
such chemotherapy-induced toxicities, they have failed to account for the potential 
influence other side-effects may have on simultaneously occurring symptoms (cluster 
symptoms). Here, our data highlights the need for research into simultaneous side-effects 
occurring as a result of chemotherapy treatment, focusing on the gut and CNS, in particular 
examining neuroimmune consequences resulting from 5IGT and opioid treatment.  
The significant weight loss and increased intestinal MPO data following 5-FU 
administration confirmed that this model induced gut toxicity in rats. Rats co-administered 
with CAR and BUP maintained a similar reduction in bodyweight as the 5-FU control 
group when compared to the SAL control group. The potentiated bodyweight reduction 
following TRAM co-administration was anticipated due to anecdotal evidence on the 
effects of opioids on feeding behaviour and bodyweight [290, 291]. Although conflicting 
results on opioid-induced behavioural and bodyweight changes report increased or 
decreased bodyweight depending on opioid selectivity and dosage, the feeding behaviour 
and bodyweight changes following exogenous opioid administration have been 
unequivocally linked to changes in the endogenous opioid system [291].  
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The MPO enzyme found in the intracellular granules of neutrophils was used as an 
indicator of acute intestinal inflammation [292]. As anticipated in the small intestine, acute 
intestinal inflammation was identified by a significant increase in jejunal and ileal MPO 
expression following 5-FU administration. This finding was in accordance with previous 
studies [108, 109, 288]. It was anticipated that acute intestinal inflammation during the 
Peak Injury Phase of 5IGT would be attenuated following co-administration of CAR, 
considering the selective COX-2 inhibitory nature of CAR and its anti-inflammatory 
action yet, MPO levels remained similar to the 5-FU control group. Interestingly, jejunal 
MPO expression during the Peak Injury Phase of 5IGT was ameliorated by both opioids.  
Opioid receptors are not only widely distributed throughout the central and peripheral 
nervous systems, but also in the gastrointestinal tract [293, 294]. Opioids have long been 
used in clinical gastroenterology due to their effects on gut motility and visceral pain 
[141]. Visceral pain is often managed with opioids as they exert their effects on peripheral 
(spinal afferents) and central (spinocerebral pathways and anterior cingulate cortex) sites, 
which reduce gut sensitivity and modify pain perception [142, 295, 296]. In fact, some 
opioids protect the gastric mucosa under stress, having anti-inflammatory effects in 
experimental colitis [297]. The analogue of buprenorphine (BU08070) used in their study 
reported a dual activity at the nociceptive and µ opioid receptor levels, showing efficacy in 
reducing the severity of experimental colitis. Furthermore, delta and µ opioid receptor 
agonists, as well as typical opioids like tramadol, exert protective effects in the rat mucosa 
under gastric stress [298, 299]. Importantly, Gyires and Ronai (2001) [299] discovered 
that vagal innervation played an integral role in the gastroprotective effects of opioids. 
Further, they identified that nitric oxide and prostaglandin synthesis in the mucosa may 
also be involved in opioid-induced gastric protection. From this, it was not surprising that 
BUP and TRAM attenuated MPO levels during the Peak Injury Phase of 5IGT and we 
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suggest this anti-inflammatory effect may at least be partially due to opioid-induced 
gastroprotective effects. Further investigations are warranted to clarify the mechanistic 
implications for the BUP- and TRAM-related MPO effects under the 5IGT conditions 
described in the current study. 
Neuroinflammation includes increased microglial and astrocyte expression and the 
subsequent synthesis of various pro-inflammatory cytokines and mediators, such as IL-1β 
[118, 120, 121]. Many chemotherapy drugs readily cross the blood brain barrier, including 
5-FU, resulting in direct cellular and molecular changes [87, 115]. Nonetheless, the acute
high 5-FU dose used in the current study failed to modulate hippocampal GFAP, CD11b or 
IL-1β expression levels. This was surprising considering short-term systemic 5-FU 
administration at a lower dosage induced apoptosis in multiple CNS regions, including the 
hippocampus of mice [115]. It is plausible that the peak injury time-point selected for the 
current study may have been suboptimal for hippocampal changes or that hippocampal 
changes require multiple dosages, more representative of a clinical setting. Neural 
progenitor cells, glial precursors and non-dividing oligodendrocytes are particularly 
vulnerable to toxicities associated with chemotherapy drugs and regimes, such as cisplatin 
and cyclophosphamide-methotrexate-5-FU [182, 300]. Although a hippocampal 
neuroinflammatory response was not present in the current study under 5IGT conditions, 
neuroinflammation has been previously suggested as a possible mechanism contributing to 
CICI utilising 5-FU as part of a regime [182]. This study did not present any spinal cord or 
gastrointestinal data, although gut toxicity would have most likely been present in their 
model.  
Thoracic GFAP expression was significantly increased during the Peak Injury Phase of 
5IGT, which supports our hypothesis that gut toxicity would induce thoracic astrogliosis. It 
was predicted this change would occur as a result of gastric innervation; that acute 
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intestinal inflammatory changes would activate a neurally-driven peripheral-to-central 
communication pathway mediating thoracic GFAP expression changes. Enteric astrogliosis 
(abnormal increase in the number of astrocytes) has been reported in a model of irinotecan-
induced intestinal mucositis [301, 302]. Whilst this study importantly indicated that 
irinotecan-induced intestinal inflammation modified enteric glial cell expression, once 
again this study focused on intestinal neuronal and astrocyte segments, potentially missing 
critical data in other CNS regions. To our knowledge, one other study has examined spinal 
cord gliosis under CIGT conditions [134]. Wardill et al. (2016) [134] reported TLR-4 
dependent mechanisms mediating irinotecan-induced gut toxicity and pain as identified by 
lumbar astrocyte activation and facial grimace changes. Facial grimace scores are regularly 
used as an indicator of pain associated with various disorders, but in this case CIGT. 
Although Wardill et al. (2016) indicated significant changes in this pain measure, 
Whittaker et al. (2016) was unable to detect any significant changes in a 5IGT model using 
the same measure [134, 287]. Whilst both studies utilised a single dose chemotherapy 
model, 270mg/kg of irinotecan was a significantly higher dose compared to the 150mg/kg 
of 5-FU and may have accounted for the lack of pain scores reported by Whittaker et al. 
(2016). It is astounding that so few studies exist considering the role spinal glia play in 
pain and the incidence of pain associated with both cancer and CIGT [1, 169, 264]. 
Nonetheless, some data exists on the role spinal astrogliosis plays in various models of 
cancer-induced pain [303-305]. In other peripheral inflammatory models, such as multiple 
sclerosis, neuropathic pain, arthritis and more recently, endometriosis, the role spinal glia 
play in pain continues to be intensively studied [304, 306-308].  
Considering the steep elevation in thoracic GFAP expression, it was predicted that a 
similar increase in CD11b expression would occur, however this was not the case in the 
current model. Microglia have long been considered the major resident immunocompetent 
Chapter Three. Neuroimmune changes in CIGT and opioid exposure 
143 
cells in the CNS [118, 119, 121, 309]. Due to their innate surveillance role in their 
quiescent state, microglia are in a favourable position to be the first in-line to respond to 
stressors [119]. Substantial evidence suggests an interaction between microglia and 
astrocytes; that both cells work in unison to modulate the microenvironment, playing 
pivotal roles in CNS development, maintenance and pathology [124, 125]. As microglia 
have classically been referred to as the initial neuroimmunological defence cells, it was 
surprising that 5IGT induced astrocyte activation, yet had no effect on microglial CD11b 
expression. However, the lack of CD11b expression changes in the current study was in 
accordance with a previous study whereby, lumbar region glial activation was 
immunohistochemically identified using GFAP and Iba-1 expression markers in rats with 
irinotecan-induced gut toxicity [6]. At 72 h, GFAP expression was significantly increased 
compared to the control group, yet Iba-1 changes were not reported. GFAP expression was 
significantly increased at 6 h and 72 h following irinotecan administration. Other 
compelling evidence linking central astrogliosis to CIGT has been identified in models 
using oxaliplatin and vincristine [132, 133, 310]. These findings coupled with the lack of 
microglial marker changes in the current study implicate astrocytes in playing a 
preponderant role in response to peripherally driven inflammatory events, such as CIGT. It 
is possible that the current study missed the peak time-point of microglial activation, as 
this may have occurred prior to the 72 h end-point. Future studies should fully characterise 
the time course of glial activation. Whilst it is widely accepted that microglia are the first 
to respond to central insults, our data suggests that astrocytes take on this role in response 
to peripheral inflammatory events, such as 5IGT.  
Experimentally-induced glial activation models have also reported the simultaneous up-
regulation of various pro-inflammatory cytokines, such as TNF-α and IL-1β [303, 307]. 
Thus, it was anticipated that 5IGT-induced GFAP up-regulation would also result in 
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elevated IL-1β expression levels. This was indeed the case in the thoracic region of rats 
with 5IGT. Regardless, the current study was unable to clarify the mechanistic significance 
of the thoracic astrocyte and IL-1β modulation observed in 5IGT and hence further 
investigation is warranted. Nonetheless, the findings presented here suggest that 5IGT 
resulted in thoracic neuroimmunological changes mediated by a neural immune-to-central 
signalling pathway. Characterising the pro-inflammatory and anti-inflammatory cytokine 
profiles as well as behavioural changes in future studies of 5IGT-induced glial 
dysregulation would identify potential mechanistic adaptations. Importantly, behavioural 
and pain assessment would identify whether CIGT has negative effects on cognition, as 
this has been previously suggested [61, 302]. 
Centrally, it was expected that the selected opioids would modify glial and IL-1β 
expression levels due to the relationship between opioids and spinal cord immune 
signalling [126]. CAR also has central effects indicating that analgesia may be partially 
mediated by serotonergic mechanisms [311]. CAR significantly altered hippocampal and 
thoracic CD11b expression in rats with 5IGT. However, it is important to note that in the 
hippocampus, CD11b and GFAP expression was not altered by 5IGT when compared to 
controls. As there was no modulation identified in the 5IGT group, the question remains as 
to why CAR reduced CD11b from normal expression levels. This could be explained by 
the anti-inflammatory effect CAR had in a mouse model of traumatic brain injury [312]. 
More specifically, CAR reduced microglial numbers in the post-traumatic brain via 
inhibition of COX-2 [312]. From this it is plausible that CAR in the presence of 5IGT 
resulted in a synergistic effect on microglia in the hippocampus. Future behavioural data 
on hippocampal-dependent cognitive changes utilising this analgesic would clarify 
potential functional adaptations and the significance of these findings.  
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In the thoracic region, CAR significantly increased CD11b expression during the Peak 
Injury Phase of 5IGT. Here, it should also be noted that CD11b in the 5IGT control group 
was not statistically different from the SAL control group, although a trend in down-
regulation was evident. Whilst the BUP and TRAM control groups elevated thoracic 
CD11b expression when compared to 5-FU treated rats, the 5-FU-induced CD11b changes 
were not statistically significant. In this instance, although the thoracic CD11b results are 
somewhat ambiguous, we can conclude that CAR in 5IGT and BUP and TRAM alone 
result in microglial activation as indicated by increased CD11b expression. Whether these 
changes in expression level occurred as a result of a reduction in microglial cell number or 
morphological changes remains to be elucidated and further studies will elucidate the 
changes seen in this model.  
Neuroinflammation was present in the thoracic region of rats with 5IGT as determined by 
increased GFAP expression and elevated IL-1β expression, yet CAR and BUP attenuated 
this response. TRAM failed to have any direct effect on GFAP expression during the Peak 
Injury Phase of 5IGT. Accordingly, CAR and BUP administration had an anti-
neuroinflammatory effect during the Peak Injury Phase of 5IGT; central immune signalling 
could explain this finding. Clinically, the findings of the current study suggest that CAR 
and BUP would be the optimal analgesic if the goal were to reduce thoracic 
neuroinflammation in 5IGT. The anti-neuroinflammatory effect of CAR and BUP in 5IGT 
could be at least partially mediated by the reduced IL-1β expression at this time-point. 
Interestingly, whilst TRAM failed to attenuate GFAP expression changes, it effectively 
reduced IL-1β expression to normal levels, like CAR and BUP. The mechanism underlying 
the reduction in thoracic IL-1β in the TRAM group is therefore unable to be explained by 
central immune signalling or mediated by the neuroimmune system in 5IGT.  
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Here we identified a main neuroimmunological effect on thoracic astrocyte activation and 
increased IL-1β expression during the Peak Injury Phase of 5IGT. We suggest that this 
regional neuroinflammatory state was indirectly driven by 5IGT thoracic innervation and 
mediated by a neural peripheral-to-central immune signalling pathway. From a 
neuroimmunological perspective, these findings indicate that TRAM had the least 
ameliorating effect on GFAP expression changes in either region where neuroinflammation 
was present. Taken into consideration, this may have significant implications clinically as 
TRAM may not be optimal at reducing pain associated with CIGT. However, we 
acknowledge that making such clinical suggestions warrants more detailed characterisation 
of the neuroimmunological consequences of 5IGT and importantly, studies more 
replicative of a clinical oncology setting are critical. Similarly, the up-regulation of 
hippocampal IL-1β expression following TRAM co-administration in 5IGT indicated a 
pathological synergistic adaptation, which could potentially contribute to a neurotoxic 
environment with detrimental outcomes for surrounding neurons. Nonetheless in 
conclusion, BUP co-administration during 5IGT was the most efficacious analgesic option 
in this study. Not only did BUP offer some anti-neuroinflammatory and potentially 
neuroprotective effect as determined by thoracic GFAP expression attenuation and reduced 
pro-inflammatory parameters, but it also had a positive effect on intestinal acute 
inflammation as it reduced MPO expression during the Peak Injury Phase of 5IGT.   
Despite recent advancements in our understanding of pain associated with CIGT, pain 
management for cancer and CIGT continues to be an issue. Choosing the optimal analgesic 
for pain associated with CIGT is challenging due to the risks associated with opioid 
tolerance, dependence and enhanced pain states. It is important to understand the wider 
implications of opioid use in the oncology arena and this study has helped to fill the gap on 
the neuroimmune consequences of 5IGT and opioid treatment. Microglia and astrocytes 
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are critical in CNS homeostasis forming a close relationship with the synapse. Glial 
dysregulation plays a role in a range of neurodegenerative diseases and pathological pain 
syndromes and it is plausible that under chemotherapy conditions, they may contribute to 
cognitive changes and pain states. Future studies should critically assess the 
morphological glial adaptations described in the current study via immunohistochemistry 
and this is acknowledged as a limitation of the current study. Chemotherapy-induced glial 
dysregulation and the consequences arising from opioid treatment should be further 
investigated as the benefit of using this form of analgesic may outweigh the risks and 
complications associated with opioid use. 
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CHAPTER FOUR, in vivo 
“Big Brain” and “Little Brain” Consequences in 5-
Fluorouracil-Induced Gut Toxicity and Indomethacin-
Induced Enteropathy; Neuroimmune and Microbiome 
Implications 
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Statement of context 
This manuscript has been submitted to the Journal of Molecular Cancer Therapeutics. 
Bajic, JE, Howarth GS, Selway CA, Weyrich LS and Hutchinson MR. 
Chapter Four provides a detailed characterisation of intestinal damage in rats with acute 
5IGT and INDO-enteropathy. It describes and quantifies astrocyte protein expression 
changes in the thoracic region of rats with 5IGT and suggests this was mediated by a 
neural peripheral-to-central immune signalling mechanism. Additionally, this chapter 
provides histological data which supports the reactive astrocyte phenotype suggested by 
the up-regulation of thoracic GFAP expression. Finally, this chapter reports on the caecal 
microbiota changes observed in the chemotherapy group and discusses the potential 
functional significance of these findings.  
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Abstract 
Chemotherapy-induced (CI) gut toxicity (CIGT) and cognitive impairment (CICI) are a 
significant burden at the individual, clinical and global levels. The need to clarify 
mechanisms contributing to CIGT and CICI are critical, and the neuroimmune system and 
gut microbiota are ideally positioned to influence both toxicities. Using a single high-dose 
rat model of 5-Fluorouracil (5-FU)-induced gut toxicity (5IGT) we sought to determine 
whether intestinal inflammation would induce caecal microbiota changes and glial 
reactivity in the brain and spinal cord. Effects were compared to a low-dose, non-
chemotherapy inflammatory model of non-steroidal anti-inflammatory drug (NSAID)-
enteropathy. It was proposed that glial reactivity may be mediated by peripheral-to-central 
immune signalling pathways (humoral and neural). 5IGT reduced bodyweight, elevated 
myeloperoxidase activity and significantly altered the mucosal architecture in the small 
intestine of rats during the Peak Injury Phase (72 h). 5IGT resulted in changes to the caecal 
microbiota, significantly reducing alpha phylogenetic diversity, decreasing the relative 
abundance of commensal bacterial taxa and elevated some non-commensals, such as 
Bacteroides. Spinal thoracic astrocyte reactivity was observed in rats with 5IGT via 
increased protein marker expression changes and histological assessment. The mucosa of 
NSAID-treated rats was maladapted compared to vehicle controls (reduced villus height 
and crypt depth), and bodyweight, acute intestinal inflammatory parameters, caecal 
microbial and astrocyte marker changes were not affected at 72 h. The findings 
demonstrate that inflammation in the “little brain” (5IGT) results in “big brain” 
inflammation (spinal thoracic astrocyte reactivity) via a neurally-mediated immune 
signalling mechanism. The microbiota perturbations and neuroimmune findings indicate 
that these two disparate, yet connected mechanisms, are not only playing a role in the 
pathogenesis of regimen-related gut and central toxicities, but suggest that they are 
uniquely positioned to influence both CIGT and CICI symptoms. 
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Background 
The central nervous system (CNS; “big brain”) and gastrointestinal tract (GIT; “little 
brain”) form the primary organs susceptible to toxicities associated with chemotherapy 
treatment. Clinically, CNS changes referred to as chemotherapy-induced cognitive 
impairment (CICI), whilst GIT perturbations are termed chemotherapy-induced gut 
toxicity (CIGT) [1, 272, 313]. Both disorders often occur simultaneously and cause a 
significant strain on patient quality of life. Extensive research has provided mechanistic 
explanations for each toxicity, yet they have not considered the direct or indirect influence 
each disorder has on the other. This is surprising considering the multiple mechanisms and 
pathways involved in gut-brain signalling and vice versa – the integration of information 
from many systems. The central, autonomic and enteric nervous systems, the microbiota-
gut-brain axis, neuroendocrine, enteroendocrine and neuroimmune input make up some of 
these systems and have been extensively reviewed elsewhere [3-5, 8, 14, 15, 36, 314, 315]. 
CIGT is comprised of five constantly overlying pathophysiological phases described by 
Sonis (2004) [1]. Whilst chemotherapy drugs have differing mechanisms of action, the 
model proposed by Sonis can be applied to most treatment modes. Recently, the unique 
roles of additional pathological features to specific drugs have been highlighted. For 
instance, the widely utilised chemotherapy drug, 5-Fluorouracil (5-FU) induced enteric 
neurotoxicity and colonic dysmotility [107]. Particular interest has been given to the role of 
an unbalanced intestinal microbiota in 5-FU-induced gut toxicity (5IGT) [213, 316]. 
Specifically, a shift in the bacterial composition from Gram-positive to Gram-negative 
organisms was observed in 5-FU-treated rats [214]. Development of the research term 
“oncomicrobiome” purely focuses on the role of the microbiota in cancer aetiology, 
including cancer risk, as well as identifying mechanisms that influence the toxicity and 
efficacy of various chemotherapy drugs [38, 208]. This is important as commensal bacteria 
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play pivotal roles in host innate and adaptive immune responses [317]; thus, changes in 
microbiota can influence CNS disorders, such as Alzheimer’s disease, depression and 
Parkinson’s disease [18-20]. The influence of CIGT-induced microbiota changes has yet to 
be examined in the context of CICI, regardless of the influential and bidirectional nature of 
the microbiota-gut-brain axis.  
Intestinal epithelial homeostasis is maintained by an interaction between commensal 
bacteria and Toll-like receptors (TLRs), innate pattern recognition receptors [192]. TLRs 
belong to a family of receptors which are sensitive to immune insults and critically initiate 
innate immune responses [318]. Release of immune messages, such as pro-inflammatory 
cytokines, from the intestine are able to reach higher order brain regions via humoral and 
neural communication routes [144, 277]. This triggers a neuroimmunological response 
involving glial cell reactivity, increased synthesis of immune cytokines, mediators and 
neurotrophic factors, which include glutamate, interleukins (ILs) and bone-derived 
neurotrophic factor (BDNF), ultimately assisting the host in healing [121, 122, 143]. The 
immune-like cells of the CNS, primarily glial cells (microglia and astrocytes), form an 
intimate relationship with the synapse and are pivotal in CNS homeostasis [118, 120]. 
Increased glial cell expression and neuroinflammation contributes to many central and 
peripheral disorders, ranging from neuropathic pain and peripheral neuropathies, to 
neurodegenerative disorders, such as Parkinson’s disease and depression [124, 131, 133, 
157, 267, 319]. Nevertheless, few studies have focused on the role of the neuroimmune 
system (glial cells) in CIGT [134, 320]. Due to the intimate relationship glial cells have 
with the synapse, they are ideally positioned to influence, contribute to or potentiate 
learning and memory deficits in the context of CICI.  
CICI affects a substantial subset of cancer patients [321-323] in memory, attention, 
executive function and processing speed [321]. Various biological and molecular factors 
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predispose cancer patients to CICI, such as cognitive reserve, immune function and 
genetics [84, 113]. Direct chemotherapy drug interactions in higher order brain regions, 
regardless of drug mechanism of action, reduce hippocampal neurogenesis in CICI 
experimental models [86, 87]. These studies link chemotherapy-induced hippocampal 
changes to learning and memory deficits in rodents. Drugs widely utilised in cancer and 
CICI studies, such as 5-FU, are also selected in CIGT studies. Whilst all CICI 
investigations will have most likely resulted in gut toxicity, the influence of intestinal 
inflammation on CICI has yet to be examined. A neuroimmunological mechanism for 
CICI has been proposed [62, 302], although few studies have reported findings [134, 320] 
and this highlights the need for further examination. Regional spinal astrocyte activation 
and pain were mediated by TLR-4 following systemic administration of irinotecan in mice 
[134], whereas methotrexate activated hippocampal microglia but was unable to elevate 
central cytokine expression [320]. Importantly, the findings from these studies indicate a 
potential role for the neuroimmune system in mediating the pathogenesis of both regimen-
related toxicities, in the “little brain” and “big brain”.  
In light of the increasing incidence of cancer and use of chemotherapy treatments, there is 
a clear need to better understand the pathophysiological mechanisms underpinning both 
disorders. The current study sought to determine whether 5IGT induced acute intestinal 
inflammation and caecal microbiota changes in rats. Secondly, it determined whether 5-FU 
would directly induce glial cell reactivity in higher order brain regions, by directly crossing 
the blood brain barrier (BBB), indicating a humorally-mediated immune signalling 
pathway. It was also postulated that systemic 5-FU would induce spinal cord glial 
reactivity, indirectly resulting from 5-FU-induced intestinal inflammation, indicative of a 
neurally-mediated signalling pathway. Thirdly, utilising a single high-dose model of 5IGT, 
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the current study aimed to determine whether the effects were unique to 5-FU by 
comparing microbiota and regional glial changes in a rat model of reduced 
intestinal inflammation, induced by a low-dose of the non-steroidal anti-
inflammatory drug (NSAID), indomethacin. 
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Materials and methods 
Female Dark Agouti rats (110-140g, n=36) were sourced from the Animal Resources 
Centre in Western Australia (barrier maintained Specific-Pathogen Free production 
facility). Animal experimentation was approved by the Animal Ethics Committee of the 
University of Adelaide. The animal protocol described in this study minimised pain and 
discomfort to the animals by complying with the Australian National Health and Medical 
Research Council Code of Practice for Animal Care in Research and Teaching (8th Edition, 
2013). Rats were randomly grouped (n=12/group; 8/group for molecular and 4/group for 
immunohistochemical analysis) and group-housed (with a combination of rats from each 
group) in a room maintained at 21-23°C with a 12 h reversed light-dark cycle. All rats 
were provided ad libitum access to water and standard rat chow. Following an 
acclimatisation period (>2 weeks), at 0 h, rats were intraperitoneally administered a single 
dose of saline (SAL), 5-FU (150mg/kg; Mayne Pharma Pty Ltd, Mulgrave, Victoria, 
Australia) or indomethacin (INDO, 20mg/kg; Sigma-Aldrich, Missouri, United States of 
America, #17378-10G).  
Daily Metabolic and Disease Activity Index
Bodyweight and severity of gut toxicity were measured daily using a disease activity index 
(DAI) [324]. To assess the severity of gut toxicity, overall condition, bodyweight and stool 
consistency (evidence of rectal bleeding) were measured using a scale (0-3) with 
increasing severity for each parameter. Scores were totalled to achieve an overall DAI, 
described previously [324, 325]. Overall condition was determined by, 1) mobility/agility: 
healthy rats are active and alert, whereas rats treated with 5-FU or INDO characteristically 
become weakened, often sitting hunched with little movement, and (2) fur: healthy rats are 
well groomed with flat, shiny hair that sits close to their body, whereas unhealthy rats 
appear scruffy, with a dull, ruffled coat.   
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Tissue Collection and Preparation
Gastrointestinal tract. Following CO2 asphyxiation, the gastrointestinal contents of each 
animal were removed, measured, emptied of contents and the intestine weighed. Small 
intestinal segments were collected at approximately 10% (jejunum) and 90% (ileum) of the 
total small intestinal length and snap frozen for biochemical analysis. Further segments of 
the small intestine (jejunum, jejunum-ileum (JI) junction and ileum; 2 cm) were dissected 
and placed in 10% neutral-buffered formalin for histological analysis. The remaining 
visceral organs (thymus, lungs, heart, liver, kidneys and spleen) were weighed and 
discarded. Caecal contents were isolated and frozen at -20ºC for bacterial diversity 
profiling.  
CNS. Following removal of organs, rats were decapitated and the vertebral column 
dissected. The entire spinal cord was isolated and the brain was carefully removed whole 
from the skull and snap frozen in liquid nitrogen for biochemical analysis. An additional 4 
animals from each group were perfused with 4% PFA and decapitated. The spinal cord 
was isolated and sectioned into cervical (C3-C5), thoracic (T7-T9) and lumbar (L2-4) 
regions. Coronal sections of the hippocampus were isolated between bregma -5.00 to -5.50 
following a conventional rat brain atlas (Paxinos and Watson, 2006). 
Intestinal Biochemical Analyses
Myeloperoxidase (MPO) is an enzyme in the intracellular granules of neutrophils, thus 
providing a quantitative analysis of acute inflammation [292]. Jejunal and ileal segments 
were thawed and prepared for MPO assay via homogenisation in 10mM phosphate buffer 
(pH 6.1). Homogenised samples were centrifuged at 13,000 rpm for 12 min and the 
supernatant discarded. The remaining pellet was resuspended with 0.5% 
hexadecyltrimethyl ammonium bromide buffer and vortexed prior to a final centrifuge 
(13,000 rpm for 2 min). Supernatant from each sample (50µL aliquot) was dispensed into a 
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96-well plate and the MPO reaction was initiated with an O-dianisidine dihydrochloride
solution (200µL/well; 4.2mg O-dianisidine dihydrochloride, 12.5µL hydrogen peroxide 
(30%) in 2.5mL potassium phosphate buffer (50mM, pH 6.1) and 22.5mL distilled H2O). 
A spectrometer (Victor X4 Multilabel Reader, Perkin Elmer, Singapore, South East Asia) 
measured absorbance (450nm) at 1 min intervals over a 15 min period. The change in 
absorbance was used to calculate MPO activity within a tissue sample (MPO units/g of 
intestinal tissue). 
Intestinal Histological Analyses
Following removal from formalin, intestinal samples were transferred to 70% ethanol 24 h 
post-collection. Samples were embedded in paraffin wax and sections (4µm) were 
routinely processed and stained with haematoxylin and eosin (H&E). Nanozoomer™ and 
Digital Pathology Software (Hamamatsu Photonics, Japan and Histalim, Montpellier, 
France) was utilised to visualise histological intestinal changes at 3.5 x and 10 x 
magnification. Villus height (VH) and crypt depth (CD) were measured in the small 
intestine and determined for 20 well-orientated villi and crypts per small intestinal tissue 
section, per rat and a mean value was obtained for statistical analysis [326]. All intestinal 
histological analyses were performed in a blinded-fashion using ImageJ 1.49 software 
(NIH Image, Maryland, USA).  
Immunohistochemical assessment of Astrocyte Reactivity Expression Markers
Thoracic spinal cord (T7-9) sections (5µm) were sliced on a rotary microtome and 
mounted on to Superfrost® microscope slides (Menzel-Glăser, Braunschweig, Germany). 
Astrocytic reactivity was performed using Glial Fibrillary Acidic Protein (GFAP; Clone 
6F2, DakoCytomation, Dako, Denmark; #M0761. Briefly, sections were dewaxed in 
xylene and dehydrated in 100% ethanol before being quenched for endogenous peroxidase 
activity in methanol with 0.5% hydrogen peroxide for 30 min. Slides were washed in 0.1% 
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M PBS (pH 7.4, 3 x 2min) before undergoing heat-mediated antigen retrieval using 0.1 M  
citrate buffer (pH 6.0). Non-specific binding was blocked by 3% normal horse serum 
(NHS; Sigma-Aldrich, NSW, Australia) at room temperature for 30 min. GFAP (diluted in 
3% NHS) was applied overnight at room temperature in a humid chamber (GFAP 
2mg/µL). Following removal of GFAP stain, a secondary goat biotinylated anti-rabbit IgG 
antibody (Vector Laboratories, California, USA, anti-rabbit #BA1000, at 6mg/µL) was 
applied to the sections at room temperature for 30 min. After washing with PBS (3 x 2 
min) slides were incubated with Pierce™ streptavidin peroxidase conjugate (ThermoFisher 
Scientific, VIC, Australia, #21130, at 2mg/µL) at room temperature for 30 min followed 
by a PBS rinse. Immunocomplex was visualised with DAB (Sigma-Aldrich, NSW, 
Australia, #D5637) precipitation in the presence of hydrogen peroxide (3%). Slides were 
washed to remove excess DAB and lightly counter-stained with haematoxylin, dehydrated 
and mounted with DePeX from histolene. Slides were scanned and assessed using the 
Nanozoomer™ and Digital Pathology Software (Hamamatsu Photonics, Japan and 
Histalim, Montpellier, France). Staining was assessed in the dorsal column of the spinal 
cord using ImageJ 1.49 software and the previously validated colour deconvolution 
method [327]. 
Western Blot Protocol for CNS Tissue
Hippocampal, pre-frontal cortex and hypothalamus brain regions, and cervical (C2-C5) 
and thoracic (T7-T9) (spinal) regions were dissected and immersed in cell lysis buffer 
(Tris-base saline; pH 8.0, 50mM, 1% Triton X-100; 1% protease inhibitor cocktail, 
#P8340, Sigma-Aldrich, Castle Hill, NSW, Australia); 300μl (spinal cord) and 500μl 
(hippocampus) aliquots. Samples were sonicated (10 sec followed by at least 1 min on ice) 
then centrifuged (15,000 x g) for 40 min. Protein concentration of the supernatants were 
determined via BCA-Protein Assay (Pierce® BCA Protein Assay Kit; #23225, Thermo  
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Fisher Scientific Inc., Victoria, Australia.). Homogenised proteins of known 
concentrations were suspended in 2 x sample buffer (SDS reducing sample buffer: 
deionised H2O, 0.5M Tris-HCl pH 6.8, glycerol, 10% SDS solution and 0.5% 
bromophenol blue) and heated at 70˚C for 10 min. Equal amounts of protein from each 
sample (25μg) were loaded and separated by gel electrophoresis in acrylamide gradient 
gels. Gels were homemade (SDS page 8-10%; 40% Acrylamide/Bis; gel buffer (Resolving 
gel: 1.5M Tris-HCl, pH 8.8, and Stacking gel: 0.5M Tris-HCl pH 6.8); 10% w/v SDS; 
10% ammonium persulfate; TEMED) and optimised to suit antibody specifications. 
Protein transfer onto nitrocellulose filter paper (Sigma-Aldrich) used a boric acid transfer 
buffer (pH 8.9; boric acid, EDTA for 2 h at 600 mA) and ponceau stain performed. 
Membranes were blocked with 5% skim milk (lower kDa proteins) at room temperature 
for 1.5 h. Protein expression utilised antibodies for GFAP (1:2000; #ab7260, Abcam, 
Cambridge, UK) and Ionized calcium binding adaptor molecule-1 (Iba-1; 1:1000 WAKO; 
#019-19741, Osaka, Japan) indicators of astrocyte and microglia expression changes, 
respectively. Overnight incubation at 4˚C achieved primary antibody staining. β-actin 
(1:2000; #a2066, Sigma Aldrich, St. Louis, MO, USA) standardised sample loading 
(control) and accounted for protein loading variability during gel electrophoresis. An 
additional internal sample control (2μL from each sample) determined changes between 
gel integrity and normalised band detection. Electrochemiluminescence (ECL) enabled 
visualisation of the protein bands using secondary antibodies: anti-rabbit/sheep/mouse 
antibody (peroxidase-conjugated Affinipure Donkey Anti-rabbit/sheep/mouse IgG; 
1:20,000; #711-035-152, #713-035-003, #715-035-150; Jackson ImmunoResearch 
Laboratories, Inc., PA, USA). Immunoblots were developed using an in-house ECL 
reagent (10mL of 100mM Tris HCl (pH 8.5), 22μL of 90mM coumaric acid, 50μL of 
250mM luminol and 3μL of H2O2) and were visualised using the ImageQuant 4100 
imaging system (GE Health Care, Buckinghamshire, UK) 
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 [289]. Ratio-metric analysis quantified band densities and were measured as a fold-change 
relative to control group, accounting for normalisation as described earlier. 
Bacterial Diversity Profiling
Bacterial DNA was extracted from 500mg of rat caecal material using the DNeasy 
PowerSoil Kit (Qiagen, MO Bio Laboratories, Carlsbad, CA, USA, #12888-100), 
following manufacturer’s instructions. Extraction blank controls (EBC) were performed in 
parallel to monitor DNA present in the laboratory and within reagents. Using Illumina Inc. 
(San Diego, CA, USA) primers, the V4 region of the 16S rRNA was targeted and 
amplified in triplicate. Individual polymerase chain reactions (PCR) (25µL) contained 
18.05µL of DNA-free water, 2.5µL 10x HiFi Taq buffer (ThermoFisher), 1.0µL MgSO4 
(25mM), 0.2µL dNTPS (25mM) (ThermoFisher), 0.25µL HiFi Platinum Taq DNA 
polymerase (ThermoFisher), 1µL of each V4 primer (10mM; barcoded reverse primer) and 
1µL of DNA extract. Cycling conditions were as follows: 95°C for 6 min; 38 cycles of 95°
C for 30 sec, 50°C for 30 sec, 72°C for 90 sec; and a final extension at 60°C for 10 min. A 
no-template control (NTC) monitored laboratory and reagent contamination for each PCR 
group. Once amplified, triplicate PCR products were pooled and the presence of a 16S 
rRNA V4 gene product was verified by gel electrophoresis, using a 2.5% agarose gel. 
Amplifiable products from EBCs and NTCs were prepared for sequencing and 
investigated laboratory and reagent contamination in order to avoid the presence of false 
positives as true biological signal. 16S rRNA libraries were quantified using a Qubit 
dsDNA HS assay kit (ThermoFisher) and pooled in equimolar concentrations (30 samples 
per group). Pooled libraries were then size selected and cleaned using AxyPrep to remove 
excess primers and primer dimers. The pooled, cleaned libraries were then quantified 
using a broad sensitivity D1000 Screentape on an Agilent 2200 Tapestation. Quantitative 
PCR (qPCR; KAPA Illumina Primer mix) was carried out to accurately determine the 
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concentration of this final library (LightCycler 96 System, Roche Life Science), before 
diluting to a 2nM concentration for sequencing. Libraries were sequenced on the Illumina 
Miseq using 2 x 150 bp kits with custom sequencing primers. DNA sequences were 
demultiplexed, quality filtered and operational taxonomic units (OTU) were identified 
from fastq sequences in QIIME (v 1.8.). After demultiplexing and quality filtering 
sequences based on their unique barcode identifier, a file containing all sequences assigned 
to each sample (seq.fna) was produced and combined with a seqs.fna from all 16S rRNA 
libraries created at the Australian Centre for Ancient DNA (ACAD; n=1692). Finally, 
open and closed reference OTU strategies were applied to identify sequences according to 
the Greengenes reference database (v13.8). The open reference OTU picking provides all 
the closed OTUs (those identified in the Greengenes (v13.8) database), as well as any 
unique OTUs that cluster separately (de novo). A filtering process was performed to ensure 
contaminant sequences were removed before proceeding with diversity analyses and 
taxonomic profiling. 
Statistical Analysis
Bodyweight and Metabolic Parameters: Statistical analyses were conducted using IBM 
SPSS Statistics Program (v 25). These data were tested for normality using the Shapiro-
Wilk analysis. All data were analysed using a one-way analysis of variance (ANOVA) 
with Tukey’s post hoc comparison tests. Bodyweight was analysed using a repeated 
measures ANOVA. Whilst some main effects were not observed using an ANOVA, 
significant interactions at different levels were reported utilising post hoc analyses. 
Consequently, it may be anticipated that the main effect would not translate to a post hoc 
and thus, it is acknowledged that this approach of statistical reporting presents as a 
potential limitation of this study. All data expressed as mean (unless otherwise stated in 
Figure legends) ± SEM with values of  p<0.05 deemed significant. 
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Microbial Diversity Analyses
Alpha and beta diversity (diversity within and between samples, respectively) was 
calculated, and the taxonomic composition of samples was summarised. For alpha 
diversity, two metrics were used: (1) observed species; bacterial species richness, and (2) 
phylogenetic diversity; phylogenetic distance of bacteria within samples. Samples were 
rarefied to 8000 sequences and an alpha diversity statistic (two-way t-test) was applied. 
Beta diversity measured the diversity between samples using a distance matrix. Due to the 
abundance of various taxa within 16S data sets being biased, only the unweighted UniFrac 
(a phylogenetic metric not weighted on the abundance of taxa) metric was used. OTUs 
were summarised into their taxonomic classification via analysing the genera driving the 
alpha- and beta-diversity. Category significance (beta diversity statistics) was determined 
via adonis and ANOSIM analyses which investigated the variation between categories 
within each metadata field. The effect size (R2) and dissimilarity between groups (R value) 
determined the p-value.  
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Results 
INDO and 5-FU Treatment Decreased Bodyweight
Following administration, bodyweight percentages decreased on day 1 in the majority of 
rats compared to experimental day -2, regardless of treatment type, although this failed to 
reach significance between treatment groups (p>0.05). When compared to VEH controls, 
INDO and 5-FU treatment significantly decreased bodyweight on day 2 (p<0.05 and 
p<0.01, respectively; Figure 4.1). The average reduction in bodyweight percentage for 5-
FU treated rats on this day was -2.6g, compared to VEH controls averaging an increase of 
1.9g. Whilst the INDO group bodyweight percentage returned to baseline levels on day 3, 
5-FU rats maintained a significantly reduced bodyweight (average -1.29g) on day 3
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Figure 4.1. Bodyweight represented as a percentage from baseline (day -2). All data expressed as mean % 
of each treatment group from baseline (day -2) ± SEM. * indicates p<0.05, ** indicates p<0.01 and *** 
indicates p<0.001 compared to vehicle controls. 5-Fluorouracil; 5-FU, indomethacin; INDO, vehicle; VEH. 
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INDO and 5-FU Reduced Small Intestinal Length and Differentially Affected Visceral Organ 
Weights
The total length of the small intestine (SI; jejunum and ileum) of rats treated with INDO 
and 5-FU significantly reduced compared to VEH controls (p<0.01 and p<0.001, 
respectively; Table 4.1A). Additionally, SI weight was significantly increased in INDO 
treated rats compared to 5-FU treated animals, which decreased compared to VEH 
controls (p<0.05 and p<0.001, respectively). Colon and duodenum lengths were unaffected 
by either drug (p>0.05). Other significant INDO- and 5-FU-induced organ weight changes 
were evident in the thymus, liver and spleen compared to vehicle controls (p<0.05; Table 
4.1B). Colonic weight was significantly increased in 5-FU treated rats compared to VEH   
Table 4.1. GI and organ lengths (A) and weights (B). Weight data were calculated according to bodyweight 
adjustments for each animal in each group. Data expressed as mean (% relative to bodyweight) ± standard error of 
the mean. * indicates p<0.05, ** indicates p<0.01 and *** indicates p<0.001 compared to VEH control. 
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5-FU Administration Increased DAI on Day 2
Although a slight increase in DAI scores was evident on day 1 following VEH, INDO and 
5-FU administration (mean increasing from an average of 0.3-0.5 on day 0 to 0.6-0.9 on
day 1), this was not statistically significant (p>0.05; Table 4.2). On day 2, DAI scores 
increased in rats with INDO-enteropathy and 5IGT, though this only reached statistical 
significance with the 5-FU group when compared with VEH controls (p=0.002; Table 4.2). 
Whilst rats with 5IGT maintained an elevated DAI mean on day 3, this was insignificant 
compared with VEH controls (p=0.06).  
 
Table 4.2. DAI scores of rats with 5IGT and INDO-enteropathy at 72 h. Data expressed as mean score (range). ** 
indicates p<0.01 compared to VEH controls. Disease activity index; DAI, 5-Fluorouracil-induced gut toxicity; 5IGT, 
indomethacin; INDO, vehicle; VEH. 
Chapter Four. 5IGT: implications for the “little” and “big” brain 
169 
5-FU Administration Significantly Elevated MPO Activity in the Small Intestine
MPO expression in the jejunum and ileum was significantly elevated in rats with 5IGT 
compared to VEH controls (>435% increase and p<0.001 in both regions, Figure 4.2A and 
B). Whilst the MPO expression of rats with INDO-induced enteropathy failed to reach 
significance compared to VEH controls, there was a trend for elevated levels in both 
















Figure 4.2. MPO activity in the jejunum (A) and ileum (B) of rats with 5IGT and INDO-enteropathy. Data expressed as 
units of MPO per gram of tissue ± SEM. *** indicates p<0.001 compared to VEH controls. Myeloperoxidase; MPO, 
vehicle; VEH, indomethacin; INDO, 5-Fluorouracil; 5-FU. 
Jejunum Ileum 
A B
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5-FU and INDO administration significantly altered jejunal mucosal structural architecture
5-FU and INDO administration significantly reduced VH and CD compared to VEH
controls (p<0.0001 for both groups; Table 4.3). Representative H&E images of jejunal 
sections indicate drug-induced gut toxicity compared to VEH group via morphological 
changes in 5IGT and INDO-enteropathy groups (Figure 4.3; panels A, B and C 
respectively). INDO revealed moderate signs of tissue injury and toxicity in the jejunum as 
characterised by crypt ablation and villous shedding and fusion (Figure 4.3B). 5-FU treated 
rats showed severe signs of mucosal injury with compromised villus and crypt integrity, 
decreased muscularis layer, areas of luminal surface showing little to no evidence of villi 
structures, inflammatory infiltrate and epithelial shedding from muscularis wall (Figure 
3C). 
Table 4.3. Jejunal villus height (VH) and crypt depth (CD) of rats with 5IGT and INDO-enteropathy at 72 h. Data 
expressed as mean (length; µm) ± SEM. **** indicates p<0.0001 compared to VEH controls. 5-Fluorouracil-induced 
gut toxicity; 5IGT, indomethacin; INDO, vehicle; VEH. 
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Figure 4.3A, B and C. Representative histological H&E images of rat jejunal sections (4µm); VEH treated (panel A), 
INDO-enteropathy (panel B) and 5IGT (panel C) rats. INDO-enteropathy rats show moderate jejunal injury and 
intestinal toxicity by reduced VH and CD. Panel C shows severe villus and crypt injury and toxicity. Blue scale bars 
show 500µm (left) and 250µm (right). Hematoxylin and eosin; H&E, vehicle; VEH, indomethacin; INDO, 5-
Fluorouracil-induced gut toxicity; 5IGT, villus height; VH, crypt depth; CD. 
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Evidence for Thoracic Spinal Region Astrocyte Reactivity in Rats Following 5-FU Injection
During the Peak Injury Phase of 5IGT, thoracic spinal cord GFAP expression was 
significantly increased compared to the VEH group, as shown by WB analysis (p=0.003; 
Figure 4.4A.1). A marginal down-regulation in the INDO-enteropathy group was observed 
compared to the control group, though this was insignificant. IL-1β expression was also 
elevated in the thoracic spinal cord region of rats following 5-FU injection, compared to 
VEH controls (p=0.0004; Figure 4.4A.2). GFAP DAB staining was significantly elevated 
in the thoracic region (T7 and T8) of rats with 5IGT compared with VEH controls (p<0.01 
and p<0.001, respectively; Figure 4.4B.1). Qualitative images of the thoracic spinal dorsal 
horn of VEH controls (Figure 4.4B.2) and rats with 5IGT (Figure 4.4B.3) support the 
increased GFAP molecular and staining findings. Astrocyte reactivity (astrogliosis) is 
evident through changes in cellular phenotype; somatic hypertrophy (yellow box), 
elongated (blue box) and thickened (black box) processes. No other molecular regional 
GFAP, IL-1β or Iba-1 protein expression changes were observed in the other brain or 
spinal cord regions of rats with 5IGT or INDO-enteropathy (data not shown). 
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Figure 4.4A. Thoracic spinal cord GFAP (1) and IL-1β (2) expression in VEH, INDO and 5-FU treated rats, as assessed by 
WB. Data expressed as GFAP/IL-1β expression relative to β-actin (% change) ± SEM. ** indicates p<0.01 and *** indicates 
p<0.001 compared to VEH controls. Glial fibrillary acidic protein; GFAP, western blot; WB, vehicle; VEH, indomethacin; 
INDO, 5-Fluorouracil; 5-FU. 
VEH   INDO  5-FU 
GFAP (50 kDa) 
IL-1β (15 kDa) 
Β-actin (42 kDa) 
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Figure 4B. GFAP immunostaining was assessed in the left dorsal column of the thoracic spinal cord (1). Data 
expressed as adjusted DAB weight (%) group mean ± SEM. ** indicates p<0.01 and *** indicates p<0.001, 
compared to VEH controls. Representative images of VEH (2) and 5-FU (3) T8 spinal cord sections (left dorsal horn). 
Rats with 5IGT displayed morphological changes in astrocyte phenotype indicative of astrocyte activation (C); 
somatic hypertrophy (yellow box), elongated (blue box) and thickened (black box) processes. Scale bars represent 
50µm and 10µm for representative images and subset images, respectively. Glial fibrillary acidic protein; GFAP, 5-
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5IGT Results in a Change in Microbiota Composition in the Rat Caecum
The caecal contents of rats with 5IGT resulted in significantly decreased phylogenetic 
alpha diversity compared to VEH and INDO rats (approximately -40% reduction; Figure 
4.5A). The diversity of the 5IGT caecal contents were significantly reduced compared to 
the VEH group using X metric (p=0.036; Figure 4.5B). Similarly, beta diversity was also 
significantly different in the 5-FU treated rats than those from the VEH and INDO groups 
(adonis: R2= 0.228, p=0.001; Figure 4.6). Changes in alpha and beta diversity were 
demarcated by significant changes in the relative abundance of different bacterial genera 
(Figure 4.7). Bacteroides, Phascolarctobacterium and Desulfovibrio increased in rats 
treated with 5-FU compared to VEH controls (Figure 4.8). Noticeable reductions were also 
observed in the relative abundance of commensal taxa in 5IGT compared to VEH controls, 
and included Oscillospira, Ruminococcus, Clostridiales, S24-7, Prevotella and 
Lachnospiraceae taxa. Interestingly, the commensal bacterial taxa Oscillospira and S24-7




Figure 4.5. Phylogenetic alpha diversity as represented by rarefaction measure (A) and box plot (B). The caecal contents of 
VEH and INDO groups display more phylogenetic diversity than the 5-FU group (p<0.05). * indicates p<0.05 compared to 
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Figure 4.7. Taxa summary of the caecal samples in relative abundance at the genus level. Each colour is representative of a 
specific genus as identified in the legend. Vehicle; VEH, indomethacin; INDO, 5-Fluorouracil; 5-FU and phylogenetic 
diversity; PD. Data presented as relative abundance (%). 
Figure 4.6. Beta diversity as represented by a principal component plot using a distance matrix based on the unweighted 
UniFrac metric. Caecal samples are represented by a sphere and the distance between samples identifies variance 
(similar or dissimilar) in the microbial communities. ** indicates p<0.01 compared to vehicle controls. Vehicle; VEH, 
indomethacin; INDO, 5-Fluorouracil; 5-FU. 
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Figure 4.8. Caecal microbial changes as represented by % of relative abundance at the genus level: taxa of 
interest taken from Figure 4.7. Data presented as relative abundance (%) and expressed as 10-2. Vehicle; VEH, 
indomethacin; INDO and 5-Fluorouracil; 5-FU.  
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Discussion 
GI and cognitive disturbances associated with chemotherapy treatment remain a significant 
burden to cancer patients, and mechanisms are still unclear. Recent research has suggested 
involvement of the innate immune system, including TLRs, glial reactivity and 
neuroinflammation, in the aetiology of both disorders as well as pain associated with CIGT 
[134, 182, 189, 302, 328, 329]. The present study implicates 5-FU-induced microbiota 
changes in the pathogenesis of CIGT. In addition, the thoracic astrogliosis response to 
5IGT suggests an indirect activation of a neural-driven immune signalling pathway.  
5IGT resulted in significant weight loss, increased DAI, reduced thymus and spleen 
weight, severe SI injury and acute intestinal inflammation in accordance with previous 
studies [108, 110, 286, 330]. Whilst the bodyweight of rats with 5IGT remained 
significantly reduced until 72 h, weight loss in rats administered INDO only occurred on 
experimental days 1 and 2, yet returned to baseline at 72 h. INDO also resulted in 
decreased SI length and weight, decreased thymus weight and increased liver and spleen 
weight, as well as elevated DAI scores on day 1 and 2 in accordance with previous studies 
[331]. VH and CD were significantly decreased in the jejunum of both 5-FU and INDO 
treated rats compared to VEH controls. Upon closer examination of jejunal histological 
H&E staining, mild-to-moderate structural changes were evident in the mucosa of the 
INDO group, whereas severe mucosal injury and toxicity was evident in rats administered 
5-FU. The metabolic and intestinal findings in the current study confirmed that the selected
INDO dose was sufficient to cause mild-to-moderate gut toxicity when compared to the 
severity of intestinal damage observed in the 5-FU treated rats.  
The current study sought to determine whether the chemotherapy drug, 5-FU was unique at 
inducing gut toxicity and spinal astrocyte activation, by comparing its effects to a lower 
intestinal inflammatory response, induced using a non-chemotherapy drug, INDO. In order 
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to achieve this, a high-dose of 5-FU and lower dose of INDO was utilised which resulted 
in a high versus low intestinal response, as indicated by the MPO data. Whilst some 
evidence for INDO-induced intestinal injury was present (e.g. days 1-2 weight loss and 
increased DAI; mild to moderate histological jejunal injury at 72 h), the absence of MPO 
changes at 72 h implied that the peak mucosal injury occurred earlier. As MPO is released 
by neutrophils upon intestinal injury [292] and neutrophil infiltration has been 
demonstrated to play a role in the primary events leading up to mucosal damage in both 
5IGT and INDO-enteropathy [65, 332], it was anticipated that MPO would be elevated in 
both experimental groups at 72 h. The lack of INDO-MPO expression changes at 72 h 
may be partially explained by its differing mechanistic action to 5-FU.  
NSAID-enteropathy develops following a direct intestinal insult coupled with 
enterohepatic and systemic effects [333]. The downstream effects result in increased 
mucosal permeability and activation of the inflammatory cascade, elevating pro-
inflammatory cytokines, such as IL-1β [332]. Neutrophils are recruited to the ulcerated 
area to facilitate the recovery and healing process [332, 334]. Previously, INDO treated 
rats showed significant increased MPO expression in the small intestine at 24h post-
injection [335]. Whilst the previous study used the same dosage as the current study, the 
route of administration differed (intragastric injection). 5-FU on the other hand enters the 
cell by mimicking the nucleic acid, uracil, and misincorporating into RNA and DNA, 
leading to mutations in strands and inducing cellular apoptosis [1, 336]. In the present 
study, the timing for the assessment of intestinal injury may have not reflected optimal 
alignment of the peak effects of the two models. In future, pilot studies should be 
employed to determine the precise characterisation of 5-FU and INDO gut toxicity, with 
differing dosages and time-points which can adequately assess the similarity of varying 
levels of intestinal inflammation in each group. Alternatively, the use of other methods, 
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such as ELISA, effectively determining the cytokine profile of these animals, would verify 
the inflammatory condition of the intestine. 
As well as inducing severe GI disturbances, 5-FU (mostly in combination with other 
chemotherapy drugs) is commonly reported to induce acute and delayed central toxicities. 
Chemotherapy recipients undergoing 5-FU treatment often report trouble in several 
cognitive domains, involving executive function, attention and verbal memory [322, 337]. 
Imaging studies and experimental models have confirmed that 5-FU induces structural and 
cellular brain alterations, such as reductions in frontal cortex size and the restructuring of 
brain networks, leukoencephalopathy and delayed cerebral demyelinating syndrome [175, 
177, 338]. One of the most common findings in experimental models of CICI is 
hippocampal cellular reductions, frequently associated with learning and memory deficits 
[87, 115, 116]. Considering previous short-term systemic administration of 5-FU using a 
lower dose than that used in the present study, resulted in apoptosis in multiple brain 
regions, including the hippocampus, it was surprising that the acute high-dose used 
resulted in no sign of inflammation or glial activation in the higher order brain regions 
examined at the selected time-point. Differences in dosing regimens and species strain may 
have accounted for some of the regional apoptosis observed in the previous models. Not all 
studies have reported cognitive deficits following 5-FU administration. Some models have 
even reported improvements in mice [95]. The complex and sometimes contradictory 
nature of CICI mechanisms highlight the need for continued detailed investigations.  
In the CNS, the selected time-point for optimal intestinal injury assessment may have also 
critically missed glial reactivity and may partially explain the lack of either glial cell 
changes in the INDO group and microglial changes in the 5-FU group. Microglia are 
highly mobile, dynamic brain surveillance cells (even in their quiescent ‘resting’ state) 
[339], which typically become activated upon acute immune insults, whether the 
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inflammatory source is central or peripheral [340, 341]. Astrogliosis generally occurs more 
slowly at later stages of immune responses [121, 124, 342]. As microglia express 
mediators which recruit astrocytes, it is plausible that in the current study, microglial 
reactivity occurred at an earlier time-point and future studies would benefit from a 
thorough time course of 5-FU-induced glial changes. Astrocyte and IL-1β activity were up-
regulated in the thoracic spinal region of rats with 5IGT, indicating that the drug indirectly 
induced neuroinflammation via a neurally-driven immune signalling pathway [302]. 
Spinal astrocytes are particularly reactive to a variety of peripheral immune insults, such as 
bone cancer and endometriosis and have been suggested to play a role in pain associated 
with these disorders [127, 303, 305, 343]. In the GIT, astrogliosis is evident in the lumbar 
region of mice during the chronic phase of experimental colitis, whereas microglia play an 
active role in the acute stage [344]. In this model of chronic colonic inflammation, 
hippocampal neurogenesis was also reduced and importantly this indicates that 
inflammatory events in the “little brain” resulted in a neuromodulatory response in the “big 
brain” [344]. Thus, providing mechanistic evidence supporting the hypotheses outlined in 
the current study. Further, enteric astrogliosis occurred in rats following administration of 
the chemotherapy drug, oxaliplatin [301]. From this it is plausible that enteric astrocytes 
may actively communicate with their spinal counterparts and contribute to this 
maladaptation. Astrocytes are capable of communicating with each other, propagating 
information over long distances through calcium ion waves [121]. The present study can 
only speculate reasons for the 5-FU-induced thoracic astrocyte up-regulation. Nonetheless, 
the spinal astrogliosis findings presented here are consistent with other chemotherapy 
models investigating pain associated with gut toxicity, neuropathic pain and peripheral 
neuropathy [133, 134, 310, 345]. Accordingly, it could be assumed that astrogliosis in the 
present model may have contributed to pain associated with 5IGT. Importantly, the 
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aforementioned studies highlight the primary role of spinal astrogliosis as opposed to 
microglial activation in the pathogenesis of these chemotherapy-induced disorders.  
The importance of a balanced microbial environment is pivotal in host development and 
immunity as it assists in the maintenance of multiple aspects of central and gut 
homeostasis, and modulates adaptive and innate immune responses [5, 346]. Disruptions in 
microbial composition can be caused by various factors, including age, diet, environmental 
changes and drugs, such as analgesics, antibiotics and chemotherapy treatment [201, 217]. 
It is now widely recognised that a bidirectional relationship exists between the microbiota, 
CNS and gut; recognised as the microbiota-gut-brain axis [5, 17, 36]. From this, changes in 
microbial composition have been linked to the pathogenesis of many gut- and central-
related disorders, such as inflammatory bowel and coeliac disease, Alzheimer’s disease 
and autism spectrum disorder [14, 15, 18, 36, 166, 347, 348]. Changes in microbiota 
composition also play a critical role in the development of CIGT [38, 134, 208, 213, 215]. 
Microbiota-induced mechanisms influencing the pathogenesis of CIGT involve 
inflammatory and oxidative stress pathways, changes in mucous layer composition, 
intestinal permeability and hence, epithelial repair mechanisms and release of immune 
effector molecules [38]. Healthy mice transplanted with the faeces of mice with 5IGT 
show reduced bodyweight and colon length, which infers the direct impact of the 
microbiota on gut toxicity and metabolic parameters [349].  
In accordance with previous studies investigating 5-FU-induced microbiome effects, the 
present study showed a reduction in caecal microbial diversity in 5IGT rats [214, 316]. 
Specifically, an increase in the abundance of gram-negative bacterial taxa were evident and 
has been reported previously [214, 350]. Whilst Bacteroides and Desulfovibrio generally 
have symbiotic relationships with the host, they also can transition into pathogenic 
bacterium involved in the development of chronic GI disorders and lethal infections [351, 
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352]. Phascolarctobacterium is found in relative abundance in the healthy human gut 
[353]. Interestingly, although the present study revealed an elevated abundance of 
Phascolarctobacterium compared to controls, reductions have been linked with colonic 
inflammation in patients with ulcerative colitis [354]. Importantly, this implied that 
elevated levels of this bacterium may be implicated in the pathogenesis of 5-FU-induced 
intestinal inflammation. Recent studies have highlighted gender-specific prevalence for this 
bacterium in metabolic syndromes [355]. From this, caution should be taken with 
translating the significance of changes in the relative abundance of some intestinal 
bacterium from experimental to clinical studies. For instance, the reductions in the relative 
abundance of several commensal species (Oscillospira, Ruminococcus, Clostridiales, 
S24-7, Prevotella and Lachnospiraceae) in the rats with 5IGT. The precise mechanistic 
implications of these changes require further investigation, though relative changes in 
some of these strains mentioned here, have been suggested to contribute to inflammatory 
processes [356, 357]. Interestingly, whilst a reduced abundance of Prevotella was present 
in rats with 5IGT and is also observed in lung conditions, such as asthma and chronic 
obstructive pulmonary disease, increased abundance is commonly reported in systemic and 
localised inflammatory conditions [357]. Whist the microbial changes noted here implicate 
5-FU-induced alterations, it is acknowledged that these changes may result from reductions 
in bodyweight and food/water intake. As food/water intake was not recorded, this 
represents a limitation of the current study. 
Mounting evidence of the roles the microbiome plays in carcinogenesis [358] and 
interactions on the efficacy and toxicity of anti-cancer treatments [359], coupled with the 
literature presented here, highlight the diverse and complex nature of the microbiome-gut-
CNS relationships. Recent findings supporting the concept of the intestinal microbiota as a 
key regulator priming neuroinflammation in response to brain injury [21], aligns with the 
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concepts presented in the present study. Further, the emerging roles of probiotics [316, 
360] and faecal microbiota therapy [361] in treating not only gastrointestinal, but central
disorders also shows promise for alleviating symptoms associated with CIGT and CICI. 
Until recently, the GI and central toxicities associated with chemotherapy treatment have 
been studied independently. Importantly, the present study provides evidence of an 
indirectly (neurally)-mediated central neuroinflammatory response in rats with 5IGT; that 
inflammation in the “little brain” results in intestinal microbiota changes and “big brain” 
inflammation, as indicated by spinal thoracic GFAP and IL-1β up-regulation. In 
conclusion, given the ubiquitous involvement of the microbiota, innate immunity, 
signalling and glia in central and gut homeostasis, glia and the microbiota may be uniquely 
positioned to influence both CIGT and CICI.  
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CHAPTER FIVE, in vivo 
Comparing and Characterising Glial Consequences in
the Brain and Spinal Cord of Experimentally-Induced
Chronic Ulcerative Colitis and Colorectal Cancer
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Abstract 
The central comorbidities associated with chronic inflammatory disorders of the colon 
remain under-investigated. Chronic ulcerative colitis (UC) patients are at higher risk of 
developing colitis-associated colorectal cancer (CA-CRC). We investigated the role of the 
neuroimmune system (glial cell reactivity and neuroinflammation) and peripheral-to-
central immune pathways mediating the pathogenesis of central comorbidities associated 
with CA-CRC. Therefore, we sought to determine whether experimentally-induced chronic 
UC and CA-CRC resulted in regional higher order brain region and spinal cord changes in 
mice using glial cell markers in western blot: ionised calcium binding adaptor molecule 1 
(Iba-1) for microglia; and glial fibrillary acidic protein (GFAP) for astrocytes. Chronic UC 
was induced via dextran sulphate sodium (DSS) water cycling and azoxymethane 
(AOM)/DSS was used to induce CA-CRC. GFAP and Iba-1 expression was up-regulated 
in the hippocampus of both treatment groups (p<0.05). Hypothalamic GFAP expression 
was also elevated in the CA-CRC group when compared to saline controls (p<0.01). In the 
lumbar spinal region, GFAP expression was downregulated in the chronic UC group 
(p<0.05) in contrast to GFAP up-regulation in the CA-CRC group when compared to 
controls (p<0.01). Iba-1 expression in the lumbar region was increased in both treatment 
groups compared to saline controls (p<0.0001). Our data implicates glial dysregulation in 
the pathogenesis of chronic UC and CA-CRC and suggests these changes occur via neural- 
and humoral-mediated peripheral-to-central immune signalling pathways. 
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Background 
The incidence and reported prevalence rates of inflammatory bowel disease (IBD) and 
colorectal cancer (CRC) have been increasing each year [362, 363]. Ulcerative colitis (UC) 
and Crohn’s disease are the two major forms of IBD and both prominently feature chronic 
intestinal inflammation. The risk of developing CRC is higher in patients with IBD and 
approximately twelve percent of patients develop colitis-associated CRC (CA-CRC) in ten 
years following IBD symptom onset [364]. During episodes, histopathological 
manifestations include ulceration, mucosal damage, breakdown of the intestinal epithelial 
lining and consequently, a marked increase of infiltrating cells from the innate and 
adaptive immune systems into the lamina propria [365]. Local invasion of these immune 
cells results in the synthesis and release of a battery of pro- and anti-inflammatory 
cytokines and mediators, such as interleukin (IL)-1β, IL-6 and tumour necrosis factor 
(TNF)-α.  
Genetic and environmental factors are key players in IBD development, yet accumulating 
evidence has indicated the critical role the unbalanced or dysfunctional gut microbiota 
plays in intestinal barrier function [366, 367]. Classical IBD symptoms include increased 
or  decreased stool consistency, abdominal pain (visceral hypersensitivity), cramping and 
in severe cases, malnutrition and the presence of blood and mucus in stools [368]. 
Extraintestinal manifestations of IBD may include fever, weight loss, delayed growth and 
arthritis [369]. Other common but less reported comorbidities associated with IBD are 
neurological, such as seizure disorders and peripheral neuropathy [370]. More recently 
however, behavioural and cognitive alterations have been associated with IBD, although 
these comorbidities are often overlooked and poorly understood with little to no treatment 
options available [371, 372]. Depression, anxiety, fatigue, low self-esteem and cognitive 
impairment, particularly in the executive function domain affect a significant proportion of 
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IBD patients and these complications, combined with managing clinical symptoms, puts 
enormous strain on the patients’ occupational, financial, social and relationship well-being 
[373]. In addition, it is common for IBD patients to present to doctors with a recent 
stressful event and accordingly, it is thought that stress may exacerbate IBD symptoms or 
episodes [40]. Suggested mechanisms in the development of central disorders stemming 
from IBD include malabsorption, metabolic agents, infections arising from 
immunosuppressive complications, side-effects of medication and immunological 
abnormalities [370]. More recently however, a growing body of literature suggests that 
immune dysregulation associated with various chronic disease states, including cancer and 
peripheral inflammatory disorders results in an innate central-immune response which can 
modify behaviours. Whilst chronic UC and CA-CRC have been associated with central 
comorbidities [49, 59], the potential mechanisms remain under investigated.  
Neuroinflammatory processes initiate as a host defence mechanism, resolving insults by 
returning normal structure and function to injured tissue [374]. The resultant 
neuroinflammatory microenvironment may become neurotoxic, unregulated and self-
propagate with deleterious effects contributing to the pathogenesis of various 
neurodegenerative diseases, such as Alzheimer’s disease, multiple sclerosis and 
neuropathic pain [267, 319, 375]. Neuroimmunological cells (glia), particularly microglia 
and astrocytes, are not only responsible for maintaining neuronal and central nervous 
system (CNS) homeostasis in their resting/quiescent state, but also initiate 
neuroinflammatory responses to a range of central (direct; e.g. traumatic brain injury) and 
peripheral (indirect; e.g. bone cancer) insults [127, 153, 374]. Due to the close bidirectional 
relationship glia share with neurons at the synapse (tetrapartite synapse) they have the 
potential to influence brain function, modify behaviours and contribute to neuropathic pain 
[122]. Glia may become primed via peripheral-to-central immune pathways (humoral or 
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neural immune signalling) whereby circulating pro-inflammatory cytokines either directly 
or indirectly access the brain [82, 144]. Glial priming and chronic neuroinflammation have 
been associated with cognitive impairment following systemic exposure to noxious, 
infectious or even chemical exposure, such as chemotherapy [182, 277]. Importantly, 
chronic intestinal inflammation induces microglial activation in the hippocampus and 
spinal cord which has been attributed to visceral hypersensitivity [376, 377].  
The current study aimed to characterise neuroimmunological complications arising from 
chronic intestinal inflammatory conditions, focussing on chronic UC and CA-CRC, in vivo. 
We sought to identify whether neuroimmune modifications (glial activation) occurred in 
the lumbar spinal cord region as a result of the inflamed/malignant colon, and if changes 
occurred in higher order brain regions of mice with experimentally-induced chronic UC 
and CA-CRC. To date, the potential role glial dysregulation plays in the central 
comorbidities of both disorders remain elusive. In the present study we examined 
microglia and astrocyte markers (ionized calcium binding adaptor molecule 1, Iba-1; and 
glial fibrillary acidic protein, GFAP; respectively) in mouse models of dextran-sulphate 
sodium (DSS)-induced chronic UC and CA-CRC utilising azoxymethane (AOM)/DSS.  
Chapter Five. Neuroimmune consequences in chronic gut inflammation
194 
Material and Methods 
Female C57BL/6 mice (8 wks) were group-housed (10 per cage) in a temperature-
controlled room with a 12 h light-dark cycle. All animals were sourced from the Animal 
Resource Centre (Perth, Western Australia) and were acclimatised for one week before the 
trial commencement. All animal studies complied with the Australian National Health and 
Medical Research Council Code of Practice for Animal Care in Research and Teaching (8th 
Edition, 2013) and were approved by the Children, Youth and Women's Health Service 
and The University of Adelaide Animal Ethics Committees. The animals used in this study 
formed the controls for larger studies examining naturally sourced treatments in the 
treatment of chronic UC and CA-CRC [378, 379]. Mice (n=9-12) were randomly allocated 
into either control (saline), chronic UC (DSS) or CA-CRC (AOM/DSS) groups. Chronic 
UC was induced via ad libitum drinking water (2% w/v DSS dissolved in water bottles) 
every three weeks for a period of seven weeks (Figure 5.1). During weeks one, three and 
six, DSS bottles replaced standard water drinking bottles in the chronic UC group. CA-
CRC mice followed the same DSS water cycling schedule, however at day zero an AOM 
injection was administered (7.4mg/kg bodyweight; Sigma-Aldrich, Castle Hill NSW). The 
CA-CRC groups had an additional 12 days with standard water to allow for tumour 
development following the third cycle of DSS water before euthanasia (Figure 5.1). 
Chronic UC mice were euthanised on day 51 and CA-CRC mice on day 63 via CO2
asphyxiation. Metabolic data, including indicators of disease activity and intestinal 
measures from 192 animals in 24 groups have been previously published and have been 
reported here, as these data were collected at the same time and served as the key controls 
across multiple studies [378, 379]. UC and CA-CRC was determined by clinical and 
histological means already published [378, 379]. Diseased animals showed reductions in 
bodyweight, increased DAI and crypt depth in the colon. Colitis progression was monitored 
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 Figure 5.1. Timeline of mice with experimentally-induced chronic UC and CA-CRC. UC was induced via ad libitum 
drinking water containing DSS (2%) during weeks 1, 3 and 6. UC mice were euthanised 2 days after the third DSS cycle at 
day 51. The CA-CRC group followed the same DSS cycles except this group received a single AOM injection at day 0 and 
were euthanised on day 63. UC; ulcerative colitis, CA-CRC; colitis-associated colorectal cancer, DSS; dextran-sulphate 
 sodium, AOM; azoxymethane. 
Western Blot Analysis 
Following thawing, mice brains were isolated into hippocampal, pre-frontal cortex and 
hypothalamus sections whilst the spinal cords were sectioned into cervical (C2-C5), thoracic 
(T7-T9) and lumbar (L3-L6) regions. CNS sections were homogenised in cell lysis buffer 
(Tris-base saline; pH 8.0; 50mM, 1% Triton-x100, 1% protease inhibitor cocktail; Sigma 
Aldrich, #P8340); 300μl (spinal cord, pre-frontal cortex and hypothalamus) and 500μl 
(hippocampus) aliquots. Samples were sonicated (10 sec bursts, followed by a minimum of 
1 min on ice) and centrifuged at 15,000 x g for 40 min. Protein was determined using 
BCA-Protein Assay (Pierce® BCA Protein Assay Kit; #23225, Thermo Fisher Scientific 
Inc., Victoria, Australia). Homogenised proteins of known concentrations were suspended 
in 2X sample buffer (SDS reducing sample buffer: dH2O, 0.5M Tris-HCl pH 6.8, glycerol, 
10% SDS solution and 0.5% bromophenol blue) and heated at 70˚C for 10 min. Protein
by colonoscopy at regular intervals and colonic tumour size and numbers were recorded. 
The brain and spinal cord of each animal were snap frozen for future molecular analysis.  
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samples (25μg) were loaded and separated by gel electrophoresis in acrylamide homemade 
gels (SDS page 8-10%; 40% Acrylamide/Bis, gel Buffer (Resolving gel: 1.5M Tris-HCl  
pH 8.8 & Stacking gel: 0.5M Tris-HCl pH 6.8); 10% w/v SDS; 10% ammonium persulfate 
(APS); TEMED). Protein transfer occurred onto nitrocellulose filter paper (Sigma-
Aldrich) using boric acid pH 8.9 (boric acid, EDTA for 2 h @ 600mA) transfer buffer. 
Membranes were blocked with 5% skim milk at room temperature for 1.5 h. Protein 
expression utilised antibodies for GFAP (1:2000 Abcam; #Ab7620, Cambridge, UK) and 
Iba-1 (1:1000 WAKO; #019-19741, Osaka, Japan); indicators of astrocyte and microglial 
activation, respectively, with an overnight incubation (4˚C). The total protein content 
standardised sample loading and was used as the relative control. An additional internal 
sample control (2μl from each sample) determined changes between gel integrity and was 
used to normalise band detection. Secondary antibodies allowed visualisation of the 
protein bands (peroxidase-conjugated Affinipure Donkey Anti-rabbit IgG; 1:20,000; 
#711-035-152; Jackson ImmunoResearch Laboratories, Inc., PA, USA). Enhanced 
chemiluminescence (ECL) enabled detection of bands using an in-house ECL reagent 
(10mL of 100mM Tris HCl; pH 8.5, 22μL of 90mM coumaric acid, 50μL of 250mM 
luminol and 3μL of H202) and bands were visualised using the ImageQuant 4100 imaging 
system (GE Health Care, United Kingdom) described previously [289]. Band densities 
were measured as a fold change relative to control group, accounting for normalisation as 
described earlier.   
Statistical Analysis 
Statistical analyses were conducted using GraphPad Prism 6.02 for Windows (GraphPad 
Software Inc., San Diego, CA, USA). Data were tested for normality using the Shapiro-
Wilk analysis. All western blot data were analysed using unpaired t-tests. All data were 
expressed as mean ± SEM with values of p<0.05 deemed significant. 
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Results 
Chronic UC and CA-CRC Disrupts Glial Marker Expression in the Hippocampus and
Hypothalamus
Hippocampal GFAP expression was up-regulated in both chronic UC and CA-CRC groups 
when compared to vehicle controls (p=0.0275 and p=0.0002, respectively; Figure 5.2A 
and B). Iba-1 expression was also elevated in both chronic UC and CA-CRC groups 
(p=0.0016 and p=0.0007, respectively; Figure 5.3A and B). GFAP expression was 
significantly increased in the hypothalamus of mice with CA-CRC (p=0.004; Figure 5.4). 
Although hypothalamic Iba-1 expression resulted in no significant changes, the range of 
Iba-1 expression in this group was considerably modified in the CA-CRC group when 
compared to the data range of Iba-1 expression in the vehicle controls (Figure 5.4). No 































Figure 5.2A and B. Effects of DSS and AOM/DSS on hippocampal GFAP expression in mice with experimentally-induced chronic UC (A) and CA-CRC (B). GFAP expression is 
represented as a percentage of the total protein content. Both chronic UC and CRC groups resulted in a significant increase in hippocampal GFAP expression when compared to VEH 
control groups. *p<0.05, ***p<0.001 when compared to VEH controls. VEH; vehicle treated mice, DSS; dextran-sulphate sodium, AOM; azoxymethane, GFAP; glial fibrillary acidic 



















Figure 5.3A and B. Effects of DSS and AOM/DSS on hippocampal Iba-1 expression in mice with experimentally-induced chronic UC (A) and CA-CRC (B). Iba-1 expression is represented 
as a percentage of the total protein content. Both chronic UC and CRC resulted in significant increases in hippocampal Iba-1 expression when compared to VEH control groups. 
**p<0.01,  ***p<0.001 when compared to VEH controls. VEH; vehicle treated mice, DSS; dextran sulphate sodium, AOM; azoxymethane, IBA-1; ionized calcium binding adaptor












Figure 5.4A and B. Effects of AOM/DSS on hypothalamic GFAP (A) and Iba-1 (B) expression in mice with experimentally-induced CA-CRC. GFAP and Iba-1 expressions are represented 
as a percentage of the total protein content. AOM/DSS resulted in a significant increase in hypothalamic GFAP expression when compared to VEH control groups. Iba-1 expression was 
disrupted by AOM/DSS when compared to the VEH control group. **p<0.01 when compared to vehicle controls. VEH; vehicle treated mice, DSS; dextran sulphate sodium, AOM; 
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Glial Marker Expression Changes in the Lumbar Region of Mice with Chronic UC and CA-CRC
GFAP expression was significantly reduced in the lumbar spinal region of mice with chronic UC 
when compared to vehicle controls (p=0.0293; Figure 5.5A). However, GFAP expression was 
increased in the lumbar region of CA-CRC mice when compared to vehicle controls (p=0.0014; 
Figure 5.5B). Both chronic UC and CA-CRC mice showed elevations in Iba-1 expression in the 
lumbar region when compared to vehicle controls (both groups p<0.0001; Figure 5.6A and B). 
Cervical and thoracic spinal cord regions yielded no significant changes in the expression of either 


















Figure 5.5A and B. Effects of DSS and AOM/DSS on lumbar GFAP expression in mice with experimentally-induced chronic UC (A) and CA-CRC (B). GFAP 
expression is represented as a percentage of the total protein content. Chronic UC caused a significant reduction in GFAP expression in the lumbar region, compared 
with CA-CRC mice which resulted in significant increase in lumbar GFAP expression when compared to VEH control groups. *p<0.05, **p<0.01 when compared 
to VEH controls. VEH; vehicle treated mice, DSS; dextran sulphate sodium, AOM; azoxymethane, GFAP; glial fibrillary acidic protein, UC; ulcerative colitis, CA-







































Figure 5.6A and B. Effects of DSS and AOM/DSS on lumbar Iba-1 expression in mice with experimentally-induced chronic UC (A) and CRC (B). Iba-1 expression is 
represented as a percentage of the total protein content. Chronic UC caused a significant increase in Iba-1 expression in the lumbar region, compared with the CRC 
group which resulted in substantial increase in lumbar Iba-1 expression when compared to vehicle control groups. ****p<0.0001 when compared to vehicle controls. 
VEH; vehicle treated mice, DSS; dextran sulphate sodium, AOM; azoxymethane, Iba-1; ionized calcium binding adaptor molecule 1, UC; ulcerative colitis, CA-CRC; 
colitis-associated colorectal cancer. 
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Discussion 
The central comorbidities associated with chronic inflammatory disorders of the bowel 
remain under-investigated. This is surprising for two reasons: firstly, the central 
comorbidities associated with IBD place enormous strain on many aspects of patient 
quality of life. The emotional toll central comorbidities place on IBD patients affects the 
individual’s self-value and confidence, thought processing, social functioning and 
relationship capabilities, which in turn has negative effects on education, employment 
opportunities and often results in financial burden [49]. Secondly, the gut and the brain are 
intimately connected via a multitude of pathways and mechanisms which opens many 
doorways for experimental investigation. The findings from our study add to the growing 
literature on the neuroimmunological manifestations associated with chronic gut 
inflammatory disorders. Importantly, we have described neuroimmunological changes in 
the lumbar spinal region and higher order brain regions of mice with experimentally-
induced chronic UC and CRC. Elevated GFAP and Iba-1 expression indicated astrocyte 
and microglial reactivity, respectively, which are prominent features of neuroinflammation 
[118, 120, 121]. We anticipated this central response in our models, as preliminary data by 
our group has shown glial activation and neuroinflammation in the thoracic region of rats 
with 5-FU-induced gut toxicity in an acute setting [263]. Primarily, the current study 
determined the presence of regional neuroimmunological responses in experimentally-
induced chronic UC and CRC, and also that spinal cord glial changes were representative 
of the inflamed/malignant gut section which innervated the spinal cord, e.g. inflamed colon 
innervated the lumbar spinal region. Importantly, we identified that higher order brain 
regions may also be susceptible to neuroinflammation under experimentally-induced 
chronic UC or CRC conditions, as determined by hippocampal increases in GFAP and Iba-
1 expression. Previously, we reported no changes in higher order brain regions utilising 
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markers for microglia and astrocytes in rats with 5-FU-induced gut toxicity, and we 
suggest that this may have resulted from the acute setting used in this model [263]. 
In the current study, both chronic UC and CRC resulted in a stark increase in hippocampal 
GFAP and Iba-1 expression. Furthermore, increased hypothalamic GFAP expression was 
present in the CRC group when compared to the control group, yet this was not evident in 
the chronic UC group. Hypothalamic changes were anticipated in response to the generally 
recognised role of stress and hypothalamic-pituitary-adrenal axis in the pathogenesis of 
IBD [13, 380]. Whilst hypothalamic Iba-1 expression in the CRC group in the current 
study was not statistically different to the control group, the distribution of individual Iba-1 
scores when compared to the control group suggested that CRC induced dysregulation of 
Iba-1 expression in the hypothalamus. Nonetheless, as we were unable to collect 
histological data in our study, we were unable to determine morphological changes in the 
treatment groups.  
Irrespective of this, the hippocampal findings in our study raises three important 
points/questions. Firstly, are immune messages from the inflamed colon directly accessing 
the brain via a humorally-mediated peripheral-to-central immune communication pathway? 
Although the humoral route is slower than the neural route, it enables passage of cytokines 
and pro-inflammatory mediators from the periphery to enter the brain via 
circumventricular organs [144, 268]. In this capacity, glial cells may have been directly 
activated by peripheral immune messages accessing the brain at circumventricular organs. 
Or were the intestinal immune signals indirectly altered and transduced by primary afferent 
neurons? In this sense, highly reactive spinal glia could have stimulated neurogenic 
inflammatory pathways and promoted peripheral inflammatory processes which could 
have conducted the immune messages to higher order brain regions, such as the 
hippocampus. In attempt to answer these questions, we examined all spinal cord regions 
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and reported no significant changes in GFAP or Iba-1 expression in the thoracic or cervical 
regions of mice with chronic UC or CRC. This suggested that the hippocampal GFAP and 
Iba-1 expression changes occurred via humorally-mediated mechanisms. Further 
investigations are warranted to clarify this finding, in particular performing a vagatomy on 
mice under the same experimentally-induced UC and CRC conditions would validate this 
finding if the same hippocampal findings were reported.  
Neuroinflammation is a widely accepted central immune response classically characterised 
by glial activation and subsequent inflammatory cytokine profile changes; reduced anti-
inflammatory cytokine output; and increased release of pro-inflammatory cytokines [125]. 
Neuroinflammation contributes to the pathogenesis of various central disease states, 
involving neurodegeneration and pain syndromes, such as in the case of Alzheimer’s 
disease and neuropathic pain, as well as in the periphery, for example in bone cancer-
induced pain [127, 129, 319]. This innate immune response may be driven by 
lipopolysaccharide (LPS; the active fragment of endotoxin from Gram negative bacteria) 
and cytokines, such as IL-1β, which can be detected by the specific immunosurveillance 
Toll-like receptor (TLR), TLR-4 [381, 382]. The physiological and behavioural responses 
triggered by LPS and exogenous cytokines are referred to as sickness behaviours which 
include, but are not exclusive to, fever, malaise, social withdrawal and cognitive changes 
[80, 382, 383]. Interestingly, cytokine-induced sickness behaviours mimic the symptom 
cluster experienced by cancer and chemotherapy recipients [62].  
TLRs belong to a transmembrane protein family responsible for recognising common 
structural patterns (for example, pathogen associated molecular patterns) and a diverse 
range of molecules (pro-inflammatory cytokines) which mediate appropriate innate 
immune responses to assist with host survival [381, 384]. At the mucosal level, TLR 
signalling plays an integral part in intestinal integrity and in inflammatory processes. More 
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specifically, TLR-4 activation in enterocytes promotes intestinal injury and inhibits 
intestinal repair [385]. Recently it has been shown that TLR-4 plays an important role in 
mediating chemotherapy-induced gut toxicity and pain [134]. As well as being key players 
in intestinal inflammation, TLRs mediate astrocyte and microglial cell activation 
displaying exaggerated expression levels and initiate neuroinflammation via the activation 
of signalling cascades, such as NF-κB and My-D88 [386]. Expanding our understanding of 
the multiple organ sites of inflammation in gut inflammatory disorders may lead to the 
exploration and discovery of treatment approaches that target inflammation in both the gut 
and the brain. It has already been proposed that TLR-4 mediates pain associated with 
chemotherapy-induced gut toxicity [387] and evidence has indeed confirmed the validity 
of this hypothesis [134]. This evidence combined with the findings from our study suggest 
that further investigations are warranted into the role of TLR, as it may mediate intestinal 
inflammation and neuroinflammation in experimentally-induced chronic UC and CRC.  
One study has attempted to elucidate our understanding of the simultaneous and regional 
inflammatory mechanisms at play in a rat model of 2,4,6-trinitrobenzenesulfonic acid 
(TNBS)-induced colitis utilising positron emission tomography (PET) imaging [388]. In 
this study, a tracer ([11C]PBR28) was used to target a translocator protein which becomes 
up-regulated when microglia and macrophages are activated. Although the PET imaging 
resulted in no significant changes of the tracer between the diseased and controls groups at 
day 4, ex vivo biodistribution studies contrastingly revealed significant changes in the gut 
and the brain of rats with TNBS-colitis when compared to the control group at day 4. At 
day 11, PET imaging resulted in higher tracer uptake in the cerebellum of rats with TNBS-
colitis. The lack of PET imaged inflammatory changes could be partially explained by the 
acute nature of this model and that the selected time-points may have not been optimal to 
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detect/identify the acute and chronic inflammatory responses occurring in the higher order 
brain regions.  
Future studies involving the collection of cognitive data will clarify the mechanistic 
implications of the neuroimmune findings in the current study. Abundant evidence 
implicating the development of central comorbidities with chronic gut inflammatory 
disorders warrants further exploration of the potential cognitive behavioural changes in the 
models described in the current study. It is important to note that experimentally-induced 
colitis-like colonic inflammation studies have reported impaired spatial recognition 
memory and depressive- and anxiety-like behaviours in mice [389, 390]. Both of the 
aforementioned studies did not examine glial changes, yet importantly confirmed the link 
between cognitive and mood fluctuations in experimentally-induced colitis.  
Further insights into the cognitive and mood changes induced by chronic gut 
inflammatory-induced glial activation may result in the exploration of targeted therapeutic 
approaches which are readily available, for example utilising the glial attenuators, Ibudilast 
(AV-411) or minocycline [140, 390, 391]. When administered prior to chemotherapy, 
Ibudilast has shown therapeutic promise in supressing tactile allodynia (pain from stimuli 
that does not usually induce pain) and improving cognitive impairment associated with the 
chemotherapy drug, oxaliplatin [392]. Minocycline suppresses microglial activation and 
plays a pivotal role in morphine-induced reward and pain modulation [140]. In 
experimentally-induced colitis, minocycline has effectively attenuated TNBS-induced 
visceral hypersensitivity, a hallmark feature of IBS [376]. In colitis patients, grey matter 
changes appear to be mediated by intestinal inflammation, supporting the gut-brain 
involvement in IBD [393]. Further investigation into the therapeutic potential of such glial 
attenuators in chronic inflammatory conditions of the gut, including CRC may lead to the 
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discovery of not only positive central molecular changes, such as reduced glial activation, 
but also behavioural improvements. 
In addition to the hippocampal findings, we reported glial dysregulation via expression 
changes in GFAP and Iba-1 in the lumbar region of rats with chronic UC and CRC. 
Interestingly, we report a reduction in GFAP expression in the chronic UC group when 
compared to controls which was contrastingly different to the increase in GFAP expression 
in the CRC group. It is difficult to determine whether the reduction in GFAP expression 
resulted from a reduced number of astrocyte cells or that the cells themselves retracted 
their processes (which occurs prior to astrocyte activation). It is plausible that the intestinal 
inflammatory response was greater in the CRC group when compared to the chronic UC 
group due to the addition of the malignancy. Inflammation has been acknowledged as the 
seventh hallmark of tumour progression and development [68]. We anticipated the 
neuroimmunological manifestations in this region would occur via the neurally-mediated 
peripheral-to-central immune signalling mechanism. Previous studies have revealed the 
sensitivity of spinal glia in reacting to various models of peripheral inflammation, 
including cancer-induced pain, multiple sclerosis, neuropathic pain models and 
chemotherapy-induced gut toxicity [134, 303, 306, 307].  
Studies using TNBS-induced colitis mouse models have reported similar microglial 
reactivity in the hippocampus and spinal cord [377]. We postulate that spinal glia were 
activated by the neural (vagal) pathway in which primary afferent neurons detect immune 
messages from the colon. Colon-projecting afferent neurons undergo exacerbated 
spontaneous activity during experimentally-induced colonic inflammation in mice [389]. 
As a result of this, at the spinal level glia may indirectly become dysregulated due to the 
inflammatory innervation of the colon in both diseased groups in our study. These immune 
messages then become transduced into a neural message which is then able to be relayed 
Chapter Five. Neuroimmune consequences in chronic gut inflammation
210 
by higher order brain regions [144]. Within the brain parenchyma, the neural messages are 
re-transduced back into an immune signal whereby local expression of cytokines increases, 
this in turn, has direct effects on neurons and glia. This immune-to-central signalling 
pathway may also, partially account for the hippocampal changes evident in both diseased 
groups as well as the hypothalamic GFAP expression increase and Iba-1 dysregulation 
evident in the CRC group. Due to the GFAP and Iba-1 expression changes identified in the 
hippocampus, hypothalamus and lumbar regions, we suggest that both humoral and neural 
pathways were activated and at least, in part, explain the glial marker expression changes 
evident in the models used in our study.  
Previously, experimentally-induced colitis has reported elevated pro-inflammatory 
cytokines and reduced neurogenesis in the hippocampus [344]. Hippocampal neurogenesis 
is responsible for the proliferation and division of neural stem cells into new neurons or 
astrocytes, whilst critically contributing to hippocampal circuit plasticity and memory 
consolidation [179, 180].  In a study by Zonis, et al. (2015) a similar DSS water cycling 
model was used; 3% wt/vol DSS for five days with two days break reverting back to 
normal drinking water before the next DSS cycle begun for a total of 26 days [344]. 
During the acute inflammatory phase, hippocampal neuroinflammation was present as 
assessed by microglial marker activation and increased expression of pro-inflammatory 
markers. The neuroinflammatory response continued into the chronic phase of DSS-
induced colitis whereby evidence was provided of reduced hippocampal neurogenesis, yet 
astrocyte activation was present. Molecular and cellular changes in the hippocampus are of 
particular significance as this region is fundamental in multiple aspects of cognition 
including neurogenesis, functioning processes, mood control and memory formation [179, 
394]. This is of primary importance considering the cognitive and mood comorbidities 
associated with UC and CRC, warranting further investigation.  
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In view of the aforementioned data, we conclude that regional neuroimmunological 
manifestations of experimentally-induced chronic UC and CRC contribute to the complex 
pathophysiology of both disorders. To our knowledge, this is the first study showing an 
increase in GFAP expression in the hypothalamus of mice with CA-CRC. The mechanistic 
understanding of the spinal and higher order brain region neuroimmunological findings 
requires further investigation. Future exploration into the behavioural and histological 
parameters, including cytokine profile changes and microbiota analysis in chronic UC and 
CRC will assist in our understanding of the central comorbidities associated with chronic 
UC and CRC. Nonetheless, our findings support existing literature on the neuroimmune 
gut-brain interactions of chronic gut inflammatory disorders and suggests humoral and 
neural peripheral-to-central pathways mediate these responses.  
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Statement of Context 
This manuscript has been submitted to the Breast Cancer Research and Treatment
Journal.
Bajic JE, Hutchinson AD, Howarth GS and Hutchinson MR. 
Chapter Six examines various perceptions of BCSs on their cognition, gut disturbances 
and other confounding factors since their chemotherapy treatment. It uses exploratory 
investigator-led questions to determine whether allergies are related to perceptions on 
cognition, gut disturbances and pain. It also used validated measures to assess mood-
disorders and fatigue to identify the impact these have on patient quality of life. To my 
knowledge, this is the first study of its kind to investigate the relationship of allergies to 
cognitive, gut and pain disturbances. This novel approach opens up a pathway for future 
studies that may predict gut, pain and cognitive outcomes in chemotherapy recipients 
following allergy-related measures.  
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Abstract
The breast cancer (BC) and chemotherapy experience results in a myriad of cellular and 
molecular responses throughout the body. The two primary organs most susceptible to the 
toxicities of chemotherapy are the brain and gastrointestinal tract. Cognitive deficits and 
gut-related disturbances have been clinically termed chemotherapy-induced cognitive 
impairment (CICI) and gut toxicity (CIGT), respectively. The gut and brain are 
intrinsically connected in a bidirectional manner in both health and disease. Whether 
symptoms associated with CIGT contribute to, or exacerbate, cognitive symptoms remains 
undetermined. We hypothesised that CIGT would be positively correlated with CICI 
symptoms via neuroimmune and peripheral-to-central immune signalling; and secondly, 
that allergies, as a marker of general immune reactivity, may predispose chemotherapy 
recipients to gut or cognitive changes and increased sensitivity to pain. Here, in this 
retrospective correlational pilot study we examined the subjective responses of Australian 
BC survivors (BCS) experiencing cognitive changes after commencing chemotherapy 
treatment. We explored perceived cognitive impairment and its relationships to other 
symptoms (fatigue, depression, anxiety, stress, abdominal symptoms and allergies). Using 
Pearson’s coefficients and Chi-square analyses, the current study identified positive 
relationships between perceived increased sensitivity to pain and perceived learning and 
memory difficulties (PLMD) following chemotherapy treatment (r=2.77; p<0.05). Allergy 
susceptibility in this patient population was also related to the incidence of PLMD 
(r=3.22; p<0.05) and the presence of gastrointestinal disturbances during treatment 
(p<0.01). Perceived cognitive issues positively correlated with fatigue (p<0.01), yet 
negatively correlated to depression, anxiety, and stress. When controlling for the effects of 
fatigue, depression, anxiety and stress, perceived cognitive ability positively correlated 
with perceived comments from others (p<0.05). From this preliminary study we conclude 
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that relationships occur between allergy susceptibility and cognitive changes, and allergy 
gastrointestinal disturbances during chemotherapy treatment. Although greater power is 
required in future studies to confirm the clinical significance of these findings, 
mechanistically we propose that neuroimmunological manifestations may be mediating the 
perceived gut and cognitive induced changes in a subset of BCS. Further, our findings 
imply that patient allergy susceptibility may be used as a predictive tool in the 
identification of individuals susceptible to unwanted gut and cognitive changes following 
chemotherapy treatment.  
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Background 
Central- and gut-induced toxicities associated with chemotherapy treatment place 
significant strains on patient quality of life. In the central nervous system (CNS), reports of 
learning and memory difficulties have been clinically termed chemotherapy-induced 
cognitive impairment (CICI) and incidence estimates differ substantially, ranging from 15- 
85% of cancer patients [93, 172, 321, 322, 395]. The most commonly reported cognitive 
domains affected by CICI are executive functioning, attention, memory, decision making 
and speed of processing [174]. 
Other systemic unwanted side-effects of chemotherapy exposure are also common. In the 
gastrointestinal (GI) tract (GIT), mucositis is the umbrella term used to describe regimen-
related mucosal damage and its aetiology has been comprehensively characterised by Sonis 
[1]. Since then, additional mechanisms contributing to the pathogenesis of mucositis have 
been identified, and the term mucositis has been superseded by chemotherapy-induced gut 
toxicity (CIGT). CIGT incorporates the influence of the microbiome and damage to enteric 
neurons [107, 208]. CIGT occurs in up to 40% of patients undergoing a standard dose 
regimen and up to 80% with higher dose regimens [396, 397]. 
The symptoms associated with both CICI and CIGT affect patients’ quality of life in many 
domains, such as social, emotional, financial and physical, with symptom severity 
negatively impacting the ability to withstand treatment at effective doses [113, 322, 398]. 
The clinical and economic implications of both disorders warrant further investigation of 
the mechanisms related to the pathologies.  
Whilst the gut and the brain are regionally disparate, they are intimately connected via 
various mechanisms and pathways. Information is signalled bidirectionally to both regions 
encompassing the central, autonomic and enteric nervous systems, with input from the gut-
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brain-microbiota axis, neuroendocrine, enteroendocrine and neuroimmune systems [4, 5, 
15, 314, 315]. The immune system becomes particularly compromised during cancer and 
its treatment. Many immunological processes become dysregulated due to the complex, 
and at times contradictory, nature of endogenous inflammatory events occurring at 
different sites [66, 68]. For example, inflammatory signalling molecules initiate pathways 
which attempt to rid the host of the malignancy, yet can simultaneously assist in the 
establishment and progression of cancer [67]. Accordingly, the immune profiles of patients 
undergoing anti-cancer treatments often become dysregulated; whilst increased systemic 
pro-inflammatory markers are commonly reported, suppressed immune activity may also 
be promoted by immunomodulatory antibodies [78, 399]. Finally, anti-cancer treatments 
target rapidly regenerating healthy cells. The gut lining and hippocampal brain region are 
particularly susceptible to toxicities associated with treatments, resulting in symptoms 
which have been attributed to CIGT and CICI, independently [64, 86, 116, 235]. 
Nonetheless, investigations into whether the two disorders contribute to, or potentiate, the 
pathogenesis of one another are lacking. 
Further complicating immune dysregulation in the context of cancer is the association of 
allergies. Several systematic reviews have highlighted lines of evidence linking allergies 
either increased or decreased risk of developing specific cancer types [70, 71, 400, 401]. 
Whilst there is strong evidence for allergies having a protective role in cancer development 
(glioma, cancers of the GIT; oral, oesophageal, stomach and colorectal cancer), a history of 
allergies has also been linked to increased risk for lung, bladder, prostate and lymphoma 
cancer [71]. The hypothesis that allergies can increase risk for certain cancer types has 
been challenged and disputed amongst the literature. Accordingly, three major mechanisms 
mediating the relationship between allergies and cancer have been postulated, which 
involve: (1) chronic inflammation; (2) immune-surveillance (enhanced immune 
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responsiveness); and (3) prophylaxis (allergic reactions expel mutagenic triggers); all of 
which have yet to be elucidated [70].  
The allergy status of an individual may demonstrate differing set-points of the system 
which promote pro-inflammatory processes. Accordingly, a challenge such as 
chemotherapy exposure may result in worse outcomes for gut toxicity and cognition, hence 
allergy status may serve as a predictive tool for patients at risk of severe toxicities to these 
regions, including visceral pain, severe mouth ulcers, diarrhoea and cognitive dysfunction 
that affect daily functioning. The current study thus proposed an association between 
allergies and risk of developing chemotherapy-induced toxicities. We hypothesised that if 
an individual already has an established heightened immune response to certain triggers, 
they may be predisposed to developing more severe gut and cognitive symptoms 
associated with chemotherapy treatment. Therefore, allergies may predispose a subset of 
chemotherapy recipients to more severe perceived CIGT and CICI symptoms. 
The neuroimmune system and peripheral-to-central immune signalling pathways present as 
a plausible mechanism linking both disorders. Intestinal inflammation arising from CIGT 
may act as the catalyst, whereby peripheral inflammatory signals and mediators, such as 
interleukin-1 beta (IL-1β) or lipopolysaccharide (Gram-negative bacteria) signal the brain 
to orchestrate a series of physiological and behavioural responses [256, 382, 383]. 
Peripheral-to-central immune signalling pathways (humoral, neural and cellular routes) 
activate what is now commonly recognised as cytokine-induced sickness behaviours [382, 
394]. Profound CNS activation initiates a host of “sickness responses” which include fever, 
fatigue, heightened sensitivity to pain, anorexia, and social isolation [382]. This 
constellation of behaviours ultimately aims to return the host to a homeostatic state. 
Interestingly, cytokine-induced sickness behaviours mimic many of the symptoms 
experienced by chemotherapy recipients, such as cognitive dysfunction, gastrointestinal 
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disturbances, depression, pain, anxiety and fatigue [79, 80]. Therefore, it has been 
postulated that interactions between CIGT and CICI may be mediated by peripheral-to-
central immune signalling pathways which implicate the neuroimmune system in the 
pathogenesis of cognitive symptoms [302].  
Neuroimmune cells, glia, form an intimate relationship with the synapse and are critical in 
health and disease [121, 122]. In particular, microglia and astrocytes are sensitive to 
increases in systemic pro-inflammatory cytokines and mediators released by peripheral 
inflammatory events. Once activated, glia release a host of pro-inflammatory cytokines and 
mediators, inducing neuroinflammation, and the subsequent neurotoxic microenvironment 
can contributes to various peripheral and central disorders, such as neuropathic pain and 
Parkinson’s disease [131, 319]. In higher order brain regions involved in learning in 
memory, such as the hippocampus, glial activation and neuroinflammation have been 
proposed to contribute to CICI which warrants further investigation [84, 302]. In 
preliminary studies, our group has shown that glial activation occurs in the hippocampus of 
mice with colitis-associated colorectal cancer and in the spinal cord of rats in a non-
malignant CIGT model (unpublished). Whilst the acute chemotherapy model failed to 
observe higher order brain glial dysregulation, further exploration utilising a more 
clinically representative approach (chronic model) may yield support for this hypothesis. 
Increased expression of microglial and astrocyte markers in the hippocampus of mice with 
colitis-associated colorectal cancer suggested that glial-induced chronic inflammatory gut 
conditions were mediated by peripheral-to-central immune signalling pathways, such as 
the humoral (hippocampal changes) and neural (spinal changes) routes.  
Our current understanding of mechanisms relating to CICI and CIGT fail to acknowledge 
the impact CIGT may have on CICI. Therefore, the current study additionally sought to 
bridge this gap and identify the potential impact these chemotherapy-induced side-effects 
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have on the quality of life in breast cancer survivors (BCS) in Australia. Through an 
exploration of subjective CIGT and CICI in BCS, the current study hypothesised that the 
severity of CIGT and CICI symptoms would be correlated. To further explore the 
relationship between symptoms and quality of life in BCS, various factors such as, 
depression, anxiety, stress, fatigue, allergy susceptibility and pain were also measured. 
This was a cross-sectional correlational pilot study which used exploratory statistical 
analyses to identify associations between a range of peripheral and central side-effects 
induced by chemotherapy treatments. The current study was separated into two arms 
whereby the initial analyses (Phase One: partial dataset) directed a more guided, detailed 
and appropriate statistical approach for the second arm of analyses (Phase Two: fulll 
dataset). The first arm of the study focused on subjective exploratory questions 
surrounding perceived cognitive impairment (PCI), identifying specific time-points for 
perceived changes, as well as other side-effects of treatment; for example relating to pain, 
stressors and allergy susceptibility. The Phase One analysis aimed to determine whether 
individual susceptibility to allergies could serve as a predictive sign for CIGT development 
in BCS, owing to their hypothesised shared immune basis. The Phase One questionnaire 
was developed by the lead investigators and answers were converted into categorical 
variables for statistical analyses. Phase Two utilised already validated measures, such as 
the Functional Assessment for Cancer Therapies (FACT), Functional Assessment of 
Chronic Illnesses Therapy (FACIT) (FAC(I)T) and the Depression, Anxiety and Stress 
Scale (DASS). The Phase Two analysis aimed to quantify relationships between perceived 
symptoms and quality of life, offering insight into the impact these side-effects have on 
BCS perceived quality of life. 
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Materials and Methods 
Procedure 
Approval was granted by The University of Adelaide’s Human Research Ethics 
Committee (# H-2015-167; Appendix Five) and all elements of the survey were guided by 
the National Statement on Ethical Conduct in Human Research (2007). BCS (total n=72) 
were recruited through the Breast Cancer Network Australia (BCNA) Review and Survey 
Group. Initial power analysis was based on an effect size of 0.3 with 90% power; sample 
size n=88, however, the recruited sample size did not reach this number. As a result of 
this, the current study was separated into two arms to ensure sufficient statistical power in 
identifying potential links between allergies and perceived GI or learning and memory 
difficulties. Fewer participants than anticipated completed the questionnaire in full (Phase 
One and Two) or met the inclusion criteria. However, their responses informed the 
question of the relationship between allergy, PLMD and GI disturbances. Therefore, they 
were considered separately in Phase One of the analyses. It is for these reasons that Phase 
One (n=58; effect size of 0.5 with 95% power); focused on exploratory questions, whereas 
Phase Two (n=31; effect size of 0.5 with 80% power) were a subset of the original (n=58) 
population and adopted more stringent inclusion and exclusion criteria, including specific 
validated measures (see Figure 6.1: Venn diagram). Basic inclusion criteria for all 
consenting participants included in both phases of this study were that they: 1) had all been 
diagnosed with breast cancer; 2) were 30+ years old; and 3) had all undergone and 
completed chemotherapy treatment. BCS were only included in Phase Two of the study if 
they were non-smokers, non-diabetic, free from psychiatric 
(including major depression) or neurological disorders and had no pre-existing gut 
disorders (for example, inflammatory bowel diseases) prior to chemotherapy treatment. 
Participants not meeting these criteria were excluded because smoking, diabetes and gut 
disorders may predispose BCS to CIGT due to altered cytokine profiles and increased risks 
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of infection and disease [364, 402, 403]. As some pharmaceuticals alter cognition, 
participants were also free from using any medications, such as opioids, which can impact 
cognitive outcomes [404]. BCS included in the Phase Two analysis reported experiencing 
difficulties with their cognition and GI disturbances since commencement of 
chemotherapy treatment. Finally, the Phase Two participants were only included if they 
had received their last anti-cancer treatment within two years of the current study. 
Figure 6.1. Venn diagram depicting Phase One and Two breakdown. Of the 72 consented participants, 58 were eligible 
for Phase One analysis involving exploratory questions/measures only, not using the FAC(I)T/DASS measures. 
Inclusion and exclusion criteria were applied to the Phase One arm, resulting in 31 eligible participants to be included in 
the Phase Two arm of the study focusing on the FAC(I)T/DASS measures.  
Participants 
All initial correspondence with participants was via the BCNA by email (Appendix Four), 
which contained a participant information sheet, inclusion and exclusion criteria checklist, 
and the participant’s contact project and complaints form. Willing participants were given 
the option to complete the study online (SurveyMonkey), or alternatively by requesting a 
hardcopy from the primary investigator by email. Participant responses were anonymous. 
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Measures 
Participants completed an online self-report questionnaire which were separated into two 
phases (four participants completed hard-copy version; see Appendix Three for full 
questionnaire).  
The first phase of the questionnaire (see Appendix Three) was primarily designed by 
investigators to determine demographic, medical and personal lifestyle information, as well 
as identifying specific exploratory questions relating to the time-course of perceived 
learning and memory difficulties (PLMD) and perceived GI disturbances after 
chemotherapy treatment. For example, participants were asked whether PLMD or GI 
issues were noticed before treatment but after diagnosis, during treatment or after treatment 
ceased. This initial phase also identified the importance of exercise to each individual by 
rating it on a scale (1: extremely important to 5: not at all important) and identified how 
often exercise was undertaken in a typical week. Specific questions relating to allergies, 
pain and factors associated with pain were examined. BCS were asked to report on how 
often they experienced pain prior to diagnosis (1: daily to 7: rarely) and commented on the 
type of pain most commonly experienced. Following treatment cessation, they were also 
asked whether they noticed an increase in their sensitivity and frequency of pain (yes/no) 
and to indicate their previous and current use of various ‘habits’ associated with pain 
including dieting, consumption of caffeine and alcohol, illicit drug use, and vitamin 
supplementation. Participants responded currently, yes; currently, no; previously, yes; or 
previously, no. Participant stressors were assessed by categories focusing on the following 
areas: familial or employment, relationships in both areas, financial and health stress. All 
stressors were rated in terms of the level of stress in these areas of their life (1: no stress; 2: 
intermittent stress; 3: persistent stress and 4: overwhelming stress).  
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The second phase of the questionnaire (see Appendix Three) followed a directed statistical 
approach by quantifying perceived cognitive and GI disturbances using valid and reliable 
surveys: FACT-Cognitive (Cog) Scale, FACIT-Abdominal Disturbances (AD), FACIT-
Diarrhoea (D) and FACIT-Fatigue (F). Depressive and anxiety symptoms were assessed 
using the DASS to control for these as confounding factors potentially associated with both 
cognition and GI disturbances. The Phase One analysis of this study exclusively relates to 
data outlined in the first phase of the questionnaire, which included demographic and 
exploratory questions regarding personal, lifestyle and medical issues designed specifically 
for this study by the lead investigators (see Appendix Three). Phase Two followed a 
directed statistical approach utilising the data obtained from the FAC(I)T and DASS 
measures. 
Phase One: Demographic and medical information. All participants were asked to report 
their age, sex, education, employment status, exercise level, allergy susceptibility, stress 
levels in various aspects of life, marital status and medical information. Medical 
information included time post-treatment, types of adjuvant therapies, and a range of 
investigator-led exploratory questions surrounding PLMD and GI issues, as well as 
reporting on their use of additional therapies, such as anti-hormonal medications. 
Following the initial results obtained from the global Phase One analysis, stringent 
screening of the inclusion and exclusion criteria were applied to the Phase One 
participants. Ultimately, this resulted in a subsample which enabled more targeted 
statistical analyses in Phase Two.  
Phase Two: Perceived cognitive function. Perceptions on cognitive changes were 
measured using the FACT-Cog (v 3) [405]. This version of FACT-Cog has 37 questions 
rated on a five point Likert scale (0: never or not at all – 4: several times a day/very much) 
[406]. Four subscales cover PCI (20 items), perceived cognitive abilities (PCA; 9 items), 
Chapter Six. Understanding chemotherapy: allergies, pain, cognitive and gut disturbances
228 
perceptions on comments from others (OTH; 4 items) about their cognitive function and 
quality of life (QOL; 4 items). Negatively worded items were reverse scored. Overall, 
higher scores reflect fewer cognitive problems. FACT-Cog is a self-report measure which 
has demonstrated good validity and reliability in previous BCS studies examining CICI 
[276, 406, 407].  
Fatigue. The FACIT-Fat (v 4) was used to measure the severity of fatigue symptoms over a 
seven-day period on a five point-scale with response options ranging from 0 (not at all) to 
4 (very much so). This tool has been specifically designed for cancer patients [408] and has 
shown good validity and reliability in BCS populations [409-411]. Responses are summed 
to calculate a total score with high scores reflecting low levels of fatigue and the FACIT-F 
scale has strong internal consistency, including test-re-test reliability [406].  
Depressive and anxiety symptoms. The DASS is a 42 item questionnaire [412]. 
Participants indicate the extent to which symptoms applied to them over the past week on a 
four-point Likert scale ranging from 0 (Did not apply to me at all) to 3 (Applied to me very 
much, or most of the time). DASS measures participants’ emotional states of depression, 
anxiety and stress during the past week. DASS has high internal consistency with 
Cronbach alphas of 0.91, 0.84 and 0.90 for depression, anxiety and stress subscales 
respectively [413, 414]. Although this instrument was not created specifically for cancer 
patients, it has previously demonstrated reliability when used in breast cancer studies [413, 
414].  
Gastrointestinal discomfort. The FACIT-AD and FACIT-D scales assessed participants’ 
perceived well-being and gastrointestinal disturbances during their treatment. Subscales 
were classified into physical well-being (7 items), social/family well-being (6 items), 
emotional well-being (6 items) and functional well-being (7 items). Responses were scored 
using a five-point Likert scale ranging from 0 (not at all) to 4 (very much). Both 
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instruments produced three subscales: physical well-being, social/family well-being, 
emotional and functional well-being. To avoid repetition of the same questions, the 
primary investigator received permission from the FACT/FACIT organisation to 
orchestrate a unique set of questions which were tailored specifically for the participants in 
this study and in turn, relabelled it the FACIT-D/AD. The ‘additional concerns’ sub-
sections from both instruments (3:AD + 11:D) were combined to make a specific 14 item 
section which avoided repetition of questions presented in both surveys. Higher scores 
indicated that participants had a better perceived QOL and reduced GI disturbances.  
Statistical Analysis
All statistics were performed using IBM SPSS Statistics program (v 25). Frequencies were 
used to describe the samples in both phases of analysis and were also used to report on the 
exploratory questions in Phase One analysis. In Phase One, Chi-squared tests were 
employed to explore relationships between PLMD and GI symptom severity during 
treatment, including allergy susceptibility and increased sensitivity to pain. A Pearson’s 
correlation matrix was also performed as an overall guide to identify potential links in 
Phase One of the analysis. The Phase Two analyses used further Pearson’s correlation 
coefficients to explore relationships between PCI, FACT-Cog total scores and the subscale 
scores of other symptoms associated with perceived QOL, such as emotional well-being 
and abdominal disturbances whilst controlling for the effects of fatigue, depression, 
anxiety and stress. This nested statistical approach was developed due to the preliminary 
nature of this study.  




Table 6.1 contains participant demographic and medical information. Of the 72 
participants, 58 were eligible for inclusion in the Phase One analysis with all demographic 
and exploratory questions fully completed. Demographic frequencies remained similar for 
participants in Phase One and Phase Two of the analysis. The majority of participants were 
50-69 years of age, post-menopausal and married. Participants most commonly reported
they were working full time (32-34.4% in both phases) and the majority had completed 
some form of tertiary education. Early breast cancer (EBC) was the primary diagnosis for 
the majority of BCS (60.3-65% in both phases). Six participants reported being diagnosed 
with at least one or more additional diagnoses, such as ductal or lobular carcinoma in situ. 
One EBC survivor disclosed multiple diagnoses which included Paget’s disease of the 
nipple, ductal carcinoma in situ and locally advanced breast cancer. In addition to 
chemotherapy treatment, most BCSs had surgery (partial or full mastectomy) and/or 
radiation. Participants most commonly reported undergoing their anti-cancer treatment 
regimens for less than one year and were in remission for less than 24 months.  
In Phase Two the number of participants reached 31 after the inclusion and exclusion 
criteria were applied. The most common reasons for exclusion were that participants had 
exceeded 24 months since their last chemotherapy treatment, had not experienced any 
gastrointestinal disturbances during their chemotherapy treatment, or had pre-existing 
mental health issues. Although some participants reported no pre-existing mental health 
issues, they reported that they reported anti-depressant medication. These participants were 
included in the Phase Two analysis under the assumption it was for another use, such as in 
the treatment for hot flushes during menopause. For a breakdown of the Phase One and 
Phase Two demographic, medical and exploratory data, refer to Table 6.1. 
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Internal consistency of the subscales in all FACT and DASS questionnaires were evaluated 
using Cronbach’s coefficient alpha. Internal consistency is considered acceptable for group 
comparisons if α >0.7. Internal consistency was high for all DASS subscales (depression, 
anxiety and stress scores; >0.9), PCI and PCA reached >0.9, yet comments from others and 
QOL scales were <0.5, FACIT-F was 0.8, whereas FACIT:D-AD subscales were weak 
(<0.4).   
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Lifestyle and Reported Changes Since Treatment 
In Phase One, exercise was important to approximately 70% of participants with 43.1% 
susceptible to allergies. The most commonly reported allergies in the current study related 
to medication (e.g. penicillin) and plants/pollen, followed by food and insects/animals, 
with only a few individuals reporting allergies to dust, alcohol and tapes/latex. Hormone 
therapy was the most commonly reported regular medication (58.6%). Persistent or 
overwhelming stressors were reported by 29 of the participants and were mainly related to 
health, family, parents, children, finances, work and co-workers. Of those, 13 reported 
multiple areas of stress in their life, as an example one participant expressed persistent or 
overwhelming stress in relation to their health, family, parents and children, as well as in 
their workplace.  
When asked whether their cancer diagnosis or anti-cancer treatment prevented them from 
working, 67.2% participants agreed. The main reasons for not being able to continue 
working related to treatment side-effects (71.4%), with cognitive changes (33.3%) and pain 
(23.8%) most commonly reported. Aside from work duties, other normal daily activities 
were negatively affected by cancer diagnosis and anti-cancer treatment (81%). Prior to 
receiving a cancer diagnosis and anti-cancer treatment, the majority of participants 
reported rarely experiencing pain (56.9%), though 70.7% reported noticing an increase in 
their sensitivity to pain (and frequency) following commencement of anti-cancer 
treatments.  
All participants in Phase One reported experiencing problems with cognition since their 
cancer diagnosis but the majority specifically reported noticing issues following 
commencement of their anti-cancer treatment (70.7%). Of those, 86.2% continued to 
experience PLMD. Cognitive changes were reported to be more noticeable post-
chemotherapy treatment sessions (62.1%) and 87.9% said that their PLMD had not 
Chapter Six. Understanding chemotherapy: allergies, pain, cognitive and gut disturbances
234 
returned to their capacity prior to anti-cancer treatment. Although 84.5% of participants 
reported GI disturbances throughout their anti-cancer treatment, only 69% reported that 
they consulted their doctor. Most doctors provided participants with analgesic intervention 
or coping strategies to help manage GI issues (56%). Of those reporting GI disturbances, 
only 10.3% of the participants were clinically diagnosed with mucositis (oral and/or 
intestinal) although 56.9% reported that their GI complaints were more severe post 
chemotherapy treatment.  
Phase One: Categorical Relationships Between Perceived Increased Sensitivity to Pain, 
PLMD, Perceived Severity of GI Disturbances and Allergies
Initial Pearson’s correlation analysis was performed to identify potential links between 
perceived allergy, pain, PLMD and GI issues in Phase One BCS (n=58). A significant 
interaction between BCSs reporting increased frequency and sensitivity to pain with PLMD 
was identified (Pearson’s r=0.277, p<0.05; Table 6.2). When comparing the frequency of 
self-reported susceptibility to allergies and PLMD since undergoing treatment, a significant 
interaction was also found (Pearson’s r=0.322, p<0.05; Table 6.2). Following the initial 
analysis, multiple chi-squared tests of independence were performed to further explore 
these relationships. The majority (85.5%) of participants who reported PLMD since 
undergoing treatment also reported GI disturbances during treatment (χ2(1)=0.766, 
p=0.403; Table 6.3). There was a significant interaction between the exploratory pain and 
allergy data with 51% of participants reporting increased sensitivity and pain frequency, 
also reporting allergy susceptibility (χ2(1)=3.575, p>0.048; Table 6.3). 45.5% of 
participants who were susceptible to allergies also reported experiencing cognitive changes 
since undergoing treatment (χ2(1)=2.397, p=0.255; Table 6.3).  
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Perceived learning and memory difficulties (PLMD), gastrointestinal (GI).
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Phase Two: Relationships Amongst PCI, QOL and Other Symptoms (Fatigue, Depression, 
Anxiety and Stress)
Phase Two included only those participants who met more stringent inclusion criteria to 
control for the impact of potential confounders. In this analysis, PCI was significantly 
related to QOL and fatigue (r=0.55, p<0.05 and r=0.69, p<0.01; respectively; Table 6.4). 
PCI was negatively associated with depression, anxiety and stress scores (r<-0.5 and 
p<0.01 for all measures; Table 6.4). There were also negative correlations with fatigue and 
depression, anxiety and stress scores (r<-0.5 and p<0.01 for all measures; Table 6.4).  
Relationships Between PCI, Well-being and GI Disturbances, Controlling for Confounding 
Factors
In Phase Two, the subscale scores generated from the FACT-Cog, well-being and GI 
disturbances data were examined, whilst controlling for DASS and fatigue measures. This 
analysis identified whether positive relationships occurred between PCI and well-being or 
GI disturbances; higher scores for PCI (worse perceived cognitive impairment) would 
positively correlate with higher scores for well-being or GI disturbances (better perceived 
well-being or worse perceived GI symptoms). Following application of the stringent 
eligibility criteria to participants, an n=31 was reached. PCA was related to perceived 
comments from others (r=0.388; p=0.04; Table 6.5). Whilst a negative trending association 
was observed between PCI and social/family well-being, and PCI and diarrhoea, these 
failed to reach statistical significance (r=-0.33, p=0.095 and r=0.37, p=0.057, respectively; 
Table 6.5). Perceived comments from others was also trending towards a negative 
association with emotional or physical well-being (r=-0.320 and r=-0.336, respectively; 
Table 6.5), as well as with abdominal disturbances (r=-0.353; Table 6.5), though these also 
failed to reach statistical significance (p=0.10, p=0.09 and p=0.07, respectively; Table 7.5). 
Perceived diarrhoea symptoms were positively related to perceived social and family well-
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being (r=0.530; p=0.004; Table 6.5), as well as showing a positive trend toward emotional 
well-being, though this just failed to reach statistical significance (r=0.361; p=0.06; Table 
6.5).  
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Perceived cognitive impairment (PCI), quality of life (QOL), functional assessment of cancer therapy-cognition (FACT-Cog), well-being (WB), functional assessment of chronic illnesses therapy-
diarrhoea/abdominal disturbances (FACTI:D-AD), others (OTH).
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Discussion 
The cognitive and GI disturbances associated with cancer and anti-cancer treatments place 
significant burdens on the individual and on health services at a national level [264, 415]. 
Regimen-related GI and cognitive symptoms negatively impact cancer patients in many 
ways, placing significant strains on their ability to function (from eating and speaking, to 
functioning in normal roles, such as parenting or working), to financial hardships. Cancer 
patients with moderate-to-severe GI and cognitive deficits experience reductions in income 
due to maintaining oncology appointments, feeling unwell or unfit for work, and even 
hospitalisations [264]. This, combined with increased financial strain associated with 
cancer diagnosis, treatment and hospitalisations, results in a significant burden on cancer 
survivorship. At the national level, these regimen-related toxicities often become so severe 
that infection results in hospitalisations, which can have significant impacts on national 
healthcare systems in an aging population.  
Whilst regimen-related GI symptoms are generally acute and resolve upon treatment 
cessation, cognitive deficits are often delayed, persistent and distressing to survivors as 
they are difficult to manage [321]. At the heart of oncology, is the complex nature of the 
simultaneous symptom clusters that patients experience. In an effort to elucidate global 
mechanisms contributing to concurrent central and GI symptoms in BCS, the 
neuroimmune system is ideally positioned as it incorporates immune dialogue between the 
periphery and the CNS. Therefore, the purpose of the present study was to determine 
whether relationships between the perceived severity of CIGT symptoms were correlated 
with perceived cognitive difficulties in BCS. Additional side-effects associated with 
treatment (fatigue and depression) were also accounted for, as well other individual factors 
which may affect immunological outcomes, such as, allergy susceptibility and lifestyle 
choices, such as exercise.  
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One of the prominent findings from Phase One was that frequency and sensitivity to pain 
following chemotherapy was positively related to PLMD after treatment. Pain and 
cognition are intrinsically and reciprocally intertwined, yet mechanisms contributing to 
their interaction are unclear [416, 417]. The concept of pain perception factors in not only 
the sensory modality, but the conscious experience which involves a myriad of cognitive 
processes, including emotional and psychological factors [417]. The integration of these 
processes results in a cognitive-evaluative dimension of pain, which encompasses memory 
retrieval, adaptive learning and active decision making [418]. Chronic pain sufferers 
appear to be particularly susceptible to reporting learning and memory deficits in attention 
and working and verbal memory domains [419, 420]. Studies utilising placebo analgesia 
and cognitive tasks (distraction) to alleviate pain in chronic pain syndromes provide strong 
evidence that the two paradigms are intimately linked [421, 422]. Pain is amongst one of 
the most commonly reported symptoms associated with cancer and anti-cancer treatments 
[423]. Approximately 16-73% of BCS report pain as a significant emotional, financial and 
physical burden, yet the ability to appropriately evaluate pain is difficult due to the 
complexity of the disease itself and the subjective experience of pain [424]. Chronic pain 
occurs in 43% of BCS for up to 3 years post mastectomy surgery [425]. Accordingly, pain 
management guidelines for cancer and its treatment have been developed by the World 
Health Organisation which advise using (in increasing intensity) mild, moderate and more 
powerful analgesic options, such as non-steroidal anti-inflammatory drugs, partial or weak 
opioids, followed by typical/classic opioids [266].  
Growing evidence has highlighted the role innate immune signalling and the neuroimmune 
system has in modulating general and neuropathic pain, opioid analgesia, cognitive 
changes and symptom clusters (alike to sickness behaviours) in the cancer population [123, 
136, 191, 319, 426]. Due to the intimate relationship glia have at the synapse, microglia 
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and astrocytes are uniquely positioned to influence neuronal excitability, which in 
particular brain regions may result in central sensitisation, increased nociceptive signalling 
and behavioural and cognitive adaptations [123, 127, 132, 134, 136, 329, 427]. 
Importantly, recent data has implicated genetic polymorphisms in neuroimmune activation 
of the innate pathway, My-D88, in cognitive dysfunction amongst cancer patients [329]. 
My-D88 (adaptor protein for many Toll-like receptors; TLRs) is pivotal in innate immune 
activation involving opioids, danger-associated molecular patterns and interleukin [IL]-1 
receptors [428]. Combined with molecular studies identifying a role for neuroinflammation 
in CICI [182] and glial activation in mediating pain-associated with CIGT [134], this may 
partially explain the cognitive-pain interaction observed in the present study. Pain-
cognition interactions can be two-way (effects of pain on cognition and cognitive load 
effects on pain) and are observed in acute and chronic pain settings [429-431].  
There are three theories that could, at least partially explain, the association between 
perceived pain and PLMD found in the current study [416]. Firstly, it is plausible that the 
same (or at least some) cognitive processes involved in the perception of pain are 
competing with the negatively-affected cognitive domains; the limited resource theory. 
Persistent nociceptive inputs from pain have been suggested to compete with other sensory 
inputs, resulting in a negative effect on cognitive performance [432]. Alternatively, the 
neuroplasticity theory involves neural rewiring or reorganisation in chronic pain which 
interferes with normal cognitive functioning. For example, morphological adaptations, 
such as volume changes or cellular changes (e.g. oligodendrocytes, white matter) in 
specific brain regions, such as the pre-frontal cortex, or deficits in hippocampal 
neurogenesis or long-term potentiation modifications, have been proposed to have 
deleterious effects on cognition in patients experiencing chronic pain [417]. Finally, pain 
may result in the dysregulated release of intermediate neuromediators, such as pro-
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inflammatory cytokines, monoamines and neurotrophic factors; some of which are released 
by glial cells. Increased or decreased release of these intermediate neuromediators may 
negatively affect cognition in various brain regions which can be explained by the 
neuromediator theory. It is unlikely that one mechanism or theory is responsible for the 
perceived pain-cognitive relationship observed in the BCS in the current study, rather all 
these theories could work in unison. Whilst a mild pain-cognition association was observed 
in Phase One, it was unable to be determined whether the pain perception BCSs influenced 
cognitive dysfunction, or vice versa, due to the cross-sectional approach adopted. In 
addition, it is also important to consider depression, anxiety and stress as confounding 
factors as they have all been associated with learning and memory deficits [419]. 
Nonetheless, these emotional components were not measured or accounted for in the Phase 
One analysis. Teasing apart these factors would require further detailed longitudinal 
examination of both objective and subjective cognitive, emotional and pain measures taken 
prior to chemotherapy, during and after treatment cessation.  
Allergy susceptibility in the current BCS population was associated with PLMD, pain and 
GI disturbances during treatment in Phase One. Whilst the link between allergies and 
cancer development is well established [71], evidence connecting interactions between 
allergies and regimen-related toxicities is lacking. To our knowledge, this is the first study 
that identifies a relationship between allergies and PLMD, pain and GI disturbances in 
BCS. Certain chemotherapy drug types, including platinum compounds and taxanes, have 
high potential to cause allergic reactions (hypersensitivity) in some cancer patients [433], 
though none were reported in the current study. Evidence suggests that risk factors 
associated with hypersensitivity to chemotherapy drugs include prior chemotherapy 
exposure and a history of allergies [434, 435]. In a similar light, it is plausible that BCS 
with a prior history of allergies may have a primed immunological response that can be 
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triggered by chemotherapy treatment and potentially contribute to perceived severity of 
CICI, CIGT and pain symptoms. The aetiology of immunologic responses, such as atopic 
dermatitis, food allergies and hypersensitivity to drugs (e.g. penicillin) are multifactorial 
and, aside from genetic susceptibility, other influences, such as early-life and 
environmental exposures, infection and autoreactivity, have been identified [436-439]. 
Recently, it has been suggested that food allergies and asthma may be associated with 
changes in cognitive status [440, 441]. From this, one can assume that the allergy-
cognition relationship identified in the current study may somewhat contribute to these 
findings. Although a link has been suggested to occur between food allergies and other GI 
disorders, such as IBD and IBS [442, 443], whether this is purely a coincidental or causal 
relationship, remains elusive. The potential involvement of an allergy-related primed or 
heightened immune (innate and adaptive) response and its effect on cognition in BCS in 
the current study warrants further investigation.  
Innate and adaptive immune responses create a cascade of non-specific and specific 
defence mechanisms to protect the host from invading pathogens [238, 444]. Immune cells 
constantly circulating the lamina propria and submucosal areas of the GIT are pivotal to 
the mucosal immune system [346]. Consequently, the most noticeable manifestations of 
primary or acquired immunodeficiency disorders are infections of the soft tissue, in 
particular the oral cavity whereby recurrent viral, fungal and parasitic infections are 
commonly reported [445]. Patients undergoing radiotherapy or chemotherapy are included 
in this category as they are usually also immunocompromised, and like patients with 
autoimmune disorders, they frequently report inflammation and ulceration in the oral 
cavity (oral mucositis) or gut-related disturbances (visceral pain, bloating, diarrhoea, 
constipation, rectal bleeding, nausea and vomiting) [264]. Recently, the role of the 
neuroimmune system in the development of allergic reactions has been recognised [446]. 
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Advancements in our understanding of the neuroimmune interactions mediating food, skin 
and lung allergic reactions have provided us with insights into mechanisms that have 
superseded the classical role of the immune system and nervous system in allergies [447-
449]. This exciting avenue of research may offer novel targeted therapeutic approaches 
that dampen allergic responses via inhibiting the neuroimmune system, though detailed 
studies are required to elucidate these mechanisms. In the same sense, the neuroimmune 
system could be targeted in chemotherapy recipients, in an attempt to globally reduce 
regimen-related toxicities with an inflammatory component, such as CICI or CIGT, and 
even cancer-induced pain.  
Taken together, these data presented here, coupled with the involvement of the 
neuroimmune system in allergic reactions [447], provide some mechanistic evidence for 
the allergy-related findings in Phase One of the present study. The translatable potential 
for the preliminary allergy-related findings in this study, suggest that chemotherapy 
recipients who are susceptible to allergies, may in fact have a heightened immune response 
and therefore, may be prone to developing more severe cognitive, pain or gut disturbances 
during and/or after treatment. This predisposition may allow clinicians to encourage 
patients who will be undergoing chemotherapy regimens to use preventative strategies that 
may alleviate or reduce the severity of these symptoms associated with chemotherapy-
induced toxicities. Larger studies, with greater statistical power, are required to clarify the 
mechanisms contributing to the weak allergy-related relationships with PLMD, pain and 
gut disturbances reported in the current study.  
In Phase Two, PCI positively correlated with QOL and fatigue, yet, in this small BCS 
population, PCI was negatively associated with depression, anxiety and stress. Strong 
positive associations between PCI and depression, anxiety and fatigue have been 
frequently reported in both BCS and other cancer patient populations undergoing 
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chemotherapy treatment [59, 337, 450-453]. Breast cancer diagnosis alone often results in 
feelings of depression and anxiety which can have negative effects on cognition and QOL 
[146]. Interpretation of this strong association should be treated with caution as the 
direction of the relationship is unclear, and may be cyclical; depression and anxiety may 
have substantial effects on PCI, yet PCI may also affect depression and anxiety [190]. 
Although it has been previously argued that depression and anxiety may in fact potentiate 
CICI [415, 454], in the general population negative associations between these parameters 
have been reported [454]. Some studies report mild-to-moderate negative depressive and 
anxiety effects on objective neuropsychological functioning [455]. Higher recruitment 
numbers and more statistical power, including the addition of effective control groups 
(healthy and cancer, no chemotherapy) will assist in future non-biased comparisons. 
Furthermore, as recommended by the International Cognition and Cancer Task Force, pre-
chemotherapy cognitive scores are critical to address potential cognitive issues and/or 
reserve prior to treatment commencement as a baseline.  
In the Phase Two analysis, FACT-Cog total scores strongly correlated with fatigue scores 
which was in accordance with previous studies [456]. Nonetheless, other studies using 
different fatigue scales have yielded negative associations between perceived cognitive 
changes and fatigue [451]. Various factors contributing to the prevalence of fatigue in 
cancer survivors have been attributed to physiological (pain, anaemia), psychological 
(depression, anxiety), chronobiological (circadian sleep rhythms) and social/cultural 
(education, socio-economic status) factors [457]. The discrepancies in the positive and 
negative associations between perceived cognitive changes and fatigue in these BC 
populations may be related to methodological differences and individual patient variances, 
such as, the use of different tools and measures, to testing cognitive reserve and emotional 
status prior to treatment and time-point of data collection, as examples.  
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Web-based technologies are advantageous as they offer researchers an economically viable 
and readily accessible tool to examine various factors of regimen-related toxicities. Online 
questionnaires are less invasive for participants, as they can complete tasks in the comfort 
of their home (or even a café). This methodological approach was utilised in the current 
pilot study to take a quick snap-shot of links, albeit some of the correlations were weak in 
nature, which may support further neuroimmunological examination on the perceived side-
effects associated with chemotherapy treatment in this BCS population. Several pitfalls 
were identified with this approach and mostly related to difficulties surrounding the 
recruitment of BCS and incompletion or only partial completion of the questionnaire. The 
challenges with recruitment and uncompleted questionnaires resulted in a lack of statistical 
power which required the current study to consider participants who did not meet all 
criteria for Phase One of the study. This was the primary reason for dividing the analysis 
into two phases; whereby one focussed on specific questions relating to the investigator-led 
questions, and Phase Two utilised the fully completed questionnaire containing responses 
from the FAC(I)T and DASS measures only. A more detailed methodological approach 
containing subjective versus objective measures, and qualitative versus quantitative data, 
pre- and post-chemotherapy time-points, is recommended for future analyses to overcome 
these limitations. 
Whilst objective neuropsychological testing has been considered the gold standard for 
cognitive impairment assessment, it is not always feasible for several reasons. For instance, 
neuropsychological test batteries often demand qualified and trained professionals making 
them not only unaffordable, but time intensive [458]. The time associated with 
neuropsychological testing limits their use in practice and more importantly may lead to 
conflicting test results due to fatigue, loss of concentration and decreased motivation [459]. 
Paradoxically, this complicates neuropsychological testing as fatigue, lapses in 
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concentration and decreased motivation compound cognitive abilities, negatively affecting 
the cognitive domains of which the tests are initially intended to determine.  
Further complicating research is the subtle nature of cognitive changes that have been 
objectively assessed and reported in BCS [83, 94, 170]. Moreover, objectively assessed 
cognitive changes may not appropriately reflect the day-to-day cognitive struggles BCS 
experience. Perceived cognitive changes in this patient population are equally important as 
they offer researchers critical insights to the impact cognitive changes have on QOL. Due 
to the cost, time and possibility of conflicting test results, it is not surprising that subjective 
cognitive changes in BCS are more commonly reported than objective measures [460]. 
Some researchers have attempted to overcome these inconsistencies by conducting both 
objective and subjective measures [85, 113, 170, 461], yet inconsistencies in the 
prevalence of CICI still remain. To highlight this variance, Hutchinson, et al. (2012) 
examined the relationship between objective and subjective measures of cognitive 
impairment in BCS [460]. This extensive systematic review identified that only 8 out of 
the 24 studies included in the study, found a relationship between objective and subjective 
measures. In addition, the prevalence of objectively-reported cognitive impairment in these 
studies varied from 1-63% compared with 8-95% for subjective assessments. Importantly, 
this study suggested that discrepancies between objective and subjective measures may be 
attributed to inconsistencies in the definition of cognitive impairment, study design 
(longitudinal versus cross-sectional), actual time measured (objective tests measure 
specific points in time, whereas subjective tests measure performance over a period of 
time), the effect of mood and/or psychological distress and the awareness of research 
purpose. Given these limitations, both forms of assessment are useful tools in 
understanding the cognitive side-effects associated with chemotherapy exposure in BCS. 
Chapter Six. Understanding chemotherapy: allergies, pain, cognitive and gut disturbances
248 
Irrespective, subjective measures importantly provide us with valuable insights to 
perceptions on daily functioning and quality of life.  
Research in this area is compounded by a number of factors. The majority of BCS are over 
40 years old and age alone may influence findings and must be considered. The natural 
process of aging involves biological processes which promote the gradual loss of 
homeostatic maintenance, including the structure and function of the brain [462-464]. 
Cognitive decline naturally occurs with age and has been associated with reduced 
hippocampal size [465]. Additionally, BCS in this age bracket may be undergoing 
hormonal changes as a result of menopause which can also affect cognition [466]. Natural 
age-induced cognitive and hormonal changes occur at different rates for everyone across 
an individual’s life. This presents researchers with considerable challenges, due to 
difficulties surrounding measuring natural age-related changes on an individual basis. 
However, several studies have reported that age was not a confounding factor accounting 
for CICI symptoms [467]. In addition, the time course of cognitive changes in this patient 
population may be difficult to reconcile, as some studies report acute deficits that resolve 
within 12 months of cessation of treatment [322, 323, 453], whilst others indicate delayed 
onset and continued difficulties up to 20 years post treatment cessation [98]. Discrepancies 
also exist with the interaction of PCI and changes in the cytokine profile of BCS. Whilst 
PCI has been associated with higher plasma concentrations of pro-inflammatory cytokines, 
such as IL-1β and IL-6, some studies have reported no significant correlations [60, 468]. 
The discrepancies in these findings may result from different treatment regimens and 
methodological variances.  
The complex nature of CICI is multifactorial and variances in findings are frequently 
reported in the BC population. Research in this field has significantly advanced since the 
1990s, when cognitive complaints were initially dismissed by doctors as a result of the 
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stress, depression and anxiety associated with the initial diagnosis of cancer [272]. The 
realisation of methodological problems and continued expansion of more detailed 
longitudinal studies have resulted in studies yielding more clinical validity and translatable 
evidence. Experimental models have supported clinical evidence and begun to unravel the 
complex nature of the mechanisms associated with CICI [116, 272, 392]. Of particular 
interest to the present study is recent data implicating the neuroimmune system in CICI and 
pain associated with CIGT [134, 182, 392].  
In summary, the implication of the neuroimmune system in allergic reactions, and the 
findings presented in the current study related to the links between allergies, perceived 
learning and memory difficulties and pain, highlight the need for continued research in this 
area. Indeed, the neuroimmune system is uniquely positioned to have beneficial effects on 
chemotherapy-induced peripheral and central toxicities. Larger longitudinal studies with 
greater power will assist in elucidating the functional implications of the somewhat weak 
correlations observed in the current study, assisting in our understanding of the impact the 
simultaneous side-effects have on daily life. To understand the mechanistic implications, 
allergy-cancer animal models determining pain, GI and cognitive outcomes should be 
adopted to assess cellular and molecular neuroimmunological complications in the brain 
and spinal cord. This will critically identify the influence glial cells have on the 
relationships observed in the current study. Ultimately, harnessing the neuroimmune 
system may enable us to intervene with potential novel treatments, which target both 





The deleterious GI and CNS effects produced by cancer and chemotherapy are well 
established, yet our understanding of the mechanisms contributing to their development are 
incomplete. The impact both cognitive and GI treatment-related toxicities have on daily 
functioning, coupled with the financial burden they place on the individual, as well as 
national health systems, makes them a considerable problem. Pain, ulceration, bleeding 
and gut motility issues associated with chemotherapy-induced oral and gut toxicity renders 
patients unable to perform normal daily tasks such as eating, drinking or speaking [1]. 
Mild-to-moderate oral and gut toxicities can often be managed with analgesic 
interventions, antibiotics, histamines, mouth creams/lozenges, certain probiotics and gut 
motility modifying agents (e.g. laxatives for constipation or anti-diarrhoea medication). 
However, severe cases can often result in infections requiring hospitalisations and 
additional therapies, involving liquid diets, fluid replacements, anti-fungal and anti-viral 
medications [264].  
The average estimated costs of cancer patients with chemotherapy-induced oral/gut 
toxicity hospitalisations is US$6277 with oral toxicity, and US$9132 with gut toxicity, per 
chemotherapy cycle [264]. Predictions on the financial impact of cognitive complications 
arising from cancer and anti-cancer treatments are limited as differences in employment 
status and pay amongst patients prior to diagnosis are so broad. Nonetheless, reductions in 
work hours, unpaid leave and, in some cases, unemployment, have been linked to 
treatment-induced cognitive changes [83]. These down-stream work-related financial 
effects, combined with the need to commence treatment and seek assistance from health 
care services, therapies, and medication associated with cancer diagnosis, results in 
significant hardship on patient survivorship [469]. The financial impact that chemotherapy-
induced oral/gut toxicity has on the patient is short-term compared with the potential for 
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cognitive issues to continue for many years following completion of cancer treatment 
therapies.  
Involvement of the neuroimmune system in the pathological manifestations associated with 
chemotherapy treatment is becoming more evident. The neuroimmune interface is uniquely 
positioned to influence both the gut and the brain in mediating the development of both 
comorbidities and also has the potential to play a key role in treatment approaches and 
preventative strategies. Collectively, the gut inflammatory-mediated neuroimmune 
findings described in this thesis offer novel hypotheses relating to the activity of glial cells 
and the activation of peripheral-to-central immune signalling pathways under these 
conditions. The allergy-cognition and allergy-pain relationships identified in the BCS 
study (Chapter Six) are the first of its kind and will shape further investigations. A 
discussion of the overall findings from this thesis now follows. 
This body of work aimed to explore the neuroimmunology of 5-FU and to identify whether 
altered central glial reactivity was unique to this widely utilised chemotherapy drug, or 
whether changes occurred due to a generalised inflammatory response in the GIT. In order 
to investigate this, several experimental gut inflammatory models were adopted. The acute 
models included a high dose of chemotherapy (5-FU) (Chapters Three and Four), a low 
dose non-chemotherapy (INDO) drug (Chapter Four) and the influence of analgesics on 
regional glial reactivity and IL-1β expression (Chapter Three). The chronic models 
compared glial reactivity in non-chemotherapy treated mice with chronic UC (non-
malignancy) to CA-CRC (inflammatory-induced malignancy) (Chapter Five). The 
preliminary studies forming these Chapters revealed that spinal cord astrocytes displayed 
heightened reactivity in disorders of the gut which involve a high inflammatory 
component, irrespective of GI region; whether the disorder was acute or chronic; and 
whether the inflammation was malignancy or chemotherapy-related. Interestingly, changes 
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in spinal cord microglial reactivity only occurred simultaneously with altered astrocyte 
reactivity in the chronic models employed in this thesis (Chapter Five).  
The collection of works presented here highlights the need to address current limitations in 
the assessment of gut and central chemotherapy-related toxicities. Critically, 5IGT, chronic 
UC and CA-CRC resulted in neuroimmunological manifestations which have the potential 
to contribute to central comorbidities associated with each disorder. Specifically, the 
findings generated from these works and the overarching hypotheses determined that: 
• 5-FU was not unique in causing gut toxicity and altered glial reactivity in the brain
and spinal cord of rats (Chapters Three and Four). Thoracic GFAP expression
adaptations occurred at the spinal level corresponding with small intestinal toxicity,
yet this single high dose did not result in hippocampal changes. Alterations to glial
reactivity were also present in the lumbar spinal cord of both chronic UC and CA-
CRC models, as well as the hippocampus (Chapter Five). Although INDO-
enteropathy was unable to induce any central glial changes, gut toxicity was
confirmed by reduced bodyweight and histological assessment (Chapter Four).
Therefore, the glial changes reported here are indicative of a generalised
inflammatory response in the gut, rather than systemic 5-FU alone. This is an
important discovery which adds to the field, as the incidence of inflammatory
conditions of the gut continues to rise, so do the central comorbidities associated
with their pathogenesis;
• Opioid exposure attenuated 5-FU-induced thoracic GFAP expression, rather than
exacerbating the response as postulated (Chapter Three). The analgesics selected
for these experiments resulted in regional glial cell expression adaptations which




• Positive relationships between allergies and PLMD, allergies and pain, pain and
PLMD, PLMD and GI disturbances were observed in the BCS population (Chapter
Six).
Whilst one of the primary overarching hypotheses proposed that 5-FU-induced glial 
dysregulation would be associated with, or potentiate, learning and memory deficits in the 
context of CICI, this was unable to be ascertained as behavioural data were lacking. The 
spinal and hippocampal glial ramifications of these works indicate a potential 
neuroimmunological role in the pathogenesis of CICI which will be discussed below. 
Additional key results from the studies presented which can be specifically related to the 
aims presented in this thesis are: 
• 5IGT resulted in altered thoracic spinal cord astrocyte reactivity during the Peak
Injury Phase of mucositis and resolved during the Recovery Phase (Chapter Three);
• 5-FU-induced thoracic astrocyte reactivity was proposed to be mediated by a neural
peripheral-to-central immune signalling pathway (Chapter Three);
• 5IGT resulted in caecal microbiota changes, yet the low-dose INDO-enteropathy
model failed to induce glial reactivity or microbiota changes (Chapter Four);
• The findings presented above support the hypotheses outlined in the first two
chapters, that CIGT results in neuroimmunological manifestations (Chapter One)
and several stages of the gut-brain-axis become dysregulated under chemotherapy
conditions (Chapter Two);
• Chronic inflammation resulting from the chronic UC and CA-CRC models induced
astrocyte and microglial marker expression changes in the lumbar spinal cord and
hippocampal region (Chapter Five);
• Similar to the thoracic results in Chapters Three and Four, the spinal lumbar region
glial marker expression changes in Chapter Five indicated a neurally-mediated
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peripheral-to-central immune signalling pathway. However, the concurrent 
hippocampal glial changes indicated that the humoral route was mediating this 
response; 
• The findings from Phase One of the BCS trial identified an association between
patient allergy susceptibility and PLMD and GI disturbances, independently.
Additionally, increased pain perception correlated with PLMD since chemotherapy
treatment cessation. Phase Two analysis revealed that PCI correlated with QOL and
fatigue, yet a negative relationship occurred between PCI and depression, anxiety
and stress.
• The findings in relation to allergies and its relationship with PLMD, GI
disturbances and pain warrant further investigation.
The causal and directional nature of these distinct, yet connected pathological findings, 
opens up a pathway for further investigation into gut-mediated neuroimmune 
manifestations, specifically in relation to cancer, chemotherapy and IBD. The findings 
summarised above leave many new questions which will be addressed below. For example, 
is 5-FU-induced gut toxicity driving microbiota changes, or vice versa? Also, are the 5-
FU-induced microbiota changes important in mediating changes in spinal astrocyte 
reactivity?
Glial Adaptations in the Spinal Cord: Implications for 5-FU, Chronic UC and CA-
CRC 
The spinal glial adaptations identified throughout this thesis demonstrated a 
neuroimmunological role in the pathogenesis of 5IGT, chronic UC and CA-CRC. 
Nonetheless, we can only speculate on the mechanistic significance of these findings and, 
as such, future prospective studies should focus on specific functional relationships 
between gut toxicity and spinal glial reactivity. Astrocytes and microglia are classically 
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recognised as playing key roles in pathological and chronic pain conditions [123]. Both 
neuroimmune cell classes are uniquely positioned around the synapse (forming the 
tetrapartite synapse) to enhance neuronal transmission and amplify nociceptive signalling 
under pathological conditions. Intense, repeated and sustained nociceptive signalling 
results in central sensitisation in the spinal dorsal horn. Neuronal and biochemical 
processing at the central synapses at these sites are transitioned into a “pain-facilitatory” 
state, involving the increased expression of pro-inflammatory receptors and mediators 
[470, 471]. These adaptations have been well-characterised and extensively reviewed [123, 
471, 472], but briefly involve the phosphorylation of many receptors, which can increase 
synaptic efficacy by promoting receptor trafficking to the membrane. These conditions 
enable low-threshold sensory fibres, which are usually activated by innocuous stimuli, to 
activate high-threshold sensory neurons [472]. Critically, glial and immune cell-derived 
mediators modulate excitatory and inhibitory synaptic transmission by binding to receptors 
on pre- and post-synaptic terminals in the spinal dorsal horn [123]. This results in 
nociceptive hypersensitisation, which is characteristic of central sensitisation [123].  
TLRs are expressed by glial cells and their involvement in central immune signalling plays 
a pivotal role in the initiation and maintenance of heightened pain states [473]. However, 
the reactive phenotype of some glia is always not synonymously connected with pro-
inflammatory and pro-nociceptive phenomena. Interestingly, some reactive glial cells have 
been shown to exhibit anti-inflammatory properties, which contribute to the resolution of 
nociceptive hypersensitivity [319, 474]. Recently, it has been argued that gliosis may be 
considered a beneficial process which assists the host in healing, yet when glial processes 
become dysfunctional, a condition referred to as a “gliopathy”, they are key players in 
pathological pain states [475, 476]. From this, it is plausible that the reactive phenotype of 
astrocytes observed in the acute 5-FU model in this thesis, were in fact exerting a 
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protective effect. Although the simultaneous increased expression of IL-1β was indicative 
of a regional pro-inflammatory response, no anti-inflammatory cytokines were assessed in 
this model. We can only presume that the reactive astrocytes and the increase in IL-1β 
were linked. We are unable to determine whether the increase in spinal thoracic IL-1β 
expression was mediated by immune signals from the inflamed intestine or whether the 
pro-inflammatory change was driven by reactive astrocytes. Future studies clarifying IL-1β 
receptor changes on astrocyte membranes during the astrocyte response to 5-FU, would 
mechanistically elucidate the findings from these works. Identifying a complete cytokine 
profile would enable detection of changes in pro- and anti-inflammatory cytokines. 
Additionally, the assessment of pain behaviours would further identify whether the spinal 
cord glial adaptations were associated with pain in rats with 5IGT.   
Although it is widely recognised that microglia are the “first responders” in various models 
of pain [477-481], astrocytes are increasingly becoming recognised for having a primary 
role in pain conditions, such as acute pain associated with arthritis [482]. Recently it was 
shown that microglial signalling was actively involved in the transformation of astrocytes 
from a quiescent to reactive state [483]. Whilst the acute 5-FU model presented in this 
thesis observed adaptations in thoracic spinal astrocyte reactivity marker expression with 
no change in microglial reactivity marker expression, it is possible that microglial changes 
would have presented at the earlier stage of intestinal inflammation (day one or two) [480]. 
Such changes in microglial expression/phenotype may have subsided by day three, and 
accordingly played a role in the initiation of the reactive astrocyte phenotype present at this 
time-point.  
The increased expression of microglial markers in the lumbar spinal region of mice with 
chronic UC and CA-CRC may have occurred via the amalgamation of numerous “hits” of 
acute inflammation. In these models, a series of acute inflammatory states were induced by 
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the DSS water cycles, however over the course of the experimental period, a secondary 
immune response develops. In the CA-CRC model, the administration of AOM and the 
repeated “hits” of acute inflammation accelerate the development of tumours in the colon 
[378]. Accordingly, repeated intestinal inflammatory “hits” may prime (sensitise) lumbar 
spinal cord microglia and explain the increased expression of microglial reactivity markers 
observed in these models. The “two-hit” paradigm explains this phenomenon, whereby an 
initial immune challenge primes microglia to over-respond to subsequent challenges, 
enhancing pain intensity and duration [484]. It is plausible that the multiple inflammatory 
“hits” used in both models primed microglia and astrocytes and hence, resulted in the 
significant increased expression of CD11b/Iba-1 and GFAP reactivity markers, 
respectively.  
Spinal Glial Involvement in Pain Associated with Cancer and CIGT
Although astrocytic marker expression changes are commonly reported in experimental 
models of cancer-induced pain, the functional and mechanistic adaptations are still unclear. 
Bone cancer pain is the most widely used model and a commonly reported feature is spinal 
microglial and astrocyte reactivity [127, 303, 305, 485, 486]. Rodent models have 
implicated various signalling pathways and receptors in the development of gliosis-
dependent bone cancer pain, such as TNF-α, TLR4, metabotropic glutamate receptors and 
chemokine signalling [127, 303, 305, 486]. Increased expression of the chemokines, 
CXCL12 and CXCR4, mediate neuronal sensitisation and spinal glial reactivity and have 
been linked to the development and maintenance of bone cancer pain in rats [486]. Some 
studies have however, suggested that cancer pain is not necessarily correlated with 
overexpression of spinal reactive glial markers [487]. This importantly highlights the 
complex nature of cancer pain with the potential involvement of multiple pain syndromes, 
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which have inflammatory, neuropathic, compressive and ischaemic mechanisms [488]. It is 
plausible that in the chronic UC and CA-CRC models, multiple pathways that drive hyper-
nociception were occurring simultaneously. Consequently, teasing apart these mechanisms 
is problematic.  
Although recent data has implicated a role for spinal gliosis in the development of pain 
associated with CIGT, few studies have identified the mechanistic origins for these 
findings. Innate immune receptors, such as TLR4, are expressed on microglia and 
astrocytes [489, 490]. Wardill et al. (2016), reported that TLR4 mediated irinotecan-
induced gut toxicity and pain in mice, which was attributed to increased spinal lumbar 
astrocyte reactivity and heightened facial grimace scores [134]. TLR signalling has also 
been shown to impair host-microbial communication mediating gut commensal bacteria 
and critically, contribute to the severity of intestinal damage followed by chemotherapy 
[491]. Coller et al. (2015), identified a diagnostic marker capable of predicting CIGT in 
certain cancer types via TLR2 and TNF-α genetic variability [492]. Whilst the studies 
presented here highlight the involvement of innate immune signalling in pain associated 
with CIGT, mechanisms underpinning the spinal gliosis presented in this thesis remain 
undetermined. However, it is plausible that the acute or chronic intestinal inflammation 
induced by 5-FU, DSS or AOM/DSS, led to reactive gliosis in the spinal cord, which in 
turn may contribute to pain signalling. To clarify the mechanistic pain-related implications, 
further studies examining the role of innate immune signalling, such as the TLR4 pathway, 
as well as utilising rodent pain measures, such as Von Frey or hot plate testing, should be 
explored.   
Further complicating innate immune signalling in CIGT are enteric immune cells, namely 
EGC which are prone to becoming reactive following systemic chemotherapy 
administration. EGC reactivity has been reported to contribute to intestinal damage in two 
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CIGT models using chemotherapy drugs with different mechanisms of action [301, 493]. In 
Swiss mice, irinotecan enhanced S100β marker (specifically released by EGC in the 
intestine) and GFAP expression, increasing TNF-α and IL-6 expression, yet reduced enteric 
neuronal (HUC/D marker) expression in the small intestine [301]. In another 5IGT model 
which utilised the same markers, a similar trend of intestinal EGC up-regulation 
(increased co-expression for GFAP and S100β) and reduced neuronal (HUC/D) expression 
were attributed to the S100B/RAGE/NFκB pathway [493]. In this model, the S100β 
inhibitor, pentamidine, reduced intestinal glial reactivity (attenuating GFAP and S100β 
expression) and improved neuronal loss, as shown by an increase in HUC/D expression. 
Whether EGCs communicate with their central counterparts remains undetermined and 
should continue to be investigated. This knowledge may lead the way in novel preventative 
or treatment approaches which target EGC pathologies, and in turn, they may have a 
positive effect on astrocyte reactivity in the CNS. From this, the mechanisms of signalling 
between EGC and central glial cells present as a possible pathway mediating pain in not 
only CIGT, but other gut disorders, such as IBD and cancer. Future gut inflammatory 
models which examine the central and enteric glial components (GFAP and S100β), as well 
as the role of innate immune signalling (TLR-4) and pro-inflammatory cytokines, will 
assist in unravelling the complex nature of these findings, offering insight to further 
peripheral-to-central mechanisms which may influence CIGT and CICI. 
Implications for Chronic UC- and CA-CRC-Induced Reactive Glia in the 
Hippocampus
It is increasingly becoming evident that central comorbidities occur in gut disorders with 
an inflammatory component. These are heavily researched in IBD and in oncology, where 
malignancy and systemic chemotherapy often induce multiple toxicities in the periphery 




inflammation results in altered hippocampal neurogenesis [39, 93, 344] was the foundation 
for exploring whether acute and chronic intestinal inflammation results in central GFAP 
and CD11b/Iba-1 expression changes. Astrocytes form an integral part of the synapse and 
contribute to the molecular signalling of the tripartite synapse [154] which has been 
extensively reviewed elsewhere [154, 495-499]. Accordingly, the concept of glia-neuron 
bidirectional signalling is widely accepted. Given the role glia play in healthy brain 
function, it is not surprising that glia may play a role in the early stages of various diseases 
of the CNS, involving neurodegeneration. The widely recognised perspective on microglia 
being the “first responders” has indeed, been challenged as emerging data has revealed the 
dynamic exchange that occurs between hippocampal astrocytes and synapses [500]. A 
study using hippocampal slices containing the simultaneous manipulation of neurons and 
astrocytes, provided evidence for astrocytes changing morphologically and behaviourally 
within minutes of an immune challenge [500]. In order to determine which glial cell was 
the “first responder” in the gut inflammatory conditions presented in this thesis, a full 
characterisation of the time-course for the acute- and chronic-induced glial dysregulation is 
required.  
The essential role microglia have in central homeostasis enables them to contribute to 
many central pathologies, and potentially influence cognition. Microglia release cytokines, 
neurotransmitters and extracellular matrices which, regulate neuronal and synaptic activity 
involved in functional plasticity [501-503]. In early development, unchallenged microglia 
regulate neurogenesis in the sub-granular zone of the hippocampus by eliminating excess 
newborn neurons which are processed by apoptotic pathways [504]. It has been suggested 
that microglia have a dual role in neurogenesis [505]. Acute LPS exposure induces 
microglial phenotype changes which have detrimental effects on the survival and 
differentiation of neural stem cells in the adult brain [506, 507]. The morphology, 
phenotype and cytokine expression changes observed in microglia when they transition 
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from an acute to chronic insult, mean that they may be detrimental in the early stages of 
acute injury, yet offer a supportive or even protective role in the later stages of injury. 
Taken together, the functional role for the elevated Iba-1 protein expression in the 
hippocampus of rats with chronic UC and CA-CRC may have been a beneficial adaptation. 
Importantly, determining the morphology, phenotype and cytokine profile of glia under the 
disease states presented in this thesis, will offer insights into the mechanistic (detrimental 
or beneficial) alteration of their expression. For example, ramified glia may be contributing 
to neuroinflammation, yet in this state they may also be releasing neurotransmitters 
(glutamate and dopamine) into the synapse, which are critical for functional plasticity. To 
tease apart these potential beneficial or detrimental outcomes, it is suggested that the 
simultaneous release of neurotransmitters be examined alongside the microglial-mediated 
cytokine profiles.  
A summary of the findings from this thesis and new questions relating to central glial 
changes in the various gut inflammatory models are presented in Figure 7.1. The chronic 
models reported suggest a role of peripherally-mediated hippocampal glial reactivity and 
we propose that this may contribute to or exacerbate CICI symptoms. Further studies 
utilising behavioural models to elucidate learning and memory consequences, 
immunohistochemistry for morphological cell changes, and cytokine immune profiling, 
will clarify mechanisms directly relating to microglial and astrocyte responses under these 
experimentally-induced conditions. Furthermore, the concept of an “astrocyte activation 
spectrum” [508] and debate surrounding the beneficial and detrimental heterogenous 
phenotype of microglia [509-511], highlight the need for continued research into the varied 
cellular profiles and functional significance of glial cells in both acute and chronic 
inflammatory states. From the bottom up, spinal cord glial reactivity has the potential to 
mediate intestinal microbiota changes and contribute to nociceptive signalling (Figure 7.1). 
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Figure 7.1. Proposed mechanisms from the neuroimmune findings presented in this thesis. The gut inflammatory models 
(5-FU, DSS and AOM/DSS) confirmed that spinal cord glial reactivity occurred in both acute and chronic settings. 
Additionally, the chronic gut models confirmed that some higher order brain regions resulted in altered glial reactivity. We 
propose that the changes in glial reactivity in the higher order brain regions may contribute to or exacerbate CICI 
(cognitive and behavioural). Finally, the changes in spinal cord glial reactivity is postulated to contribute to intestinal 
microbiota changes and pain signalling. 5-Fluorouracil; 5-FU, 5-FU-induced gut toxicity; 5IGT, ulcerative colitis; UC, 
colitis-associated colorectal cancer; CA-CRC, dextran-sulphate sodium; DSS, Azoxymethane; AOM, hippocampus; HIP, 
hypothalamus; HYP.
Implications for Hypothalamic Glial dysregulation
The hypothalamus (and HPA axis; stress system) is responsible for the maintenance of 
basal and stress-related homeostasis [512]. The hypothalamus senses a wide array of inputs 
from the periphery, such as blood-borne cytokines. Acute activation of the stress system 
results in various physiological and behavioural responses, such as accelerated motor 
reflexes, increased tolerance of pain, and inhibition of immune-mediated inflammation 
[513]. The increased expression of the circulating pro-inflammatory cytokines, such as IL-
1β and TNF-α, plays a major role in activating the HPA axis [514, 515]. As IL-1β and 
TNF-α are elevated in patients with CIGT, IBD and colorectal cancer [516], it was 
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postulated that hypothalamic glial reactivity marker expression changes would occur in 
these experimentally-induced disease states. The increased expression of GFAP and the 
dysregulated distribution of Iba-1 in the hypothalamus of CA-CRC mice implied that, in 
this region, glia were sensitive to immune-mediated input from the gut. As the 
hypothalamus integrates immune signals and responds accordingly, it is plausible that in 
chronic gut inflammatory conditions, regional glial cells in close proximity to the 
hypothalamus, respond by becoming dysregulated or reactive to assist the host in healing. 
Although GFAP and Iba-1 changes in the hypothalamus of CA-CRC rats demonstrated 
glial dysregulation, the absence of glial changes in the chronic UC (and acute 5IGT) 
animals implies that the addition of the malignancy in this model, may at least partially 
explain the glial discrepancies. Here, in these preliminary findings we report gross protein 
expression changes. Future studies should clarify the functional significance by 
undertaking immunohistochemistry for cellular morphological adaptations and 
visualisation of cell positioning via immunofluorescence and confocal imaging. Due to the 
significant impact the hypothalamus has on the immune system and vice versa, emphasis 
on mechanisms involving the neuroimmune (glial) system and the HPA axis warrant 
further exploration. This may lead the way for new therapeutic approaches that target 
HPA-neuroimmune signalling, which may alleviate symptoms associated with chronic 
inflammatory disorders, such as CA-CRC.  
IL-1β and Neuroinflammation
The pro-inflammatory function of IL-1β is to respond to tissue injury via recognising 
PAMP and DAMP signals released by the injured tissue [517]. IL-1β mediates tightly 
regulated innate immune responses which rapidly induce the transcription of multiple 
genes in many cell types, from monocytes to endothelial cells [518, 519]. Simultaneously, 
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these genes are capable of causing a positive-feedback loop which amplifies the IL-1β 
response by inducing its own expression [520]. IL-1β is a key cytokine associated with 
CIGT and CICI aetiology [1, 468]. It is for this reason that Chapters Three and Four sought 
to explore the potential for IL-1β expression changes to occur in the brain and spinal cord 
of rodents with experimentally-induced CIGT. Additionally, astrocytes and microglia 
express IL-1β and in their heightened reactive states increase synthesis and receptor 
availability for this cytokine [521]. In particular, morphological changes in microglia, 
together with the up-regulation of central IL-1β, has accrued formidable experimental 
support for the role they play in amplifying neuroinflammation in various CNS disorders, 
such as Alzheimer’s disease [375, 522-524]. In specific brain regions, increased IL-1β 
expression is also a potent mediator of cytokine-induced sickness responses, which closely 
mimic chemotherapy-related toxicities [80, 82]. Recently it has been shown that the rapid 
increase in expression of microglial IL-1β (mRNA) preceded elevations in Iba-1 
immunoreactivity following systemic LPS administration in mice [525]. This study also 
showed that IL-1β mRNA in astrocytes was significantly increased and correlated with 
sickness responses in these animals. As previously mentioned, the cognitive and 
gastrointestinal symptoms associated with chemotherapy treatment mimic some of the 
physiological and behavioural adaptations in cytokine-mediated sickness responses.  
Further studies examining the inflammatory profile of the experimental models used in this 
thesis will determine whether the brain IL-1β expression changes can be linked to glial 
dysregulation, though chronic chemotherapy models should be used as they are more 
clinically representative. The thoracic spinal IL-1β findings in the rats treated with 5-FU 
may be directly related to the altered astrocyte reactivity observed in this model. However, 
it is difficult to ascertain whether the observed IL-1β findings were a consequence of 
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astrocyte reactivity, or whether astrocyte reactivity mediated this pro-inflammatory 
response.  
As well as being involved in CNS diseases, IL-1β is also critical at initiating astrocyte 
reactivity [526, 527] and plays an active role in central regenerative processes [528]. 
Specifically, IL-1β-mediated astrocyte reactivity is paradoxically influential in its effects 
on the synapse and the microenvironment: it is able to release cytokines with pro- and anti-
inflammatory properties, trigger the expression of chemokines, provide trophic factors and 
alter gene expression, which can result in interrupted astrocyte-to-astrocyte communication 
[517, 529-531]. Nonetheless, in the 5IGT model presented in this thesis, we propose that 
the thoracic spinal IL-1β expression changes were contributing to a neuroinflammatory 
microenvironment, due to the simultaneous up-regulation of GFAP and thus, astrocyte 
reactivity observed in this region.   
The Use of Probiotics to Improve Symptoms Associated with CIGT: Implications for 
5IGT-Induced Microbial Changes
The recent expansion of evidence linking microbiota changes to a range of gut- and 
centrally-mediated disorders warrants investigation of these mechanisms. We have only 
just begun to unravel the complex gut microbial genome in terms of the mechanistic 
implications of dysregulated microbial populations under chemotherapy conditions. The 
well-characterised mucositis model by Sonis [1] made no mention of the intestinal 
microbiota, yet investigations since the early 2000’s have indeed reported that 
chemotherapy exposure can have a profound effect on intestinal microbial composition 
[38, 215, 532]. Furthermore, the microbiota has been implicated in carcinogenesis and is 
reported to influence the efficacy and toxicity of some anti-cancer therapies [358, 359]. 
The changes in caecal microbial composition of rats with 5IGT support evidence of 
General Discussion 
267 
microbiota changes in CIGT, owing to the reduced abundance of bacterial diversity and 
increased abundance of Bacteroides. The individual changes in species abundance requires 
further exploration as the mechanisms relating specifically to the pathogenesis of 5IGT are 
not clear. As the microbiome plays an integral role in maintaining intestinal integrity, it 
appears that microbiota changes may contribute to alterations in intestinal permeability. 
Under chemotherapy conditions, it should also be clarified which event occurs first: do 
microbial changes precede impaired intestinal permeability or vice versa?  
Given the microbial perturbations identified in this thesis, treatments with probiotics may 
have broader implications for CICI. The use of probiotics in alleviating symptoms 
associated with CIGT have been generally supported by clinicians, yet studies have only 
recently identified mechanisms supporting this consensus. Pre-treatment with probiotics 
prior to chemotherapy ameliorated intestinal mucosal injury and intestinal permeability 
induced by 5-FU in rats [316]. The probiotic mixture used in this study, improved mucosal 
architecture, ameliorated MPO expression and reduced intestinal pro-inflammatory 
cytokine profiles. Critically, this study also reported that the probiotic treatment was able 
to restore caecal microbiome homeostasis, as well as reversing the 5-FU-induced TLR-2 
and TLR-4 expression changes in the ileal mucosa. Although the precise mechanisms 
relating to microbial-immune and microbial-intestinal barrier interactions are largely 
unknown, gut microbial-host interactions are mediated through TLRs and have been 
extensively reviewed elsewhere [22, 23, 238, 491, 533-535]. In this sense, chemotherapy-
induced microbial perturbations act as a catalyst in the initiation of innate immune 
responses and may have played a role in the astrocyte changes evident in the rats with 
5IGT. As astrocytes express TLRs, it is plausible that the 5IGT-microbial changes 
triggered an innate neuroimmune response via TLR signalling, although thorough 
investigations will be needed to confirm this suggestion. 
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Recent findings which implicate reduced species diversity and bacterial overgrowth of 
Bacteroides in intestinal barrier dysfunction and priming the neuroinflammatory response 
to brain injury (stroke) support the overarching hypotheses presented in this thesis [21]. 
The reduced diversity of species and the increased abundance of Bacteroides identified in 
the caecal microbiota of rats with 5IGT may, in this same manner, partially explain the 
spinal neuroimmune adaptations observed via thoracic GFAP up-regulation. Research 
specifically relating to these findings within the context of oncology, whereby 
chemotherapy induces intestinal barrier dysfunction, microbiota changes, neuroimmune 
dysregulation and cognitive impairment, are lacking. This opens a path for discovery into 
the potential microbiome-neuroimmune links mediating CIGT and CICI responses (Figure 
7.2). Importantly, this highlights the potential for targeting the microbiome to protect or 
enhance central processes in inflammatory conditions of the gut.  
Figure 7.2. Potential microbiome-
neuroimmune link mediating CIGT and 
CICI. Chemotherapy induces gut responses 
(intestinal inflammation and microbiota 
changes; CIGT). Chemotherapy also results 
in central responses (neuroimmune 
dysregulation and cognitive impairment). It 
is suggested that chemotherapy-induced gut 
inflammation and microbiota changes 
contribute to or potentiates central responses, 
such as glial dysregulation and cognitive 
impairment. Highlighting a potential 
microbiome-neuroimmune mechanism 
linking CIGT and CICI . 
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Allergy, GI and Cognitive Disturbances in BCS: A Novel Paradigm Warranting 
Further Exploration
In the final research chapter of this thesis, the proposed concept that an innate immune 
system primed by allergy susceptibility may be linked to, or exacerbate, CICI and CIGT 
symptoms, was unchartered territory. The preliminary findings in this chapter indicated an 
association between allergies and treatment-induced GI disturbances and PLMD. Whilst 
more rigorous investigations with greater power are necessary to validate these findings, to 
our knowledge this was the first study identifying an association between allergies and 
PLMD and GI issues in BCS. Importantly, this implied that allergies may serve as a 
predictive tool for patient susceptibility to cognitive and GI chemotherapy-induced 
toxicities. If these preliminary findings are indeed confirmed, the potential for clinicians to 
offer/advise on taking preventative measures, such as increasing physical activity and 
taking probiotics prior to commencing anti-cancer treatment, may reduce patients’ risk of 
developing, or the severity of, GI and cognitive disturbances. Additionally, the relatively 
simple and blunt nature of the allergy question presented here presents further queries. For 
example, are ‘better’ immune-based predictive biomarkers available that can be identified 
prior to treatment, which predict outcomes based on the immune reactive phenotype? 
Future investigations should employ pre-treatment, during treatment and post-treatment 
subjective measures as well as effective control groups to generate reliable group 
comparisons.  
Targeting the Neuroimmune System to Alleviate Symptoms Associated with CICI 
and CIGT - Attenuating Glial Reactivity and IL-1β Expression as Potential 
Therapies
Although the gut-induced neuroimmunological complications presented in this thesis 
require further exploration to identify symptom-related associations with CICI and CIGT, 
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several therapeutic approaches are presented for consideration. Some glial attenuators, 
such as minocycline, have provided neuroprotection in stroke and alleviated depressive 
symptoms in bipolar disorders and multiple sclerosis [536-538]. However, blocking the 
inflammatory activities of reactive microglia can exacerbate certain CNS diseases [539, 
540]. Emerging evidence targeting the neuroimmune system has resulted in positive effects 
on some psychiatric and cognitive symptoms across a range of central disorders, such as 
LPS-induced cognitive impairment, Alzheimer’s disease and addiction [541-544]. 
Minocycline may improve some cognitive parameters, yet differences in its effect on 
hippocampal neurogenesis in adult compared with aged mice, imply the potential variance 
in microglial functions across the lifespan of an animal, implicating limitations in its use 
for different age groups [545]. Considering the elevated hippocampal GFAP and Iba-1 
expression observed in both chronic models in Chapter Five of this thesis, we can assume 
that reactive gliosis was occurring. It was unclear whether this regional glial reactivity was 
having a negative or positive effect on cognition, or even whether it had an effect at all. 
LPS induces cognitive dysfunction in rats via prolonged activation of hippocampal 
microglia [546, 547].  
Further, the increased expression of immune molecules associated with hippocampal 
microglial and astrocyte reactivity in neurodegenerative disorders, such as Alzheimer’s 
disease, provides evidence of the strong association between hippocampal glial reactivity 
and cognitive outcomes [129, 498]. Thus, it was most likely that under the chronic 
conditions presented in this thesis, microglia and astrocytes were contributing to 
neuroinflammation in this region.  
Morphological examination of glial cell states, including detailed cytokine profiling and 
assessment of pain and behavioural outcomes, involving hippocampal-dependent learning 
and memory tests, will clarify the mechanistic implications of these findings. In order to 
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tease apart the distinction between whether gut inflammatory disorders have the ability to 
potentiate cognitive deficits, particularly in oncology, it is recommended that a full 
characterisation of both the short-term and delayed (time-course) central- and gut-related 
consequences of CIGT and CICI be assessed in the same animals. This would be achieved 
by comparing the aforementioned parameters in a healthy group, a non-malignant/non-
chemotherapy but inflammation (acute versus chronic UC) group, a non-
malignant/chemotherapy (5-FU alone or in combination with other chemotherapies – acute 
and chronic dosages) group, a malignant (comparing breast to colorectal cancer)-non-
chemotherapy group and a malignant/chemotherapy group. This kind of thorough 
examination has the potential to clarify the synergistic and functional effects of gut-
mediated glial dysregulation in the spinal cord and higher order brain regions. Ultimately, 
it will offer insight into the influence gut-mediated neuroimmunological manifestations 
may have on cognitive outcomes in pre-clinical studies, having important implications for 
cancer patients in the longer term.  
Following on from this, targeted neuroimmune therapeutic approaches may indeed 
improve symptoms associated with both distinct regional toxicities.  
In models where neuroinflammation plays a pathogenic role in the development of central 
disorders, focussing attention on the inflammatory profile of reactive glial cells may offer a 
deeper understanding of the cognitive adaptations. Slight increases in IL-1 have been 
shown to improve hippocampal-dependent memory in mice, whereas substantial deviations 
from normal physiological levels impair cognition, including ablation of IL-1 signalling 
[548]. Several lines of evidence have linked increased expression of IL-1 to treatment-
related symptom clusters in cancer patients [549] which, as previously mentioned, mimic 
cytokine-induced sickness responses. This response has been specifically related to 
cognitive deficits in breast cancer patients [60, 468]. Although the involvement of IL-1β in 
General Discussion 
272 
the pathogenesis of CICI and CIGT has been strongly supported, therapies targeting this 
signalling molecule may have detrimental downstream effects as its central and peripheral 
inflammatory functions are critical in host homeostasis. 
Opioids have been a commonly prescribed analgesic to alleviate pain associated with 
cancer and treatment-related toxicities [550], yet the burden associated with opioid-
induced adverse events may significantly influence patients’ symptomatology [551]. 
Adverse side-effects associated with opioids have the potential to exacerbate GI and 
cognitive symptoms in cancer patients. For example, dry mouth, nausea and vomiting are 
regularly reported in patients undergoing chemotherapy (whether diagnosed with CIGT or 
not), yet are also adverse events following opioid exposure. Centrally, opioids cause 
drowsiness and confusion, which can further complicate CICI symptoms in cancer 
patients. The myriad of confounding opioid findings presented in Chapter Three, support 
the suggestion that caution should be taken by clinicians when prescribing opioids to 
cancer patients. The analgesic benefit for opioid use may be negatively outweighed by not 
only the adverse effects on patient symptomatology, but also that spinal glial and IL-1β 
changes have the ability to influence pain signalling and activity in higher order brain 
regions that contribute to normal cognitive function. The mechanistic implications of the 
central neuroimmune adaptations in 5IGT and analgesic interventions therefore warrant 
further exploration. Identifying behavioural, learning and memory deficits, as well as pain 
and histological assessment of glial morphology, will assist in better understanding the 
influences these effects have on CIGT and CICI.  
The multifaceted nature of the neuroimmune system in the outcomes of various central 
physiological processes makes glial- and IL-1β-induced manipulation challenging. As 
mentioned, the risks for complications may outweigh the benefits observed, and a one size-
fits-all approach may be unfeasible. For instance, long-term treatment of cognitive or 
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psychiatric deficits by pharmacologically blocking microglia, may prevent microglial cells 
from exhibiting their neuroprotective functions later in life. One of the major limitations in 
pharmacologically attenuating neuroimmune activity resides within the need to preserve 
the neuroprotective function of glia and IL-1β yet reduce the deleterious outcomes; 
requiring careful consideration. Accordingly, continued research on the short-term and 
delayed consequences of glial attenuation is of paramount importance. 
Exploring Preventative Treatment Strategies that have Potential in Improving
Cognitive Outcomes or Reversing Neuroinflammation in CICI
Anti-inflammatory paradigms have been examined in the search for therapies that improve 
cognitive outcomes in central disorders. For example, the protective effect of NSAIDs in 
Alzheimer’s disease emphasised that rather ‘simple’ and well-established therapies have 
the potential to improve cognitive outcomes [552]. However, this treatment approach may 
be unsuitable in the context of CICI, whereby chemotherapy-cancer-host interactions are 
complex, including the involvement of drug-drug interactions. Interestingly, the findings in 
Chapter Three showed that CAR (NSAID) ameliorated spinal thoracic GFAP and IL-1β 
expression in rats with 5IGT. Although we were unable to conclude whether the increased 
expression of GFAP and IL-1β was beneficial or negative, CAR displayed a robust ability 
to reverse this effect, whereas CAR elevated spinal thoracic CD11b in rats with 5IGT. 
Comparatively, CAR reduced CD11b expression in the hippocampus of rats with 5IGT, yet 
5-FU alone was unable to alter CD11b expression. CAR also attenuated MPO expression
in the ileum of rats with 5IGT, which confirmed that this drug has both gut- and central-
mediated effects. Considering CAR co-administration elevated thoracic CD11b, yet 
attenuated GFAP expression in rats with 5IGT, regionally, this NSAID may induce 
differential effects on glial cell populations at this disease time-point. Accordingly, NSAID 
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therapies may present as an effective mediator of both spinal and hippocampal 
neuroinflammation in such settings. Future studies should explore the potential for 
pharmacological intervention using NSAIDs to improve neuroinflammation in central 
disorders, including CICI.  
Current evidence indicates that the pharmacological management of cognitive alterations 
in CICI is generally unfavourable [553]. Turning the attention away from reversing 
cognitive alterations to either enhancing cognitive function or preventing onset is a more 
practicable approach. Non-pharmacological approaches utilising cognitive behavioural 
therapy and computerised cognitive training have yielded conflicting results [554, 555, 
556]. Nonetheless, the speed of processing training and memory training have produced 
positive findings, which supports the use of these tools to improve specific cognitive 
domains in CICI [554]. Although these strategies are promising, methodological 
challenges have prevented concrete recommendations for clinical practice. Accordingly, 
the formation of the International Cognition and Cancer Taskforce has recommended 
principles and guidelines to overcome these pitfalls in making future assessments 
standardised [557]. These recommendations, such as assessing cognitive parameters prior 
to commencing anti-cancer treatment, will improve the homogeneity of research designs 
and facilitate inter-study comparisons (including meta-analyses).   
The rather “simple act” of exercise or increasing physical activity has been shown to be 
extremely efficacious in ameliorating cognitive deficits across a wide range of 
experimental models, from mild cognitive impairment to multiple sclerosis and CICI [274, 
5558, 559]. Several mechanisms mediating the beneficial cognitive effects of physical 
activity include neurogenesis, synaptogenesis and angiogenesis [560]. As 
neuroinflammation is a common underlying feature of many neurodegenerative diseases, it 
has been hypothesised that physical activity could minimise brain diseases via modifying 
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glial-induced neuroinflammation [561]. Exercise has also shown promise in ameliorating 
pain and reversing glial hyperactivity in the dorsal horn of mice with nerve injury-induced 
neuropathic pain [562]. From these novel findings, it is proposed that exercise may improve 
cognitive symptoms in CICI patients, ameliorate altered central glial reactivity, and 
potentially offer pain relief to rodents with CIGT, CICI, chronic UC and CA-CRC. Whilst 
at a first glance this approach seems appealing on many levels (affordability, sustainability, 
global health benefits – improving perceived quality of life, practicality, etc.), patient 
cooperation to perform exercise or increase their level of activity may prove difficult. At 
the heart of this difficulty is that some of the very symptoms ‘the act’ may improve, 
may also contribute to patients’ inability to make such lifestyle changes during this 
already tumultuous time in their lives. For example, fatigue, gastrointestinal disturbances, 
depression and anxiety, and difficulties with cognitive processes (including the sheer act of 
remembering to exercise) may inhibit CICI, UC and CRC patients’ ability to exercise. 
Nonetheless, the importance of exercise in managing cognitive deficits should be 
fundamentally emphasised in the early stages of disease and diagnosis, regardless of 
disease type or treatment strategies, provided that patients are fit to do so. 
Evidence for Neural- and Humoral-Mediated Peripheral-to-Central Immune 
Signalling Pathways in the Development of CIGT and CICI
Throughout this thesis, it was proposed that neural- and/or humoral-mediated peripheral-
to-central immune signalling pathways would mediate the gut inflammatory-induced spinal 
and higher order brain glial and IL-1β dysregulation (Figure 7.3). It was anticipated that 
either the actions of the drugs or the immune signals released from the drug actions (e.g. 
damage to intestinal epithelial layer) would induce glial/IL-1β changes via the neural or 
humoral immune signalling routes. In view of the spinal-mediated glial and IL-1β changes 
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in the collection of these works, it was proposed that the effects of 5-FU, CAR, BUP, 
TRAM, DSS and AOM/DSS on the various models of gut inflammation, indirectly 
resulted in spinal cord changes which were innervated by the inflamed gut region. This 
was considered an indirect pathway as the action of the drug induced intestinal 
inflammation, which in turn, indirectly mediated the activation of the neural pathway 
through immune signals from the inflamed intestine (see Figure 7.3; yellow arrows). This 
neural route has been extensively researched and reviewed in its influence on sickness 
behaviours [25, 145, 256, 383]. In order to determine whether this route was indeed 
activated and responsible for the glial/IL-1β spinal changes evident in these models, 
surgical vagotomy interventions are suggested.  
The glial changes observed in the hippocampal region implied that the humoral route was 
potentially mediated by two mechanisms (Figure 7.3; blue arrows): 1) drugs directly 
crossing the BBB and causing central damage, or 2) immune signals from systemic 
infiltration of mediators and cytokines released by inflamed gut crossing the BBB and 
causing neuroinflammation. Teasing apart the two mechanisms presented here is 
challenging in this setting, as the drugs induce gut toxicity which will always ultimately 
result in increased expression of pro-inflammatory cytokines in the systemic circulation. 
Assessing hippocampal glial changes in an experimental model which utilises a 
chemotherapy drug that does not result in severe gut toxicity may help to elucidate whether 
the humoral route is indeed responsible for these changes. Further detailed assessment of 
cytokine profiles (as mentioned above) will also assist in teasing apart this mechanism. 
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Figure 7.3. Neural vs humoral peripheral-to-central immune signalling pathways. HUMORAL PATHWAY (blue 
arrows): 1) Drug enters circulation via systemic (intraperitoneal administration of 5-FU/INDO/AOM or subcutaneous 
CAR/BUP/TRAM) or oral (DSS) administration; 2) Drug induces systemic pro-inflammatory activation; 3) Drugs or 
pro-inflammatory cytokines from the peripheral circulation access the brain, directly crossing the BBB via the humoral 
route; 4) Drugs or intermediate pro-inflammatory molecules at BBB travel to higher order brain regions; 5) Drugs or 
intermediate pro-inflammatory molecules activate glia in higher order brain regions. NEURAL PATHWAY (yellow 
arrows): 1) Drug enters circulation via systemic or oral administration; 2) Drug induces systemic pro-inflammatory 
activation; 6) Drugs target rapidly dividing intestinal cells; 7) Resulting in an inflamed intestine and microbiota 
changes; 8) Pro-inflammatory cytokines and mediators signal primary afferent neurons in the intestinal wall; 9) Pro-
inflammatory cytokines and mediators are transduced into a neural message and relayed to higher order brain regions 
via afferent signalling pathways (dorsal horn of the spinal cord). 5-Fluorouracil; 5-FU, indomethacin; INDO, 




Cognitive and gut disturbances continue to be some of the most debilitating side-effects of 
chemotherapy treatment. The ever-increasing incidence of cancer, and hence the acute-gut 
and delayed-cognitive consequences of chemotherapy, pose a considerable burden on the 
health and well-being of millions of cancer patients, their families, clinicians and national 
health systems. A complete understanding of the molecular mechanisms of glial 
dysregulation in CICI and CIGT will aid greatly in the development of new strategies and 
treatment approaches to alleviate chemotherapy-related toxicities.  
The central glial alterations presented throughout this thesis have provided evidence for 
neuroimmune adaptations to occur under acute chemotherapy and chronic inflammatory 
conditions of the gut. The significance of these findings requires further morphological and 
functional investigation, to determine whether the neuroimmune adaptations contribute to, 
or potentiate the pathogenesis of either disorder. As the dichotomous nature of glial cells 
and their reactivity orchestrates both beneficial and detrimental processes in health and 
disease, harnessing their neuroprotective mechanisms may enhance the beneficial 
outcomes in CNS disorders. It will be important to understand the functional implications 
of the varying states of glial reactivity, to define the regional differences in the models 
presented here. Moreover, in an effort to develop urgently needed therapies that improve 
the gastrointestinal and cognitive status of cancer patients, it is also necessary to probe the 
molecular and cellular targets of IL-1β, as an influential driver of many inflammatory 
processes. 
Chemotherapy disrupts the delicate equilibrium of bacterial communities in the GIT and 
recent data on host-microbiota-neuroimmune interactions highlights the need for continued 
research. Understanding and normalising the microbial balance of commensal bacteria in 
the intestine could be an appropriate strategy to improve not only the intestinal 
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architecture, but also the cognitive status of patients receiving chemotherapy. In addition, 
the novel allergy-related findings in the BCS patient population may serve as a predictive 
tool for clinicians to identify patients, who may be at a higher risk for developing more 
severe gut or cognitive disturbances following chemotherapy treatment. Critically, further 
studies with higher statistical power may have the potential to introduce early intervention 
strategies that can improve the negative gut and cognitive outcomes of not only BCS, but 
also patients with other cancer-types. Allergy-cognitive relationships should be further 
explored in other gut inflammatory disorders which have a cognitive/mood component.  
The increasing rates of cancer survivorship and negative impact CIGT and CICI have on 
patient quality of life, highlight the need for continued research into the common biological 
pathways and mechanisms linking the disparate disorders. From the bottom up, this thesis 
confirmed that several gut inflammatory conditions influence the neuroimmune system, as 
identified by glial adaptations in spinal and higher order brain regions. In conclusion, it is 
anticipated that the present findings will promote future research efforts that will ultimately 
improve our understanding and treatment of the central comorbidities associated with gut 
inflammatory disorders. In particular, the ultimate aim will be to significantly improve the 
livelihood of patients with gut disorders, involving cancer, chemotherapy and 
inflammatory bowel diseases – I know the patients, survivors, their families and friends 




1. Sonis, S.T., The pathobiology of mucositis. Nat Rev Cancer, 2004. 4(4): p. 277-84.
2. Furness, J.B., Integrated Neural and Endocrine Control of Gastrointestinal Function. Adv
Exp Med Biol, 2016. 891: p. 159-73.
3. Al Omran, Y. and Q. Aziz, The brain-gut axis in health and disease. Adv Exp Med Biol, 2014.
817: p. 135-53.
4. Mayer, E.A., Gut feelings: the emerging biology of gut–brain communication. Nature
reviews. Neuroscience, 2011. 12(8): p. 10.1038/nrn3071.
5. Carabotti, M., et al., The gut-brain axis: interactions between enteric microbiota, central
and enteric nervous systems. Ann Gastroenterol, 2015. 28(2): p. 203-209.
6. Ongur, D. and J.L. Price, The organization of networks within the orbital and medial
prefrontal cortex of rats, monkeys and humans. Cereb Cortex, 2000. 10(3): p. 206-19.
7. Holstege, G., R. Bandler, and C.B. Saper, The emotional motor system. Prog Brain Res,
1996. 107: p. 3-6.
8. Mayer, E.A., The neurobiology of stress and gastrointestinal disease. Gut, 2000. 47(6): p.
861-9.
9. Mason, P., From descending pain modulation to obesity via the medullary raphe. Pain,
2011. 152(3 Suppl): p. S20-4.
10. Fields, H., State-dependent opioid control of pain. Nat Rev Neurosci, 2004. 5(7): p. 565-75.
11. Welgan, P., H. Meshkinpour, and L. Ma, Role of anger in antral motor activity in irritable
bowel syndrome. Dig Dis Sci, 2000. 45(2): p. 248-51.
12. Valentino, R.J., R.R. Miselis, and L.A. Pavcovich, Pontine regulation of pelvic viscera:
pharmacological target for pelvic visceral dysfunctions. Trends Pharmacol Sci, 1999. 20(6):
p. 253-60.
13. Tsigos, C. and G.P. Chrousos, Hypothalamic-pituitary-adrenal axis, neuroendocrine factors
and stress. J Psychosom Res, 2002. 53(4): p. 865-71.
14. Mayer, E.A., T. Savidge, and R.J. Shulman, Brain-gut microbiome interactions and
functional bowel disorders. Gastroenterology, 2014. 146(6): p. 1500-12.
15. Catanzaro, R., et al., The gut microbiota and its correlations with the central nervous
system disorders. Panminerva Med, 2014.
16. Gagniere, J., et al., Gut microbiota imbalance and colorectal cancer. World J
Gastroenterol, 2016. 22(2): p. 501-18.
17. Tillisch, K., The effects of gut microbiota on CNS function in humans. Gut Microbes, 2014.
5(3): p. 404-10.
18. Jiang, C., et al., The Gut Microbiota and Alzheimer's Disease. J Alzheimers Dis, 2017. 58(1):
p. 1-15.
19. Naseribafrouei, A., et al., Correlation between the human fecal microbiota and depression.
Neurogastroenterol Motil, 2014. 26(8): p. 1155-62.
20. Scheperjans, F., et al., Gut microbiota are related to Parkinson's disease and clinical
phenotype. Mov Disord, 2015. 30(3): p. 350-8.
21. Singh, V., et al., Microbiota Dysbiosis Controls the Neuroinflammatory Response after
Stroke. J Neurosci, 2016. 36(28): p. 7428-40.
22. Carvalho, F.A., et al., Toll-like receptor-gut microbiota interactions: perturb at your own
risk! Annu Rev Physiol, 2012. 74: p. 177-98.
23. Frosali, S., et al., How the Intricate Interaction among Toll-Like Receptors, Microbiota, and
Intestinal Immunity Can Influence Gastrointestinal Pathology. J Immunol Res, 2015. 2015:
p. 489821.
24. Furness, J.B., The enteric nervous system and neurogastroenterology. Nat Rev
Gastroenterol Hepatol, 2012. 9(5): p. 286-94.
 References
281 
25. Furness, J.B., et al., The enteric nervous system and gastrointestinal innervation:
integrated local and central control. Adv Exp Med Biol, 2014. 817: p. 39-71.
26. Lyte, M., L. Vulchanova, and D.R. Brown, Stress at the intestinal surface: catecholamines
and mucosa-bacteria interactions. Cell Tissue Res, 2011. 343(1): p. 23-32.
27. Gopal, R., D. Birdsell, and F.P. Monroy, Regulation of toll-like receptors in intestinal
epithelial cells by stress and Toxoplasma gondii infection. Parasite Immunol, 2008. 30(11-
12): p. 563-76.
28. Seminowicz, D.A., et al., Regional gray matter density changes in brains of patients with
irritable bowel syndrome. Gastroenterology, 2010. 139(1): p. 48-57 e2.
29. Gulbransen, B.D. and K.A. Sharkey, Purinergic neuron-to-glia signaling in the enteric
nervous system. Gastroenterology, 2009. 136(4): p. 1349-58.
30. Gershon, M.D., Serotonin: its role and receptors in enteric neurotransmission. Adv Exp
Med Biol, 1991. 294: p. 221-30.
31. Berger, M., J.A. Gray, and B.L. Roth, The expanded biology of serotonin. Annu Rev Med,
2009. 60: p. 355-66.
32. Evans, B.W., et al., Tegaserod for the treatment of irritable bowel syndrome and chronic
constipation. Cochrane Database Syst Rev, 2007(4): p. Cd003960.
33. Xu, Y., et al., Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease
and Parkinson's disease. Prog Neurobiol, 2012. 97(1): p. 1-13.
34. Bischoff, S.C., et al., Role of serotonin in intestinal inflammation: knockout of serotonin
reuptake transporter exacerbates 2,4,6-trinitrobenzene sulfonic acid colitis in mice. Am J
Physiol Gastrointest Liver Physiol, 2009. 296(3): p. G685-95.
35. Rhee, S.H., C. Pothoulakis, and E.A. Mayer, Principles and clinical implications of the brain-
gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol, 2009. 6(5): p. 306-14.
36. De Palma, G., et al., The microbiota-gut-brain axis in gastrointestinal disorders: stressed
bugs, stressed brain or both? J Physiol, 2014. 592(14): p. 2989-97.
37. Frank, D.N., et al., Molecular-phylogenetic characterization of microbial community
imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A, 2007.
104(34): p. 13780-5.
38. van Vliet, M.J., et al., The role of intestinal microbiota in the development and severity of
chemotherapy-induced mucositis. PLoS Pathog, 2010. 6(5): p. e1000879.
39. Nyuyki, K.D. and Q.J. Pittman, Toward a better understanding of the central consequences
of intestinal inflammation. Ann N Y Acad Sci, 2015. 1351(1): p. 149-54.
40. Bernstein, C.N., et al., A prospective population-based study of triggers of symptomatic
flares in IBD. Am J Gastroenterol, 2010. 105(9): p. 1994-2002.
41. Drossman, D.A., et al., Psychosocial aspects of the functional gastrointestinal disorders.
Gut, 1999. 45 Suppl 2: p. II25-30.
42. Whitehead, W.E., O. Palsson, and K.R. Jones, Systematic review of the comorbidity of
irritable bowel syndrome with other disorders: what are the causes and implications?
Gastroenterology, 2002. 122(4): p. 1140-56.
43. Kennedy, P.J., et al., Cognitive performance in irritable bowel syndrome: evidence of a
stress-related impairment in visuospatial memory. Psychol Med, 2014. 44(7): p. 1553-66.
44. Dancey, C.P., et al., Words fail me: the verbal IQ deficit in inflammatory bowel disease and
irritable bowel syndrome. Inflamm Bowel Dis, 2009. 15(6): p. 852-7.
45. Attree, E.A., et al., Cognitive function in people with chronic illness: inflammatory bowel
disease and irritable bowel syndrome. Appl Neuropsychol, 2003. 10(2): p. 96-104.
46. Jones, M.P., et al., Brain-gut connections in functional GI disorders: anatomic and
physiologic relationships. Neurogastroenterol Motil, 2006. 18(2): p. 91-103.
47. Padhy, S.K., et al., Irritable bowel syndrome: Is it "irritable brain" or "irritable bowel"? J
Neurosci Rural Pract, 2015. 6(4): p. 568-77.
 References
282 
48. Fond, G., et al., Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a
systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci, 2014. 264(8): p.
651-60.
49. Filipovic, B.R. and B.F. Filipovic, Psychiatric comorbidity in the treatment of patients with
inflammatory bowel disease. World J Gastroenterol, 2014. 20(13): p. 3552-63.
50. Drossman, D.A., Presidential address: Gastrointestinal illness and the biopsychosocial
model. Psychosom Med, 1998. 60(3): p. 258-67.
51. Dinan, T.G., et al., Hypothalamic-pituitary-gut axis dysregulation in irritable bowel
syndrome: plasma cytokines as a potential biomarker? Gastroenterology, 2006. 130(2): p.
304-11.
52. Sperber, A.D., et al., Fibromyalgia in the irritable bowel syndrome: studies of prevalence
and clinical implications. Am J Gastroenterol, 1999. 94(12): p. 3541-6.
53. Sanovic, S., D.P. Lamb, and M.G. Blennerhassett, Damage to the enteric nervous system in
experimental colitis. Am J Pathol, 1999. 155(4): p. 1051-7.
54. Agostini, A., et al., New insights into the brain involvement in patients with Crohn's
disease: a voxel-based morphometry study. Neurogastroenterol Motil, 2013. 25(2): p. 147-
e82.
55. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-
424.
56. Parkin, D.M., Global cancer statistics in the year 2000. Lancet Oncol, 2001. 2(9): p. 533-43.
57. Downie, F.P., et al., Cognitive function, fatigue, and menopausal symptoms in breast
cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after
formal assessment. Psychooncology, 2006. 15(10): p. 921-30.
58. Myers, J.S., Chemotherapy-related cognitive impairment: the breast cancer experience.
Oncol Nurs Forum, 2012. 39(1): p. E31-40.
59. Vardy, J., et al., Cognitive function and fatigue after diagnosis of colorectal cancer. Ann
Oncol, 2014. 25(12): p. 2404-12.
60. Janelsins, M.C., et al., Differential expression of cytokines in breast cancer patients
receiving different chemotherapies: implications for cognitive impairment research.
Support Care Cancer, 2012. 20(4): p. 831-9.
61. Johnston, I.N., Chemotherapy-induced cognitive deficits, white matter pathologies and
cytokines. Brain Behav Immun, 2014. 35: p. 21-2.
62. Lee, B.N., et al., A cytokine-based neuroimmunologic mechanism of cancer-related
symptoms. Neuroimmunomodulation, 2004. 11(5): p. 279-92.
63. Lin, W.W. and M. Karin, A cytokine-mediated link between innate immunity, inflammation,
and cancer. J Clin Invest, 2007. 117(5): p. 1175-83.
64. Keefe, D.M., et al., Chemotherapy for cancer causes apoptosis that precedes hypoplasia in
crypts of the small intestine in humans. Gut, 2000. 47(5): p. 632-7.
65. Soares, P.M., et al., Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal
mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol, 2008.
63(1): p. 91-8.
66. Coussens, L.M. and Z. Werb, Inflammation and cancer. Nature, 2002. 420(6917): p. 860-7.
67. de Visser, K.E., A. Eichten, and L.M. Coussens, Paradoxical roles of the immune system
during cancer development. Nat Rev Cancer, 2006. 6(1): p. 24-37.
68. Colotta, F., et al., Cancer-related inflammation, the seventh hallmark of cancer: links to
genetic instability. Carcinogenesis, 2009. 30(7): p. 1073-81.
69. Shacter, E. and S.A. Weitzman, Chronic inflammation and cancer. Oncology (Williston
Park), 2002. 16(2): p. 217-26, 229; discussion 230-2.
70. Josephs, D.H., et al., Epidemiological associations of allergy, IgE and cancer. Clin Exp
Allergy, 2013. 43(10): p. 1110-23.
 References
283 
71. Merrill, R.M., R.T. Isakson, and R.E. Beck, The association between allergies and cancer:
what is currently known? Ann Allergy Asthma Immunol, 2007. 99(2): p. 102-16; quiz 117-
9, 150.
72. Medzhitov, R., Toll-like receptors and innate immunity. Nat Rev Immunol, 2001. 1(2): p.
135-45.
73. Han, J. and R.J. Ulevitch, Limiting inflammatory responses during activation of innate
immunity. Nat Immunol, 2005. 6(12): p. 1198-205.
74. Harmey, J.H., et al., Lipopolysaccharide-induced metastatic growth is associated with
increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer, 2002.
101(5): p. 415-22.
75. Luo, J.L., et al., Inhibition of NF-kappaB in cancer cells converts inflammation- induced
tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell,
2004. 6(3): p. 297-305.
76. Jego, G., et al., Pathogen-associated molecular patterns are growth and survival factors
for human myeloma cells through Toll-like receptors. Leukemia, 2006. 20(6): p. 1130-7.
77. Elsea, C.R., et al., Inhibition of p38 MAPK suppresses inflammatory cytokine induction by
etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS
One, 2008. 3(6): p. e2355.
78. Laird, B.J., et al., The systemic inflammatory response and its relationship to pain and
other symptoms in advanced cancer. Oncologist, 2013. 18(9): p. 1050-5.
79. Asher, A., Cognitive dysfunction among cancer survivors. Am J Phys Med Rehabil, 2011.
90(5 Suppl 1): p. S16-26.
80. Dantzer, R., Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y
Acad Sci, 2001. 933: p. 222-34.
81. Kelley, K.W., et al., Cytokine-induced sickness behavior. Brain Behav Immun, 2003. 17
Suppl 1: p. S112-8.
82. Dantzer, R. and K.W. Kelley, Twenty years of research on cytokine-induced sickness
behavior. Brain Behav Immun, 2007. 21(2): p. 153-60.
83. Boykoff, N., M. Moieni, and S.K. Subramanian, Confronting chemobrain: an in-depth look
at survivors' reports of impact on work, social networks, and health care response. J
Cancer Surviv, 2009. 3(4): p. 223-32.
84. Ahles, T.A. and A.J. Saykin, Candidate mechanisms for chemotherapy-induced cognitive
changes. Nat Rev Cancer, 2007. 7(3): p. 192-201.
85. Debess, J., et al., Cognitive function after adjuvant treatment for early breast cancer: a
population-based longitudinal study. Breast Cancer Res Treat, 2010. 121(1): p. 91-100.
86. Seigers, R., et al., Methotrexate decreases hippocampal cell proliferation and induces
memory deficits in rats. Behav Brain Res, 2009. 201(2): p. 279-84.
87. El Beltagy, M., et al., The effect of 5-fluorouracil on the long term survival and proliferation
of cells in the rat hippocampus. Brain Res Bull, 2012. 88(5): p. 514-8.
88. Fardell, J.E., et al., The long-term impact of oxaliplatin chemotherapy on rodent cognition
and peripheral neuropathy. Behav Brain Res, 2015. 291: p. 80-8.
89. Yang, M., et al., Cyclophosphamide impairs hippocampus-dependent learning and memory
in adult mice: Possible involvement of hippocampal neurogenesis in chemotherapy-
induced memory deficits. Neurobiol Learn Mem, 2010. 93(4): p. 487-94.
90. Kempermann, G., L. Wiskott, and F.H. Gage, Functional significance of adult neurogenesis.
Curr Opin Neurobiol, 2004. 14(2): p. 186-91.
91. Shors, T.J., et al., Neurogenesis may relate to some but not all types of hippocampal-
dependent learning. Hippocampus, 2002. 12(5): p. 578-84.
92. Bendel, O., et al., Reappearance of hippocampal CA1 neurons after ischemia is associated




93. Christie, L.A., et al., Impaired cognitive function and hippocampal neurogenesis following
cancer chemotherapy. Clin Cancer Res, 2012. 18(7): p. 1954-65.
94. Shilling, V. and V. Jenkins, Self-reported cognitive problems in women receiving adjuvant
therapy for breast cancer. Eur J Oncol Nurs, 2007. 11(1): p. 6-15.
95. Fremouw, T., et al., Preserved learning and memory in mice following chemotherapy: 5-
Fluorouracil and doxorubicin single agent treatment, doxorubicin-cyclophosphamide
combination treatment. Behav Brain Res, 2012. 226(1): p. 154-62.
96. Collins, B., et al., Cognitive effects of chemotherapy in post-menopausal breast cancer
patients 1 year after treatment. Psychooncology, 2009. 18(2): p. 134-43.
97. de Ruiter, M.B., et al., Cerebral hyporesponsiveness and cognitive impairment 10 years
after chemotherapy for breast cancer. Hum Brain Mapp, 2011. 32(8): p. 1206-19.
98. Koppelmans, V., et al., Neuropsychological performance in survivors of breast cancer more
than 20 years after adjuvant chemotherapy. J Clin Oncol, 2012. 30(10): p. 1080-6.
99. Longley, D.B., D.P. Harkin, and P.G. Johnston, 5-fluorouracil: mechanisms of action and
clinical strategies. Nat Rev Cancer, 2003. 3(5): p. 330-8.
100. Wigmore, et al., Effects of 5-FU. Adv Exp Med Biol, 2010. 678: p. 157-64.
101. Cameron, D.A., H. Gabra, and R.C. Leonard, Continuous 5-fluorouracil in the treatment of
breast cancer. Br J Cancer, 1994. 70(1): p. 120-4.
102. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer:
evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J
Clin Oncol, 1992. 10(6): p. 896-903.
103. Bonadonna, G., et al., Adjuvant cyclophosphamide, methotrexate, and fluorouracil in
node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med, 1995.
332(14): p. 901-6.
104. Wohlhueter, R.M., R.S. McIvor, and P.G. Plagemann, Facilitated transport of uracil and 5-
fluorouracil, and permeation of orotic acid into cultured mammalian cells. J Cell Physiol,
1980. 104(3): p. 309-19.
105. Diasio, R.B. and B.E. Harris, Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet,
1989. 16(4): p. 215-37.
106. Peters, G.J., C.J. van Groeningen, and H.M. Pinedo, Dihydropyrimidine dehydrogenase in
livers from mouse and rat, and in human liver, colon tumors, and mucosa in relation to
anabolism of 5-fluorouracil. Adv Exp Med Biol, 1998. 431: p. 633-6.
107. McQuade, R.M., et al., Gastrointestinal dysfunction and enteric neurotoxicity following
treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol
Motil, 2016.
108. Mashtoub, S., C.D. Tran, and G.S. Howarth, Emu oil expedites small intestinal repair
following 5-fluorouracil-induced mucositis in rats. Exp Biol Med (Maywood), 2013.
238(11): p. 1305-17.
109. Mashtoub, S., et al., Oral Nucleotides Only Minimally Improve 5-Fluorouracil-Induced
Mucositis in Rats. Nutr Cancer, 2015. 67(6): p. 994-1000.
110. Bajic, J.E., et al., Rhubarb extract partially improves mucosal integrity in chemotherapy-
induced intestinal mucositis. World J Gastroenterol, 2016. 22(37): p. 8322-8333.
111. Howarth, G.S., et al., Milk growth factors enriched from cheese whey ameliorate intestinal
damage by methotrexate when administered orally to rats. J Nutr, 1996. 126(10): p. 2519-
30.
112. Bourke, R.S., et al., Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid
and brain following intravenous injection in a primate. Cancer Res, 1973. 33(7): p. 1735-
46.
113. Ahles, T.A., et al., Longitudinal assessment of cognitive changes associated with adjuvant




114. Schagen, S.B., et al., Cognitive deficits after postoperative adjuvant chemotherapy for
breast carcinoma. Cancer, 1999. 85(3): p. 640-50.
115. Han, R., et al., Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin
destruction in the central nervous system. J Biol, 2008. 7(4): p. 12.
116. Mustafa, S., et al., 5-Fluorouracil chemotherapy affects spatial working memory and
newborn neurons in the adult rat hippocampus. Eur J Neurosci, 2008. 28(2): p. 323-30.
117. Abraham, J., et al., Adjuvant chemotherapy for breast cancer: effects on cerebral white
matter seen in diffusion tensor imaging. Clin Breast Cancer, 2008. 8(1): p. 88-91.
118. Graeber, M.B. and W.J. Streit, Microglia: biology and pathology. Acta Neuropathol, 2010.
119(1): p. 89-105.
119. Lynch, M.A., The multifaceted profile of activated microglia. Mol Neurobiol, 2009. 40(2):
p. 139-56.
120. Allaman, I., M. Belanger, and P.J. Magistretti, Astrocyte-neuron metabolic relationships:
for better and for worse. Trends Neurosci, 2011. 34(2): p. 76-87.
121. Allen, N.J. and B.A. Barres, Neuroscience: Glia - more than just brain glue. Nature, 2009.
457(7230): p. 675-7.
122. Araque, A., et al., Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci,
1999. 22(5): p. 208-15.
123. Grace, P.M., et al., Pathological pain and the neuroimmune interface. Nat Rev Immunol,
2014. 14(4): p. 217-31.
124. Parpura, V., et al., Glial cells in (patho)physiology. J Neurochem, 2012. 121(1): p. 4-27.
125. O'Callaghan, J.P., K. Sriram, and D.B. Miller, Defining "neuroinflammation". Ann N Y Acad
Sci, 2008. 1139: p. 318-30.
126. Thomas, J., et al., The relationship between opioids and immune signalling in the spinal
cord. Handb Exp Pharmacol, 2015. 227: p. 207-38.
127. Mao-Ying, Q.L., et al., Robust spinal neuroinflammation mediates mechanical allodynia in
Walker 256 induced bone cancer rats. Mol Brain, 2012. 5: p. 16.
128. Areti, A., et al., Oxidative stress and nerve damage: role in chemotherapy induced
peripheral neuropathy. Redox Biol, 2014. 2: p. 289-95.
129. Eikelenboom, P., et al., The significance of neuroinflammation in understanding
Alzheimer's disease. J Neural Transm, 2006. 113(11): p. 1685-95.
130. Barnum, C.J. and M.G. Tansey, Neuroinflammation and non-motor symptoms: the dark
passenger of Parkinson's disease? Curr Neurol Neurosci Rep, 2012. 12(4): p. 350-8.
131. Mena, M.A. and J. Garcia de Yebenes, Glial cells as players in parkinsonism: the "good,"
the "bad," and the "mysterious" glia. Neuroscientist, 2008. 14(6): p. 544-60.
132. Di Cesare Mannelli, L., et al., Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol,
2014. 261: p. 22-33.
133. Ji, X.T., et al., Spinal astrocytic activation contributes to mechanical allodynia in a rat
chemotherapy-induced neuropathic pain model. PLoS One, 2013. 8(4): p. e60733.
134. Wardill, H.R., et al., Irinotecan-Induced Gastrointestinal Dysfunction and Pain Are
Mediated by Common TLR4-Dependent Mechanisms. Mol Cancer Ther, 2016. 15(6): p.
1376-86.
135. Watkins, L.R., E.D. Milligan, and S.F. Maier, Glial activation: a driving force for pathological
pain. Trends Neurosci, 2001. 24(8): p. 450-5.
136. Hutchinson, M.R., et al., Exploring the neuroimmunopharmacology of opioids: an
integrative review of mechanisms of central immune signaling and their implications for
opioid analgesia. Pharmacol Rev, 2011. 63(3): p. 772-810.
137. Cui, Y., et al., Activation of p38 mitogen-activated protein kinase in spinal microglia
mediates morphine antinociceptive tolerance. Brain Res, 2006. 1069(1): p. 235-43.
138. Raghavendra, V., M.D. Rutkowski, and J.A. DeLeo, The role of spinal neuroimmune
activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J
Neurosci, 2002. 22(22): p. 9980-9.
 References
286 
139. Hutchinson, M.R., et al., Reduction of opioid withdrawal and potentiation of acute opioid
analgesia by systemic AV411 (ibudilast). Brain Behav Immun, 2009. 23(2): p. 240-50.
140. Hutchinson, M.R., et al., Minocycline suppresses morphine-induced respiratory depression,
suppresses morphine-induced reward, and enhances systemic morphine-induced
analgesia. Brain Behav Immun, 2008. 22(8): p. 1248-56.
141. De Luca, A. and I.M. Coupar, Insights into opioid action in the intestinal tract. Pharmacol
Ther, 1996. 69(2): p. 103-15.
142. Greenwood-Van Meerveld, B., et al., Preclinical studies of opioids and opioid antagonists
on gastrointestinal function. Neurogastroenterol Motil, 2004. 16 Suppl 2: p. 46-53.
143. Capuron, L. and A.H. Miller, Immune system to brain signaling:
neuropsychopharmacological implications. Pharmacol Ther, 2011. 130(2): p. 226-38.
144. Dantzer, R., et al., Neural and humoral pathways of communication from the immune
system to the brain: parallel or convergent? Auton Neurosci, 2000. 85(1-3): p. 60-5.
145. Goehler, L.E., et al., Vagal immune-to-brain communication: a visceral chemosensory
pathway. Auton Neurosci, 2000. 85(1-3): p. 49-59.
146. Chan, C.M., et al., Effects of depression and anxiety on mortality in a mixed cancer group:
a longitudinal approach using standardised diagnostic interviews. Psychooncology, 2014.
147. Kuzeyli Yildirim, Y., M. Uyar, and C. Fadillioglu, [Cancer pain and its influence on quality of
life]. Agri, 2005. 17(4): p. 17-22.
148. Wigmore, The Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory.
Curr Top Behav Neurosci, 2012.
149. Bhatia, V. and R.K. Tandon, Stress and the gastrointestinal tract. J Gastroenterol Hepatol,
2005. 20(3): p. 332-9.
150. Chakiath, R.J., et al., Descending pain modulation in irritable bowel syndrome (IBS): a
systematic review and meta-analysis. Syst Rev, 2015. 4: p. 175.
151. Tracey, K.J., The inflammatory reflex. Nature, 2002. 420(6917): p. 853-9.
152. Pavlov, V.A. and K.J. Tracey, The vagus nerve and the inflammatory reflex--linking
immunity and metabolism. Nat Rev Endocrinol, 2012. 8(12): p. 743-54.
153. He, F. and Y.E. Sun, Glial cells more than support cells? Int J Biochem Cell Biol, 2007. 39(4):
p. 661-5.
154. Bains, J.S. and S.H. Oliet, Glia: they make your memories stick! Trends Neurosci, 2007.
30(8): p. 417-24.
155. Dodds, K.N., et al., Glial contributions to visceral pain: implications for disease etiology
and the female predominance of persistent pain. Translational Psychiatry, 2016. 6(9): p.
e888.
156. Agrawal, S.M. and V.W. Yong, The many faces of EMMPRIN - roles in neuroinflammation.
Biochim Biophys Acta, 2011. 1812(2): p. 213-9.
157. Bilbo, S.D., S.H. Smith, and J.M. Schwarz, A lifespan approach to neuroinflammatory and
cognitive disorders: a critical role for glia. J Neuroimmune Pharmacol, 2012. 7(1): p. 24-41.
158. Laskaris, L.E., et al., Microglial activation and progressive brain changes in schizophrenia.
Br J Pharmacol, 2015.
159. McGeer, P.L., et al., Reactive microglia are positive for HLA-DR in the substantia nigra of
Parkinson's and Alzheimer's disease brains. Neurology, 1988. 38(8): p. 1285-91.
160. Myers, J.S., Chemotherapy-related cognitive impairment. Clin J Oncol Nurs, 2009. 13(4): p.
413-21.
161. Feng, Q., W.D. Chen, and Y.D. Wang, Gut Microbiota: An Integral Moderator in Health and
Disease. Front Microbiol, 2018. 9: p. 151.
162. Keefe, D.M., et al., Effect of high-dose chemotherapy on intestinal permeability in humans.
Clin Sci (Lond), 1997. 92(4): p. 385-9.
163. Keller, F.S.S., William N., Principles of Psychology: A Systematic Text in the Science of
Behavior. 1950, New York: Irvington Publishers.
 References
287 
164. Dinan, T.G. and J.F. Cryan, Gut-brain axis in 2016: Brain-gut-microbiota axis - mood,
metabolism and behaviour. Nat Rev Gastroenterol Hepatol, 2017. 14(2): p. 69-70.
165. Mu, C., Y. Yang, and W. Zhu, Gut Microbiota: The Brain Peacekeeper. Front Microbiol,
2016. 7: p. 345.
166. Barbara, G., et al., The Intestinal Microenvironment and Functional Gastrointestinal
Disorders. Gastroenterology, 2016.
167. Scully, C., J. Epstein, and S. Sonis, Oral mucositis: a challenging complication of
radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and
prophylaxis of mucositis. Head Neck, 2003. 25(12): p. 1057-70.
168. Gibson, R.J. and D.M. Keefe, Cancer chemotherapy-induced diarrhoea and constipation:
mechanisms of damage and prevention strategies. Support Care Cancer, 2006. 14(9): p.
890-900.
169. Gibson, R.J., et al., Systematic review of agents for the management of gastrointestinal
mucositis in cancer patients. Support Care Cancer, 2013. 21(1): p. 313-26.
170. Vardy, J. and I. Tannock, Cognitive function after chemotherapy in adults with solid
tumours. Crit Rev Oncol Hematol, 2007. 63(3): p. 183-202.
171. Potrata, B., et al., 'Like a sieve': an exploratory study on cognitive impairments in patients
with multiple myeloma. Eur J Cancer Care (Engl), 2010. 19(6): p. 721-8.
172. Schagen, S.B., et al., Cognitive complaints and cognitive impairment following BEP
chemotherapy in patients with testicular cancer. Acta Oncol, 2008. 47(1): p. 63-70.
173. Mitchell, T., The social and emotional toll of chemotherapy - patients' perspectives. Eur J
Cancer Care (Engl), 2007. 16(1): p. 39-47.
174. Von Ah, D., et al., Impact of perceived cognitive impairment in breast cancer survivors. Eur
J Oncol Nurs, 2013. 17(2): p. 236-41.
175. McDonald, B.C., et al., Gray matter reduction associated with systemic chemotherapy for
breast cancer: a prospective MRI study. Breast Cancer Res Treat, 2010. 123(3): p. 819-28.
176. Silverman, D.H., et al., Altered frontocortical, cerebellar, and basal ganglia activity in
adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer
Res Treat, 2007. 103(3): p. 303-11.
177. Bruno, J., S.M. Hosseini, and S. Kesler, Altered resting state functional brain network
topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis, 2012. 48(3): p.
329-38.
178. Yang, M., et al., Acute treatment with methotrexate induces hippocampal dysfunction in a
mouse model of breast cancer. Brain Res Bull, 2012. 89(1-2): p. 50-6.
179. Deng, W., J.B. Aimone, and F.H. Gage, New neurons and new memories: how does adult
hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci, 2010. 11(5): p.
339-50.
180. Ming, G.L. and H. Song, Adult neurogenesis in the mammalian brain: significant answers
and significant questions. Neuron, 2011. 70(4): p. 687-702.
181. Briones, T.L. and J. Woods, Chemotherapy-induced cognitive impairment is associated
with decreases in cell proliferation and histone modifications. BMC Neurosci, 2011. 12: p.
124.
182. Briones, T.L. and J. Woods, Dysregulation in myelination mediated by persistent
neuroinflammation: Possible mechanisms in chemotherapy-related cognitive impairment.
Brain Behav Immun, 2013.
183. Bajic, J.E., et al., Neuroimmunological Manifestations of Chemotherapy Exposure:
Implications for Mucositis, Glia and Cognition. Cancer Med Anticancer Drug, 2016. 1(2): p.
1-9.
184. Network, N.C.C., National Comprehensive Cancer Network Practice Guidelines in Oncology
N.C.C. Network, Editor. 2015: Fort Washington.
185. Vance, D.E., et al., Interventions for Cognitive Deficits in Breast Cancer Survivors Treated
With Chemotherapy. Cancer Nurs, 2017. 40(1): p. E11-E27.
 References
288 
186. Wardill, H.R., et al., Toll-like receptor 4 signaling: A common biological mechanism of
regimen-related toxicities. Cancer Treatment Reviews, 2015. 41(2): p. 122-128.
187. Akira, S. and K. Takeda, Functions of toll-like receptors: lessons from KO mice. C R Biol,
2004. 327(6): p. 581-9.
188. Doyle, S.L. and L.A. O'Neill, Toll-like receptors: from the discovery of NFkappaB to new
insights into transcriptional regulations in innate immunity. Biochem Pharmacol, 2006.
72(9): p. 1102-13.
189. Gibson, R.J., et al., Chemotherapy-induced gut toxicity and pain: involvement of TLRs.
Support Care Cancer, 2016. 24(5): p. 2251-2258.
190. Hutchinson, M.R., et al., Opioid activation of toll-like receptor 4 contributes to drug
reinforcement. J Neurosci, 2012. 32(33): p. 11187-200.
191. Hutchinson, M.R., et al., Evidence that opioids may have toll-like receptor 4 and MD-2
effects. Brain Behav Immun, 2010. 24(1): p. 83-95.
192. Rakoff-Nahoum, S., et al., Recognition of commensal microflora by toll-like receptors is
required for intestinal homeostasis. Cell, 2004. 118(2): p. 229-41.
193. Lyons, L., et al., Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in
the rat hippocampus by a mechanism of prevention rather than recovery. PLoS One, 2012.
7(1): p. e30010.
194. Wilson, C.L. and E.T. Weber, Chemotherapy drug thioTEPA exacerbates stress-induced
anhedonia and corticosteroid responses but not impairment of hippocampal cell
proliferation in adult mice. Behav Brain Res, 2013. 236(1): p. 180-5.
195. Ginos, J.Z., et al., [13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus
intravenous chemotherapy for malignant brain tumors. J Nucl Med, 1987. 28(12): p. 1844-
52.
196. Gangloff, A., et al., Estimation of paclitaxel biodistribution and uptake in human-derived
xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med, 2005. 46(11): p. 1866-71.
197. Ley, R.E., D.A. Peterson, and J.I. Gordon, Ecological and evolutionary forces shaping
microbial diversity in the human intestine. Cell, 2006. 124(4): p. 837-48.
198. Qin, J., et al., A human gut microbial gene catalogue established by metagenomic
sequencing. Nature, 2010. 464(7285): p. 59-65.
199. Ley, R.E., et al., Evolution of mammals and their gut microbes. Science, 2008. 320(5883):
p. 1647-51.
200. O'Hara, A.M. and F. Shanahan, The gut flora as a forgotten organ. EMBO Rep, 2006. 7(7):
p. 688-93.
201. Jalanka-Tuovinen, J., et al., Intestinal microbiota in healthy adults: temporal analysis
reveals individual and common core and relation to intestinal symptoms. PLoS One, 2011.
6(7): p. e23035.
202. Clemente, J.C., et al., The impact of the gut microbiota on human health: an integrative
view. Cell, 2012. 148(6): p. 1258-70.
203. Abt, M.C., et al., Commensal bacteria calibrate the activation threshold of innate antiviral
immunity. Immunity, 2012. 37(1): p. 158-70.
204. Ichinohe, T., et al., Microbiota regulates immune defense against respiratory tract
influenza A virus infection. Proc Natl Acad Sci U S A, 2011. 108(13): p. 5354-9.
205. Hakansson, A., et al., Immunological alteration and changes of gut microbiota after
dextran sulfate sodium (DSS) administration in mice. Clin Exp Med, 2015. 15(1): p. 107-20.
206. Dalal, S.R. and E.B. Chang, The microbial basis of inflammatory bowel diseases. J Clin
Invest, 2014. 124(10): p. 4190-6.
207. Garcia-Lafuente, A., et al., Incrimination of anaerobic bacteria in the induction of
experimental colitis. Am J Physiol, 1997. 272(1 Pt 1): p. G10-5.
208. Touchefeu, Y., et al., Systematic review: the role of the gut microbiota in chemotherapy- or
radiation-induced gastrointestinal mucositis - current evidence and potential clinical
applications. Aliment Pharmacol Ther, 2014. 40(5): p. 409-21.
 References
289 
209. Morgan, X.C., et al., Dysfunction of the intestinal microbiome in inflammatory bowel
disease and treatment. Genome Biol, 2012. 13(9): p. R79.
210. Zitvogel, L., et al., Cancer and the gut microbiota: an unexpected link. Sci Transl Med,
2015. 7(271): p. 271ps1.
211. Vanhoecke, B., et al., Microbiota and their role in the pathogenesis of oral mucositis. Oral
Dis, 2015. 21(1): p. 17-30.
212. Dzutsev, A., et al., The role of the microbiota in inflammation, carcinogenesis, and cancer
therapy. Eur J Immunol, 2015. 45(1): p. 17-31.
213. Lin, X.B., et al., Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour
bearing rats. PLoS One, 2012. 7(7): p. e39764.
214. Von Bultzingslowen, I., et al., Oral and intestinal microflora in 5-fluorouracil treated rats,
translocation to cervical and mesenteric lymph nodes and effects of probiotic bacteria.
Oral Microbiol Immunol, 2003. 18(5): p. 278-84.
215. Stringer, A.M., et al., Irinotecan-induced mucositis manifesting as diarrhoea corresponds
with an amended intestinal flora and mucin profile. Int J Exp Pathol, 2009. 90(5): p. 489-
99.
216. Stringer, A.M., et al., Chemotherapy-induced diarrhea is associated with changes in the
luminal environment in the DA rat. Exp Biol Med (Maywood), 2007. 232(1): p. 96-106.
217. Montassier, E., et al., 16S rRNA gene pyrosequencing reveals shift in patient faecal
microbiota during high-dose chemotherapy as conditioning regimen for bone marrow
transplantation. Microb Ecol, 2014. 67(3): p. 690-9.
218. Manichanh, C., et al., The gut microbiota predispose to the pathophysiology of acute
postradiotherapy diarrhea. Am J Gastroenterol, 2008. 103(7): p. 1754-61.
219. Zwielehner, J., et al., Changes in human fecal microbiota due to chemotherapy analyzed
by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS One, 2011. 6(12): p.
e28654.
220. Sears, C.L. and W.S. Garrett, Microbes, microbiota, and colon cancer. Cell Host Microbe,
2014. 15(3): p. 317-28.
221. Wilson, I.D. and J.K. Nicholson, Gut microbiome interactions with drug metabolism,
efficacy, and toxicity. Transl Res, 2017. 179: p. 204-222.
222. Carmody, R.N. and P.J. Turnbaugh, Host-microbial interactions in the metabolism of
therapeutic and diet-derived xenobiotics. J Clin Invest, 2014. 124(10): p. 4173-81.
223. Iida, N., et al., Commensal bacteria control cancer response to therapy by modulating the
tumor microenvironment. Science, 2013. 342(6161): p. 967-70.
224. Viaud, S., et al., The intestinal microbiota modulates the anticancer immune effects of
cyclophosphamide. Science, 2013. 342(6161): p. 971-6.
225. Sivan, A., et al., Commensal Bifidobacterium promotes antitumor immunity and facilitates
anti-PD-L1 efficacy. Science, 2015. 350(6264): p. 1084-9.
226. Vetizou, M., et al., Anticancer immunotherapy by CTLA-4 blockade relies on the gut
microbiota. Science, 2015. 350(6264): p. 1079-84.
227. Pennisi, E., Biomedicine. Cancer therapies use a little help from microbial friends. Science,
2013. 342(6161): p. 921.
228. Greenhill, C., Gut microbiota: Anti-cancer therapies affected by gut microbiota. Nat Rev
Gastroenterol Hepatol, 2014. 11(1): p. 1.
229. Lokody, I., Tumour microenvironment: bacterial balance affects cancer treatment. Nat Rev
Cancer, 2014. 14(1): p. 10.
230. Bordon, Y., Tumour immunology: Anticancer drugs need bugs. Nat Rev Immunol, 2014.
14(1): p. 1.
231. Mukaida, N., Intestinal microbiota: unexpected alliance with tumor therapy.
Immunotherapy, 2014. 6(3): p. 231-3.
232. Wardill, H.R., et al., Irinotecan disrupts tight junction proteins within the gut : implications
for chemotherapy-induced gut toxicity. Cancer Biol Ther, 2014. 15(2): p. 236-44.
 References
290 
233. Powell, D.W., Barrier function of epithelia. Am J Physiol, 1981. 241(4): p. G275-88.
234. Balda, M.S. and K. Matter, Tight junctions as regulators of tissue remodelling. Curr Opin
Cell Biol, 2016. 42: p. 94-101.
235. Carneiro-Filho, B.A., et al., Intestinal barrier function and secretion in methotrexate-
induced rat intestinal mucositis. Dig Dis Sci, 2004. 49(1): p. 65-72.
236. Beutheu Youmba, S., et al., Methotrexate modulates tight junctions through NF-kappaB,
MEK, and JNK pathways. J Pediatr Gastroenterol Nutr, 2012. 54(4): p. 463-70.
237. Nguyen, T.L., et al., How informative is the mouse for human gut microbiota research? Dis
Model Mech, 2015. 8(1): p. 1-16.
238. Cario, E., Innate immune signalling at intestinal mucosal surfaces: a fine line between host
protection and destruction. Curr Opin Gastroenterol, 2008. 24(6): p. 725-32.
239. Cavaletti, G. and P. Marmiroli, Chemotherapy-induced peripheral neurotoxicity. Curr Opin
Neurol, 2015. 28(5): p. 500-7.
240. Wang, X.M., et al., Discovering cytokines as targets for chemotherapy-induced painful
peripheral neuropathy. Cytokine, 2012. 59(1): p. 3-9.
241. Windebank, A.J. and W. Grisold, Chemotherapy-induced neuropathy. J Peripher Nerv Syst,
2008. 13(1): p. 27-46.
242. Park, S.B., et al., Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA
Cancer J Clin, 2013. 63(6): p. 419-37.
243. Gill, J.S. and A.J. Windebank, Cisplatin-induced apoptosis in rat dorsal root ganglion
neurons is associated with attempted entry into the cell cycle. J Clin Invest, 1998. 101(12):
p. 2842-50.
244. Cavaletti, G., et al., Distribution of paclitaxel within the nervous system of the rat after
repeated intravenous administration. Neurotoxicology, 2000. 21(3): p. 389-93.
245. Theiss, C. and K. Meller, Taxol impairs anterograde axonal transport of microinjected
horseradish peroxidase in dorsal root ganglia neurons in vitro. Cell Tissue Res, 2000.
299(2): p. 213-24.
246. McDonald, E.S. and A.J. Windebank, Cisplatin-induced apoptosis of DRG neurons involves
bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis,
2002. 9(2): p. 220-33.
247. Chen, Y., et al., Collateral damage in cancer chemotherapy: oxidative stress in nontargeted
tissues. Mol Interv, 2007. 7(3): p. 147-56.
248. Isoardo, G., et al., Thalidomide neuropathy: clinical, electrophysiological and
neuroradiological features. Acta Neurol Scand, 2004. 109(3): p. 188-93.
249. Descoeur, J., et al., Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion
channel expression in nociceptors. EMBO Mol Med, 2011. 3(5): p. 266-78.
250. Tatsushima, Y., et al., Involvement of substance P in peripheral neuropathy induced by
paclitaxel but not oxaliplatin. J Pharmacol Exp Ther, 2011. 337(1): p. 226-35.
251. Mihara, Y., et al., Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-
induced mechanical allodynia in rats. Mol Pain, 2011. 7: p. 8.
252. Wafai, L., et al., Effects of oxaliplatin on mouse myenteric neurons and colonic motility.
Front Neurosci, 2013. 7: p. 30.
253. Vera, G., et al., Enteric neuropathy evoked by repeated cisplatin in the rat.
Neurogastroenterol Motil, 2011. 23(4): p. 370-8, e162-3.
254. Katsuura, G., et al., Involvement of organum vasculosum of lamina terminalis and preoptic
area in interleukin 1 beta-induced ACTH release. Am J Physiol, 1990. 258(1 Pt 1): p. E163-
71.
255. Dantzer, R., Innate immunity at the forefront of psychoneuroimmunology. Brain Behav
Immun, 2004. 18(1): p. 1-6.
256. Goehler, L.E., et al., Interleukin-1beta in immune cells of the abdominal vagus nerve: a link
between the immune and nervous systems? J Neurosci, 1999. 19(7): p. 2799-806.
 References
291 
257. Tomas, F.M., A.J. Murray, and L.M. Jones, Modification of glucocorticoid-induced changes
in myofibrillar protein turnover in rats by protein and energy deficiency as assessed by
urinary excretion of Ntau-methylhistidine. Br J Nutr, 1984. 51(3): p. 323-37.
258. Banchereau, J. and R.M. Steinman, Dendritic cells and the control of immunity. Nature,
1998. 392(6673): p. 245-52.
259. Reis e Sousa, C., A. Sher, and P. Kaye, The role of dendritic cells in the induction and
regulation of immunity to microbial infection. Curr Opin Immunol, 1999. 11(4): p. 392-9.
260. Ricart, B.G., et al., Dendritic cells distinguish individual chemokine signals through CCR7
and CXCR4. J Immunol, 2011. 186(1): p. 53-61.
261. Szabo, A., et al., Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset
of human dendritic cells. Sci Rep, 2018. 8(1): p. 1765.
262. Holst, K., et al., The serotonin receptor 5-HT(7)R regulates the morphology and migratory
properties of dendritic cells. J Cell Sci, 2015. 128(15): p. 2866-80.
263. Bajic, J.E., et al., Intestinal mucositis induced by 5-fluorouracil results in spinal astrocyte
expression changes in rats. J Neurochem, 2015. 134(1): p. 102.
264. Elting, L.S., et al., The burdens of cancer therapy. Clinical and economic outcomes of
chemotherapy-induced mucositis. Cancer, 2003. 98(7): p. 1531-9.
265. Elting, L.S., et al., Risk, outcomes, and costs of radiation-induced oral mucositis among
patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys, 2007. 68(4): p.
1110-20.
266. Miller, E., The World Health Organization analgesic ladder. J Midwifery Womens Health,
2004. 49(6): p. 542-5.
267. Dheen, S.T., C. Kaur, and E.A. Ling, Microglial activation and its implications in the brain
diseases. Curr Med Chem, 2007. 14(11): p. 1189-97.
268. Quan, N. and W.A. Banks, Brain-immune communication pathways. Brain Behav Immun,
2007. 21(6): p. 727-35.
269. Hutchinson, M.R. and L.R. Watkins, Why is neuroimmunopharmacology crucial for the
future of addiction research? Neuropharmacology, 2014. 76 Pt B: p. 218-27.
270. Hart, B.L., Biological basis of the behavior of sick animals. Neurosci Biobehav Rev, 1988.
12(2): p. 123-37.
271. Tannock, I.F., et al., Cognitive impairment associated with chemotherapy for cancer:
report of a workshop. J Clin Oncol, 2004. 22(11): p. 2233-9.
272. Wigmore, P., The effect of systemic chemotherapy on neurogenesis, plasticity and
memory. Curr Top Behav Neurosci, 2013. 15: p. 211-40.
273. Fardell, J.E., J. Vardy, and I.N. Johnston, The short and long term effects of docetaxel
chemotherapy on rodent object recognition and spatial reference memory. Life Sci, 2013.
93(17): p. 596-604.
274. Fardell, J.E., et al., Cognitive impairments caused by oxaliplatin and 5-fluorouracil
chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl), 2012.
220(1): p. 183-93.
275. Lyons, L., et al., The effects of cyclophosphamide on hippocampal cell proliferation and
spatial working memory in rat. PLoS One, 2011. 6(6): p. e21445.
276. Cheung, Y.T., et al., Minimal clinically important difference (MCID) for the functional
assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. J
Clin Epidemiol, 2014. 67(7): p. 811-20.
277. McCusker, R.H. and K.W. Kelley, Immune-neural connections: how the immune system's
response to infectious agents influences behavior. J Exp Biol, 2013. 216(Pt 1): p. 84-98.
278. Quan, N., M. Whiteside, and M. Herkenham, Time course and localization patterns of
interleukin-1beta messenger RNA expression in brain and pituitary after peripheral
administration of lipopolysaccharide. Neuroscience, 1998. 83(1): p. 281-93.
 References
292 
279. Plotkin, S.R., W.A. Banks, and A.J. Kastin, Comparison of saturable transport and
extracellular pathways in the passage of interleukin-1 alpha across the blood-brain
barrier. J Neuroimmunol, 1996. 67(1): p. 41-7.
280. Cunningham, E.T., Jr. and E.B. De Souza, Interleukin 1 receptors in the brain and endocrine
tissues. Immunol Today, 1993. 14(4): p. 171-6.
281. Goldbach, J.M., J. Roth, and E. Zeisberger, Fever suppression by subdiaphragmatic
vagotomy in guinea pigs depends on the route of pyrogen administration. Am J Physiol,
1997. 272(2 Pt 2): p. R675-81.
282. Riendeau, D., et al., Comparison of the cyclooxygenase-1 inhibitory properties of
nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using
sensitive microsomal and platelet assays. Can J Physiol Pharmacol, 1997. 75(9): p. 1088-
95.
283. Davis, M.P., Twelve reasons for considering buprenorphine as a frontline analgesic in the
management of pain. J Support Oncol, 2012. 10(6): p. 209-19.
284. Raffa, R.B., et al., Opioid and nonopioid components independently contribute to the
mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther,
1992. 260(1): p. 275-85.
285. Bowen, J.M., R.J. Gibson, and D.M. Keefe, Animal models of mucositis: implications for
therapy. J Support Oncol, 2011. 9(5): p. 161-8.
286. Mashtoub, S., et al., Emu Oil Combined with Lyprinol Reduces Small Intestinal Damage in a
Rat Model of Chemotherapy-Induced Mucositis. Nutr Cancer, 2016. 68(7): p. 1171-80.
287. Whittaker, A.L., et al., Differential Effectiveness of Clinically-Relevant Analgesics in a Rat
Model of Chemotherapy-Induced Mucositis. PLoS One, 2016. 11(7): p. e0158851.
288. Wang, H., et al., Effects of Supernatants from Escherichia coli Nissle 1917 and
Faecalibacterium prausnitzii on Intestinal Epithelial Cells and a Rat Model of 5-
Fluorouracil-Induced Mucositis. Nutr Cancer, 2017. 69(2): p. 307-318.
289. Senthilkumaran, M., M.E. Johnson, and L. Bobrovskaya, The Effects of Insulin-Induced
Hypoglycaemia on Tyrosine Hydroxylase Phosphorylation in Rat Brain and Adrenal Gland.
Neurochem Res, 2016. 41(7): p. 1612-24.
290. Bodnar, R.J., Endogenous opioids and feeding behavior: A decade of further progress
(2004-2014). A Festschrift to Dr. Abba Kastin. Peptides, 2015. 72: p. 20-33.
291. Johnson, R.D., Opioid involvement in feeding behaviour and the pathogenesis of certain
eating disorders. Med Hypotheses, 1995. 45(5): p. 491-7.
292. Lau, D., et al., Myeloperoxidase mediates neutrophil activation by association with
CD11b/CD18 integrins. Proc Natl Acad Sci U S A, 2005. 102(2): p. 431-6.
293. Xia, Y. and G.G. Haddad, Ontogeny and distribution of opioid receptors in the rat
brainstem. Brain Res, 1991. 549(2): p. 181-93.
294. Bagnol, D., et al., Cellular localization and distribution of the cloned mu and kappa opioid
receptors in rat gastrointestinal tract. Neuroscience, 1997. 81(2): p. 579-91.
295. Ness, T.J., Kappa opioid receptor agonists differentially inhibit two classes of rat spinal
neurons excited by colorectal distention. Gastroenterology, 1999. 117(2): p. 388-94.
296. Wilder-Smith, C.H., et al., Effects of morphine and tramadol on somatic and visceral
sensory function and gastrointestinal motility after abdominal surgery. Anesthesiology,
1999. 91(3): p. 639-47.
297. Zielinska, M., et al., Anti-inflammatory effect of dual nociceptin and opioid receptor
agonist, BU08070, in experimental colitis in mice. Eur J Pharmacol, 2015. 765: p. 582-90.
298. Laudanno, O.M., et al., [Autonomic nervous system and gastric stress in rats]. Acta
Gastroenterol Latinoam, 1999. 29(2): p. 51-6.
299. Gyires, K. and A.Z. Ronai, Supraspinal delta- and mu-opioid receptors mediate gastric
mucosal protection in the rat. J Pharmacol Exp Ther, 2001. 297(3): p. 1010-5.
300. Dietrich, J., et al., CNS progenitor cells and oligodendrocytes are targets of
chemotherapeutic agents in vitro and in vivo. J Biol, 2006. 5(7): p. 22.
 References
293 
301. Nogueira, L.T., et al., The involvement of mast cells in the irinotecan-induced enteric
neurons loss and reactive gliosis. J Neuroinflammation, 2017. 14(1): p. 79.
302. Bajic, J.E., et al., Neuroimmunological Manifestations of Chemotherapy Exposure:
Implications for Mucositis, Glia and Cognition. Journal of Cancer Science and Research,
2016. 1(2): p. 1-9.
303. Geis, C., et al., Evoked pain behavior and spinal glia activation is dependent on tumor
necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain. Neuroscience,
2010. 169(1): p. 463-74.
304. Honore, P., et al., Murine models of inflammatory, neuropathic and cancer pain each
generates a unique set of neurochemical changes in the spinal cord and sensory neurons.
Neuroscience, 2000. 98(3): p. 585-98.
305. Ren, B.X., et al., Intrathecal injection of metabotropic glutamate receptor subtype 3 and 5
agonist/antagonist attenuates bone cancer pain by inhibition of spinal astrocyte
activation in a mouse model. Anesthesiology, 2012. 116(1): p. 122-32.
306. Herranz, E., et al., Neuroinflammatory component of gray matter pathology in multiple
sclerosis. Ann Neurol, 2016. 80(5): p. 776-790.
307. Bao, L., et al., Adjuvant-induced arthritis: IL-1 beta, IL-6 and TNF-alpha are up-regulated in
the spinal cord. Neuroreport, 2001. 12(18): p. 3905-8.
308. Dodds, K.N., et al., Spinal Glial Adaptations Occur in a Minimally Invasive Mouse Model of
Endometriosis: Potential Implications for Lesion Etiology and Persistent Pelvic Pain.
Reprod Sci, 2018: p. 1933719118773405.
309. Gehrmann, J., Y. Matsumoto, and G.W. Kreutzberg, Microglia: intrinsic immuneffector cell
of the brain. Brain Res Brain Res Rev, 1995. 20(3): p. 269-87.
310. Robinson, C.R., H. Zhang, and P.M. Dougherty, Astrocytes, but not microglia, are activated
in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat. Neuroscience,
2014. 274: p. 308-17.
311. Otto, K. and H.A. Adams, [Experimental studies on the central analgesic effect of the non-
steroidal anti-inflammatory drug carprofen in a sheep model -- preliminary results].
Anasthesiol Intensivmed Notfallmed Schmerzther, 2005. 40(1): p. 25-31.
312. Thau-Zuchman, O., et al., The anti-inflammatory drug carprofen improves long-term
outcome and induces gliogenesis after traumatic brain injury. J Neurotrauma, 2012. 29(2):
p. 375-84.
313. Wardill, H.R., J.M. Bowen, and R.J. Gibson, Chemotherapy-induced gut toxicity: are
alterations to intestinal tight junctions pivotal? Cancer Chemother Pharmacol, 2012.
70(5): p. 627-35.
314. Mertz, H., Role of the brain and sensory pathways in gastrointestinal sensory disorders in
humans. Gut, 2002. 51 Suppl 1: p. i29-33.
315. Yuan, Q. and W.A. Walker, Innate immunity of the gut: mucosal defense in health and
disease. J Pediatr Gastroenterol Nutr, 2004. 38(5): p. 463-73.
316. Tang, Y., et al., Administration of probiotic mixture DM#1 ameliorated 5-fluorouracil-
induced intestinal mucositis and dysbiosis in rats. Nutrition, 2017. 33: p. 96-104.
317. Maynard, C.L., et al., Reciprocal interactions of the intestinal microbiota and immune
system. Nature, 2012. 489(7415): p. 231-41.
318. Gribar, S.C., et al., The role of epithelial Toll-like receptor signaling in the pathogenesis of
intestinal inflammation. J Leukoc Biol, 2008. 83(3): p. 493-8.
319. Grace, P.M., P.E. Rolan, and M.R. Hutchinson, Peripheral immune contributions to the
maintenance of central glial activation underlying neuropathic pain. Brain Behav Immun,
2011. 25(7): p. 1322-32.
320. Seigers, R., et al., Methotrexate reduces hippocampal blood vessel density and activates




321. Janelsins, M.C., et al., Prevalence, mechanisms, and management of cancer-related
cognitive impairment. Int Rev Psychiatry, 2014. 26(1): p. 102-13.
322. Wefel, J.S., et al., Acute and late onset cognitive dysfunction associated with
chemotherapy in women with breast cancer. Cancer, 2010. 116(14): p. 3348-56.
323. Janelsins, M.C., et al., Cognitive Complaints in Survivors of Breast Cancer After
Chemotherapy Compared With Age-Matched Controls: An Analysis From a Nationwide,
Multicenter, Prospective Longitudinal Study. J Clin Oncol, 2017. 35(5): p. 506-514.
324. Howarth, G.S., C.J. Xian, and L.C. Read, Predisposition to colonic dysplasia is unaffected by
continuous administration of insulin-like growth factor-I for twenty weeks in a rat model
of chronic inflammatory bowel disease. Growth Factors, 2000. 18(2): p. 119-33.
325. Murthy, S.N., et al., Treatment of dextran sulfate sodium-induced murine colitis by
intracolonic cyclosporin. Dig Dis Sci, 1993. 38(9): p. 1722-34.
326. Yazbeck, R., et al., Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in
mice. Front Biosci, 2008. 13: p. 6850-8.
327. Helps, S.C., et al., Automatic nonsubjective estimation of antigen content visualized by
immunohistochemistry using color deconvolution. Appl Immunohistochem Mol Morphol,
2012. 20(1): p. 82-90.
328. Bajic, J.E., et al., From the Bottom-Up: Chemotherapy and Gut-Brain Axis Dysregulation.
Front Behav Neurosci, 2018. 12: p. 104.
329. Barratt, D.T., et al., Innate Immune Signalling Genetics of Pain, Cognitive Dysfunction and
Sickness Symptoms in Cancer Pain Patients Treated with Transdermal Fentanyl. PLoS One,
2015. 10(9): p. e0137179.
330. Cheah, K.Y., G.S. Howarth, and S.E. Bastian, Grape seed extract dose-responsively
decreases disease severity in a rat model of mucositis; concomitantly enhancing
chemotherapeutic effectiveness in colon cancer cells. PLoS One, 2014. 9(1): p. e85184.
331. Abimosleh, S.M., C.D. Tran, and G.S. Howarth, Emu oil reduces small intestinal
inflammation in the absence of clinical improvement in a rat model of indomethacin-
induced enteropathy. Evid Based Complement Alternat Med, 2013. 2013: p. 429706.
332. Fukumoto, K., et al., Role of tumor necrosis factor-alpha in the pathogenesis of
indomethacin-induced small intestinal injury in mice. Int J Mol Med, 2011. 27(3): p. 353-9.
333. Scarpignato, C. and R.H. Hunt, Nonsteroidal antiinflammatory drug-related injury to the
gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol Clin
North Am, 2010. 39(3): p. 433-64.
334. Boelsterli, U.A., M.R. Redinbo, and K.S. Saitta, Multiple NSAID-induced hits injure the small
intestine: underlying mechanisms and novel strategies. Toxicol Sci, 2013. 131(2): p. 654-
67.
335. Menozzi, A., et al., Diazoxide attenuates indomethacin-induced small intestinal damage in
the rat. Eur J Pharmacol, 2011. 650(1): p. 378-83.
336. Pritchard, D.M., C.S. Potten, and J.A. Hickman, The relationships between p53-dependent
apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine
intestinal epithelia. Cancer Res, 1998. 58(23): p. 5453-65.
337. Schagen, S.B., et al., Change in cognitive function after chemotherapy: a prospective
longitudinal study in breast cancer patients. J Natl Cancer Inst, 2006. 98(23): p. 1742-5.
338. Tha, K.K., et al., Diffusion-weighted magnetic resonance imaging in early stage of 5-
fluorouracil-induced leukoencephalopathy. Acta Neurol Scand, 2002. 106(6): p. 379-86.
339. Nimmerjahn, A., F. Kirchhoff, and F. Helmchen, Resting microglial cells are highly dynamic
surveillants of brain parenchyma in vivo. Science, 2005. 308(5726): p. 1314-8.
340. Gehrmann, J., et al., Microglial involvement in experimental autoimmune inflammation of
the central and peripheral nervous system. Glia, 1993. 7(1): p. 50-9.
341. Cunningham, C., Microglia and neurodegeneration: the role of systemic inflammation.
Glia, 2013. 61(1): p. 71-90.
 References
295 
342. Matsumoto, Y., K. Ohmori, and M. Fujiwara, Microglial and astroglial reactions to
inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central
nervous system. J Neuroimmunol, 1992. 37(1-2): p. 23-33.
343. Dodds, K.N., et al., Spinal Glial Adaptations Occur in a Minimally Invasive Mouse Model of
Endometriosis: Potential Implications for Lesion Etiology and Persistent Pelvic Pain.
Reprod Sci, 2019. 26(3): p. 357-369.
344. Zonis, S., et al., Chronic intestinal inflammation alters hippocampal neurogenesis. J
Neuroinflammation, 2015. 12: p. 65.
345. Li, Y., et al., Toll-like receptor 4 signaling contributes to Paclitaxel-induced peripheral
neuropathy. J Pain, 2014. 15(7): p. 712-25.
346. Ahluwalia, B., M.K. Magnusson, and L. Ohman, Mucosal immune system of the
gastrointestinal tract: maintaining balance between the good and the bad. Scand J
Gastroenterol, 2017. 52(11): p. 1185-1193.
347. De Palma, G., et al., Intestinal dysbiosis and reduced immunoglobulin-coated bacteria
associated with coeliac disease in children. BMC Microbiol, 2010. 10: p. 63.
348. Rooks, M.G., et al., Gut microbiome composition and function in experimental colitis
during active disease and treatment-induced remission. 2014. 8(7): p. 1403-17.
349. Li, H.L., et al., Alteration of Gut Microbiota and Inflammatory Cytokine/Chemokine Profiles
in 5-Fluorouracil Induced Intestinal Mucositis. Front Cell Infect Microbiol, 2017. 7: p. 455.
350. Hamouda, N., et al., Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are
Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in
Mice. Basic Clin Pharmacol Toxicol, 2017. 121(3): p. 159-168.
351. Wexler, H.M., Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev,
2007. 20(4): p. 593-621.
352. Scanlan, P.D., F. Shanahan, and J.R. Marchesi, Culture-independent analysis of
desulfovibrios in the human distal colon of healthy, colorectal cancer and polypectomized
individuals. FEMS Microbiol Ecol, 2009. 69(2): p. 213-21.
353. Watanabe, Y., F. Nagai, and M. Morotomi, Characterization of Phascolarctobacterium
succinatutens sp. nov., an asaccharolytic, succinate-utilizing bacterium isolated from
human feces. Appl Environ Microbiol, 2012. 78(2): p. 511-8.
354. Bajer, L., et al., Distinct gut microbiota profiles in patients with primary sclerosing
cholangitis and ulcerative colitis. World J Gastroenterol, 2017. 23(25): p. 4548-4558.
355. Santos-Marcos, J.A., et al., Sex Differences in the Gut Microbiota as Potential
Determinants of Gender Predisposition to Disease. Mol Nutr Food Res, 2019: p. e1800870.
356. Shen, A., Clostridium difficile toxins: mediators of inflammation. J Innate Immun, 2012.
4(2): p. 149-58.
357. Larsen, J.M., The immune response to Prevotella bacteria in chronic inflammatory disease.
Immunology, 2017. 151(4): p. 363-374.
358. Schwabe, R.F. and C. Jobin, The microbiome and cancer. Nat Rev Cancer, 2013. 13(11): p.
800-12.
359. Alexander, J.L., et al., Gut microbiota modulation of chemotherapy efficacy and toxicity.
Nat Rev Gastroenterol Hepatol, 2017. 14(6): p. 356-365.
360. Collado, M.C., et al., The impact of probiotic on gut health. Curr Drug Metab, 2009. 10(1):
p. 68-78.
361. Konturek, P.C., et al., Emerging role of fecal microbiota therapy in the treatment of
gastrointestinal and extra-gastrointestinal diseases. J Physiol Pharmacol, 2015. 66(4): p.
483-91.
362. Molodecky, N.A., et al., Increasing incidence and prevalence of the inflammatory bowel
diseases with time, based on systematic review. Gastroenterology, 2012. 142(1): p. 46-54
e42; quiz e30.
363. Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86.
 References
296 
364. Brackmann, S., et al., Relationship between clinical parameters and the colitis-colorectal
cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel
disease. Scand J Gastroenterol, 2009. 44(1): p. 46-55.
365. Bashashati, M., et al., Cytokines and irritable bowel syndrome: where do we stand?
Cytokine, 2012. 57(2): p. 201-9.
366. Cho, J.H., The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev
Immunol, 2008. 8(6): p. 458-66.
367. Abraham, C. and J.H. Cho, Inflammatory bowel disease. N Engl J Med, 2009. 361(21): p.
2066-78.
368. Sands, B.E., From symptom to diagnosis: clinical distinctions among various forms of
intestinal inflammation. Gastroenterology, 2004. 126(6): p. 1518-32.
369. Nyuyki, K.D. and Q.J. Pittman, Toward a better understanding of the central consequences
of intestinal inflammation. Ann N Y Acad Sci, 2015. 1351: p. 149-54.
370. Zois, C.D., et al., Neurologic manifestations in inflammatory bowel diseases: current
knowledge and novel insights. J Crohns Colitis, 2010. 4(2): p. 115-24.
371. Engstrom, I., Mental health and psychological functioning in children and adolescents with
inflammatory bowel disease: a comparison with children having other chronic illnesses
and with healthy children. J Child Psychol Psychiatry, 1992. 33(3): p. 563-82.
372. Tribbick, D., et al., Prevalence of mental health disorders in inflammatory bowel disease:
an Australian outpatient cohort. Clin Exp Gastroenterol, 2015. 8: p. 197-204.
373. Keightley, P., et al., Gut feelings 2. Mind, mood and gut in inflammatory bowel disease:
approaches to psychiatric care. Australas Psychiatry, 2015. 23(4): p. 407-10.
374. Finnie, J.W., Neuroinflammation: beneficial and detrimental effects after traumatic brain
injury. Inflammopharmacology, 2013. 21(4): p. 309-20.
375. Shaftel, S.S., et al., Sustained hippocampal IL-1 beta overexpression mediates chronic
neuroinflammation and ameliorates Alzheimer plaque pathology. J Clin Invest, 2007.
117(6): p. 1595-604.
376. Kannampalli, P., et al., Analgesic effect of minocycline in rat model of inflammation-
induced visceral pain. Eur J Pharmacol, 2014. 727: p. 87-98.
377. Riazi, K., et al., Microglial activation and TNFalpha production mediate altered CNS
excitability following peripheral inflammation. Proc Natl Acad Sci U S A, 2008. 105(44): p.
17151-6.
378. Chartier, L.C., et al., Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of
Colitis-Associated Colorectal Cancer. Dig Dis Sci, 2018. 63(1): p. 135-145.
379. Ghaemi, R., et al., Emu Oil Prevents Bodyweight Loss in a Mouse Model of Chronic
Ulcerative Colitis. J Nutr Inter Metab, 2016. 4 (Supp): p. 6-47.
380. Reber, S.O., Stress and animal models of inflammatory bowel disease--an update on the
role of the hypothalamo-pituitary-adrenal axis. Psychoneuroendocrinology, 2012. 37(1):
p. 1-19.
381. Park, B.S. and J.O. Lee, Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp
Mol Med, 2013. 45: p. e66.
382. Bay-Richter, C., et al., Changes in behaviour and cytokine expression upon a peripheral
immune challenge. Behav Brain Res, 2011. 222(1): p. 193-9.
383. Bluthe, R.M., et al., Lipopolysaccharide induces sickness behaviour in rats by a vagal
mediated mechanism. C R Acad Sci III, 1994. 317(6): p. 499-503.
384. Lu, Y.C., W.C. Yeh, and P.S. Ohashi, LPS/TLR4 signal transduction pathway. Cytokine, 2008.
42(2): p. 145-151.
385. Leaphart, C.L., et al., A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis
by modulating intestinal injury and repair. J Immunol, 2007. 179(7): p. 4808-20.
386. Trudler, D., D. Farfara, and D. Frenkel, Toll-like receptors expression and signaling in glia




387. Wardill, H.R., et al., Toll-like receptor 4 signaling: a common biological mechanism of
regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal
toxicity. Cancer Treat Rev, 2015. 41(2): p. 122-8.
388. Kurtys, E., et al., Evaluating [(11)C]PBR28 PET for Monitoring Gut and Brain Inflammation
in a Rat Model of Chemically Induced Colitis. Mol Imaging Biol, 2017. 19(1): p. 68-76.
389. Chen, J., et al., Genesis of anxiety, depression, and ongoing abdominal discomfort in
ulcerative colitis-like colon inflammation. Am J Physiol Regul Integr Comp Physiol, 2015.
308(1): p. R18-27.
390. Gharedaghi, M.H., et al., Dinitrobenzene sulphonic acid-induced colitis impairs spatial
recognition memory in mice: roles of N-methyl D-aspartate receptors and nitric oxide.
Psychopharmacology (Berl), 2015. 232(16): p. 3081-90.
391. Rolan, P., M. Hutchinson, and K. Johnson, Ibudilast: a review of its pharmacology, efficacy
and safety in respiratory and neurological disease. Expert Opin Pharmacother, 2009.
10(17): p. 2897-904.
392. Johnston, I.N., et al., Ibudilast reduces oxaliplatin-induced tactile allodynia and cognitive
impairments in rats. Behav Brain Res, 2017. 334: p. 109-118.
393. Hong, J.Y., et al., Regional neuroplastic brain changes in patients with chronic
inflammatory and non-inflammatory visceral pain. PLoS One, 2014. 9(1): p. e84564.
394. Di Filippo, M., et al., Effects of central and peripheral inflammation on hippocampal
synaptic plasticity. Neurobiol Dis, 2013. 52: p. 229-36.
395. Correa, D.D. and L.M. Hess, Cognitive function and quality of life in ovarian cancer.
Gynecol Oncol, 2012. 124(3): p. 404-9.
396. Naidu, M.U., et al., Chemotherapy-induced and/or radiation therapy-induced oral
mucositis--complicating the treatment of cancer. Neoplasia, 2004. 6(5): p. 423-31.
397. Peterson, D.E., R.J. Bensadoun, and F. Roila, Management of oral and gastrointestinal
mucositis: ESMO Clinical Practice Guidelines. Ann Oncol, 2011. 22 Suppl 6: p. vi78-84.
398. Lalla, R.V., S.T. Sonis, and D.E. Peterson, Management of oral mucositis in patients who
have cancer. Dent Clin North Am, 2008. 52(1): p. 61-77, viii.
399. Vinay, D.S. and B.S. Kwon, Harnessing immune checkpoints for cancer therapy.
Immunotherapy, 2018. 10(14): p. 1265-1284.
400. Turner, M.C., et al., An overview of the association between allergy and cancer. Int J
Cancer, 2006. 118(12): p. 3124-32.
401. Cui, Y. and A.W. Hill, Atopy and Specific Cancer Sites: a Review of Epidemiological Studies.
Clin Rev Allergy Immunol, 2016. 51(3): p. 338-352.
402. Chu, K.M., C.H. Cho, and V.Y. Shin, Nicotine and gastrointestinal disorders: its role in
ulceration and cancer development. Curr Pharm Des, 2013. 19(1): p. 5-10.
403. Calle, E.E., et al., Overweight, obesity, and mortality from cancer in a prospectively studied
cohort of U.S. adults. N Engl J Med, 2003. 348(17): p. 1625-38.
404. Martin del Campo, A.F., et al., Effect of 12-hour infusion of naloxone on mood and
cognition in normal male volunteers. Biol Psychiatry, 1992. 32(4): p. 344-53.
405. Lai, J.S., et al., Evaluating the dimensionality of perceived cognitive function. J Pain
Symptom Manage, 2009. 37(6): p. 982-95.
406. Von Ah, D. and E.F. Tallman, Perceived Cognitive Function in Breast Cancer Survivors:
Evaluating Relationships With Objective Cognitive Performance and Other Symptoms
Using The Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog). J Pain
Symptom Manage, 2014.
407. Deprez, S., et al., Chemotherapy-induced structural changes in cerebral white matter and
its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain
Mapp, 2011. 32(3): p. 480-93.
408. Yellen, S.B., et al., Measuring fatigue and other anemia-related symptoms with the
Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom
Manage, 1997. 13(2): p. 63-74.
References
298 
409. Tchen, N., et al., Cognitive function, fatigue, and menopausal symptoms in women
receiving adjuvant chemotherapy for breast cancer. J Clin Oncol, 2003. 21(22): p. 4175-83.
410. Bulley, C., et al., A Morbidity Screening Tool for identifying fatigue, pain, upper limb
dysfunction and lymphedema after breast cancer treatment: a validity study. Eur J Oncol
Nurs, 2014. 18(2): p. 218-27.
411. Cueva, J.F., et al., Methylphenidate in the management of asthenia in breast cancer
patients treated with docetaxel: results of a pilot study. Invest New Drugs, 2012. 30(2): p.
688-94.
412. S.H., L. and L. P.F., eds. Manual for the Depression Anxiety Stress Scales. Second Edition
ed. 1993, Psychology Foundation: Sydney.
413. Khan, F., et al., Factors associated with long-term functional outcomes and psychological
sequelae in women after breast cancer. Breast, 2012. 21(3): p. 314-20.
414. Khan, F., et al., Multidisciplinary rehabilitation in women following breast cancer
treatment: a randomized controlled trial. J Rehabil Med, 2012. 44(9): p. 788-94.
415. Bender, C.M. and B.D. Thelen, Cancer and cognitive changes: the complexity of the
problem. Semin Oncol Nurs, 2013. 29(4): p. 232-7.
416. Moriarty, O. and D.P. Finn, Cognition and pain. Curr Opin Support Palliat Care, 2014. 8(2):
p. 130-6.
417. Moriarty, O., B.E. McGuire, and D.P. Finn, The effect of pain on cognitive function: a
review of clinical and preclinical research. Prog Neurobiol, 2011. 93(3): p. 385-404.
418. Melzack, R. and K.L. Casey, Sensory, motivation and central control determinants of pain:
a new conceptual model. The Skin Senses, ed. D. Kenshalo. 1968, Springfield, Illinois:
Thomas, C.C.
419. Munoz, M. and R. Esteve, Reports of memory functioning by patients with chronic pain.
Clin J Pain, 2005. 21(4): p. 287-91.
420. Oosterman, J.M., et al., Memory functions in chronic pain: examining contributions of
attention and age to test performance. Clin J Pain, 2011. 27(1): p. 70-5.
421. Villemure, C. and M.C. Bushnell, Cognitive modulation of pain: how do attention and
emotion influence pain processing? Pain, 2002. 95(3): p. 195-9.
422. Ford, G.K., et al., Investigating the effects of distracting stimuli on nociceptive behaviour
and associated alterations in brain monoamines in rats. Eur J Pain, 2008. 12(8): p. 970-9.
423. Cleeland, C.S., et al., Pain and its treatment in outpatients with metastatic cancer. N Engl J
Med, 1994. 330(9): p. 592-6.
424. Harrington, S., L. Gilchrist, and A. Sander, Breast Cancer EDGE Task Force Outcomes:
Clinical Measures of Pain. Rehabil Oncol, 2014. 32(1): p. 13-21.
425. Macdonald, L., et al., Long-term follow-up of breast cancer survivors with post-
mastectomy pain syndrome. Br J Cancer, 2005. 92(2): p. 225-30.
426. Stevens, C.W., et al., Pharmacological characterization of LPS and opioid interactions at
the toll-like receptor 4. Br J Pharmacol, 2013. 168(6): p. 1421-9.
427. Watkins, L.R., et al., The "toll" of opioid-induced glial activation: improving the clinical
efficacy of opioids by targeting glia. Trends Pharmacol Sci, 2009. 30(11): p. 581-91.
428. Deguine, J. and G.M. Barton, MyD88: a central player in innate immune signaling.
F1000Prime Rep, 2014. 6: p. 97.
429. Seminowicz, D.A. and K.D. Davis, A re-examination of pain-cognition interactions:
implications for neuroimaging. Pain, 2007. 130(1-2): p. 8-13.
430. Dick, B., C. Eccleston, and G. Crombez, Attentional functioning in fibromyalgia,
rheumatoid arthritis, and musculoskeletal pain patients. Arthritis Rheum, 2002. 47(6): p.
639-44.
431. Wiech, K., et al., Modulation of pain processing in hyperalgesia by cognitive demand.
Neuroimage, 2005. 27(1): p. 59-69.
432. Eccleston, C. and G. Crombez, Pain demands attention: a cognitive-affective model of the
interruptive function of pain. Psychol Bull, 1999. 125(3): p. 356-66.
 References 
299 
433. Baldo, B.A. and M. Pagani, Adverse events to nontargeted and targeted chemotherapeutic
agents: emphasis on hypersensitivity responses. Immunol Allergy Clin North Am, 2014.
34(3): p. 565-96, viii.
434. Markman, M., et al., Relationship between a history of systemic allergic reactions and risk
of subsequent carboplatin hypersensitivity. Gynecol Oncol, 2003. 89(3): p. 514-6.
435. Lee, S.Y., et al., Overcoming oxaliplatin hypersensitivity: different strategies are needed
according to the severity and previous exposure. Cancer Chemother Pharmacol, 2014.
73(5): p. 1021-9.
436. Roduit, C., et al., Development of atopic dermatitis according to age of onset and
association with early-life exposures. J Allergy Clin Immunol, 2012. 130(1): p. 130-6.e5.
437. Illi, S., et al., Protection from childhood asthma and allergy in Alpine farm environments-
the GABRIEL Advanced Studies. J Allergy Clin Immunol, 2012. 129(6): p. 1470-7.e6.
438. Bin, L., et al., Staphylococcus aureus alpha-toxin modulates skin host response to viral
infection. J Allergy Clin Immunol, 2012. 130(3): p. 683-691.e2.
439. Tang, T.S., T. Bieber, and H.C. Williams, Does "autoreactivity" play a role in atopic
dermatitis? J Allergy Clin Immunol, 2012. 129(5): p. 1209-1215.e2.
440. Zhou, L., et al., Food allergy induces alteration in brain inflammatory status and cognitive
impairments. Behav Brain Res, 2018.
441. Irani, F., et al., Is asthma associated with cognitive impairments? A meta-analytic review. J
Clin Exp Neuropsychol, 2017. 39(10): p. 965-978.
442. Bischoff, S.C., J.H. Mayer, and M.P. Manns, Allergy and the gut. Int Arch Allergy Immunol,
2000. 121(4): p. 270-83.
443. Choung, R.S. and N.J. Talley, Food Allergy and Intolerance in IBS. Gastroenterol Hepatol (N
Y), 2006. 2(10): p. 756-760.
444. Huston, D.P., The biology of the immune system. Jama, 1997. 278(22): p. 1804-14.
445. Atkinson, J.C., A. O'Connell, and D. Aframian, Oral manifestations of primary
immunological diseases. J Am Dent Assoc, 2000. 131(3): p. 345-56.
446. Kabata, H. and D. Artis, Neuro-immune crosstalk and allergic inflammation. J Clin Invest,
2019. 130.
447. Voisin, T., A. Bouvier, and I.M. Chiu, Neuro-immune interactions in allergic diseases: novel
targets for therapeutics. Int Immunol, 2017. 29(6): p. 247-261.
448. Cevikbas, F., et al., Neuroimmune interactions in allergic skin diseases. Curr Opin Allergy
Clin Immunol, 2007. 7(5): p. 365-73.
449. Veres, T.Z., S. Rochlitzer, and A. Braun, The role of neuro-immune cross-talk in the
regulation of inflammation and remodelling in asthma. Pharmacol Ther, 2009. 122(2): p.
203-14.
450. Dhillon, H.M., et al., Perceived cognitive impairment in people with colorectal cancer who
do and do not receive chemotherapy. J Cancer Surviv, 2018. 12(2): p. 178-185.
451. Jacobs, S.R., et al., Evaluation of the functional assessment of cancer therapy cognitive
scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage, 2007.
33(1): p. 13-23.
452. Castellon, S.A., et al., Neurocognitive performance in breast cancer survivors exposed to
adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol, 2004. 26(7): p. 955-69.
453. Jenkins, V., et al., A 3-year prospective study of the effects of adjuvant treatments on
cognition in women with early stage breast cancer. Br J Cancer, 2006. 94(6): p. 828-34.
454. Bender, C.M., et al., Cognitive impairment associated with adjuvant therapy in breast
cancer. Psychooncology, 2006. 15(5): p. 422-30.
455. Poppelreuter, M., et al., Cognitive dysfunction and subjective complaints of cancer




456. Wagner, L., et al., Measuring patient self-reported cognitive function: development of the
functional assessment of cancer therapy-cognitive function instrument J Supp Oncol,
2009. 7: p. W32-W39.
457. Ancoli-Israel, S., P.J. Moore, and V. Jones, The relationship between fatigue and sleep in
cancer patients: a review. Eur J Cancer Care (Engl), 2001. 10(4): p. 245-55.
458. Jansen, C.E., Cognitive changes associated with cancer and cancer therapy: patient
assessment and education. Semin Oncol Nurs, 2013. 29(4): p. 270-9.
459. Ouimet, L.A., et al., Investigation of a neuropsychological screen for chemo-fog. Oncology
Reviews, 2011. 5(4): p. 205-213.
460. Hutchinson, A.D., et al., Objective and subjective cognitive impairment following
chemotherapy for cancer: a systematic review. Cancer Treat Rev, 2012. 38(7): p. 926-34.
461. Vardy, J., et al., Assessing cognitive function in cancer patients. Support Care Cancer,
2006. 14(11): p. 1111-8.
462. Liu, H., et al., Aging of cerebral white matter. Ageing Res Rev, 2017. 34: p. 64-76.
463. Salat, D.H., et al., Thinning of the cerebral cortex in aging. Cereb Cortex, 2004. 14(7): p.
721-30.
464. Driscoll, I., et al., Longitudinal pattern of regional brain volume change differentiates
normal aging from MCI. Neurology, 2009. 72(22): p. 1906-13.
465. Persson, J., et al., Structure-function correlates of cognitive decline in aging. Cereb Cortex,
2006. 16(7): p. 907-15.
466. Vega, J.N., J. Dumas, and P.A. Newhouse, Self-reported chemotherapy-related cognitive
impairment compared with cognitive complaints following menopause. Psychooncology,
2018. 27(9): p. 2198-2205.
467. Hodgson, K.D., et al., A meta-analysis of the effects of chemotherapy on cognition in
patients with cancer. Cancer Treat Rev, 2013. 39(3): p. 297-304.
468. Cheung, Y.T., et al., Association of proinflammatory cytokines and chemotherapy-
associated cognitive impairment in breast cancer patients: a multi-centered, prospective,
cohort study. Ann Oncol, 2015. 26(7): p. 1446-51.
469. Whitney, R.L., et al., Predictors of financial difficulties and work modifications among
cancer survivors in the United States. J Cancer Surviv, 2016. 10(2): p. 241-50.
470. Basbaum, A.I., et al., Cellular and molecular mechanisms of pain. Cell, 2009. 139(2): p.
267-84.
471. Ossipov, M.H., G.O. Dussor, and F. Porreca, Central modulation of pain. J Clin Invest, 2010.
120(11): p. 3779-87.
472. Latremoliere, A. and C.J. Woolf, Central sensitization: a generator of pain hypersensitivity
by central neural plasticity. J Pain, 2009. 10(9): p. 895-926.
473. Nicotra, L., et al., Toll-like receptors in chronic pain. Exp Neurol, 2012. 234(2): p. 316-29.
474. Ransohoff, R.M. and V.H. Perry, Microglial physiology: unique stimuli, specialized
responses. Annu Rev Immunol, 2009. 27: p. 119-45.
475. Gwak, Y.S., et al., Spatial and temporal activation of spinal glial cells: role of gliopathy in
central neuropathic pain following spinal cord injury in rats. Exp Neurol, 2012. 234(2): p.
362-72.
476. Ji, R.R., T. Berta, and M. Nedergaard, Glia and pain: is chronic pain a gliopathy? Pain,
2013. 154 Suppl 1: p. S10-28.
477. Suter, M.R., et al., Large A-fiber activity is required for microglial proliferation and p38
MAPK activation in the spinal cord: different effects of resiniferatoxin and bupivacaine on
spinal microglial changes after spared nerve injury. Mol Pain, 2009. 5: p. 53.
478. Kawasaki, Y., et al., Distinct roles of matrix metalloproteases in the early- and late-phase
development of neuropathic pain. Nat Med, 2008. 14(3): p. 331-6.
479. Calvo, M., et al., Neuregulin-ErbB signaling promotes microglial proliferation and
chemotaxis contributing to microgliosis and pain after peripheral nerve injury. J Neurosci,
2010. 30(15): p. 5437-50.
 References
301 
480. Tanga, F.Y., V. Raghavendra, and J.A. DeLeo, Quantitative real-time RT-PCR assessment of
spinal microglial and astrocytic activation markers in a rat model of neuropathic pain.
Neurochem Int, 2004. 45(2-3): p. 397-407.
481. Zhang, J. and Y. De Koninck, Spatial and temporal relationship between monocyte
chemoattractant protein-1 expression and spinal glial activation following peripheral
nerve injury. J Neurochem, 2006. 97(3): p. 772-83.
482. Christianson, C.A., et al., Characterization of the acute and persistent pain state present in
K/BxN serum transfer arthritis. Pain, 2010. 151(2): p. 394-403.
483. Liddelow, S.A., et al., Neurotoxic reactive astrocytes are induced by activated microglia.
Nature, 2017. 541(7638): p. 481-487.
484. Hains, L.E., et al., Pain intensity and duration can be enhanced by prior challenge: initial
evidence suggestive of a role of microglial priming. J Pain, 2010. 11(10): p. 1004-14.
485. Zhang, R.X., et al., Spinal glial activation in a new rat model of bone cancer pain produced
by prostate cancer cell inoculation of the tibia. Pain, 2005. 118(1-2): p. 125-36.
486. Shen, W., et al., CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-
mediated neuronal sensitization and glial activation in rat spinal cord. J
Neuroinflammation, 2014. 11: p. 75.
487. Ducourneau, V.R., et al., Cancer pain is not necessarily correlated with spinal
overexpression of reactive glia markers. Pain, 2014. 155(2): p. 275-91.
488. Currie, G.L., et al., Using animal models to understand cancer pain in humans. Curr Pain
Headache Rep, 2014. 18(6): p. 423.
489. Lehnardt, S., et al., Activation of innate immunity in the CNS triggers neurodegeneration
through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A, 2003.
100(14): p. 8514-9.
490. Jou, I., et al., Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am J
Pathol, 2006. 168(5): p. 1619-30.
491. Frank, M., et al., TLR signaling modulates side effects of anticancer therapy in the small
intestine. J Immunol, 2015. 194(4): p. 1983-95.
492. Coller, J.K., et al., Predictive model for risk of severe gastrointestinal toxicity following
chemotherapy using patient immune genetics and type of cancer: a pilot study. Support
Care Cancer, 2015. 23(5): p. 1233-6.
493. Costa, D.V.S., et al., 5-Fluorouracil Induces Enteric Neuron Death and Glial Activation
During Intestinal Mucositis via a S100B-RAGE-NFkappaB-Dependent Pathway. Sci Rep,
2019. 9(1): p. 665.
494. Aprile, G., et al., Application of distance matrices to define associations between acute
toxicities in colorectal cancer patients receiving chemotherapy. Cancer, 2008. 112(2): p.
284-92.
495. Adamsky, A. and I. Goshen, Astrocytes in Memory Function: Pioneering Findings and
Future Directions. Neuroscience, 2018. 370: p. 14-26.
496. Ota, Y., A.T. Zanetti, and R.M. Hallock, The role of astrocytes in the regulation of synaptic
plasticity and memory formation. Neural Plast, 2013. 2013: p. 185463.
497. Santello, M., N. Toni, and A. Volterra, Astrocyte function from information processing to
cognition and cognitive impairment. Nat Neurosci, 2019. 22(2): p. 154-166.
498. Hussaini, S.M.Q. and M.H. Jang, New Roles for Old Glue: Astrocyte Function in Synaptic
Plasticity and Neurological Disorders. Int Neurourol J, 2018. 22(Suppl 3): p. S106-114.
499. Santello, M., C. Cali, and P. Bezzi, Gliotransmission and the tripartite synapse. Adv Exp
Med Biol, 2012. 970: p. 307-31.
500. Haber, M., L. Zhou, and K.K. Murai, Cooperative astrocyte and dendritic spine dynamics at
hippocampal excitatory synapses. J Neurosci, 2006. 26(35): p. 8881-91.
501. Bechade, C., Y. Cantaut-Belarif, and A. Bessis, Microglial control of neuronal activity. Front
Cell Neurosci, 2013. 7: p. 32.
 References
302 
502. Bessis, A., et al., Microglial control of neuronal death and synaptic properties. Glia, 2007.
55(3): p. 233-8.
503. Ji, K., J. Miyauchi, and S.E. Tsirka, Microglia: an active player in the regulation of synaptic
activity. Neural Plast, 2013. 2013: p. 627325.
504. Sierra, A., et al., Microglia shape adult hippocampal neurogenesis through apoptosis-
coupled phagocytosis. Cell Stem Cell, 2010. 7(4): p. 483-95.
505. Ekdahl, C.T., Z. Kokaia, and O. Lindvall, Brain inflammation and adult neurogenesis: the
dual role of microglia. Neuroscience, 2009. 158(3): p. 1021-9.
506. Hanisch, U.K. and H. Kettenmann, Microglia: active sensor and versatile effector cells in
the normal and pathologic brain. Nat Neurosci, 2007. 10(11): p. 1387-94.
507. Ekdahl, C.T., et al., Inflammation is detrimental for neurogenesis in adult brain. Proc Natl
Acad Sci U S A, 2003. 100(23): p. 13632-7.
508. Halassa, M.M., T. Fellin, and P.G. Haydon, The tripartite synapse: roles for gliotransmission
in health and disease. Trends Mol Med, 2007. 13(2): p. 54-63.
509. Colonna, M. and O. Butovsky, Microglia Function in the Central Nervous System During
Health and Neurodegeneration. Annu Rev Immunol, 2017. 35: p. 441-468.
510. Du, L., et al., Role of Microglia in Neurological Disorders and Their Potentials as a
Therapeutic Target. Mol Neurobiol, 2017. 54(10): p. 7567-7584.
511. Rivest, S., Regulation of innate immune responses in the brain. Nat Rev Immunol, 2009.
9(6): p. 429-39.
512. Chrousos, G.P. and P.W. Gold, The concepts of stress and stress system disorders.
Overview of physical and behavioral homeostasis. Jama, 1992. 267(9): p. 1244-52.
513. Chrousos, G.P., Regulation and dysregulation of the hypothalamic-pituitary-adrenal axis.
The corticotropin-releasing hormone perspective. Endocrinol Metab Clin North Am, 1992.
21(4): p. 833-58.
514. Akira, S., et al., Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and
TNF). Faseb j, 1990. 4(11): p. 2860-7.
515. Turnbull, A.V. and C.L. Rivier, Regulation of the hypothalamic-pituitary-adrenal axis by
cytokines: actions and mechanisms of action. Physiol Rev, 1999. 79(1): p. 1-71.
516. Singh, U.P., et al., Chemokine and cytokine levels in inflammatory bowel disease patients.
Cytokine, 2016. 77: p. 44-9.
517. Weber, A., P. Wasiliew, and M. Kracht, Interleukin-1 (IL-1) pathway. Sci Signal, 2010.
3(105): p. cm1.
518. Jura, J., et al., Identification of interleukin-1 and interleukin-6-responsive genes in human
monocyte-derived macrophages using microarrays. Biochim Biophys Acta, 2008. 1779(6-
7): p. 383-9.
519. Bandman, O., et al., Complexity of inflammatory responses in endothelial cells and
vascular smooth muscle cells determined by microarray analysis. Ann N Y Acad Sci, 2002.
975: p. 77-90.
520. Gaestel, M., A. Kotlyarov, and M. Kracht, Targeting innate immunity protein kinase
signalling in inflammation. Nat Rev Drug Discov, 2009. 8(6): p. 480-99.
521. Henry, C.J., et al., Peripheral lipopolysaccharide (LPS) challenge promotes microglial
hyperactivity in aged mice that is associated with exaggerated induction of both pro-
inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun, 2009.
23(3): p. 309-17.
522. Gui, W.S., et al., Interleukin-1beta overproduction is a common cause for neuropathic
pain, memory deficit, and depression following peripheral nerve injury in rodents. Mol
Pain, 2016. 12.
523. Alyu, F. and M. Dikmen, Inflammatory aspects of epileptogenesis: contribution of
molecular inflammatory mechanisms. Acta Neuropsychiatr, 2017. 29(1): p. 1-16.
524. Stojakovic, A., et al., Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and
Decreased Voluntary Movement. Mol Neurobiol, 2017. 54(6): p. 4486-4495.
 References
303 
525. Norden, D.M., et al., Sequential activation of microglia and astrocyte cytokine expression
precedes increased Iba-1 or GFAP immunoreactivity following systemic immune challenge.
Glia, 2016. 64(2): p. 300-16.
526. Giulian, D., et al., Interleukin-1 injected into mammalian brain stimulates astrogliosis and
neovascularization. J Neurosci, 1988. 8(7): p. 2485-90.
527. John, G.R., et al., IL-1-regulated responses in astrocytes: relevance to injury and recovery.
Glia, 2005. 49(2): p. 161-76.
528. Mason, J.L., et al., Interleukin-1beta promotes repair of the CNS. J Neurosci, 2001. 21(18):
p. 7046-52.
529. John, G.R., et al., IL-1beta differentially regulates calcium wave propagation between
primary human fetal astrocytes via pathways involving P2 receptors and gap junction
channels. Proc Natl Acad Sci U S A, 1999. 96(20): p. 11613-8.
530. John, G.R., et al., Extracellular nucleotides differentially regulate interleukin-1beta
signaling in primary human astrocytes: implications for inflammatory gene expression. J
Neurosci, 2001. 21(12): p. 4134-42.
531. Meeuwsen, S., et al., Cytokine, chemokine and growth factor gene profiling of cultured
human astrocytes after exposure to proinflammatory stimuli. Glia, 2003. 43(3): p. 243-53.
532. van Vliet, M.J., et al., Chemotherapy treatment in pediatric patients with acute myeloid
leukemia receiving antimicrobial prophylaxis leads to a relative increase of colonization
with potentially pathogenic bacteria in the gut. Clin Infect Dis, 2009. 49(2): p. 262-70.
533. Mu, C., Y. Yang, and W. Zhu, Crosstalk Between The Immune Receptors and Gut
Microbiota. Curr Protein Pept Sci, 2015. 16(7): p. 622-31.
534. de Kivit, S., et al., Regulation of Intestinal Immune Responses through TLR Activation:
Implications for Pro- and Prebiotics. Front Immunol, 2014. 5: p. 60.
535. Ribeiro, R.A., et al., Irinotecan- and 5-fluorouracil-induced intestinal mucositis: insights
into pathogenesis and therapeutic perspectives. Cancer Chemother Pharmacol, 2016.
78(5): p. 881-893.
536. Malhotra, K., et al., Minocycline for acute stroke treatment: a systematic review and
meta-analysis of randomized clinical trials. J Neurol, 2018. 265(8): p. 1871-1879.
537. Soczynska, J.K., et al., A pilot, open-label, 8-week study evaluating the efficacy, safety and
tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar
Disord, 2017. 19(3): p. 198-213.
538. Zabad, R.K., et al., The clinical response to minocycline in multiple sclerosis is accompanied
by beneficial immune changes: a pilot study. Mult Scler, 2007. 13(4): p. 517-26.
539. Jin, W.N., et al., Depletion of microglia exacerbates postischemic inflammation and brain
injury. J Cereb Blood Flow Metab, 2017. 37(6): p. 2224-2236.
540. Ducruet, A.F., et al., Paradoxical exacerbation of neuronal injury in reperfused stroke
despite improved blood flow and reduced inflammation in early growth response-1 gene-
deleted mice. Neurol Res, 2011. 33(7): p. 717-25.
541. Hou, Y., et al., Minocycline protects against lipopolysaccharide-induced cognitive
impairment in mice. Psychopharmacology (Berl), 2016. 233(5): p. 905-16.
542. Choi, Y., et al., Minocycline attenuates neuronal cell death and improves cognitive
impairment in Alzheimer's disease models. Neuropsychopharmacology, 2007. 32(11): p.
2393-404.
543. Ray, L.A., et al., Opportunities for the development of neuroimmune therapies in addiction.
Int Rev Neurobiol, 2014. 118: p. 381-401.
544. Dean, O.M., et al., Minocycline: therapeutic potential in psychiatry. CNS Drugs, 2012.
26(5): p. 391-401.
545. Kohman, R.A., et al., Effects of minocycline on spatial learning, hippocampal neurogenesis
and microglia in aged and adult mice. Behav Brain Res, 2013. 242: p. 17-24.
546. Tanaka, S., et al., Lipopolysaccharide-induced microglial activation induces learning and
memory deficits without neuronal cell death in rats. J Neurosci Res, 2006. 83(4): p. 557-66.
 References
304 
547. Skaper, S.D., L. Facci, and P. Giusti, Neuroinflammation, microglia and mast cells in the
pathophysiology of neurocognitive disorders: a review. CNS Neurol Disord Drug Targets,
2014. 13(10): p. 1654-66.
548. Goshen, I., et al., A dual role for interleukin-1 in hippocampal-dependent memory
processes. Psychoneuroendocrinology, 2007. 32(8-10): p. 1106-15.
549. Wood, L.J. and K. Weymann, Inflammation and neural signaling: etiologic mechanisms of
the cancer treatment-related symptom cluster. Curr Opin Support Palliat Care, 2013. 7(1):
p. 54-9.
550. WHO Guidelines Approved by the Guidelines Review Committee, in WHO Guidelines for
the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and
Adolescents. 2018, World Health Organization
(c) World Health Organization 2018.: Geneva.
551. Corli, O., et al., THE BURDEN OF OPIOID ADVERSE EVENTS AND THE INFLUENCE ON
CANCER PATIENTS' SYMPTOMATOLOGY. J Pain Symptom Manage, 2019.
552. Vlad, S.C., et al., Protective effects of NSAIDs on the development of Alzheimer disease.
Neurology, 2008. 70(19): p. 1672-7.
553. Chan, R.J., et al., Systematic review of pharmacologic and non-pharmacologic
interventions to manage cognitive alterations after chemotherapy for breast cancer. Eur J
Cancer, 2015. 51(4): p. 437-50.
554. Von Ah, D., et al., Advanced cognitive training for breast cancer survivors: a randomized
controlled trial. Breast Cancer Res Treat, 2012. 135(3): p. 799-809.
555. Kesler, S., et al., Cognitive training for improving executive function in chemotherapy-
treated breast cancer survivors. Clin Breast Cancer, 2013. 13(4): p. 299-306.
556. Bray, VJ., et al., Evaluation of a Web-Based Cognitive Rehabilitation Program in Cancer
Survivors Reporting Cognitive Symptoms After Chemotherapy. J Clin Oncol, 2017. 35(2)
557. Wefel, J.S., et al., International Cognition and Cancer Task Force recommendations to
harmonise studies of cognitive function in patients with cancer. Lancet Oncol, 2011.
12(7): 703-8.
558. Cammisuli, D.M., et al., Aerobic exercise effects upon cognition in Mild Cognitive
Impairment: A systematic review of randomized controlled trials. Arch Ital Biol, 2017.
155(1-2): p. 54-62.
559. Sandroff, B.M., Exercise and cognition in multiple sclerosis: The importance of acute
exercise for developing better interventions. Neurosci Biobehav Rev, 2015. 59: p. 173-83.
560. Hotting, K. and B. Roder, Beneficial effects of physical exercise on neuroplasticity and
cognition. Neurosci Biobehav Rev, 2013. 37(9 Pt B): p. 2243-57.
561. Spielman, L.J., J.P. Little, and A. Klegeris, Physical activity and exercise attenuate
neuroinflammation in neurological diseases. Brain Res Bull, 2016. 125: p. 19-29.
562. Almeida, C., et al., Exercise therapy normalizes BDNF upregulation and glial hyperactivity




 Appendix One 
306 
 Appendix One 
307 
 Appendix One 
308 
 Appendix One 
309 
 Appendix One 
310 
 Appendix One 
311 
 Appendix One 
312 





 Appendix Two 
315 
 Appendix Two 
316 
 Appendix Two 
317 
 Appendix Two 
318 
 Appendix Two 
319 
 Appendix Two 
320 
 Appendix Two 
321 
 Appendix Two 
322 
 Appendix Two 
323 
 Appendix Two 
324 
 Appendix Two 
325 
 Appendix Two 
326 
 Appendix Two 
327 







Welcome to My Survey 
Thank you for participating in our survey. Your feedback is important.
Thank you for choosing to participate in the study titled, "Understanding the side-effects of chemotherapy: a cross-sectional 
correlational study of gastrointestinal symptoms and cognitive impairment in an Australian breast cancer cohort" being 
undertaken by The University of Adelaide. 
By now, you will have received an email from the Breast Cancer Network Australia detailing information about the study, 
including several attachments:
1. Participant Information Sheet,
2. Inclusion and Exclusion Check list,
3. Contacts for Information on Project and Complaints Procedure documents and
4. A consent form.
From this information you will understand that this is a retrospective study which is strictly voluntary. The questionnaire 
approach asks you to detail some of the side-effects you may have experienced when you were undergoing anti-cancer 
treatment. 
If you are reading this, then you have selected the on line option. You will not need to sign and return the consent form to the 
researchers alternatively, your consent will be given at the bottom of this page in the form of checking the "Yes, I give consent" 
box.
If at any time, you should feel distressed and alone, please don’t hesitate to call the Cancer Council on 13 11 20 for 
support, or alternatively you might prefer to contact Lifeline on 13 11 14.
If, at any time throughout this study, you wish to withdraw from the study, please see the ‘Contacts for Information on Project 
and
Complaints Procedure’ document. You may also choose to withdraw from the study at any time, without notifying the 
researchers.
Once again, the researchers thank you for your time and willingness to help us understand more about the side-effects of anti-
cancer treatments. Hopefully, one day our research will lead to the development of more targeted therapies that reduce the 
negative effects of anti-cancer treatments and thus, improve the quality of life of cancer patients.
1. By checking the box below, you are willing and volunteering to participate in this survey,
thereby giving consent for the investigators of this study to use your answers in this study.
Your answers will remain entirely anonymous. If you do not wish to participate, please do not
complete the survey.
Yes, I give consent
No, I don't give consent
Understanding the side-effects of chemotherapy: a cross-
sectional correlational study of gastrointestinal symptoms and
cognitive impairment in an Australian breast cancer cohort
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impairment in an Australian breast cancer cohort
Demographic information 





3. What is your gender?
Female
Male





In a domestic partnership or civil union
Single, but cohabiting with a significant other
Single, never married
5. Which of the following categories best describes your employment status?
Employed, working full-time
Employed, working part-time
Not employed, looking for work
Not employed, NOT looking for work
Retired
Disabled, not able to work
6. Please specify your occupation (or previous occupation if retired or not working)
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7. What is the highest level of education you have completed?
8. Please specify completed course(s) and/or degree(s)
Course(s)
Degree(s)





Not at all important
10. In a typical week, how many days do you exercise?
I don't regularly exercise
Once a week
2 to 4 days a week
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Questions about your medical history, including your cancer and treatment 
11. Please indicate your primary breast cancer diagnosis.
Ductal carcinoma in situ
Lobular carcinoma in situ
Paget’s disease of the nipple
Inflammatory breast cancer
Locally advanced breast cancer
Early breast cancer
Secondary breast cancer
12. Please enter the date of your diagnosis.
DD MM YYYY
Date / Time 
13. Please indicate your treatment type(s). More than one option may be selected.
14. Please indicate your total length of treatment time.
Less than 6 months
Less than 12 months
More than 1 year
More than 2 years 
15. Please indicate the time you have spent in remission (a decrease in or disappearance of signs
and symptoms of cancer).
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Less than 1 year
Less than 2 years
More than 2 years
16. Did your cancer diagnosis and/or treatment prevent you from working/studying?
17. Please indicate the most suitable reasons why you could no longer work. You may select more
than one option.
18. Did your cancer diagnosis and treatment regime prevent you from your normal daily activities
(other than work which was previously specified)?
If yes, please detail timeframe 
Yes
No
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The following questions are regarding pain. 
Pain is defined by the International Association for the Study of Pain as “an 
unpleasant sensory and emotional experience in association with actual or 
potential tissue damage, or described in terms of such damage”.
19. Prior to your cancer diagnosis, how often did you experience pain?
20. After your cancer diagnosis and treatment commencement, did you notice an increase in your




A couple of times a week
3-4  times a week
Once a week 
Once a fortnight 
Once a month 
Rarely 
Comment (please specify pain types), e.g. neck, headache, knee, etc. 
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21. The following are a list of “habits” that may influence pain. Please indicate the answers that
most accurately reflect your use.
Currently, yes Previously, yes Previously, no 
   Dieting 
22. Stressors. Please rate your level of stress in relation to the following areas:









Other (please specify) 
Currently, no 
Persistent stress Overwhelming stress 





Understanding the side-effects of chemotherapy: a cross-sectional 
correlational study of gastrointestinal symptoms and cognitive 
impairment in an Australian breast cancer cohort
Cognition 
23. Did you experience changes in your cognition prior to cancer diagnosis?
24. Did you notice any changes in your cognitive ability after your cancer diagnosis?
Yes
No
25. At what time-point did you notice changes in your cognitive ability?
After cancer diagnosis but before treatment
After treatment  
After treatment  








28. Did you feel your cognitive changes were more noticeable after each chemotherapy and/or
radiation treatment session?
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29. Have you ever noticed your cognitive impairments improving? If so, please detail when?
30. Do you feel as if your cognitive ability has returned to how it was previous to your cancer
diagnosis?
Please comment. 
Comments (please specify) 
Yes
No
Comments (please specify) 
Yes 
No 
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Gastrointestinal concerns 
31. Did you experience any gastrointestinal upsets throughout your treatment?
Yes
No
32. Please indicate your main gastrointestinal complaints.
   Pain 
33. Did you consult your doctor?
Yes
No
34. Did your doctor provide you with any pain relief or coping strategies? If so, please detail?












If yes, please detail
All the time Frequently Sometimes Not very often Not at all 
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Allergies and other medications 
37. Are you susceptible to allergies? If so, please specify what triggers your allergies (e.g.
penicillin, codeine, pollen, animals, hay, spring time, etc.)?
38. Please specify when your allergies are most severe.
39. Do you take any medication to relieve your allergies?
40. Are you on any other regular medications or herbal remedies (e.g. hormone therapy, St. John’s
Wort, pain medication like ibuprofen, aspirin, etc.)?
Other (please specify) 
Yes
No
Other (please comment) 
All year
Spring time
Upon contact with triggers (e.g. patting a cat)
Comment (please specify medication and if it is effective) 
Yes
No
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Depression, anxiety and stress scale 
41. Please read each statement and check the box which indicates how much the statement applied
to you during your anti-cancer treatment. There are no right or wrong answers. Do not spend
too much time on any statement.
Did not apply to me all
Applied to me to some 
degree, or some of the
time
Applied to me a 
considerable degree
Applied to me 
very much, or most 
of the time
I found myself getting upset by quite 
trivial things
I was aware of dryness of my mouth 
I couldn't seem to experience any positive 
feeling at all
I had a feeling of shakiness 
(e.g., legs going to give way)
 I found it difficult to relax 
I found myself in situations that made me so 
anxious I was most relieved when they ended
I felt that I had nothing to look forward to 
I found myself getting upset rather easily
I experienced breathing difficulty (e.g., 
excessively rapid breathing, 
breathlessness in the absence of physical
exertion)
I just couldn't seem to get 
going 
I tended to over-react to 
situations 
I felt that I was using a lot of 
nervous energy 
I felt sad and depressed 
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I perspired noticeably (e.g., hands 
sweaty) in the absence of high 
temperatures or physical exertion
I was aware of the action of my heart in 
the absence of physical exertion (e.g., 
sense of heart rate increase, heart 
missing a beat)
I found it hard to calm down after something 
upset me
I feared that I would be "thrown" by 
some trivial but unfamiliar task 
I found myself getting 
impatient when I was delayed 
in any way (e.g., lifts, traffic 
lights, being kept waiting) 
I had a feeling of faintness 
I felt that I had lost interest in 
just about everything 
I felt I wasn't worth much as a 
person 
I felt that I was rather touchy 
Applied to me a  
considerable degree
I felt scared without any good 
reason 
I felt that life wasn't worthwhile 
I found it hard to wind down 
I had difficulty in swallowing 
I couldn't seem to get any 
enjoyment out of the things I 
did 
I felt down-hearted and blue 
I found that I was very irritable 
I felt I was close to panic 
Applied to me 
very much, or 
most of the time
Applied to me to 
some degree, or 
some of the time
Did not apply to me at 
all
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I was unable to become enthusiastic about 
anything
I found it difficult to tolerate interruptions 
to what I was doing
I felt I was pretty worthless 
I was intolerant of anything that kept me 
from getting on with what I was doing 
I felt terrified 
I could see nothing in the future to be 
hopeful about
I experienced trembling (e.g., in the hands)
I found it difficult to work up the initiative 
to do things
I felt that life was meaningless
I found myself getting agitated
I was worried about situations
in which I might panic
and make a fool of myself
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PERCEIVED COGNITIVE IMPAIRMENTS
42. Below is a list of statements that other people with your condition have said are important.
Please check one number per line to indicate the response which would most accurately describe 
how you felt during your anti-cancer treatment. 
Never About once a week
Two to three times a
week Nearly every day  Several times a day
I have had trouble forming 
thoughts
I have had trouble remembering 
where I put things, like my keys 
or my wallet
I have had trouble remembering 
new information, like phone 
numbers or simple instructions
I have had trouble recalling the
I have had trouble finding the 
right word(s) to express myself
My thinking has been 
slow 
I have had trouble 
concentrating 
I have had trouble 
finding my way to a 
familiar place 
name of something to someone
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Never About once a week Two to three 
times a week 
Nearly every 
day 
Several times a day
I have had trouble saying what 
I mean in conversations with others
I have walked into a room and 
forgotten what I meant to get or do 
there
I have had to work really hard to  
pay attention or I would make a 
mistake 
I have forgotten names of people 
soon after being introduced
My reactions in everyday  
situations have been slow 
I have had to work harder than 
usual to keep track of what I was 
doing
My thinking has been slower than 
usual 
I have had to work harder than 
usual to express myself clearly
I have had to use written lists more  
often than usual so I would not 
forget things
I have trouble keeping track of what 
I am doing if I am interrupted
I have trouble shifting back and 
forth between different activities 
that require thinking
I have used the wrong word 
when I referred to an object
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COMMENTS FROM OTHERS
43. Please check one number per line to indicate the response which would most accurately
describe how you felt during your anti-cancer treatment.
Other people have told me I 
seemed to have trouble 
remembering information
Other people have told me I 
seemed to have trouble 
speaking clearly
Other people have told me I 
seemed to have trouble thinking 
clearly
Other people have told me I 
seemed confused 
Never About once a week Two to three 
times a week 
Nearly every 
day 
Several times a day
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FACT-Cognitive function (Version 3) 
PERCEIVED COGNITIVE ABILITIES
44. Please check one number per line to indicate the response which would most accurately
describe how you felt during your anti-cancer treatment.
Not at all A little bit Somewhat Quite a bit Very much
I have been able to concentrate
I have been able to bring to 
mind words that I wanted to use 
while  talking to someone
I have been able to remember 
things, like where I left my keys or 
wallet
I have been able to remember  to 
do things, like take medicine or 
buy something I needed
I am able to pay attention and keep 
track of what I am doing without 
extra effort
I am able to keep track of what 
I am doing, even if I am interrupted
My mind is as sharp as it
has always been
My memory is as good
as it has always been
I am able to shift back
and forth between two
activities that require
thinking
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IMPACT ON QUALITY OF LIFE
45. Please check one number per line to indicate the response which would most accurately
describe how you felt during your anti-cancer treatment.
These problems have interfered 
with my ability to do things I 
enjoy
These problems have interfered 
with the quality of my life  
46. Below is a list of statements that other people with your condition have said are important.
Please check one number per line to indicate the response which would most accurately describe
how you felt during your anti-cancer treatment.
Not at all SomewhatA little bit Quite a bit Very much
I feel fatigued 
Understanding the side-effects of chemotherapy: a cross-sectional 
correlational study of gastrointestinal symptoms and cognitive 
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FACIT-Fatigue Scale (Version 4) 
Not at all A little bit Somewhat Quite a bit Very much
I have been upset 
about these problems
These problems have
interfered with my ability
to work
Appendix Three
 Appendix Three 
350 
PHYSICAL WELL BEING
47. Below is a list of statements that other people with your condition have said are important.
Please check one number per line to indicate the response which would most accurately describe
how you felt during your anti-cancer treatment.
Not at all A little bit Somewhat Quite a bit Very much
I have a lack of energy 
I have nausea 
Because of my physical 
condition, I have trouble 
meeting the needs of my 
family
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SOCIAL/FAMILY WELL BEING 
48. Below is a list of statements that other people with your condition have said are important.
Please check one number per line to indicate the response which would most accurately describe
how you felt during your anti-cancer treatment.
Somewhat
I feel close to my friends 
I am satisfied with family 
communication about my illness
I feel close to my partner (or the 
person who is my main support) 
49. Regardless of your current level of sexual activity, please answer the following question. If
you prefer not to answer it, please put an X in the box below and go to the next section.
I am satisfied with my sex life 
I have pain 
I am bothered by side 
effects of treatment 
I feel ill 
I am forced to spend 
time in bed 
I get emotional support
from my family
I get support from my
friends
My family has accepted
my illness
Not at all A little bit Quite a bit Very much
SomewhatNot at all A little bit Quite a bit Very much
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50. Below is a list of statements that other people with your condition have said are important.
Please check one number per line to indicate the response which would most accurately describe
how you felt during your anti-cancer treatment.
I feel sad 
FUNCTIONAL WELL BEING
51. Below is a list of statements that other people with your condition have said are important.
Please check one number per line to indicate the response which would most accurately describe
how you felt during your anti-cancer treatment.
I am able to work
(include work at home)
I am satisfied with how I
am coping with my
illness
I am losing hope in the
fight against my illness
I feel nervous
I worry about dying
I worry that my condition
will get worse
My work (include work at 
home) is fulfilling 
I am able to enjoy life 
I have accepted my 
illness 
I am sleeping well 
I am enjoying the things 
I usually do for fun 
I am content with the 
quality of my life right 
now 
EMOTIONAL WELL BEING
SomewhatNot at all A little bit Quite a bit Very much
SomewhatNot at all A little bit Quite a bit Very much
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52. Below is a list of statements that other people with your condition have said are
important. Please check one number per line to indicate the response which would most
accurately describe how you felt during your anti-cancer treatment.
I have cramps in my stomach 
area
I have pain in my stomach area
Stomach pain interferes with my 
daily functioning
I have to limit my social activity 
because of diarrhoea
I have to limit my physical activity 
because of diarrhoea 
I have to limit my sexual activity 
because of diarrhoea
I am embarrassed by having 
diarrhoea 
I have abdominal cramps or 
discomfort due to my diarrhoea
My problem with diarrhoea keeps/
wakes me up at night
I must move my bowels frequently 
to avoid accidents
I wear pads or protection to prevent 
soiling my underwear 
Thank you for taking the time to participate in this survey.
I have control of my 
bowels 
I move my bowels more 
frequently than usual 
I am afraid to be far from
a toilet
v
SomewhatNot at all A little bit Quite a bit Very much
Initial email sent to Breast Cancer Network Australia Review and Survey Group. 
Subject: Share your experiences about how chemotherapy affects your well-being 
Dear %%First Name%% 
Women who have chemotherapy as part of their breast cancer treatment may experience a number 
of side effects. These include nausea, pain and vomiting, as well as cognitive changes, such as 
difficulty concentrating, feeling somewhat confused or having trouble with memory. 
Researchers at the University of Adelaide are inviting you to participate in a study exploring possible 
links between the gastrointestinal side effects of chemotherapy (e.g. nausea, diarrhoea, bloating 
and constipation) and women's experiences of changes to their cognition. 
Who can take part? 
You can participate in this study if you: 
• are aged 30 years or above
• are post-menopausal
• are currently undergoing chemotherapy treatment, or have had chemotherapy within the
past 24 months
• have noticed difficulties with your cognition (e.g. having trouble concentrating, memory
difficulties, feeling mildly confused)
• are a non-smoker
• are not diabetic
• have not had any pre-existing brain disorders or mental health conditions (such as major
depression, brain injury, chronic pain, dyslexia, epilepsy, etc.)
• have not had a history of inflammatory gastrointestinal disorders (such as Irritable Bowel
Disease, Crohn's Disease, ulcerative colitis, repeated stomach ulcers)
• are not on any medication that may affect your cognition (such as opioids)
What does the study involve? 
Participation involves completing a survey, either online or by hardcopy posted to you. 
The survey will take between 30 and 40 minutes to complete and your responses will be 
anonymous. 
The survey will ask some questions about you, your diagnosis and treatment, side effects of 
chemotherapy you have experienced and the impact that these side effects have on your physical 
and emotional health and wellbeing. 
To take the survey online, please visit: https://www.surveymonkey.com/r/H-2015-
167_Understandingtheside-effectsofchemotherapy_UofA. 
Or alternatively, if you wish to fill out a hardcopy of the survey, please email Ms Juliana Bajic at the 
University of Adelaide, Juliana.bajic@adelaide.edu.au, and she will mail out all the documents, 
including a stamped self-addressed envelope so you don't incur any costs. 
For more information, please read the Participant Information Statement and Participant Inclusion 
and Exclusion Check List. If you have any questions or wish to find out more about the study, please 




The researchers will make sure that the information you provide is anonymous (your name and 
contact details will not be collected or stored with your survey answers). By taking this survey you 
are providing your consent (agreement) for the researchers to collect and store your survey answers 
on Survey Monkey’s overseas server (large computer). 
Click here to view BCNA's privacy policy. 
Click here to view Survey Monkey’s privacy policy. 






This appendix includes the ethics approval numbers for the animal and human research 
undertaken throughout my PhD. As specifically stated in each chapter, some of the animals 
reported in these works, formed the controls of larger studies and accordingly, these studies 
have been acknowledged and cited appropriately. Nonetheless, I have included each 
reference and reference number, as it appears throughout my thesis, followed by the ethics 
approval numbers. All animal ethics approval was granted by the Animal Ethics Committee 
of The University of Adelaide. Permission was granted by the lead investigators of the larger 
studies mentioned here, prior to data collation, molecular work, statistical analysis and the 
write up of each chapter. The Human Research Ethics Committee of The University of 
Adelaide granted approval for the final research chapter of this thesis. 
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Please find here examples of a full western blot from each chapter. Following on from the 
examples, I have provided all full western blots used throughout this thesis. As some proteins 
were developed differently (using skim milk or BSA), it was necessary to cut the full blots to 
ensure the right developing specifications (see below). 
Example of the same blot. Blots may be cut at 75kDa. A represents the top half of the blot 
(75-200kDa) and B represents the bottom half of the blot (15-75kDa). 
A 
B 
Western blot examples: 












Chapter Four: GFAP, IL-1β and actin examples. 










Thank you for taking the time to read my thesis!
Yours sincerely, Juliana Bajic.
